CROI 2020
Conference on Retroviruses and Opportunistic Infections
Boston
March 8-11, 2020
CONTENTS

CROI FOUNDATION ..................................................... 2
IAS–USA ........................................................................ 3
CONTINUING MEDICAL EDUCATION ................................ 3
CROI 2020 PROGRAM COMMITTEE .................................. 6
   Scientific Program Committee ................................... 6
   Community Liaison Subcommittee ............................... 8
EXTERNAL REVIEWERS .................................................. 9
SCHOLARSHIP Awardees ................................................. 11
   Activities for New Investigator Awardees ..................... 11
   New Investigator Awardees ........................................ 11
   International Investigator Awardees ............................ 16
   Community Educator Awardees ................................. 16

CONFERENCE INFORMATION .......................................... 18
   Overview ..................................................................... 18
   Conference Support ................................................... 18
   Conference Resources ................................................ 19
      WiFi Access at the Conference ................................. 19
      Mobile App ........................................................... 19
      Poster Videos ....................................................... 19
      Website .................................................................. 19
      Webcasts ............................................................... 19
      USB Flashdrive ..................................................... 20
   Affiliated and Proximate Activities Policy ..................... 20
   Conference Badges .................................................... 20
   Conference Etiquette .................................................. 20

VENUE
   Conference Services ................................................ 21
   Meals ....................................................................... 22
   Emergency Services .................................................. 22
   Overflow Accommodations ....................................... 22
   Americans With Disabilities Act ................................ 22
   Child Care ............................................................... 22

CROI HOTELS ................................................................. 23

ABSTRACT PROCESS ..................................................... 25
   Abstracts Related to Study Populations .......................... 27

PRECONFERENCE SESSIONS ............................................. 28

SYMPOSIA, ORAL SESSIONS, AND THEMED DISCUSSIONS BY DAY .. 34

POSTER SESSIONS BY DAY ........................................... 66

POSTER SESSIONS BY CATEGORY ................................... 173

INDEX OF PRESENTING AUTHORS ................................. 178

CONFERENCE SCHEDULE .............................................. INSIDE BACK COVER

CONVENTION CENTER FLOOR PLANS .......................... BACK COVER

Printed in the United States of America.
© Copyright 2020 CROI Foundation/IAS–USA. All rights reserved.
ISBN #978-1-7320053-2-7
CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors
- Works closely with the CROI Program Committee (CROI PC) and the CROI Organizer to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Organizer
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance A. Benson, MD</td>
<td>President</td>
<td>University of California San Diego</td>
<td>San Diego, CA, United States</td>
</tr>
<tr>
<td>John M. Coffin, PhD</td>
<td>Secretary-Treasurer</td>
<td>Tufts University</td>
<td>Boston, MA, United States</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td></td>
<td>ICAP at Columbia University</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td></td>
<td>San Francisco Department of Public Health</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MSc</td>
<td></td>
<td>University of California Los Angeles</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>Kevin M. De Cock, MD</td>
<td></td>
<td>Centers for Disease Control and Prevention</td>
<td>Nairobi, Kenya</td>
</tr>
<tr>
<td>Scott M. Hammer, MD</td>
<td></td>
<td>Columbia University</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Sharon L. Hillier, PhD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>James A. Hoxie, MD</td>
<td></td>
<td>University of Pennsylvania</td>
<td>Philadelphia, PA, United States</td>
</tr>
<tr>
<td>John W. Mellors, MD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>Robert T. Schooley, MD</td>
<td></td>
<td>University of California San Diego</td>
<td>La Jolla, CA, United States</td>
</tr>
</tbody>
</table>
IAS–USA

The International Antiviral (formerly AIDS) Society–USA (IAS–USA) serves as the Conference Organizer for the logistical planning and organization for CROI in partnership with the CROI Foundation and Program Committee. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access primary educational and informational programs sponsored by the IAS–USA, please visit www.iasusa.org for:

- Live CME courses and webinars available for signup
- Archived webcasts of CME courses and webinars
- Topics in Antiviral Medicine™, including the annual CROI review
- Practice guidelines

CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The IAS–USA designates this live activity for a maximum of 17.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

After participating in CROI 2020, participants will be able to:

- Describe basic science research advances in HIV
- List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
- Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993, by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.
CME Credit Information

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, and symposia. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.50 MOC points in the ABIM MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, links to the daily and final evaluations will be available in your CROI profile on the CROI or IAS–USA website. Detailed instructions will be provided. You will need the email address that you used to register for this conference and your reference number (on your badge) to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations and claim forms must be submitted by April 11, 2020. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile on the CROI or IAS–USA website.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference activities, including premeeting workshops, opening session lectures, plenary lectures, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended.


Disclosure of Financial Relationships

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation.

The ACCME defines financial relationships as “those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. The ACCME has not set a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.”
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests — unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

The information is intended to make the audience aware of speaker and contributor interests and commitments with commercial interests, enabling the audience members to form their own judgments about such associations.

Each author, contributor, or person in control of content in the CME activity is required to complete this financial relationship disclosure declaration. In accordance with IAS—USA policy, the IAS—USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information is detailed in the Abstract eBook and CROI Mobile App.

**Drug and Product Disclaimer**

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The information in this Program and Conference Information Guide is current as of February 14, 2020. Subsequent program changes will be announced on the Mobile App and around the convention center.
CROI 2020 PROGRAM COMMITTEE

The Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

Sharon L. Hillier, PhD
CROI 2020 Chair
University of Pittsburgh
Pittsburgh, PA, United States

Elaine J. Abrams, MD
CROI 2020 Vice Chair
ICAP at Columbia University
New York, NY, United States

Adaora Adimora, MD
University of North Carolina
Chapel Hill, NC, United States

Galit Alter, PhD
Ragon Institute of MGH, MIT and Harvard
Cambridge, MA, United States

Katharine J. Bar, MD
University of Pennsylvania
Philadelphia, PA, United States

Constance A. Benson, MD
University of California
San Diego
San Diego, CA, United States

Susan P. Buchbinder, MD
San Francisco Department of Public Health
San Francisco, CA, United States

Connie L. Celum, MD, MPH
University of Washington
Seattle, WA, United States

Sharon L. Hillier, PhD
CROI 2020 Chair
University of Pittsburgh
Pittsburgh, PA, United States

Richard E. Chaisson, MD
The Johns Hopkins University
Baltimore, MD, United States

Nicolas Chomont, PhD
Université de Montréal
Montreal, Canada

John M. Coffin, PhD
Tufts University
Boston, MA, United States

Judith S. Currier, MD, MSc
University of California
Los Angeles
Los Angeles, CA, United States

James A. Hoxie, MD
CROI 2020 Vice Chair
University of Pennsylvania
Philadelphia, PA, United States
François Dabis, MD, PhD  
University of Bordeaux  
Bordeaux, France

Kevin M. De Cock, MD  
Centers for Disease Control and Prevention  
Nairobi, Kenya

Wafaa M. El-Sadr, MD, MPH  
ICAP at Columbia University  
New York, NY, United States

Joseph J. Eron, Jr, MD  
University of North Carolina  
Chapel Hill, NC, United States

Huldrych F. Günthard, MD  
University Hospital Zurich  
Zurich, Switzerland

Timothy Hallett, PhD  
Imperial College London  
London, United Kingdom

Diane V. Havlir, MD  
University of California  
San Francisco  
San Francisco, CA, United States

Peter W. Hunt, MD  
University of California  
San Francisco  
San Francisco, CA, United States

Ilesh V. Jani, MD, PhD  
Instituto Nacional de Saude  
Maputo, Mozambique

Angela Kashuba, PharmD  
University of North Carolina  
at Chapel Hill  
Chapel Hill, NC, United States

Frank Kirchhoff, PhD  
Ulm University  
Medical Center  
Ulm, Germany

Dennis L. Kolson, MD, PhD  
University of Pennsylvania  
Philadelphia, PA, United States

Richard A. Koup, MD  
Vaccine Research Center  
National Institute of Allergy and Infectious Diseases  
Bethesda, MD, United States

Hermione Lyall, MD  
Imperial College Healthcare National Health Service Trust  
London, United Kingdom

James A. McIntyre, MBChB, FRCP  
Anova Health Institute  
Johannesburg, South Africa

John W. Mellors, MD  
University of Pittsburgh  
Pittsburgh, PA, United States

Jonathan Mermin, MD, MPH  
Centers for Disease Control and Prevention  
Atlanta, GA, United States

Penelope L. Moore, PhD  
University of Witwatersrand  
Johannesburg, South Africa

Landon Myer, MD, PhD  
University of Cape Town  
Cape Town, South Africa

Andrew N. Phillips, PhD  
University College London  
London, United Kingdom

Peter Reiss, MD, PhD  
Amsterdam Institute for Global Health and Development  
Amsterdam, Netherlands

Douglas D. Richman, MD  
University of California  
San Diego; Veterans Affairs San Diego Healthcare System  
San Diego, CA, United States
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Dawn Averitt  
The Well Project  
South Strafford, VT, United States

Ntando Yola  
Desmond Tutu HIV Foundation  
Cape Town, South Africa

James Pickett  
AIDS Foundation of Chicago  
Chicago, IL, United States

Former Members

The CROI Foundation wishes to thank for their service the following individuals who rotated off the Program Committee in 2019:

Jintanat Ananworanich, MD, PhD  
Paul Bieniasz, PhD  
Nelly R. Mugo, MBChB, MPH

And our thanks to those who rotated off the Community Liaison Subcommittee in 2019:

Morenike Ukpong, FWACS, MBA, BChD  
Lisa Diane White, MPH
EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who, in addition to the scientific program committee members, served as volunteer external reviewers of abstract submissions for CROI 2020.

Peter L. Anderson, PharmD
University of Colorado

Ruanné V. Barnabas, MBChB, DPhil
University of Washington

Greg Behrens, MD, PhD
Hannover University

Marta Boffito, MD, PhD
Chelsea and Westminster NHS Foundation Trust

William Borkowsky, MD
New York University

Bruce J. Brew, MD, DSc, MBBS
University of New South Wales

Todd T. Brown, MD, PhD
The Johns Hopkins University

David M. Burger, PhD
Radboud University Medical Center

Maria J. Buzon, PhD
Vall d’Hebron Research Institute

Corey Casper, MD
Infectious Disease Research Institute

Ellen G. Chadwick, MD
Ann & Robert H. Lurie Children’s Hospital of Chicago

David B. Clifford, MD
Washington University in St Louis

Carlos del Rio, MD
Emory University School of Medicine

Kelly E. Dooley, MD, PhD
The Johns Hopkins University

Vuyiseka Dubula
Sonke Gender Justice

Kristine Erlandson, MD
University of Colorado Denver

David Evans, PhD
University of Wisconsin—Madison

Paul J. Farrell, PhD
Imperial College London

Courtney V. Fletcher, PharmD
University of Nebraska Medical Center

Charles W. Flexner, MD
The Johns Hopkins University

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital

John Frater, MD, PhD
University of Oxford

Jennifer Furin, MD, PhD
Harvard University

Dana H. Gabuzda, MD
Dana–Farber Cancer Institute

Monica Gandhi, MD, MPH
University of California San Francisco

Gerardo García-Lerma, PhD
Centers for Disease Control and Prevention

Elvin H. Geng, MD, MPH
University of California San Francisco

Carlo Giaquinto, MD
University of Padova

Beatriz Grinsztejn, MD
Fiocruz

James G. Hakim, MD
University of Zimbabwe

Scott M. Hammer, MD
Columbia University

P. Richard Harrigan, PhD
BC Centre for Excellence in HIV/AIDS

Theodora Hatzioannou, PhD
The Rockefeller University

Ya-Chi Ho, MD, PhD
Yale University School of Medicine

Jennifer Hoy, MD
Monash University

Priscilla Y. Hsue, MD
University of California San Francisco

Harold W. Jaffe, MD
Centers for Disease Control and Prevention

Jennifer Jao, MD
Northwestern University

Susan E. Krown, MD
AIDS Malignancy Consortium

Raphael J. Landovitz, MD
University of California Los Angeles

Scott L. Letendre, MD
University of California San Diego

Sharon R. Lewin, MD
University of Melbourne

Annie F. Luetkemeyer, MD
University of California San Francisco

Patrick W.G. Mallon, PhD, MBBS
University College Dublin

Jeanne M. Marrazzo, MD, MPH
University of Alabama at Birmingham

Grace A. McComsey, MD
University Hospitals Cleveland Medical Center
General Information

Graeme Meintjes, PhD, MBChB  
University of Cape Town

Nyaradzo Mgodi, MBChB, MMed  
University of Zimbabwe

Ronald T. Mitsuyasu, MD  
University of California Los Angeles

Jean-Michel Molina, MD, PhD  
Hôpital Saint-Louis

Victor Musiime, PhD, MBChB  
Makerere University

Susanna Naggie, MD, MHS  
Duke University

Jean-Michel Pawlotsky, MD, PhD  
Hôpital Henri Mondor

Martina Penazzato, MD, PhD  
World Health Organization

Thomas F. Schulz, MD  
Hannover University

Kenneth E. Sherman, MD, PhD  
University of Cincinnati

Marco Siccardi, PhD  
University of Liverpool

Viviana A. Simon, MD, PhD  
Icahn School of Medicine at Mt Sinai

Mario Stevenson, PhD  
University of Miami

Patrick S. Sullivan, MD  
Emory University

Alexandra Trkola, PhD  
University of Zurich

Alice Tseng, PharmD  
Toronto General Hospital

Gert U. van Zyl, MD, PhD  
Stellenbosch University

Lucy Wanjiku Njenga  
Positive Young Women Voices

Timothy Wilkin, MD  
Weill Cornell Medicine

Alan Winston, MD  
Imperial College London

David L. Wyles, MD  
Denver Health and Hospital Authority

Robert Yarchoan, MD  
National Cancer Institute

Markella V. Zanni, MD  
Massachusetts General Hospital
SCHOLARSHIP AWARDEES

CROI is committed to supporting new and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. New Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors.

In addition, CROI offers scholarships to international investigators and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

For more information regarding CROI scholarships, please visit: www.CROIconference.org/scholarships

CROI features the following special content for New Investigator Scholarship recipients:

Optional Session: The Hitchhiker's Guide to NIH Funding for HIV/AIDS Research
Sunday, March 8, 2020, at 8:00 AM
Ballroom BC
This optional session will assist applicants looking for funding from the National Institutes of Health to better match their fields of science to the standing study sections, anticipate the expectations of reviewers, and seek out information and clarity on review policy changes.

Scientific Program Committee Workshop for New Investigators and Trainees
Sunday, March 8, 2020, at 9:00 AM
Ballroom BC
This required workshop for New Investigator scholarship recipients will highlight key presentations at CROI 2020 in basic, translational, and clinical, and epidemiology/public health research.

NEW: Breakfast Networking Sessions for New Investigators
Monday, Tuesday, and Wednesday, at 7:15 AM
Rooms 109, 110, and 111
Each day, 3 leaders in HIV research will briefly preview the content of the day at CROI in basic science, clinical, and epidemiology/public health research. Following the overviews, the speakers will network with attendees in small-group breakouts. Breakfast will be available in the room prior to the start of the session. Attendance is limited to New Investigator Scholarship awardees who signed up in advance.

New Investigator Awardees

Bukola Adeoye
Boston University
Erika Ahlgren
Gothenburg University
Elena Alvarez-Barco
University College Dublin
Nanina Anderegg
University of Bern
Brent Appelman
University of Amsterdam
Antonio Astorga Gamaza
Vall d’Hebron Research Institute
Max Augustin
Cologne University Hospital
Ann W.N. Auma
Case Western Reserve University
Samuel Bailin
Vanderbilt University Medical Center
Gianmaria Baldin
Università Cattolica del Sacro Cuore
Eve-Marie A. Benson
The Johns Hopkins University
Pooja Bhardwaj
Vitalant Research Institute
Shivkumar Biradar
University of Pittsburgh
Cherie S. Blair
University of California Los Angeles
Oscar Blanch-Lombarte
InCiCeana Institute for AIDS Research
David Charles Boettiger
University of New South Wales
Milana Bogorodskaya
MetroHealth
Tania Sultana Bonny
The Johns Hopkins University
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Felix Stader</td>
<td>University Hospital Basel</td>
</tr>
<tr>
<td>Randy Stalter</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Melanie Stecher</td>
<td>University of Cologne</td>
</tr>
<tr>
<td>Karl Stefic</td>
<td>Université de Tours</td>
</tr>
<tr>
<td>Paula Suanses</td>
<td>University Hospital Vall d`Hebron</td>
</tr>
<tr>
<td>Alfredo Tagarro</td>
<td>Fundación Investigación Biomédica Hospital 12 Octubre</td>
</tr>
<tr>
<td>Phillip Tomeszko</td>
<td>Harvard University</td>
</tr>
<tr>
<td>Diana M. Tordoff</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Milana Vachuska</td>
<td>University of California San Diego</td>
</tr>
<tr>
<td>Eugenio Valdano</td>
<td>University of California Los Angeles</td>
</tr>
<tr>
<td>Malon Van den Hof</td>
<td>Emma Children’s Hospital</td>
</tr>
<tr>
<td>Ricardo de Paula Vasconcelos</td>
<td>University of Sao Paulo</td>
</tr>
<tr>
<td>Frances Vernon</td>
<td>University of Colorado</td>
</tr>
<tr>
<td>Rosanne Verwijs</td>
<td>Eisaius University Medical Center</td>
</tr>
<tr>
<td>Lorena Vigón</td>
<td>Instituto de Sabad Carlos III</td>
</tr>
<tr>
<td>Hylke Waalewijn</td>
<td>Radboud University Medical Centre</td>
</tr>
<tr>
<td>Xiao Qian Wang</td>
<td>The Westmead Institute for Medical Research</td>
</tr>
<tr>
<td>Zheng Wang</td>
<td>University of Pittsburgh</td>
</tr>
<tr>
<td>Catherine J. Wedderburn</td>
<td>London School of Hygiene and Tropical Medicine</td>
</tr>
<tr>
<td>Julian Weiss</td>
<td>Yale University</td>
</tr>
<tr>
<td>Shamaya Whitby</td>
<td>Oak Ridge Associated Universities</td>
</tr>
<tr>
<td>Andrew B. Wilson</td>
<td>George Washington University</td>
</tr>
<tr>
<td>Bethel Woldu</td>
<td>The Johns Hopkins Hospital</td>
</tr>
<tr>
<td>Colline Wong</td>
<td>Brigham and Women’s Hospital</td>
</tr>
<tr>
<td>Fei Wu</td>
<td>Tulane University</td>
</tr>
<tr>
<td>Jenna Yager</td>
<td>University of Colorado</td>
</tr>
<tr>
<td>H Manisha Yapa</td>
<td>University of New South Wales</td>
</tr>
<tr>
<td>Yang-Hui Yeh</td>
<td>Yale University</td>
</tr>
<tr>
<td>Alexis Yero</td>
<td>Université du Québec à Montréal</td>
</tr>
<tr>
<td>Katherine Yu</td>
<td>Western University</td>
</tr>
<tr>
<td>Sonia Zicari</td>
<td>Bambino Gesù Children’s Hospital</td>
</tr>
<tr>
<td>Jerry Simbarashe Zifodya</td>
<td>University of Washington Medical Center</td>
</tr>
<tr>
<td>Kathrin Zürcher</td>
<td>University of Bern</td>
</tr>
</tbody>
</table>
International Investigator Awardees

Mahmoud Tareq Abdelwahab
University of Cape Town

Adedayo Olubummi Adegbeni
Centers for Disease Control and Prevention

Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership

Kim Anderson
University of Cape Town

Vivian Iida Avelino-Silva
University of Sao Paulo

Mara Biasin
University of Milan

Prossy Bibangambah
Mbarara University of Science and Technology

Michael Terence Boswell
University of Oxford

Johannes Christiaan Botha
Stellenbosch University

Maganoa Chagomerana
University of North Carolina Project–Malawi

Jun Chen
Shanghai Public Health Clinical Center

Veronique De Jager
Task Appleid Science

Jose Francis
University of Cape Town

Lisa Frigati
Stellenbosch University

Sivaporn Gatechompol
Thai Red Cross AIDS Research Center

Ndova Makau George
Kenya Medical Research Institute

Sethunya Gotulweng
Botswana Harvard Partnership

Rulan Griesel
University of Cape Town

Kondwani C. Jambo
Malaw-Liverpool-Welctome Trust Clinical Research Programme

Moses Katbi
US Agency for International Development

Patrick Katoto
Catholic University of Bukavu

Darik Ssebagalla Kigozi
Rakai Health Sciences Program

Tadeo Kandole Kiiza
Makerere University

Stanzi Maria Ie Roux
University of Cape Town

Kwana Lechiile
Botswana Harvard Partnership

Rory Forseth Leisegang
Uppsala University

Lara Lewis
Centre for the AIDS Programme of Research in South Africa

Hlengwi Pretty Madlala
University of Cape Town

Neema Makyao
National AIDS Control Program

Ashokkumar Manickam
National Institute for Research in Tuberculosis

Emily Martyn
Makerere University

Gaerolwe Masheto
Botswana Harvard Partnership

Grace McHugh
Biomedical Research and Training Institute

Grace Mongo-Bua
Rakai Health Sciences Program

Muhammed Shiraz Moosa
University of Cape Town

Jorge Salomão Moreira
University of Sao Paulo

Johannes P. Mouton
University of Cape Town

Sikhulile Moyo
Botswana Harvard Partnership

Elton Emmanuel Mukonda
University of Cape Town

Randy George Mungwira
World Health Organization

Hadijja Nakawooya
Rakai Health Sciences Program

Chaunyi Ning
Guangxi Medical University

Samuel Pierre
GEMSAID

Maria Laura Polo
National Scientific and Technical Research Council

Morris Kyozo Rutakingirwa
Infectious Diseases Institute

Theodora Savory
Center for Infectious Disease Research

Pavlo Smyrnow
Alliance for Public Health

Betty Bawuba Tukei
Right to Care

Marta Vasylyev
Lviv Regional Public Health Center

Ly Trieu Vo
Ho Chi Minh City Medicine and Pharmacy University

Elizabeth Wahome
Kenya Medical Research Institute

Beatrice Namuti
University of Washington

Tanyaporn Wansom
Dreamloptions

(continued on next page)

Community Educator Scholarship Awardees

Oluwatosin Bamidele Alaka
New HIV Vaccine and Microbicide Advocacy Society

Giorgio Barbareschi
European AIDS Treatment Group

Devi Leena Bose
International AIDS Vaccine Initiative

Damian Cabrera
SexTEAM

Giulio Maria Corbelli
Plus Onlus

Michael Dorosh
Treatment Education Network

Denis Godlevskiy
AIDS Statistics Health

Ángel L. Hernández
University of Puerto Rico

Rena Janamnuaysook
HIV – NAT, Thai Red Cross AIDS Research Centre

Andy H. Kaytes
University of California San Diego

Sandris Klaivins
AGHAS

(continued on next page)
## Community Educator Scholarship Awardees (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization/Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grace Kumwenda</td>
<td>Pakachere Institute of Health and Development Communication</td>
</tr>
<tr>
<td>Udom Likhitwonawut</td>
<td>Thai Red Cross AIDS Research Center</td>
</tr>
<tr>
<td>Michael Meulbroek</td>
<td>Asociación para el Transplante de Órganos a Seropositivos</td>
</tr>
<tr>
<td>Kennedy Mupeli</td>
<td>Center for Youth of Hope</td>
</tr>
<tr>
<td>Kyomuhangi Lilian Mworekom</td>
<td>International Community of Women Living with HIV Eastern Africa</td>
</tr>
<tr>
<td>Shakirah Namwanje</td>
<td>Peer to Peer Uganda</td>
</tr>
<tr>
<td>Simon Odiuvor Ondiek</td>
<td>Centre for Health Advocacy, Research and Programs</td>
</tr>
<tr>
<td>David A. Palm</td>
<td>University of North Carolina</td>
</tr>
<tr>
<td>Ace Robinson</td>
<td>National Minority AIDS Council</td>
</tr>
<tr>
<td>Paul Sixpence</td>
<td>Centre Stage Media Arts Foundation</td>
</tr>
<tr>
<td>Marcelo Maia Soares</td>
<td>ACT UP New York</td>
</tr>
<tr>
<td>Jeff Taylor</td>
<td>HIV+ Aging Research Project</td>
</tr>
<tr>
<td>Harry Clayton Tembo</td>
<td>Zambia Community Advisory Platform</td>
</tr>
<tr>
<td>Mercy Mutonyi Wafula</td>
<td>Bar Hostess Empowerment and Support Program</td>
</tr>
</tbody>
</table>


CONFERENCE INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Conference Support
CROI is largely supported by participant registration fees. CROI registration fees cover all hosted attendee meals (including the welcome reception) and travel expenses for invited participants (eg, speakers, leaders, moderators, and CROI PC members), as well as selected meeting materials and other conference expenses.

CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the CME portions of the program or abstract review and selection processes. Commercial support is used to cover some of the costs of the conference venue, audiovisual services, and other conference expenses.

CROI 2020 received grant support commitments from the following commercial companies:

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Additional support has been provided by
AbbVie Inc.
Theratechnologies Inc.
Conference Resources

WiFi ACCESS AT THE CONFERENCE
Complimentary WiFi access is provided at the conference venue. Network information is as follows:

Network name: CROI2020

The WiFi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will help maximize the internet speeds for those devices actively in use. The password for each day of the conference is listed below, and is case sensitive.

Saturday password: 2020saturday
Sunday password: 2020sunday
Monday password: 2020monday
Tuesday password: 2020tuesday
Wednesday password: 2020wednesday

If you are having a problem with WiFi access, please contact an IAS–USA staff member.

MOBILE APP
To access the CROI Mobile App, use your reference number (on your name badge) and the email address you used to register for CROI.

The CROI 2020 Mobile App has many features to enhance your conference experience, including to:

- View abstracts
- Find information about speakers and other CROI attendees
- Contact and communicate with other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- Email session notes
- Receive the latest changes to the CROI program
- View electronic posters and video descriptions of presentations

The Mobile App is compatible with iOS and Android devices. Search “CROI 2020” in your mobile device App store. Access is restricted to registered attendees. Your login information and password are provided with the registration materials.

POSTER VIDEOS
Poster presenters may upload a short video (up to 5-minute description) of their research. Poster presenter videos are available to attendees during the conference via the CROI Mobile App and to the public after the conference on the CROI website.

WEBSITE
For additional information about the conference and to access electronic materials, please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2020 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014 to 2019 are available at www.CROIconference.org/abstracts/search-abstracts/

WEBCASTS
Plenary lectures, symposia, oral abstract sessions, and themed discussions will be available as webcasts within 24 hours of the end of the relevant session. Webcasts are also available as streaming videos for the Apple iPad and iPhone.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts.
USB FLASH DRIVE
Any registrant who purchased a USB flash drive with the Abstract eBook loaded will receive it in their welcome packet at registration. Abstracts can also be found in the Abstract eBook and searchable database on the CROI website after the session in which the abstract is presented.

Affiliated or Proximate Activities
The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) have been approved to host Affiliated or Proximate Activities occurring outside CROI session times. Affiliated or Proximate Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2020. An Affiliated or Proximate Activity is one that occurs during or immediately before or after CROI, and involves any CROI attendees.

If an activity is found to have violated the Guidelines for Affiliated or Proximate Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated or Proximate Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and damages, and could negatively impact the registration status and attendance of those attending an unapproved activity.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

Conference Badges
Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. The CROI badge must be worn at all times during the conference in order to gain entry to all official meeting activities, including the poster sessions. Attendees will not be admitted into the meeting spaces without their CROI badge. THE CROI BADGE MAY ONLY BE USED BY THE PERSON NAMED ON THE BADGE AND CANNOT BE TRANSFERRED OR SHARED WITH OTHERS. USING ANOTHER INDIVIDUAL’S BADGE OR GIVING YOUR BADGE TO SOMEONE ELSE TO GAIN ACCESS TO THE CONFERENCE IS STRICTLY PROHIBITED AND IS A VIOLATION OF CROI POLICIES. DO NOT LOSE YOUR BADGE. Payment of US$885 will be required to replace a lost badge.

Conference Etiquette
Please ensure all mobile devices are turned off or set on SILENT mode in session rooms. In consideration for the work of the presenters at CROI and the CROI copyright policy, attendees may not photograph posters, record parts of talks, or post data without the presenter’s consent.
## VENUE

<table>
<thead>
<tr>
<th>Service</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Badge Pickup</strong></td>
<td>Registration Area on the Plaza Level</td>
<td>Monday to Wednesday: 7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Attendee Services</strong></td>
<td></td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday: 7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td><strong>Housing Information</strong></td>
<td></td>
<td>Monday to Wednesday: 7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Continental Breakfast</strong></td>
<td>2nd Floor Prefunction Area</td>
<td>Monday to Wednesday: 7:30 AM – 8:30 AM</td>
</tr>
<tr>
<td><strong>Boston Visitors Information</strong></td>
<td>Registration Area on the Plaza Level</td>
<td>Saturday: 2:30 PM – 7:30 PM, Sunday: 2:00 PM – 9:00 PM, Monday to Wednesday: 10:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Bag and Coat Check</strong></td>
<td>Plaza Level Room 107</td>
<td>Sunday: 8:00 AM – 9:30 AM, Monday to Wednesday: 7:00 AM – 6:30 PM</td>
</tr>
<tr>
<td><strong>Cyber Cafe</strong></td>
<td>3rd Floor Boylston Hallway</td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday: 7:00 AM – 7:00 PM, Monday to Wednesday: 7:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>IAS–USA Office</strong></td>
<td>Room 203</td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday to Wednesday: 7:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Speaker Ready Room</strong></td>
<td>Room 200</td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday to Wednesday: 6:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Personal Considerations Room</strong></td>
<td>Room 308</td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday: 9:00 AM – 7:00 PM, Monday to Wednesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>New Mother’s Room</strong></td>
<td>Room 307</td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday: 9:00 AM – 7:00 PM, Monday to Wednesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Networking Areas</strong></td>
<td>Cafeteria, Rooms 303, 305, and Poster Halls</td>
<td>Saturday: 3:00 PM – 6:00 PM, Sunday: 9:00 AM – 7:00 PM, Monday to Wednesday: 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td><strong>Convention Center Emergency Medical Services</strong></td>
<td>Registration Area on the Plaza Level</td>
<td>Sunday: 9:00 AM – 9:00 PM, Monday to Wednesday: 8:30 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Badges and conference materials can be picked up at this location.

**Note:** Continental Breakfast is available.

**Note:** Computers with internet access are available.

**Note:** The Media Center is a work space with WiFi and is the location of the daily press conferences open exclusively to registered, accredited media.

**Note:** IAS-USA staff are available to answer questions or concerns regarding the conference.

**Note:** Oral abstract, invited, and themed discussion session speakers must drop off presentations here at least 24 hours before their presentation. Poster presenters must submit an electronic version of their poster through the abstract submission website before the start of the conference.

**Note:** The Personal Considerations Room is set aside for those who require a short-term private space for personal health needs. This room is available on a first-come, first-served basis.

**Note:** The New Mother’s Room is set aside for nursing mothers who require a short-term private room. Use of this room is on a first-come, first-served basis. There is also a Mamava Nursing Pod at the Plaza Level Prudential entrance to the convention center.

**Note:** These areas are set up with tables and chairs for attendees to gather and network with colleagues.
Meals
Morning coffee and a light continental breakfast will be available to conference registrants from 7:30 AM to 8:30 AM, Monday, Tuesday, and Wednesday, in the 2nd Floor prefunction area outside of the Auditorium. An afternoon snack break will be available at 2:30 PM in the Poster Halls. Attendees are on their own for all other meals, including lunch and dinner, each day. If you have downloaded the CROI Mobile App in your mobile device, you may access a list of food service options located in the conference venue or within a short walking distance.

Emergency Services
In the event of an emergency please contact the convention center command center, open 24 hours daily, or notify CROI staff. The command center can be reached at (617) 954-2111 and is located by the Boylston Street entrance to the convention center. In addition, security desks are located throughout the building at each of the building’s entrances.

The convention center Emergency Medical Services are located in the registration area on the plaza level.

Overflow Accommodations
Simultaneous overflow is located in Room 302. Screens will live stream all of the concurrent sessions (Oral Abstracts, Themed Discussions, and Symposia). Headsets with an audio switch will be available for easy transitioning between the concurrent session channels.

Overflow monitors for individual session rooms will become available as needed. CROI staff will direct you to these locations.

Americans with Disabilities Act
CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Attendee Services booth on the Plaza level during the conference.

Child Care
Out of respect for the presenters and conference attendees, children are not permitted in meeting rooms, including the poster halls. If you require child care services, you may refer to the following resources suggested by local hosts. You may also contact the concierge of your hotel. The following list is provided by Signature Boston as a courtesy only.

**Boston Sitter Company**
www.bostonsitterco.com/services

**Care.com**
www.care.com
CROI HOTELS

CROI 2020 hotels are listed below. For more detailed housing information, please visit the CROI 2020 conference website: www.CROIconference.org/housing. Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Conference area (ie, within a 50-mile radius of the conference venue) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system.

**Boston Marriott Hotel Copley Plaza**
110 Huntington Ave
Boston, MA 02116
Phone: + 1 617 236-5800

**Midtown Hotel**
220 Huntington Ave
Boston, MA 02115
Phone: + 1 617 262-1000

**Boston Park Plaza**
50 Park Plaza
Boston, MA 02116
Phone: + 1 617 426-2000

**Revere Hotel Boston Common**
200 Stuart St
Boston, MA 02116
Phone: + 1 617 482-1800

**The Colonnade**
120 Huntington Ave
Boston, MA 02116
Phone: + 1 617 424-7000

**The Revolution**
40 Berkeley St
Boston, MA 02116
Phone: + 1 617 848-9200

**Fairmont Copley Plaza**
138 St James Ave
Boston, MA 02116
Phone: + 1 617 267-5300

**Sheraton Boston**
39 Dalton St
Boston, MA 02199
Phone: + 617 236-2000

**Hilton Boston Back Bay**
40 Dalton St
Boston, MA 02115
Phone: + 1 617 236-1100

**Westin Copley Place**
10 Huntington Ave
Boston, MA 02116
Phone: + 1 617 262-9600

**Mandarin Oriental**
776 Boylston St
Boston, MA 02199
Phone: + 1 617 535-8888

*Any hotels added after February 11, 2020, are not reflected.*
Hynes Convention Center
Boston Marriott Hotel Copley Place
Boston Park Plaza
The Colonnade
Fairmont Copley Plaza
Hilton Boston Back Bay
Mandarin Oriental
Midtown Hotel
Revere Hotel Boston Common
The Revolution
Sheraton Boston
Westin Copley Place
# ABSTRACT PROCESS

<table>
<thead>
<tr>
<th>Track</th>
<th>Scientific Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>A. Virology</td>
</tr>
<tr>
<td></td>
<td>B. Pathogenesis: Human Studies and Animal Models</td>
</tr>
<tr>
<td></td>
<td>C. HIV-Associated Tumor Viruses</td>
</tr>
<tr>
<td></td>
<td>D. Host Immune Responses to Infection, Vaccines, and Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>E. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy</td>
</tr>
<tr>
<td></td>
<td>F. Neuropathogenesis and Neurologic Complications</td>
</tr>
<tr>
<td>Clinical</td>
<td>G. Clinical Pharmacology</td>
</tr>
<tr>
<td></td>
<td>H. Antiretroviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy and Effectiveness Studies</td>
</tr>
<tr>
<td></td>
<td>I. HIV Drug Resistance</td>
</tr>
<tr>
<td></td>
<td>J. Hepatitis Viruses and Liver Complications</td>
</tr>
<tr>
<td></td>
<td>K. AIDS-Related Malignancies</td>
</tr>
<tr>
<td></td>
<td>L. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy</td>
</tr>
<tr>
<td></td>
<td>M. Other Complications of HIV Infection and Antiretroviral Therapy</td>
</tr>
<tr>
<td></td>
<td>N. Tuberculosis and Other Opportunistic Infections</td>
</tr>
<tr>
<td></td>
<td>O. Maternal and Fetal HIV</td>
</tr>
<tr>
<td></td>
<td>P. Pediatrics and Adolescents</td>
</tr>
<tr>
<td>Epidemiology/</td>
<td>Q. Epidemiology</td>
</tr>
<tr>
<td>Public Health</td>
<td>R. Testing</td>
</tr>
<tr>
<td></td>
<td>S. Prevention Interventions</td>
</tr>
<tr>
<td></td>
<td>T. Contraception, Sexually Transmitted Infections, and Reproductive Health</td>
</tr>
<tr>
<td></td>
<td>U. Implementation and Scale-Up of Treatment and Care</td>
</tr>
</tbody>
</table>

**Note:** The following colors are used throughout the CROI Program and Information Guide and Poster Halls to group abstract poster presentations in their assigned tract:
- Basic Science Track = Purple
- Clinical Track = Red
- Epidemiology/Public Health Track = Blue

**Abstract Content**

Author names, institutions, titles, and abstracts in the CROI Program and Information Guide, Abstract eBook, Mobile App, and other materials are presented largely as submitted by the submitting author. The submitting author is responsible for ensuring that all coauthors have reviewed and approved the abstract before submission and for providing the complete and accurate contact information for all authors, including email address. **THE SUBMITTING AUTHOR MUST ENSURE THAT THE EMAIL ADDRESSES OF ALL LISTED AUTHORS IN THEIR SUBMISSION ARE CORRECT** in order for authors to receive important information regarding dispositions, presentation details, registration and housing information, and other CROI-related announcements.
Special Notes on Abstract Content

Presentations from randomized trials and cohorts should follow the International Committee of Medical Journal Editors (ICMJE) guidelines, including reporting of study designs, (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables.

Appropriate information and correct terminology should be used with regard to sex and gender. For human clinical or epidemiologic studies, sex-stratified results should be provided or who was included if the study includes only a single population. Appropriate terminology such as cisgender (people whose gender match the sex assigned at birth) or transgender (people whose gender does not match the sex assigned at birth) should be used. Both sex and gender data should be provided in the presentation. Presentations of preclinical data including use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex and gender, this should be identified as a limitation in your presentation.

Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.”

Presenting Author Responsibilities

The presenting author is responsible for presenting the abstract at the conference and must be present at the poster during the entire session. Submitting authors are responsible for ensuring that all coauthors have reviewed and approved the abstract contents before submission.

Embargo Policies and Social Media

All research presented at CROI 2020 is embargoed until the conclusion of the study’s presentation at the conference. For example, if a study is presented from 2:15 PM to 2:30 PM, as part of a session that begins at 2:00 PM and ends at 3:00 PM, the embargo on that study lifts at 2:30 PM. Embargoes on poster presentations lift at the beginning of the session in which the poster is presented.

If a study to be presented at CROI 2020 is included in an official CROI press conference that takes place before the scheduled presentation of the study, the embargo on that study lifts at the conclusion of the press conference panel in which the study is featured.

No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs) or social media (eg, Twitter, Instagram, Facebook). Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Abstract Review Process

The PC and a panel of volunteer external reviewers reviewed more than 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

Abstracts were reviewed for the quality and originality of the work and were scored numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate.

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores were discussed. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (distinct from a late submission, as they must meet a high threshold of scientific merit).
Common Reasons for Abstract Rejection
• Subject matter is not appropriate for CROI
• All coauthors did not approve the abstract prior to submission
• Information is not novel (new enough)
• Abstract is duplicative of other submissions
• Format does not follow guidelines (e.g., data missing, more than 1 table or figure submitted)
• Submission is poorly written and difficult to understand
• Background does not summarize the hypothesis
• Methodology is inadequate or insufficient to support conclusions
• Controls are absent or inadequate
• Statistical evaluation is inadequate or absent
• Summary of essential results is inadequate or absent
• Data are not included or offer inadequate or insufficient support for conclusions
• Submission reports clinical trial data from unplanned analyses or incomplete or ongoing studies

Statistics for Abstracts
General abstract submitted .................................................. 1852
General abstracts accepted .................................................. 1035
General oral abstracts ........................................................ 85
General poster abstracts ....................................................... 878
Late-breaking abstracts submitted ......................................... 188
Late-breaking abstracts accepted .......................................... 46
Late-breaking oral abstracts ................................................ 17
Late-breaking poster abstracts ............................................. 29
Total abstracts submitted .................................................. 2040
Total abstract accepted ..................................................... 1081

All Representing Authors on Accepted Abstracts

<table>
<thead>
<tr>
<th>Region</th>
<th>N</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>84</td>
<td>9%</td>
</tr>
<tr>
<td>Asia</td>
<td>17</td>
<td>2%</td>
</tr>
<tr>
<td>Australia</td>
<td>19</td>
<td>2%</td>
</tr>
<tr>
<td>Central and South America</td>
<td>10</td>
<td>1%</td>
</tr>
<tr>
<td>Europe</td>
<td>206</td>
<td>23%</td>
</tr>
<tr>
<td>North America</td>
<td>570</td>
<td>63%</td>
</tr>
</tbody>
</table>

Abstracts Related to Study Populations
1. Adolescents ............................................................ 52
2. Men who have sex with men (MSM) .................................. 118
3. People who inject drugs (PWID) ................................... 38
4. Transgender men or women .......................................... 19
5. Women ................................................................. 114

Authors have noted specific populations as the focus of their study, if applicable. Indexes that list abstracts that relate to specific populations are on the CROI Mobile App and Abstract eBook on the CROI website. These indexes are developed for attendees with an interest in these areas.
Preconference Session • Sunday

SUNDAY MARCH 8, 2020

Optional Workshop • THE HITCHHIKER’S GUIDE TO NIH REVIEW FOR HIV/AIDS RESEARCH
Ballroom BC 8:00 AM – 8:50 PM

Target Audience: This optional workshop is directed toward senior postdoctoral fellows and new investigators. However, it is open to all CROI attendees.

Level of Knowledge: It is assumed that the participants have been conducting active research in the field for fewer than 3 years.

Objectives: At the completion of the session, participants will be able to:
• Match their fields of science to the standing study sections
• Explain the expectations of reviewers
• Identify how to seek out information and/or clarity on review policy changes

WELCOME
Guido Silvestri, Emory University, Atlanta, GA, USA

OVERVIEW OF HIV/AIDS REVIEW AT CSR
Shiv A. Prasad, National Institutes of Health, Bethesda, MD, USA

THE NIH GRANT APPLICATION PROCESS
Dimitrios Vatakis, National Institutes of Health, Bethesda, MD, USA

A NEW INVESTIGATOR’S PERSPECTIVE
Sarah Beth Joseph, University of North Carolina, Chapel Hill, NC, USA

Workshop W-01 • PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
Ballroom BC 9:00 AM - 12:25 PM

Target Audience: This workshop is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). Attendance is mandatory for all scholarship recipients and it is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for fewer than 3 years.

Objectives: At the completion of the session, participants will be able to:
• Describe the current state-of-the-art of selected areas of HIV basic, epidemiologic, and clinical research
• List the leading research themes being presented at CROI 2020
• Navigate CROI 2020, maximize the knowledge gained, and interact with research colleagues
• Clarify their individual research interests in relation to the priorities discussed at the workshop and CROI 2020 overall
Conveners
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, USA
Serena S. Spudich, Yale University, New Haven, CT, USA

1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

ADVANCES IN MOLECULAR VIROLOGY
Wesley I. Sundquist, University of Utah, Salt Lake City, UT, USA

ADVANCES IN HIV IMMUNOLOGY AND VACCINES
Richard A. Koup, National Institutes of Health, Bethesda, MD, USA

ISSUES IN MATERNAL, INFANT, AND CHILD HEALTH
Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK

ADVANCES IN HIV PREVENTION
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

ADVANCES IN HIV CURE
Nicolas Chomont, Université de Montréal, Montreal, Canada

LUNCH AND MARTIN DELANEY PRESENTATION
Ballroom BC 12:25 PM - 1:40 PM

Description: The Martin Delaney Presentation is held annually during the workshops for New Investigators, International Investigators, and Community Educator Scholars in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), new investigators (both international and domestic), and community educators. Attendance is mandatory for all scholarship recipients and is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

Objectives: At the completion of the session, participants will be able to:

- Describe the “dying from, living with, thriving despite” trajectory of the HIV epidemic
- Assess the role of stigma in the lives of people living with HIV over the life course
- Describe the physical and mental challenges associated with living with HIV over the life course and how these challenges impact the management of HIV disease and overall holistic health

Moderator
Jim Pickett, AIDS Foundation of Chicago, Chicago, IL, USA
Panelists
Martha Tholanah
Just Associates, Harare, Zimbabwe
Gabriel Maldonado, MBA
TruEvolution, Los Angeles, CA, USA
Celeste Watkins-Hayes
Northwestern University, Evanston, IL, USA

2  SHIFTING FROM ACUTE TO CHRONIC, AGING, LONGEVITY
AND LIVED EXPERIENCE

Workshop W-02 FRONTERS IN LABORATORY SCIENCE
Room 304-306  2:00 PM - 4:00 PM
Target Audience: This session is directed to students, researchers, and clinicians
who are interested in learning the hot new technologies that are influencing HIV
research or hold a substantial potential for research.
Level of Knowledge: It is assumed that the participants are familiar with the main
technologic and data analysis approaches used in HIV research.
Objectives: After attending this session, learners will be able to:
• Describe new synthetic vaccine design approaches
• Explain replication-competent latent viruses
• Explain how viral integration is defined
• Describe new EpiTOF approaches to probe the epigenome

Conveners
Galit Alter, Ragon Institute of MGH, MIT and Harvard,
Cambridge, MA, USA
Frank Kirchhoff, Ulm University Medical Center,
Ulm, Germany

3  SHAPING VACCINES WITH DNA ORIGAMI
Mark Bathe, Massachusetts Institute of Technology,
Cambridge, MA, USA

4  CONCEPTS IN RESERVOIR MEASUREMENTS
Janet M. Siliciano, The Johns Hopkins University School of
Medicine, Baltimore, MD, USA

5  CHARTING GENOME-WIDE INTEGRATION
Mary F. Kearney, National Cancer Institute, Frederick,
MD, USA

6  SINGLE-CELL EPIGENETICS: COLORING IMMUNE
CELLS WITH A RICH PALETTE OF HISTONE MARKS
Alex J. Kuo, Stanford University, Stanford, CA, USA

Workshop W-03 CLINICAL TRIAL DESIGN AND ANALYSIS
Ballroom A  2:00 PM - 4:00 PM
Target Audience: This session is directed to clinicians and scientists who are
interested in designing or interpreting clinical and epidemiologic studies.
Level of Knowledge: It is assumed that participants are familiar with the
basic design of randomized and observational clinical trials and of basic HIV
epidemiologic studies.
Objectives: At the completion of the session, participants will be able to:
- Identify analytic approaches for treatment interventions
- Describe the rationale and structure of phase IIc trials
- Explain the challenges and approaches of non-inferiority trials
- Describe the rationale for the inclusion of diverse populations in studies

Conveners
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, USA

7  PUTTING ANALYSIS INTO ANALYTICAL TREATMENT INTERRUPTIONS
   Lu (Summer) Zheng, Harvard T. H. Chan School of Public Health, Boston, MA, USA

8  ADVANCING FROM PHASE II TO PHASE III: NAVIGATING THE LAND OF EXPECTATIONS
   Patrick P.J. Phillips, University of California San Francisco, San Francisco, CA, USA

9  NONINFERIORITY COMPLEX
   Jeffrey S. Murray, Food and Drug Administration, Silver Spring, MD, USA

10 INCLUSION OF DIVERSE POPULATIONS IN TRIALS
    Mark Harrington, Treatment Action Group, New York, NY, USA

Workshop W-04 INTERACTIVE CASE-BASED WORKSHOP: WHAT’S EATING YOUR LIVER?
Ballroom BC 2:00 PM - 4:00 PM
Target Audience: This session is directed to clinicians and scientists who are interested in the management of hepatitis C, D, or E virus infections as well as the liver disease associated with HIV infection and treatment.
Level of Knowledge: It is assumed that the participants are familiar with the general principles of hepatitis treatment and the medications used as well as the basics of fatty liver disease.
Objectives: At the completion of the session, participants will be able to:
- Diagnose and manage liver disease in HIV coinfection including NASH, and hepatitis A, C, D, and E virus infections
- Describe strategies in treating patients with advanced stages of liver disease

Conveners
Oluwaseun Falade-Nwulia, The Johns Hopkins University, Baltimore, MD, USA
Nadine Kronfli, McGill University Health Centre, Montreal, Canada

11 WHEN AT THIRD YOU DON’T SUCCEED
    David L. Wyles, Denver Health and Hospital Authority, Denver, CO, USA

12 "A" CASE TO REMEMBER: HEPATITIS A - MANAGING AN OLD VIRUS IN NEW POPULATIONS AT RISK
    Darcy Wooten, University of California San Diego, San Diego, CA, USA
13  HEPATOCELLULAR CARCINOMA
Susanna Naggie, Duke University, Durham, NC, USA

14  NONALCOHOLIC STEATOHEPATITIS
Kathleen E. Corey, Massachusetts General Hospital, Boston, MA, USA

NOTES
OPENING SESSION
Auditorium / Hall C / Auditorium Balcony
5:00 PM - 7:00 PM

Session Hosts

Sharon L. Hillier
University of Pittsburgh, Pittsburgh, PA, USA

Elaine J. Abrams
ICAP at Columbia University, New York, NY, USA

James A. Hoxie
University of Pennsylvania, Philadelphia, PA, USA

BERNARD FIELDS LECTURE
The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

15 THE ANCIENT AND MODERN ORIGINS OF HIV
Michael Emerman, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

N’GALY-MANN LECTURE
The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N’Galy and Jonathan Mann for their crucial, pioneering work in HIV science and care in Africa.

16 TRANSLATING HIV SCIENCE INTO POPULATION IMPACT: A REALITY CHECK FROM THE FRONTLINE
Alex G. Coutinho, Partners in Health, Kigali, Rwanda

PERFORMANCE BY THE BOSTON CHILDREN’S CHORUS
The Boston Children’s Chorus’s (BCC) vibrant, jubilant, and powerful performances showcase the talent and passion of the diverse young people of Boston. In 2013, the BCC was presented with the National Arts and Humanities Youth Program Award by First Lady Michelle Obama.

WELCOME RECEPTION
All registered CROI attendees are invited to the welcome reception immediately following the opening session on Sunday evening. This welcome reception will offer attendees the opportunity to network with colleagues. Light hors d’oeuvres will be served. Each attendee will be given 2 drink tickets with their registration materials to be used for alcoholic or nonalcoholic beverages.
MONDAY MARCH 9, 2019

**Plenary PL-01 MONDAY PLENARY SESSION**
Auditorium / Hall C / Auditorium Balcony  
8:30 AM - 9:30 AM  
(CME)

**Session Hosts**
Nicolas Chomont, Université de Montréal, Montreal, QC, Canada  
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**Oral Sessions**

**17**
**HIV CURE FROM BENCH TO BEDSIDE**
8:30
Sharon R. Lewin, University of Melbourne, Melbourne, VIC, Australia

**18**
**UNIVERSAL TEST AND TREAT (UTT): LESSONS FROM THE PAST AND FOR THE FUTURE**
9:00
Kevin M. De Cock, US CDC Nairobi, Nairobi, Kenya

**Oral Abstract O-01 UNDERSTANDING AND PREVENTING HIV REPLICATION**
Room 312  
10:00 AM - 12:00 PM

**Oral Abstract Moderators**
Gilda Tachedjian, Burnet Institute, Melbourne, Victoria, Australia  
Louis M. Mansky, University of Minnesota, Minneapolis, MN, USA

**19**
**MECHANISMS OF PSGL-1 AND CD43 RESTRICTION OF HIV INFECTION OF CD4 T CELLS**
10:00
Yajing Fu, Yuntao Wu, Sijia He, Abdul A. Waheed, Deemah Dabbagh, Hong Shang, David N Levy, Eric O. Freed

**20**
**STRUCTURAL ANALYSES OF A BOUND ANTI-CD4 ADNECTIN INHIBITOR OF HIV-1**
10:15
David Wensel, Shawn William, David P. Dixon, Paris Ward, Patti McCormick, Nestor Concha, Eugene Stewart, Xuan Hong, Shreya Pal, Charles Maxxucco, Bo Ding, Mark Krystal

**21 LB**
**SERINC3/5 PERTURB HIV MEMBRANE FUSION POST-HEMIFUSION AT FUSION-PORE DILATION STEPS**
10:30
Amanda E. Ward, Volker Kieselling, Judith M. White, Owen Pornillos, Barbie K. Ganser-Pornillos, Lukas K. Tam

**22**
**CRISPR-INDUCED MUTAGENESIS POINTS TOWARD A ROLE OF TRN-SR2 IN HIV NUCLEAR IMPORT**
10:45
Frauke Christ, Julie Janssens, Flore De Wit, Jolien Blokken, Youlia Lampi, Irena Zurnic, Rik Gijsbers, Zeger Debyser

**23**
**NUCLEAR UNCOATING OF HIV-1 OCCURS NEAR SITES OF INTEGRATION**
11:00
Ryan C. Burdick, Chenglei Li, Mohamed Husen Munshi, Jonathan Rawson, Kunio Nagashima, Wei-Shau Hu, Vinay K. Pathak

**24 LB**
**RECONSTITUTION OF HIV-1 CAPSID-DEPENDENT REPLICATION AND INTEGRATION IN VITRO**
11:15
Devin E. Christensen, Barbie K. Ganser-Pornillos, Owen Pornillos, Wesley I. Sundquist
25  STRUCTURAL BASIS OF SECOND-GENERATION HIV INTEGRASE INHIBITOR ACTION AND VIRUS ESCAPE
Nicola Cook, Wen Li, Dénes Berta, Magd Badaoui, Allison Ballandras-Colas, Andrea Nans, Abhay Kotecha, Edina Rosta, Alan N. Engelman, Peter Cherepanov

26  THE CHROMATIN LANDSCAPE AT THE HIV-1 INTEGRATION SITE DETERMINES VIRAL EXPRESSION
Gerlinde Vansant, Julie Janssens, Heng-Chang Chen, Eduard Zorita, Frauke Christ, Guillaume Filion, Zeger Debyser

Oral Abstract O-02 NOVEL ASSESSMENTS OF CENTRAL NERVOUS SYSTEM PATHOGENESIS
Room 304-306  10:00 AM - 12:00 PM

Oral Abstract Moderators
Jaime H. Vera Rojas, Brighton and Sussex Medical School, Brighton, United Kingdom
Sara Gianella, University of California San Diego, La Jolla, CA, USA

27  SINGLE-CELL GENOMIC ANALYSIS OF BLOOD AND CSF T CELLS IN HIV+ AND HIV− ADULTS
Shelli Farhadian, Ofir Lindenbaum, Jun Zhao, Rolando Garcia-Milian, Jennifer Chiarella, Michelle Chintanaphol, Rachela Calvi, Yuval Kluger, Serena S. Spudich

28  GREATER BURDEN OF INTRACRANIAL ARTERIAL-WALL ENHANCEMENT IN PERSONS LIVING WITH HIV
Felicia C. Chow, Andrew Callen, Victor Arechiga, David Saloner, Jared Narvid, Priscilla Hsue

29  PET IMAGING OF SYNAPTIC DENSITY IN HIV: PRELIMINARY FINDINGS FROM A PILOT STUDY
Julian Weiss, Rachela Calvi, Mika Naganawa, Takuya Toyonaga, Shelli Farhadian, Michelle Chintanaphol, Jennifer Chiarella, Ming-Qiang Zheng, Jim Ropchan, Yiyou Huang, Richard Carson, Serena S. Spudich

30  HIV-INFECTED MACROPHAGES EVADE NK CELL-MEDIATED KILLING WHILE DRIVING INFLAMMATION
Kiera L. Clayton, Heather Stuart, Geetha H. Mylvaganam, Alonso Villasmil Ocando, Marcela Maus, Bruce D. Walker

31  HIV DNA DETECTED IN IMMUNE CELL SUBSETS IN CSF DURING ART
Shelli Farhadian, Joshua C. Cyktor, Asma Naqvi, Michael J. Corley, Jennifer Chiarella, Rachela Calvi, Michelle Chintanaphol, Geoffrey Lyon, Diane Trotta, John W. Mellors, Serena S. Spudich

32  EFFECTS OF HIV AND AGING ON RESTING-STATE NETWORKS
Patrick Luckett, Anupama Melam, Sarah A. Cooley, Joshua Shimony, Beau Ances

33  MYELIN CONTENT IS ELEVATED IN VIROLOGICALLY UNSUPPRESSED PEOPLE LIVING WITH HIV
Dimitre Tomov, Sarah A. Cooley, Casey Bowen, Jeremy Strain, Beau Ances
Oral Abstract 0-03 THERAPEUTIC INTERVENTIONS FOR HIV TREATMENT AND ERADICATION

Auditorium • 10:00 AM - 12:00 PM

Oral Abstract Moderators

María J. Buzón, Vall d’Hebrón Research Institute, Barcelona
Aadia Rana, University of Alabama, Birmingham, AL, USA

34 CABOTEGRAVIR + RILPİVİRİNE EVERY 2 MONTHS IS NONINFERIOR TO MONTHLY: ATLAS-2M STUDY

10:00
Edgar T. Overton, Gary J. Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García-Deltoro, Paul D. Benn, Yuanyuan Wang, Krishan J. Hudson, David A. Margolis, Kimberly Smith, Peter E. Williams, William Spreen

35 PROSPECTIVE ENHANCED MONITORING OF DOLUTEGRAVIR-BASED FIRST LINE IN MALAWI

10:15
Elvis Temfack, Andreas Jahn, Thokozani Kalua, Joseph Bittilinyu-Bangoh, Rose Nyirenda, Anne-Geneviève Marcelin, Vincent Calvez, Diane Descamps, Gilles Peytavin, Sarala Nicholas, David Maman, Sofie Spiers, Elisabeth Poulet, Elisabeth Szumilin, Birgitt Schramm

36 RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV

10:30
Debbie P. Hagins, Princy N. Kumar, Michael Saag, Anson K. Wurapa, Indira Brar, Daniel S. Berger, Olayemi Osinyemi, Corinny L. Hileman, Moti Ramgopal, Cheryl McDonald, Christiana Blair, Kristen Andreatta, Sean E. Collins, Diana Brainard, Hal Martin

37 IMPACT OF ANTI-PD-1 AND ANTI-CTLA-4 ON THE HIV RESERVOIR IN VIVO: THE AMC-095 STUDY

10:45

38 A RANDOMIZED TRIAL OF THE IMPACT OF 3BNC117 AND ROMIDEPSIN ON THE HIV-1 RESERVOIR

11:00
Henning Gruell, Yehuda Z. Cohen, Jesper D. Gunst, Marie H. Pahus, Clara Lehmann, Katrina Millard, Martin Tolstrup, Julie C. Lorenzi, Michel Nussenzweig, Gerd Fätkenheuer, Florian Klein, Marina Caskey, Ole S. Søgaard

39 SAFETY & PHARMACOKINETICS OF GS-9722 IN HIV-NEGATIVE PARTICIPANTS AND PEOPLE WITH HIV

11:15
Peter Ruane, Eric Daar, Kimberly Workowski, Rebecca Begley, Rita Humeniuk, Tariro Makadzange, Steve K. West, Hui Liu, Yizhao Li, John Ling, Luisa M. Stamm, Polina German, Joseph J. Erden, Princy N. Kumar, Edwin DeJesus

40 SAFETY AND ANALYTIC TREATMENT INTERRUPTION OUTCOMES OF VESATOLIMOD IN HIV CONTROLLERS

11:30
Devi Sengupta, Moti Ramgopal, Cynthia Brinson, Edwin DeJesus, Anthony Mills, Peter Shalit, Scott McAllister, Hiba Graham, Heena Patel, Lijie Zhong, Joseph Hesselgesser, Brian Doehle, Susan Guo, Diana Brainard, Steven G. Deeks
Oral Sessions

Oral Abstract 0-04 COMMUNITY-AND CLINIC-BASED HIV TREATMENT, PREVENTION INTERVENTIONS, AND INSIGHTS

Ballroom B 10:00 AM - 12:00 PM

Oral Abstract Moderators
LaRon E. Nelson, Yale, New Haven, CT, USA
Wame Jallow, International Treatment Preparedness Coalition, Gaborone, Botswana

42 INDEX FACTORS INCREASE PARTNER NOTIFICATION YIELD FOR KENYAN PEOPLE WHO INJECT DRUGS

43 COMMUNITY-BASED MULTIMONTH DISPENSING OF ART: A CLUSTER RANDOMISED TRIAL IN LESOTHO
Betty B. Tukei, Geoffrey Fatti, Appolinaire Tiam, Vincent Tukei, Thapelo Maotoe, Ian Sanne, Thembilele Xulu, Nicky Mabhena, Francis Akpan, Ian Membe, Iyiola Faturiyele, Justine Mirembe, Kgotsotse Maile, Makatleho Sejana, Charles Chasela

44 AN MHEALTH CHW INTERVENTION TRIAL IN AN HIV HYPERENDEMIC COMMUNITY IN RAKAI, UGANDA
Larry W. Chang, Ismail Mbabali, Xiangrong Kong, K. Rivet Amico, Caitlin E. Kennedy, Fred Nalugoda, Aggrey Anok, David Serwadda, Joseph Seakasanvu, Thomas C. Quinn, Steven J. Reynolds, Ronald H. Gray, Maria Wawer, Heidi Hutton, Gertrude Nakigozi

45 IMPROVED TIME IN CARE AND VIRAL SUPPRESSION WITH STREAMLINED CARE IN THE SEARCH STUDY

46 COLLABORATIVE DATA-TO-CARE MODEL IMPROVES HIV CARE OUTCOMES IN PLWH IN PHILADELPHIA
Sindhu Shamasunder, Crystal Lucas, Shedane Shaw, Briana Gibson, Olivia Kirby, Melissa Miller, Kathleen A. Brady

47 POPULATION-LEVEL VIREMIA PREDICTS HIV INCIDENCE ACROSS UNIVERSAL TEST & TREAT STUDIES
Maya L. Petersen, Joseph Larmarange, Kathleen Wirth, Timothy Skalland, Helen Ayles, Moses R. Kamya, Shahin Lockman, Collins C. Iwuji, François Dabis, Joseph Makhema, Diane V. Havlir, Sian Floyd, Richard J. Hayes, for the UT3C

48 DECREASING COMMUNITY VIREMIA IS ASSOCIATED WITH DECREASING HIV INCIDENCE IN AUSTRALIA
Denton J. Callander, Mark Stoové, Hamish McManus, Andrew Carr, Richard Gray, Jennifer Hoy, Basil Donovan, Margaret Hellard, Andrew E. Grulich, Christopher K. Fairley, Martin Holt, David J. Templeton, Teng Liaw, James McMahon, Rebecca J. Guy, for the TAIPAN Advisory Group
**Oral Sessions**

**CROI 2020**

**Oral Sessions • Monday**

---

**49 LB COMMUNITY ART INCREASES VIRAL SUPPRESSION AND ELIMINATES DISPARITIES FOR AFRICAN MEN**

Ruanne V. Barnabas, Heidi van Rooyen, Stephen Asiimwe, Alastair van Heerden, Deenan Pillay, Adam Szpiro, Torin Schaafsma, Meighan Krows, Kombi Sausi, Nsika Sithole, Bosco Turyamureeba, Peter Ehrenkranz, Jared Baeten, Connie L. Celum, for The DO ART Study Team

**Themed Discussion TD-01 SHARPENING THE CUTTING EDGE: ADDITIONS TO THE MOLECULAR VIROLOGY TOOLKIT**

**Ballroom A** 1:30 PM - 2:30 PM

**Themed Discussion Leader**

Alan N. Engelman, Dana-Farber Cancer Institute, Boston, MA, USA

---

165 HIV-1 CAPSID-NUCLEAR ENVELOPE INTERACTIONS THAT FACILITATE NUCLEAR IMPORT

Mohamed Husen Munshi, Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak

166 REPORTER VIRUSES WITH PROTEIN BARCODES TO ANALYZE HIV LATENCY ESTABLISHMENT

Eun Hye G. Kim, Maria C. Bermúdez-González, Michael Schotsaert, Ana Fernández-Sesma, Lubbertus C. Mulder, Lara Manganaro, Viviana A. Simon

167 GAG DETERMINANTS OF SPECIFIC GENOME PACKAGING IN HIV-1 AND HIV-2

Jonathan Rawson, Olga A. Nikolaitchik, Xayathed Somoulay, Jennifer A. Yoo, Vinay K. Pathak, Wei-Shau Hu

168 EXPLORING THE REQUIREMENTS FOR HIV-1 GENOME PACKAGING THROUGH A NONVIRAL RNA BINDING

Alice Duchon, Steven Santos, Jianbo Chen, Vinay K. Pathak, Wei-Shau Hu

---

**Themed Discussion TD-02 HEARTS AND HORMONES**

**Ballroom C** 1:30 PM - 2:30 PM

**Themed Discussion Leader**

Markella V. Zanni, Massachusetts General Hospital, Boston, MA, USA

---

642 TESTOSTERONE THERAPY AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION AMONG MEN WITH HIV

Sabina A. Haberlen, Wendy Post, Matthew Budoff, Jordan E. Lake, Adrian Dobs, Frank J. Palella, Michael Plankey, Anne K. Monroe, Lawrence Kingsley, Todd T. Brown

643 POSTDISCHARGE OUTCOMES FOLLOWING ACUTE CORONARY SYNDROME IN HIV

Monica Parks, Eric A. Secemsky, Chanyu Shen, Robert W. Yeh, Eunhee Choi, Dhruv Kazi, Priscilla Hsue

644 INSOMNIA AND RISK OF INCIDENT MYOCARDIAL INFARCTION AMONG PEOPLE LIVING WITH HIV


---

**38 CROI 2020**
645  **HORMONE USE AND HIV ALTER CARDIOVASCULAR BIOMARKER PROFILES IN TRANSGENDER WOMEN**

   Jordan E. Lake, Ruibin Wang, Benjamin Barrett, Nicholas Funderburg, Emily Bowman, Paula Debroy, Jury Candelario, Linda Teplin, Jessica McGuinness, Robert Bolan, Heather McKay, Michael Plankey, Todd T. Brown, Judith S. Currier

646  **HIV SEVERITY AND INCIDENT HEART FAILURE AMONG PATIENTS IN A LARGE HEALTH CARE SYSTEM**


---

**Themed Discussion TD-03 CHRONIC DISEASES IN MATERNAL HEALTH: PERSISTENT PROBLEMS FOR PREGNANT OR POSTPARTUM WOMEN**

**Room 312 1:30 PM - 2:30 PM**

**Themed Discussion Leader**

**Risa M. Hoffman**, University of California Los Angeles, Los Angeles, CA, USA

768  **CHANGES IN BONE MINERAL DURING AND AFTER LACTATION IN UGANDAN WOMEN ON OPTION B+ ART**

   Florence Nabwire, Ann Prentice, Matthew M. Hamill, Mary Glenn Fowler, Josaphat Byamugisha, Adeodata Kekitiinwa, Gail R. Goldberg

771  **POSTPARTUM WEIGHT CHANGES IN WOMEN INITIATING DTG VS EFV IN PREGNANCY: DOLPHIN-2**

   Thokozile R. Malaba, Tao Chen, Kenneth Kintu, Christiana Papamichael, Helen Reynolds, jesca Nakibuka, Catriona Waitt, Eva Maria Hodel, Angela Colbers, Catherine Orrell, Duolao Wang, Mohammed Lamorde, Saye Khoo, Landon Myer, for the DolPHIN-2 Trial Team

772  **DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ**


774  **FACTORS ASSOCIATED WITH GESTATIONAL DIABETES IN HIV+ AND HIV− WOMEN IN PUNE, INDIA**

   Puja Chebrolu, Mallika Alexander, Ramesh Bhosale, Shilpa Naik, Nikhil Patil, Amita Gupta, Jyoti S. Mathad

769  **HIGH BLOOD PRESSURE AND ADVERSE BIRTH OUTCOMES IN HIV+ AND HIV− SOUTH AFRICAN WOMEN**

**Themed Discussion TD-04 RAPID ART START: WHERE ARE THE GAPS?**
**Ballroom B**
1:30 PM - 2:30 PM

**Themed Discussion Leader**
*Izukanji Sikazwe, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia*

**MINI LECTURE: STATE OF THE RAPID ART START**

**1071** ASSOCIATION BETWEEN TIME TO ART AND LOSS TO CARE AMONG NEWLY DIAGNOSED PLWH IN RWANDA
*Jonathan Ross, Gad Murenzi, Donald R. Hoover, Qiuhu Shi, Hae-Young Kim, Benjamin Muhoza, Athanase Munyanzeza, Remera Eric, Sabin Nsanzimana, Marcel Yotebieng, Denis Nash, Kathryn Anastos*

**1072** SAME-DAY ART IN THAILAND: THE IMPACT OF ART INITIATION PERIODS ON TREATMENT OUTCOMES

**1073** RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH
*Lorna Seybolt, Katherine Conner, Isolde Butler, Nicholas Van Sickels, Jason Halperin*

**Themed Discussion TD-05 PARTNER NOTIFICATION FOR DETECTING HIV INFECTIONS**
**Room 304-306**
1:30 PM - 2:30 PM

**Themed Discussion Leader**
*Rachel Baggaley, World Health Organization, Geneva, Switzerland*

**937** ASSISTED PARTNER NOTIFICATION SERVICES IN KAMPALA, UGANDA
*Florence Namimbi, Faridah Akuju, Martin Ssuuna, Esther Nasuuna, Rhoda Mwondha, Stella Alamo, Madina Apolot, Nelson Kalema, Alice Namale, Joanita Kigozi*

**938** TARGETED PEER MOBILISATION AND ASSISTED PARTNER NOTIFICATION SERVICES IN KENYA
*Maartje Dijkstra, Khamisi Mohamed, Alex Kigoro, Mahmoud Shally, Abdalla Wesonga, Teresia Mumba, Nana Mukuria, Margaret Juma, Evans Gichuru, Shaun Palmer, Susan M. Graham, Elisabeth M. van der Elst, Eduard Sanders*

**939** SCALE-UP OF ASSISTED PARTNER SERVICES (APS) IN BOTSWANA
*Matthew R. Golden, Matias Grande, Shreshth Mawandia, Odirile Bakae, Lenna Tau, Goabaone Mogomotsi, Esther Mmatli, Modise Ngombo, Jenny Ledikwe*

**940** OPTIMIZING TESTING INCREASES YIELD IN HIV CASE FINDING IN 24 COUNTRIES, 2018–2019
*Shahul Hameed Ebrahim, Arielle Lasry, Randy Yee, Wayne A Duffus, John Abellera, Shane T Diekman, Jacqueline Rurangirwa, Bakary Drammeh, Tiffany Ahoulou, Michael Grillo, Vincent Wong, Stephanie Behel*
942 COMPARISON OF INDEX TESTING APPROACHES TO IMPROVE HIV-TESTING EFFICIENCY IN RWANDA
Eric Remera, Elyse Tuyishime, Suthar Amithab, Mugwaneza Placidie

Symposium S-01 NOVEL CURE INTERVENTIONS
Ballroom B 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding strategies for the cure of HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with stages of the viral life cycle and have a basic understanding of molecular biology.

Objectives: At the completion of the session, participants will be able to:
• Explain novel cure interventions in terms of basic mechanisms
• Describe results from pre-clinical animal model studies on HIV cure

Conveners
Michaela Müller-Trutwin, Institut Pasteur, Paris, France
Katherine Bar, University of Pennsylvania, Philadelphia, PA, USA

50 IN VIVO MODELS FOR THE EVALUATION OF NOVEL HIV CURE INTERVENTIONS
J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

51 LRA 2.0: IMMUNE-BASED LATENCY REVERSAL
Ann Chahroudi, Emory University, Atlanta, GA, USA

52 T-CELL AND HEMATOPOIETIC STEM CELL GENE THERAPIES FOR HIV CURE
Christopher Peterson, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

53 TOWARD DURABLE CONTROL OF HIV-1 WITH eCD4-Ig
Michael Farzan, The Scripps Research Institute, La Jolla, CA, USA

Symposium S-02 HISTORY REPEATING ITSELF: SEXUALLY TRANSMITTED INFECTIONS IN WOMEN AND INFANTS
Ballroom A 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the interactions between HIV infection and sexually transmitted infections (STIs) in pregnant women and children.

Level of Knowledge: It is assumed that the participants are familiar with basic issues of the treatment and prevention of HIV and STIs as well as mother-to-child transmission.

Objectives: At the completion of the session, participants will be able to:
• Describe the global epidemiology of STIs that put the fetus at risk
• Compare screening in low- and high-income settings and links to HIV infection
• Identify treatment dilemmas in women with STIs, including drug resistance
• Identify the interactions between HIV and STIs in pregnancy and in infants
• Assess the prevention of STIs during pregnancy and breastfeeding
• Describe vaccine programs and link to HIV elimination

CME
Conveners

Karin Nielsen-Saines, University of California Los Angeles, Los Angeles, CA, USA
Victor Musiime, Makerere University, Kampala, Uganda

54  SYPHILIS CAUSES STILLBIRTH: PENICILLIN IS PREVENTION
4:00
Melanie Taylor, World Health Organization, Geneva, Switzerland

55  CHLAMYDIA AND GONORRHOEA IN PREGNANCY: SILENCE OF THE GERMS
4:30
Nicola Low, University of Bern, Bern, Switzerland

56  MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B: CAN IT BE ELIMINATED?
5:00
Yusuke Shimakawa, Institut Pasteur, Paris, France

57  BEYOND THE STIGMA: A SORELY NEEDED PERSPECTIVE ON HSV
5:30
Anna Wald, University of Washington, Seattle, WA, USA

Symposium S-03 WHAT MAKES EPIDEMICS RECEDE
Ballroom C 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the current status, challenges, and successes in HIV epidemic control in different global settings.

Level of Knowledge: It is assumed that the participants are familiar with basic epidemiological terms and HIV epidemiology.

Objectives: At the completion of the session, participants will be able to:
- Describe the geographic settings where the implementation of public health strategies have decreased HIV incidence
- Describe the strategies that must be implemented to achieve the goals for decreasing HIV incidence

Conveners

Victoria L. Mobley, North Carolina Department of Health and Human Services, Raleigh, NC, USA
Maria Prins, Public Health Service of Amsterdam, Amsterdam, Netherlands

58  REFLECTIONS ON THE UK EPIDEMIC
4:00
Valerie Delpech, Public Health England, London, UK

59  30-PLUS YEARS OF HIV IN RAKAI: THE EPIDEMIC RECEDES
4:30
Joseph Kagaayi, Rakai Health Sciences Program, Kalisizo, Uganda

60  BATTLING HIV IN THE US RURAL SOUTH
5:00
Leandro A. Mena, University of Mississippi Medical Center, Jackson, MS, USA

42 CROI 2020
NOTES
TUESDAY MARCH 10, 2020

**CME**

**Plenary PL-02 TUESDAY PLENARY SESSION**
Auditorium / Hall C / Auditorium Balcony
8:30 AM - 9:30 AM

**Session Hosts**
Jonathan Mermin, Centers for Disease Control and Prevention, Atlanta, GA, USA
Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA

**Oral Sessions**

62 8:30  PREVENTING HIV AMONG PEOPLE WHO INJECT DRUGS: PLUS ÇA CHANGE, PLUS ÇA MÊME CHOSE
Steffanie A. Strathdee, University of California San Diego, San Diego, CA, USA

63 9:00  SEX DIFFERENCES IN HIV
Eileen P. Scully, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Oral Abstract O-05 HIV-ASSOCIATED MALIGNANCIES AND TUMOR VIRUSES: AN EXPANDING LANDSCAPE**
Room 304-306 10:00 AM - 12:00 PM

**Oral Abstract Moderators**
Elizabeth A. Stier, Boston University, Boston, MA, USA
Ronald T. Mitsuyasu, University of California Los Angeles, Los Angeles, CA, USA

64 10:00  TARGETING THE KSHV TYROSINE KINASE AND VIRAL LYTIC REACTIVATION WITH INHIBITORS
Guillaume Beauclair, Eleonora Naimo, Tatyana Dubich, Dagmar Wirth, Thomas F. Schulz

65 LB 10:15  A ROLE FOR IRON METABOLISM AND FERROPTOSIS IN KAPOSI SARCOMA HERPESVIRUS PATHOGENESIS
Ashlee V. Moses, Jean Gustin

66 10:30  GENE EXPRESSION PATTERNS IN SKIN VS GASTROINTESTINAL KAPOSI SARCOMA LESIONS
Ramya Ramaswami, Takanobu Tagawa, Vishal Kopperde, Kathrynn Lurain, Anna Serquina, Annaida Widell, Irene Ekwede, Robert Yarchoan, Joseph Ziegelbauer

67 LB 10:45  IMPACT OF VALGANCICLOVIR THERAPY ON SEVERE IRIS–KAPOSI SARCOMA–ATTRIBUTABLE MORTALITY
Patricia Volkow, Beda Daniela Islas Muñoz, Leslie Chávez-Galán, Lucero Ramón-Lueng, Dora Patricia Conrofe Juárez, Judith Cruz-Velázquez, for the Kaposi Sarcoma

68 11:00  SURVEILLANCE OF Rhesus MACAQUE TISSUES IDENTIFYING GAMMAHERPESVIRUS INFECTION SITES
Vickie Marshall, Catherine Brands, Nazzarena Labo, Vicky Coalter, Jeffrey D. Lifson, Denise Whitby, Claire Deleage, Gregory Q. Del Prete

69 11:15  CONJUNCTIVAL CANCER IN PEOPLE LIVING WITH HIV: THE SAM STUDY
Tafadzwa G. Dhokotera, Mazvita Sengayi, Lina Bartels, Frédérique Chammartin, Serra L. Asangbeh, Victor Ólago, Elvira Singh, Matthias Egger, Julia Bohlius
**70** **CLEARANCE OF HPV ANAL HIGH-GRADE INTRAEPITHELIAL LESIONS WITH LOW-DOSE POMALIDOMIDE**

Mark Polizzotto, David Van Bockel, Carmella Law, Jennifer Roberts, Susanne Just, Griselda Buckland, Simon Comben, Mary Poynten, Richard Hillman, Richard Gilson, Sarah Pett, Anthony Kelleher, Sean Emery, for the SPACE Study Group

**71** **INCREASED CANCER RISK WITH LOWER CD4/CD8 RATIO AMONG ADULTS WITH HIV IN NA-ACCORD**

Jessica L. Castilho, Aihua Bian, Cathy Jenkins, Chad J. Achenbach, W. C. Mathews, Greer Burkholder, M. J. Gill, Janet Tate, Angel M. Mayor, Mari M. Kitahata, Michael J. Silverberg, Richard D. Moore, Keith M. Sigel, Staci Sudenga, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

**Oral Abstract 0-06 TARGETING THE PERSISTENT HIV RESERVOIR**

**Oral Abstract Moderators**

Guinevere Q. Lee, Weill Cornell Medicine, New York, NY USA,
Afram Okoye, Oregon Health and Science University, Beaverton, OR, USA

**72** **WHOLE-BODY PET IMAGING OF THE HIV RESERVOIR USING RADIOLabeled VRC01**

Timothy J. Henrich, Denis Beckford-Vera, Enrique Martinez-Ortiz, Maya Aslam, Cassandra Thanh, Shreya Kumar, I-Wei Katherine Wu, Rebecca Hoh, Robert Flavell, Youngho Seo, Marion Pardons, Nicolas Chomont, John R. Mascola, Steven G. Deeks, Henry VanBrocklin

**73** **ANTIGEN-DRIVEN CLONAL SELECTION SHAPES THE FATE OF HIV-INFECTED CD4+ T CELLS IN VIVO**

Francesco R. Simonetti, Hao Zhang, Garshasb Soroosh, Subul A. Beg, Jiayi Duan, Kyle Rhodehouse, Christopher L. Nobles, Jun Lai, Rebecca Hoh, Steven G. Deeks, Frederic Bushman, Janet Siliciano, Robert Siliciano

**74** **DISTINCT CHROMOSOMAL INTEGRATION SITE CONFIGURATION IN HIV-1 ELITE CONTROLLERS**

Chenyang Jiang, Ce Gao, Xiaoming Sun, Xiaodong Lian, Stephane Hua, Joshua Chevalier, Kevin Einkauf, Eric Serrao, Alan N. Engelman, Mary Carrington, Bruce D. Walker, Mathias Lichterfeld, Xu G. Yu

**75** **INTACT PROVIRAL DNA LEVELS DECLINE IN PEOPLE WITH HIV ON ANTIRETROVIRAL THERAPY**


**76** **CHIMERIC ANTIGEN RECEPTOR T CELLS CONTROL SHIV REPLICATION IN POST-ATI MACAQUES**

Blake Rust, Lucrezia Colonna, Katherine Brandenstein, Nikhita H. Poole, Willi Obenza, Colby Maldini, Gavin Ellis, Leslie Kean, James L. Riley, Hans-Peter Kiem, Christopher Peterson

**77** **DELAY IN VIRAL REBOUND WITH TLR7 AGONIST, N6-LS, AND PGT121 IN SHIV-INFECTED MACAQUES**

78 LB  
**COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV-INFECTED Rhesus Monkeys**

Dan Barouch, Noe Mercado, Abishek Chandrashekar, Erica Borducchi, Joseph Nikolola, Maria Pau, Hanneke Schuitemaker, Merlin L. Robb, Nelson L. Michael, Romas Geleziunas

79 LB  
**COMBINATION IL-15 THERAPY IN A SHIV NHP MODEL**

So-Yon Lim, Christa E. Osuna, Jina Lee, Daniela Silva-Ayala, Pratik Vikhe, Elsa Chen, Stephanie Lundgren, Margaret Eliot, Dan Schalk, Nancy Schultz-Darken, Michael S. Seaman, Jeffrey T. Saffitt, R. Brad Jones, Douglas Nixon, James Whitney

---

**Oral Abstract 0-07 CARDIOMETABOLIC AND PULMONARY COMPLICATIONS**

Balloon C  
10:00 AM - 12:00 PM

**Oral Abstract Moderators**

Matthew J. Feinstein, Northwestern University, Chicago, IL, USA

Susanne Dam Nielsen, University of Copenhagen Rigshospitalet, Copenhagen, Denmark

80  
**A MENDELIAN RANDOMIZATION ANALYSIS OF PROTEIN BIOMARKERS AND CVD IN PERSONS WITH HIV**

Cavan Reilly, James Pankow, Jason V. Baker, Álvaro H. Borges, Mark Polizzotto, Shweta Sharma, Sandra Safo, for the INSIGHT Study Group

81  
**RISKS OF METABOLIC SYNDROME, DIABETES, AND CARDIOVASCULAR DISEASE IN ADVANCE TRIAL**

Andrew Hill, Kaitlyn M. McCann, Victoria Pilkington, Michelle A. Moorhouse, Simiso Sokhela, Celicia M. Serenata, Alinda Vos, Willem D. Venter

82  
**CYP2B6 GENOTYPE AND WEIGHT-GAIN DIFFERENCES BETWEEN Dolutegravir and Efavirenz**

Rulan Griesel, Gary Maartens, Simiso Sokhela, Godspower Akpomiemie, Willem D. Venter, Michelle A. Moorhouse, Phumla Sinxadi

83  
**CHANGES IN BODY MASS INDEX AND THE RISK OF CARDIOVASCULAR DISEASE: THE D:A:D STUDY**


84  
**LOSARTAN TO REDUCE INFLAMMATION AND FIBROSIS ENDPOINTS IN HIV DISEASE (LIFE-HIV)**

Jason V. Baker, Julian Wolfson, Gary Collins, Caryn G. Morse, Frank S. Rham, Andelike Liappis, Stacey Rizza, Zelalem Temesgen, Charalampos Mystakelis, Steven G. Deeks, James Neaton, Timothy Schacker, Irini Sereti, Russell Tracy

85  
**EFFECTS OF HIV INFECTION AND IMMUNE REGULATION ON LONGITUDINAL LUNG FUNCTION DECLINE**

Jing Sun, Jacqui Astemborski, Sarath Raju, M. Brad Drummond, Robert H. Brown, Shruti H. Mehta, Richard D. Moore, Meredith C. McCormack, Gregory D. Kirk, for the Study of HIV Infection in the Etiology of Lung Disease (SHIELD) cohort

---

(continued on next page)
86  AZITHROMYCIN FOR TREATMENT OF HIV-RELATED CHRONIC LUNG DISEASE IN AFRICAN CHILDREN

Rashida A. Ferrand, Grace McHugh, Andrea M. Rehman, Hilda Mujuru, Mark Nicol, Sarah Rowland-Jones, Trond Faellegstad, Tore Gurtteberg, Victoria Simms, Elizabeth L. Corbett, Helen A. Weiss, Edith D. Majonga, Katharina Kranzer, Jon O. Odland, for the BREATHE Trial Group

87  BIC/TFC/TAF POSTEXPOSURE PROPHYLAXIS PROTECTS MACAQUES AGAINST RECTAL SHIV INFECTION

Elena Bekerman, Stephanie W. Cox, Scott McCallister, Tomas Cihlar, Christian Callebaut

88  ON-DEMAND HIV POSTEXPOSURE PROPHYLAXIS BY TAF/EVG VAGINAL INSERTS IN MACAQUES

Charles Dobard, M. Melissa Peet, Kenji Nishiura, Angela Holder, Onkar N. Singh, Timothy J. McCormick, James Mitchell, George Khalil, Gerardo Garcia-Lerma, Vivek Agrahari, Pardeep Gupta, Sriramakamal Jonnalagadda, Walid Heneine, Gustavo Doncel, Meredith Clark

89 LB  WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251

Martin Markowitz, Agegnehu Gte, Leslie St. Bernard, James Blanchard, Brooke Grasperge, Kerry Fillgrove, Lingling Xue, Neol Dube, Daria Hazuda, Jonny Gladstone

90  PHASE I PLACEBO-CONTROLLED SAFETY, PK, AND PD STUDY OF MB66 ANTI-HIV AND ANTI-HSV FILM


91  NEAR-PERFECT ACCURACY OF A REAL-TIME URINE TENOFOVIR TEST COMPARED TO LAB-BASED ELISA

Matthew A. Spinelli, Warren Rodrigues, Guohong Wang, Michael Vincent, David Glidden, Randy Stalter, Patricia A. Defechereux, Madeline Deutsch, Robert M. Grant, Kenneth Ngure, Nelly R. Mugo, Jared Baeten, Monica Gandhi, for the Partners PrEP and iBREATHE

92  LONGER-TERM SAFETY OF F/TAF AND F/TDF FOR HIV PEP: DISCOVER TRIAL WEEK-96 RESULTS

Onyema Ogbugu, Daniel Podzamczer, Laura C. Salazar, Keith Henry, David M. Asmuth, David Wohl, Richard Gilson, Yongwu Shao, Ramin Ebrahimi, Christoph Carter, Moupoli Dass, Scott McCallister, Jason M. Brunetta, Gitte Kronborg, Christoph D. Spinner

93  INITIATING PEP DURING ACUTE HIV INFECTION: WHAT IS THE RISK FOR ARV DRUG RESISTANCE?

Donn J. Colby, Chanjiraporn Pondet, Tippawan Pankam, Prapaipan Plodkratok, Rapee Trichaviroj, Carlo Sacaldan, Eugene Kroon, Srinuw Akapirat, Jintanat Ananworanich, Mark De Souza, Praphan Phanuphak, Sandhya Vasan, Nittaya Phanuphak, for the RV254/SEARCH010 Research Group
94  11:45  PEPFAR DREAMS INTERVENTION AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN RAKAI, UGANDA

Hadijja Nakawooya, Victor Ssempijja, Doreen Nabakulu, Anthony Ndyanabo, Tom Lutalo, Fred Nalugoda, Ronald H. Gray, Maria Wawer, Steven J. Reynolds, Joseph Kagaayi, Gertrude Nakigozi, Godfrey Kigozi

SPECIAL LUNCH-TIME SESSION ON COVID-19
Auditorium / Hall C / Auditorium Balcony  12:10 PM - 1:20 PM (Approximate)

OUTBREAK OF COVID-19 IN CHINA AND THE COUNTRY’S RESPONSES
Zunyou Wu, Centers for Disease Control and Prevention, Atlanta, GA, USA

GLOBAL EPIDEMIOLOGY AND PREVENTION OF COVID-19
John T. Brooks, Centers for Disease Control and Prevention

 VIROLOGY OF CORONAVIRUSES
Ralph S. Baric, University of North Carolina

THE RESEARCH RESPONSE TO COVID-19: A VIEW FROM NIAID
Anthony S. Fauci, National Institutes of Health

333  1:30 PM - 2:30 PM
Themed Discussion Leader
Pablo Tebas, University of Pennsylvania, Philadelphia, PA, USA

EFFECT OF TAMOXIFEN ON VORINOSTAT-INDUCED HIV RNA EXPRESSION IN WOMEN ON ART (A5366)
Eileen P. Scully, Athe Tsibris, Evgenia Aga, Qing Ma, Kate Starr, Kathleen E. Squires, Steven G. Deeks, Elizabeth Connick, Monica Gandhi, Ronald Bosch, Nancie Archin, Jonathan Kern, Daniel R. Kuritzkes, Rajesh T. Gandhi, for the ACTG A5366 Study team

EFFECTS OF IMMUNE CHECKPOINT THERAPY ON LATENT HIV IN PEOPLE WITH HIV AND MALIGNANCY

ABX464 DECREASES THE TOTAL HIV RESERVOIR AND HIV TRANSCRIPTION INITIATION IN VIVO
Sara Moron-Lopez, Silvia Bernal, Jean-Marc Steens, Joseph K. Wong, Javier Martinez-Picado, Steven A. Yuki

ATTACKING LATENT HIV WITH CONVERTIBLE CAR-T CELLS, A MODULAR KILLING PLATFORM
Eytan Herzig, Kaman Chan Kim, Thomas A. Packard, Noam Vard, Roland Schwarzer, Andrea Gramatica, Steven G. Deeks, Steven R. Williams, Kyle Landgraf, Nigel Killeen, David W. Martin, Leor Weinberger, Warner C. Greene

CAR-T CELLS AT 15 YEARS: PERSISTENCE OF CD4-ZETA TRANSGENE AND EFFECT ON RESERVOIR
Themed Discussion TD-07 ALTERNATIVE DIAGNOSTIC TOOLS FOR UNDERSTANDING NEUROHIV
Room 304-306 1:30 PM - 2:30 PM

Themed Discussion Leader
Avindra Nath, National Institutes of Health, Bethesda, MD, USA

405 CONSERVED CSF HIV ANTIBODY RESPONSE IN PATIENTS WITH DIVERSE NEUROLOGIC PHENOTYPES
Isobel A. Hawes, Ryan Schubert, Akshaya Ramesh, Gavin Sowa, Joanna Bellmuth, Magnus Gisslén, Richard W. Price, Michael Wilson

424 CNS HIV BEARS ENVELOPE MARKERS CONSISTENT WITH T-CELL ORIGIN IN THE FACE OF ART
Gila J. Lustig, Sandile Cele, Farina Karim, Yashica Ganga, Khadija Khan, Bernadett Gosnell, Mahomed-Yunus Moosa, Rohen Harrichandparsad, Suzaan Marais, Ravindra K. Gupta, Tulio de Oliveira, Katya Govender, John Adamson, Vinod B. Patel, Alex Sigal

418 RETINAL THINNING CORRELATES WITH BRAIN ATROPHY IN WELL-CONTROLLED HIV INFECTION
Bryan Smith, Katrina Geannopoulos, Ramiro Maldonado, Tianxiao Wu, Elizabeth F. Horne, Lillian Ham, Joseph Snow, Govind Nair, Daniel S. Reich, Chuen-Yen Lau, Emily Chew, Avindra Nath

411 BIOMARKERS OF NUCLEIC ACID OXIDATION AND NEURODEGENERATION IN CSF IN PWH
Ronald J. Ellis, David J. Moore, Erin Sundermann, Robert K. Heaton, Todd Hulgan, David C. Samuels, Sanjay R. Mehta, Scott L. Letendre

412 PREDICTIVE VALIDATION OF AN UGANDAN INFANT EYE-TRACKING TEST OF MEMORY OF HUMAN FACES

Themed Discussion TD-08 FAT IN FOCUS
Ballroom C 1:30 PM - 2:30 PM

Themed Discussion Leader
Jacqueline Capeau, Sorbonne University, Paris, France

667 FAT GAINS OCCUR AFTER ART WITHOUT CHANGES IN METABOLIC RATE OR CALORIC INTAKE
Allison Ross Eckard, Abdus Sattar, Jiao Yu, Heather Y. Hughes, Danielle Labbato, Theresa O. Rodgers, Julia C. Kosco, Grace A. McComsey

668 GREATER WEIGHT GAIN AFTER SWITCH TO INsti-BASED REGIMEN FROM NNRTI VS PI REGIMENS

669 BODY COMPOSITION CHANGES OVER THE MENOPAUSAL TRANSITION IN HIV+ AND HIV–WOMEN
Thuy Trang J. Nguyen, Yifei Ma, Rebecca Scherzer, Anjali Sharma, Mark H. Kuniholm, Audrey French, Margaret Fischl, Howard Minkoff, Michael
Oral Sessions

670  RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON InStI
Rumi Minami, Soichiro Takahama, Kazuhiko Koyama, Masahiro Yamamoto

671  ADIPOCYTE DYSFUNCTION DESPITE REDUCED ADIPOSE INFLAMMATION IN DIABETICS WITH HIV
Samuel Bailin, Spyros Kalams, Simon Mallal, Fei Ye, Run Fan, Mona Mashayekhi, Curtis Gabriel, John Koethe, Celestine Wanjalla

Themed Discussion TD-09 NOVEL APPROACHES TO STUDY PEDIATRIC ANTIRETROVIRAL DOSING AND SAFETY
Room 312  1:30 PM - 2:30 PM

Themed Discussion Leader
Adrie Bekker, Stellenbosch University, Cape Town, South Africa

839  IDENTIFICATION OF AGE-APPROPRIATE DOSING STRATEGIES OF BICTEGRAVIR IN NEONATES
Fazila S. Bunglawala, Rajith Kumar Reddy Rajoli, Hannah Kinvig, Nicolas Cottura, Andrew Owen, Marco Siccardi

842  MARAVIROC SAFETY & PHARMACOKINETICS IN HIV-EXPOSED NEONATES
Julia C. Rosebush, Brookie Best, Ellen G. Chadwick, Jack Mbye, Elizabeth Smith, Kevin Butler, Sarah Bradford, Kyle Whitson, Sisinyana R. Mathiba, Sherika Hanley, Mariam Aziz, Katy Hayward, Mark Mirochnick, Pearl Samson, for the IMPAACT 2007 Study Team

843  ABACAVIR SAFETY AND PHARMACOKINETICS IN NORMAL AND LOW BIRTH WEIGHT INFANTS WITH HIV
Tim R. Cressey, Adrie Bekker, Mae Cababasay, Jiajia Wang, Firdose Nakwa, Elizabeth Smith, Jack Mbye, Avy Violari, Mark Cotton, Bobbie Graham, Lubbe Wiesner, Helena Rabie, Mark Mirochnick, Edmund V. Capparelli, for the IMPAACT P1106 team

847  ADEQUATE DOLUTEGRAVIR EXPOSURE DOSED BID WITH RIFAMPICIN IN CHILDREN 6 TO <18 YEARS
Hylke Waalewijn, Hilda Mujuru, Pauline Amuge, Mark Cotton, Pauline Bollen, Man Chan, Shabinah Ali, Ebrahim Varsiava, Shafic Makumbi, Angela Colbers, Diana Gibb, Deborah Ford, David M. Burger, Anna Turkova, for the Odyssey trial team

845  ABACAVIR SAFETY AND EFFICACY IN YOUNG INFANTS IN SOUTH AFRICAN OBSERVATIONAL COHORTS
Renee De Waal, Helena Rabie, Karl Technau, Brian Eley, Nosisa Sipambo, Mark Cotton, Andrew Boulle, Robin Wood, Frank Tanser, Geoffrey Fatti, Matthias Egger, Mary-Ann Davies
Themed Discussion TD-10 COMING INTO THE LIGHT: HIV IN TRANSGENDER WOMEN AND MEN

Ballroom A 1:30 PM - 2:30 PM

Themed Discussion Leader
Sari L. Reisner, Harvard T.H. Chan School of Public Health, Boston, MA, USA

878 PREEXPOSURE PROPHYLAXIS ADHERENCE AND PERSISTENCE IN KENYAN TRANSGENDER WOMEN AND MSM
Makobu Kimani, Elisabeth M. van der Elst, Oscar Chirro, Fauz Ibrahim, Nana Mukuria, Tobias F. Rinke de Wit, Susan M. Graham, Eduard Sanders

879 HIV PREVALENCE AND RISK IN MALE, TRANSMALE, AND TRANSFEMALE SEX WORKERS IN ZIMBABWE
Mariëlle Kloek, Laura Van Noord, Sungai T. Chabata, Sithembile Musemburi, Sake De Vlas, Frances Cowan, Jan A. Hontelez

880 FACTORS ASSOCIATED WITH HIV, HCV, AND HSV2 SEROSTATUS AMONG US TRANSGENDER WOMEN
Morgan P. Keruly, Andrea L. Wirtz, George Mwinnyaa, Sari L. Reisner, ScD, Oliver Laeyendecker, for the American Cohort to Study HIV Acquisition among Transgender Women (LITE) Study Group

881 HIV PREVALENCE AMONG TRANSGENDER MEN AT AN NYC COMMUNITY HEALTH CENTER
Asa Radix, Zil Goldstein, Alexander Harris, Rona Vail

882 PROGRESSION THROUGH THE HIV CARE CONTINUUM FOR TRANSGENDER WOMEN IN THE NA-ACCORD

Symposium S-04 HALT, WHO GOES THERE? VIRUS SENSING AND RESTRICTION

Room 304-306 4:00 PM - 6:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding virus sensing and restriction.

Level of Knowledge: It is assumed that the participants are familiar with stages of the viral life cycle and have a basic understanding of molecular biology.

Objectives: At the completion of the session, participants will be able to:
• Describe how host cells recognize foreign viral components
• Describe how host cells respond with activities that inhibit different stages of HIV replication

Conveners
Theodora Hatziioannou, The Rockefeller University, New York, NY, USA
Jeremy Luban, University of Massachusetts Medical School, Worcester, MA, USA

95 STING IN THE TAIL: HOW DNA TRIGGERS IMMUNE RESPONSES TO VIRAL INFECTIONS
Zhijian Chen, University of Texas Southwestern, Dallas, TX, USA
Oral Sessions

96  TRIM5 RECOGNITION AND RESTRICTION OF HIV-1 AND RETROVIRUSES
4:30  
Owen Pornillos, University of Virginia, Charlottesville, VA, USA

97  HIV-1 AVOIDS BEING ZAPPED
5:00  
Janet L. Smith, University of Michigan, Ann Arbor, MI, USA

98  SERINC STRUCTURE AND RESTRICTIONS OF HIV-1 INFECTIVITY
5:30  
Valerie Pye, The Francis Crick Institute, London, UK

Symposium S-05 HIV IS ON OUR MINDS
Ballroom B  4:00 PM - 6:00 PM

This session is dedicated to the memory of Dr Kevin Robertson.

Target Audience: This session is directed to clinicians and scientists who are interested in understanding relationship of neurocognitive disorders and HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of neurocognitive disorders and HIV infection.

Objectives: At the completion of the session, participants will be able to:
• Describe the global burden of neuroHIV
• Explain the prevalence and management of HIV-associated neurocognitive disorders (HAND) in resource-limited settings
• Describe the burden of mental health complications (eg, depression, suicide, adherence) in Nigeria and other regions
• Describe the burden of cerebrovascular disease and neuroHIV in Asian populations

Conveners
Scott L. Letendre, University of California San Diego, San Diego, CA, USA
Matthias Cavassini, University of Lausanne, Lausanne, Switzerland

99  NEUROHIV IN THE GLOBAL CONTEXT: ADVANCING THE CONTINUUM OF CARE AND ACHIEVING EQUITY
4:00  
Kiran T. Thakur, Columbia University, New York, NY, USA

100  HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS AND AGING IN THE GLOBAL SETTING
4:30  
John Joska, University of Cape Town, Cape Town, South Africa

101  HIV AND MENTAL HEALTH: THE IMPACT OF THE COMORBIDITY IN RESOURCE-CONSTRAINED SETTINGS
5:00  
Bibilola D. Oladeji, University of Ibadan, Ibadan, Nigeria

102  CEREBROVASCULAR COMPLICATIONS AND NEUROHIV IN THE GLOBAL SETTING
5:30  
Felicia C. Chow, University of California San Francisco, San Francisco, CA, USA
**Symposium S-06 B CURED**

**Ballroom A**

**4:00 PM - 6:00 PM**

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding the impact of hepatitis B virus and the prospects for cure.

**Level of Knowledge:** It is assumed that participants are familiar with the general principles of hepatitis treatment and medications.

**Objectives:** At the completion of the session, participants will be able to:
- Describe the global impact of hepatitis B virus
- Evaluate the current prospects for hepatitis B infection

**Conveners**

Annie F. Luetkemeyer, University of California San Francisco, San Francisco, CA, USA

Arthur Y. Kim, Harvard Medical School, Boston, MA, USA

103 **GLOBAL ELIMINATION OF HEPATITIS B VIRUS**

Gilles Wandeler, University of Bern, Bern, Switzerland

104 **ADAPTING THE IMMUNE RESPONSE TO CURE HEPATITIS B**

Barbara Rehermann, National Institutes of Health, Bethesda, MD, USA

105 **HEPATITIS B VIRUS: NEW AGENTS**

Raymond T. Chung, Harvard University, Cambridge, MA, USA

106 **THE MATHEMATICS OF HEPATITIS B CURE**

Alan S. Perelson, Los Alamos National Laboratory,

---

**Symposium S-07 CONTRACEPTION AND HIV**

**Ballroom C**

**4:00 PM - 6:00 PM**

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding the issues around contraception and HIV.

**Level of Knowledge:** It is assumed that participants are familiar with contraception use in HIV.

**Objectives:** At the completion of the session, participants will be able to:
- Describe evidence and considerations involved in contraceptive use by women with HIV infection
- Describe state-of-the-art evidence for the association between contraceptive use and the risk of HIV acquisition

**Conveners**

James Kiarie, World Health Organization, Geneva, Switzerland

Yvette Raphael, Advocacy for Prevention of HIV and AIDS, Durban, South Africa

107 **DRUG-DRUG INTERACTIONS: THE UPS AND DOWNS OF ANTIRETROVIRALS PLUS CONTRACEPTIVES**

Kimberly K. Scarsi, University of Nebraska, Omaha, NE, USA
108  CONTRACEPTIVE IMPLANT ROLLOUT IN SOUTH AFRICA
Gregory Petro, University of Cape Town, Cape Town, South Africa

109  CONTRACEPTION AND HIV RISK: A CONUNDRUM NO MORE
Renee Heffron, University of Washington, Seattle, WA, USA

110  THE STATE OF SRHR & HIV SERVICES FOR CIS-GENDER WOMEN: A COMMUNITY PERSPECTIVE
Wame Jallow, International Treatment Preparedness Coalition, Gaborone, Botswana

LATE-BREAKING NEWS: UPDATE FROM THE HVTN 702 VACCINE (UHAMBO) TRIAL

Ballroom B  6:10 PM - 6:45 PM

On February 3, 2020 the HVTN 702 HIV vaccine efficacy trial in South Africa discontinued vaccinations because the interim review by the Data and Safety Monitoring Board reported that the vaccine candidate did not prevent HIV. There were no safety concerns. This session will provide a brief overview of the results available and provide meeting attendees with an opportunity to ask questions of the study team as they prepare for the full analysis of these data.

INTRODUCTION OF HVTN 702 STUDY
Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PRESENTATION OF HVTN 702 STUDY DATA
Glenda E. Gray, University of the Witwatersrand, Johannesburg, South Africa

Moderator
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

Panelists
Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Glenda E. Gray, University of the Witwatersrand, Johannesburg, South Africa
Steven F. Wakefield, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Please refer to the CROI Mobile App for more details.
WEDNESDAY MARCH 11, 2020

Plenary PL-03 WEDNESDAY PLENARY SESSION
Auditorium / Hall C / Auditorium Balcony 8:30 AM - 9:30 AM

Session Hosts
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, USA
Penelope L. Moore, University of Witwatersrand, Johannesburg, South Africa

111  RECENT ADVANCES IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF TUBERCULOSIS
8:30
Gavin Churchyard, The Aurum Institute, Johannesburg, South Africa

112  ENGINEERING VACCINE IMMUNITY
9:00
Shane Crotty, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA

Oral Abstract O-09 IMMUNOLOGY AND PATHOGENESIS OF LENTIVIRUS INFECTIONS
Room 312  10:00 AM - 12:00 PM

Oral Abstract Moderators
Zaza Ndhlovu, African Health Research Institute, Durban, South Africa
Sandhya Vasan, Military HIV Research Program, Bethesda, MD, USA

113  IL-6 BLOCKADE DECREASES INFLAMMATION AND INCREASES CD127 EXPRESSION IN HIV INFECTION
10:00
Benigno Rodriguez, Zhengyi Chen, Curtis Tatsuoka, Scott F Sieg, Alan Landay, Grace A. Comosy, Brian Clagett, Chris T. Longenecker, Carey Shive, Keith W. Crawford, Daniela Moisi, Michael L. Freeman, Nicholas Funderburg, Leonard Calabrese, Michael M. Lederman

114  NEUTRALIZING ANTIBODIES AND TRMS PROVIDE ENHANCED AND DURABLE RESISTANCE AGAINST HIV
10:15

115 LB  HUMAN NK CELLS DEVELOP ANTIGEN-SPECIFIC IMMUNOLOGICAL MEMORY OF HIV
10:30
Stephanie Jost, Olivier Lucar, Haley Dugan, Marcus Altfeld, Paul Goepfert, R. Keith Reeves

116  EFFICACIOUS RHCMV/SIV VECTORS ELICIT BROADLY CROSS-REACTIVE SIV-SPECIFIC CD8+ T CELLS
10:45
Benjamin N. Bimber, Shaheed Abdulhaqq, Abigail Ventura, Eric McDonald, Daniel Douek, Scott Hansen, Jonah Sacha, Louis J. Picker

117  PD-1 BLOCKADE AT TIME OF ART WITHDRAWAL FACILITATES EARLY POST-PEAK VIRAL CONTROL
11:00
118  TRACKING AND PREDICTING REBOUND IN SHIV-INFECTED INFANT MACAQUES AFTER LONG-TERM ART

Veronica Obregon-Perko, Katherine Bricker, Ferzan Uddin, Laura Rotolo, Daryll Vanover, Philip Santangelo, Stella Berendam, Genevieve Fouda, Shan Liang, Thomas Vanderford, Katharine J. Bar, George Shaw, Guido Silvestri, Sallie Permar, Ann Chahroudi

119  PERIPHERAL BLOOD SIV/HIV ORIGINATES FROM INFECTED CELLS IN TISSUES

Leticia Kuri Cervantes, Maria B. Pampena, Marcus Buggert, Meagan Watkins, David S. Khoury, Kevin McCormick, Felicity Mampe, Emily Lindemuth, Ian Frank, Max G. Itkin, Miles Davenport, Brandon F. Keele, Katharine J. Bar, Ronald Veazey, Michael R. Betts

120 LB  CD4+ T-CELL DEPLETION IN AFRICAN GREEN MONKEYS DOES NOT ALTER DISEASE PROGRESSION

Egidio Brocca-Cofano, Paola Sette, Ranjit Sivanandham, Cui Ling Xu, Adam J. Kleinman, Sindhuja Murali Kilapandal Venkatraman, Haritha Annapureddy, Colin McAndrews, Tammy Dunsmore, Jason Brenchley, Jacob D. Estes, Cristian Apetrei, Ivona Pandrea

Oral Abstract 0-10 GONE BUT NOT FORGOTTEN: HCV AFTER DIRECT-ACTING ANTIVIRAL THERAPY

Ballroom A  10:00 AM - 12:00 PM

Oral Abstract Moderators

Vincent Lo Re, University of Pennsylvania, Philadelphia, PA, USA
Naglaa H. Shoukry, Université de Montréal, Montreal, Quebec, Canada

121  INFERIORITY OF SHORT DURATION SOFOSBUVIR-VELPATASVIR FOR RECENT HCV (REACT STUDY)

Gail Matthews, Sanjay Bhagani, Marc van der Valk, Jürgen K. Rockstroh, Christine Thurnheer, Arthur Kim, Jordan J. Feld, Julie Bruneau, Edward Gane, Margaret Hellard, Tanya Applegate, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, for the REACT Study Group

122  INDIVIDUAL AND POPULATION-LEVEL IMPACT OF HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS

Javier Cepeda, David L. Thomas, Rachel E. Gicquelais, Jacquie Astemborski, Gregory D. Kirk, Shruti H. Mehta

123 LB  LARGE HIV OUTBREAK AMONG PEOPLE WHO INJECT DRUGS, WEST VIRGINIA, 2018–2019

Robert P. McClung, Nivedha Panneer, Amy Atkins, Sheryl Lyss, Senad Handanagic, Mi Chen, Michael Kilkenney, Kyle T. Bernstein, Vicki Hogan, Carolyn Wright, Erica Thomasson, Kara Willenburg, David Wills, Alexandra M. Oster, for the West Virginia HIV Response Team

124  HCV TRANSMISSION AMONG MSM: EXTERNAL INTRODUCTIONS COULD COMPLICATE MICRO-ELIMINATION

Jelle Koopsen, Edyth Parker, Colin Russell, Thijs J. Van De Laar, Elske Hoornenborg, Marc Van Der Valk, Janke Schinkel

125  NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE

Linda M. Styer, Erica Miller, Jean Rock, Lea Krein, Monica Martin, Dhanushki Samaranayake, Shu-Yin Leung, Michele Caggana, Colleen Flanigan, Monica Parker
126  HEPATOCELLULAR CARCINOMA RISK AMONG PERSONS WITH HIV IN NORTH AMERICA, 1996-2015
Jing Sun, Keri N. Althoff, H. Nina Kim, Mari M. Kitahata, Chad J. Achenbach, Gypsyamber D’Souza, Marina Klein, Bryan Lau, Joseph Lim, Vincent Lo Re, Julia L. Marcus, Angel M. Mayor, Michael J. Silverberg, Gregory D. Kirk, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

127  HIV/HCV VS HCV: PLASMA AND LIVER VIRAL DYNAMICS AND IP-10 LEVELS
Ashwin Balagopal, Jaipurasath Sachithananandham, Julia Leep-Lazar, Jeffrey Quinn, Kenneth Bowden, Kathleen M. Ward, Stephanie Katz, Mark Sulkowski

128  CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD
Lindsay T. Fourman, Takara L. Stanley, Meghan Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S. Pan, Julia Aepfelbacher, Colleen Buckless, Andrew Tsao, Kathleen E. Corey, Raymond T. Chung, Martin Torriani, David E. Kleiner, Colleen Hadigan, Steven K. Grinspoon

Oral Abstract O-11 CRITICAL ISSUES IN MATERNAL AND CHILD HEALTH
Oral Abstract Moderators
Lisa Lynn. Abuogi, University of Colorado, Denver, Aurora, CO, USA
Paula Vaz, Fundação Ariel Glaser Contra o Sida Pediatrico, Maputo, Mozambique

129  DOLUTEGRAVIR-CONTAINING ART DOES NOT REDUCE ETONOGESTREL IMPLANT CONCENTRATIONS
Rena Patel, Randy Stalter, Maricianah Onono, Evelyn Brown, Lilian Adeojo, Catherine K. Adhu, Kimberly K. Scarsi

130 LB  SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL
Lameck Chinula, Sean S. Brummel, Lauren Ziembka, Lynda Stranix-Chibanda, Anne Coletti, Chelsea Krotje, Patrick Jean-Philippe, Lee Fairlie, Tichaona Vhembo, Deo Wabwire, Risa M. Hoffman, Paul E. Sax, Jeffrey S. Stringer, Judith S. Currier, Shahin Lockman

131 LB  DIFFERENTIATED CARE FOR POSTPARTUM ART IN SOUTH AFRICAN WOMEN LIVING WITH HIV: AN RCT
Jasantha Odayar, Maia Lesosky, Thokozile R. Malaba, Siti Kabanda, Joanna Allerton, Nai-Chung Hu, Elton E. Mukonda, Stephanie Fourie, Shahieda Jacobs, David Huang, Landon Myer, for the Postpartum Adherence Clubs for Antiretroviral Therapy (PACART) Trial

132  POC EID VS CENTRAL LAB TESTING: RESULTS FROM A STEP-WEDGE RCT IN KENYA AND ZIMBABWE
Emma Sacks, Rhoderick Macheke, Bernard Ochuka, Haurowi Mafaune, Addmore Chadambuka, Collins Otiend, Agnes Mahomva, George Githuka, Jean-Francois Lemaire, Flavia Blanchi, Jennifer Cohn

133  A RANDOMIZED TRIAL OF POINT-OF-CARE EARLY INFANT HIV DIAGNOSIS IN ZAMBIA
Carla J. Chibwesha, Katie Mollan, Catherine Ford, Aaron Shibemba, Pooja Saha, Benjamin H. Chi, Lloyd Mulenga, Mildred Lusaka, Felistas Mbewe, Jeffrey S. Stringer
134 LB  
Oral Sessions  
POPULATION-LEVEL HIV-FREE INFANT SURVIVAL IN THE SEARCH TRIAL  
11:15  
Shalika Gupta, Jane Kabami, Gabriel Chamie, Norton Sang, Dalsone Kwarisimia, Douglas Black, Laura B. Balzer, James Ayieko, Craig R. Cohen, Elizabeth A. Bukusi, Moses R. Kamya, Diane V. Havlir, Maya L. Petersen, Theodore Ruel

135  
Oral Sessions  
PREDICTORS OF THE PERSISTING VIRAL RESERVOIR IN VERY EARLY TREATED INFANTS  
11:30  
Louise Kuhn, Maria Paximadis, Bianca Da Costa Dias, Sizanani Mncube, Renate Strehlau, Yanhan Shen, Stephanie Shiu, Faezah Patel, Megan Burke, Karl Technau, Shaye Loubser, Elaine J. Abrams, Caroline Tiemessen, for the LEOPARD Study Team

136  
Oral Sessions  
LONG-TERM TREATMENT OUTCOMES: EARLY VERSUS DEFERRED ART IN CHILDREN LIVING WITH HIV  
11:45  
Thanyawee Puthanakit, Jiratchaya Sophonphan, Wipaporn Natalie Songaweesin, Thidarath Jupimai, Ly Penh Sun, Pope Kasalara, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Chetta Kea, Chaiwat Ngampiyaskul, Tuangtip Theerawit, Stephen J. Kerr, Claude A. Mellins, Jintanat Ananworanich, for the PREDICT and Resilience Study Group

Oral Abstract O-12  
TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HIV TESTING  
Ballroom C  
10:00 AM - 12:00 PM

Oral Abstract Moderators  
Joshua A. Barocas, Massachusetts General Hospital, Boston, MA, USA  
Jose Miro, University of Barcelona, Barcelona, Spain

137  
Oral Sessions  
ANTIMICROBIAL PROPHYLAXIS AMONG AFRICAN ADULTS ON ART: RESULTS OF A RANDOMIZED TRIAL  
10:00  

138  
Oral Sessions  
ISONIAZID TO PREVENT MTB INFECTION IN HIV-EXPOSED UNINFECTED INFANTS  
10:15  
Sylvia LaCourse, Barbra A. Richardson, Lisa M. Cranmer, Elizabeth Maleche Obimbo, Daniel Matemo, Alex J. Warr, Jaclyn Escudero, John Knuthia, Thomas Hawn, Grace John-Stewart

139  
Oral Sessions  
PREDICTORS OF TUBERCULOSIS INFECTION IN MDR-TB HOUSEHOLD CONTACTS ≥15 YEARS OLD  
10:30  
Soyeon Kim, Amita Gupta, Xingye Wu, Michael D. Hughes, Rodney Dawson, Vidyaw Mave, Ngalingweswaran Kamarasamy, Elizabeth Smith, Roxana Rustomjee, N. Sarita Shah, Anneke Heseling, Susan Swindells, Gavin Churchyard, for the A5300/I2003 PHOENIX Feasibility Study Team

140  
Oral Sessions  
DIAGNOSTIC AND THERAPEUTIC CHALLENGES ARISE WITH EARLY HIV INFECTION ON PrEP  
10:45  
Michael J. Peluso, Monica Gandhi, Susa Coffey, Heather Hartig, Susan P. Buchbinder, Michael P. Busch, Christopher D. Pilcher, Hyman Scott, Stephanie E. Cohen, Darpun Sachdev, Pierre Crouch, Diane V. Havlir, Steven G. Deeks, Timothy J. Henrich, Sulggi Lee
141  A RANDOMIZED TRIAL OF INCENTIVES AND DEPOSIT CONTRACTS TO PROMOTE HIV RETESTING  
Dalsone Kwarisiima, Alex Ndyabakira, Kara Marson, Carol S. Camlin, Diane V. Havlir, Moses R. Kamya, Harsha Thirumurthy, Gabriel Chamie

142  COMMUNITY-BASED HIV TESTING IN URBAN KENYA: A STRATEGY TO REACH MEN AND YOUTH  
Hong-Ha M. Truong, A. Rain Mocello, David Ouma, Dena Bushman, Kevin Kadede, Eric Ating’A, Dancun O. Obunge, Elizabeth A. Bukusi, Francesca Odhiambo, Craig R. Cohen

143  EFFECTIVENESS OF 3HP ANNUALLY VS ONCE FOR HIV-POSITIVE PEOPLE: THE WHIP3TB TRIAL  
Gavin Churchyard, Vicky Cardenas, Violet Chihota, Kathryn Mngadi, Modulakgotla Sebe, William L. Brumskine, Salome Charalambous, Neil A. Martinson, Getnet Yimer, Alberto L. Garcia-Basteiro, Leeanne Masilela, Susan Van Den Hof, Richard E. Chaisson, Alison Grant, Katherine Fielding

144  RIFAPENTINE PHARMACOKINETICS AND SAFETY IN PREGNANT WOMEN WITH AND WITHOUT HIV ON 3HP  

Ballroom B 10:00 AM - 12:00 PM

Oral Abstract Moderators
Andrew Mujugira, Makerere University, Kampala, Uganda
Kate Buchacz, Centers for Disease Control and Prevention, Atlanta, GA, USA

145  NO HIV INCIDENCE INCREASE IN FIRST-TIME BLOOD DONORS WITH 12-MONTH DEFERRAL FOR MSM  
Eduard Grebe, Edward P. Notari, Roberta Bruhn, Claire Quiner, Mars Stone, Sonia Bakkour, Hong Yang, Debra Kessler, Rita Reik, Michael P. Busch, Susan Stramer, Simone Glynn, Alan Williams, Brian Custer, for the U.S. FDA Transfusion Transmissible Infections Monitoring System

146  EXPLAINING RACIAL DISPARITIES IN VIRAL SUPPRESSION AMONG MSM LIVING WITH HIV  
Justin R. Knox, Jodie L. Guest, Jeb Jones, Eric Hall, Nicole Luisi, Jennifer Taussig, Mariah Valentine-Graves, Eli Rosenberg, Travis Sanchez, Patrick S. Sullivan

147  EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID  
Steven J. Clipman, Shruti H. Mehta, Aylur K. Srikrishnan, Katie J. Zook, Priya Duggal, Shobha Mohapatra, Shanthu T. Channo, Nandagopal Paneerselvam, Muniratnam S. Kumar, Elizabeth Ogbum, Allison M. McFall, Gregory M. Lucas, Carl A. Latkin, Sunil S. Solomon

148  THE AGING OF HIV-1 INCIDENCE IN HYPERENDEMIC RURAL SOUTH AFRICA  
Adam N. Akullian, Alain Vandormael, Joel Miller, Anna Bershteyn, Edward Wenger, Diego F. Cuadros, Frank Tanser
Oral Sessions

149  HIGH HIV INCIDENCE IN YOUNG WOMEN IN THE BOTSWANA COMBINATION PREVENTION PROJECT
Faith Ussery, Pamela J. Bachanas, Mary Grace Alwano, Refeletswe Lebelonyane, Lisa Block, Kathleen Wirth, Gene Ussery, Baraedi W. Sento, Tendani Gaolathe, Etienne Kadima, William Abrams, Shahin Lockman, Janet Moore

150  RAPIDLY DECLINING HIV INCIDENCE AMONG MEN AND WOMEN IN RAKAI, UGANDA
Gertrude Nakigozi, Larry W. Chang, Steven J. Reynolds, Fred Nalugoda, Godfrey Kigozi, Thomas C. Quinn, Ronald H. Gray, Alice Kisakye, Anthony Ndyanabo, Robert Ssekubugu, David Serwadda, Maria Waver, Joseph Kagaayi, Mary K. Grabowski, for the Rakai Health Sciences Program

151  INCREASED OVERALL LIFE EXPECTANCY BUT NOT COMORBIDITY-FREE YEARS FOR PEOPLE WITH HIV
Julia L. Marcus, Wendy Leyden, Alexandra N. Anderson, Rulin Hechter, Michael A. Horberg, Hailong Hu, Jennifer O. Lam, William J. Towner, Qing Yuan, Michael J. Silverberg

152  LOW-LEVEL VIREMIA DURING ART AND THE RISK OF DEATH, AIDS, AND SERIOUS NON-AIDS EVENTS
Olof Elvstam, Gaetano Marrone, Patrik Medstrand, Carl Johan Treutiger, Anders Sönnerborg, Magnus Gisslén, Per Bjorkman

Themed Discussion TD-11 THE ROAD TO A BETTER VACCINE: CLINICAL TRIALS AND COHORT STUDIES
Room 312   1:30 PM - 2:30 PM

Themed Discussion Leader
Richard A. Koup, National Institutes of Health, Bethesda, MD, USA

287  THE RV144 VACCINE PRIMED IgG4 AND V1V2-ADCP RESPONSES IN HIV BREAKTHROUGH INFECTIONS
Thembi Mdluli, Dominic Paquin-Proulx, Bonnie Slike, Gina Donofrio, Sorachai Nitayaphan, Punnee Pitisutthithum, Supachai Rerks-Ngarm, Margaret Ackerman, Merlin L. Robb, Nelson L. Michael, Sandhya Vasan, Michael A. Eller, Shelly J. Krebs, Morgane Rolland, for the RV144 study group

288  PHASE I/II A TRIAL OF HIV CLADE C DNA WITH MF59- OR AS01B-ADJUVANTED CLADE C PROTEIN
Nigel Garrett, Cynthia L. Monaco, Philipp Mann, Julia Hutter, Allan C. deCamp, One Dintwe, Georgia Tomaras, Megan Jones, Giuseppe Pantaleo, Song Ding, Olivier Van Der Meerent, Julie McElrath, Larry Corey, James G. Kublin, for the HVTN 108 Study Team

289  MUCOSAL T AND B CELL RESPONSES INDUCED BY ALVAC-HIV/AIDSvax B/E LATE BOOST STRATEGIES

290  CANDIDATE IMMUNOGENS DIFFERENTIALLY ENGAGE HIV BROADLY NEUTRALIZING PLASMA ANTIBODIES
Irene Abela, Teja Turk, Nikolas Friedrich, Claus Kadelka, Matthias Gloegl, Brano Ivan, Peter Rusert, Merle Schanz, Roger Koyou, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study
291  ACUTE INFECTION B-CELL DETERMINANTS PREDICT DEVELOPMENT OF NEUTRALIZATION BREADTH
Samantha Townsley, Gina Donofrio, Ningbo Jian, David Leggat, Vincent Dussupt, Letzibeth Mendez-Rivera, Nicole Doria-Rose, John R. Mascola, Morgane Rolland, Sodsai Tovanabutra, Adrian B. McDermott, Nelson L. Michael, Merlin L. Robb, Shelly J. Krebs, for the RV217 Study Group

Themed Discussion TD-12 ATTACK OF THE CLONES: CLONAL EXPANSION IN THE HIV RESERVOIR
Room 304-306  1:30 PM - 2:30 PM
Themed Discussion Leader
Linos Vandekerckhove, Ghent University, Ghent, Belgium

360  PARALLEL HIV RNA, INTEGRATION SITE, AND PROVIRAL SEQUENCING IN SINGLE RESERVOIR CELLS
Kevin Einkauf, Matthew Osborn, Ce Gao, Jane Blackmer, Chenyang Jiang, Eric Rosenberg, Xu G. Yu, Mathias Lichterfeld

361  SINGLE-CELL ATLAS AND CLONAL EXPANSION DYNAMICS OF CD4+ T CELLS DURING HIV INFECTION
Jack A. Collora, Delia Pinto-Santini, Siavash Pasalar, Ricardo Alfaro, Carmela Ganoza, Jennifer Chiarella, Rachela Calvi, Javier R. Lama, Serena S. Spudich, Ann Duerr, Ya-Chi Ho

362  TCR SEQUENCING REVEALS CLONAL EXPANSIONS OF INDUCIBLE RESERVOIRS IN SPECIFIC SUBSETS
Pierre Gantner, Amelie Pagliuzza, Marion Pardons, Moti Ramgopal, Jean-Pierre Routy, Rémi Fromentin, Nicolas Chomont

363  ONLY A FEW HIV-1 INTEGRATION SITES CONFER GROWTH ADVANTAGE TO INFECTED CELLS IN VIVO

364  HIV DYNAMICS AND REPOPULATION OF RESERVOIRS IN THE HUMAN BODY
Antoine Chaillon, Sara Gianella, Simon Dellicour, Stephen A. Rawlings, Michelli Faria De Oliveira, Caroline Ignacio, Magali Porrachia, Bram Vrancken, Davey M. Smith

Themed Discussion TD-13 THE LONG AND THE SHORT OF IT: WHAT’S NEXT FOR LONG-ACTING DRUGS
Ballroom B  1:30 PM - 2:30 PM
Themed Discussion Leader
Ethel D. Weld, The Johns Hopkins University, Baltimore, MD, USA

466  CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION
Susan Ford, Herta Crauwels, Kelong Han, Stefaan Rossenu, Feifan Zhang, Jenny O. Huang, David A. Margolis, Kenneth Sutton, Krischan J. Hudson, Peter E. Williams, William Spreen, Parul Patel

467  WITHDRAWN
468  MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV INFECTION

469  DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207
Eric Daar, Cheryl McDonald, Gordon Crofoot, Peter Ruane, Gary Sinclair, Edwin DeJesus, Mezgene Berhe, Moti Ramgopal, Heena Patel, Ya-Pei Liu, Rebecca Begley, Diana Brainard, Robert H. Hyland, Martin Rhee

471  ANTIRETROVIRAL & RIFAMPICIN COTREATMENT AFFECTS DMPA EXPOSURE: DOING IMPLICATIONS
Jose Francis, Paolo Denti, Helen Mcilleron, Michelle A. Kendall, Xingye Wu, Kelly E. Dooley, Cindy Firnhaber, Catherine Godfrey, Susan E. Cohn, Rosie Mngqibisa

Themed Discussion TD-14 NEW DIAGNOSTIC ALGORITHMS FOR TUBERCULOSIS AND OPPORTUNISTIC INFECTIONS
Ballroom A 1:30 PM - 2:30 PM

Themed Discussion Leader
Andrew D. Kerkhoff, University of California San Francisco, San Francisco, CA, USA

720  PREVALENCE OF TB SYMPTOMS, DIAGNOSIS, AND TREATMENT AMONG HIV PATIENTS NOT ON ART
Alana T. Brennan, Mhairi Maskew, Bruce Larson, Isaac Tsikhutsu, Margaret Bii, Lungisile Vezzi, Matthew P. Fox, Willem D. Venter, Peter Ehrenkranz, Sydney Rosen

755  CHARACTERISATION OF SOUTH AFRICA'S XPERT MTB/RIF ULTRA "TRACE" LABORATORY RESULTS
Lesley Scott, Pedro Da Silva, Kyle Fyvie, Gabriel D. Eisenberg, Silence Ndlovu, Puleng S. Marokane, Wendy Stevens

759  PROMISING COMBINED IMMUNOLOGICAL ASSAYS TO DIAGNOSE CHILDHOOD TUBERCULOSIS
Edouard Tuallion, Mwiya Mwiya, Laurent Kremer, Melany w. Tonga, Duncan Chanda, Marianne Perriès, Amandine Pisoni, Karine Bolloré, Roselyne Vallo, Chipepo Kankasa, Philippe Van de Perre, Jean-Pierre Molès, Nicolas Nagot

743  DIAGNOSTIC PERFORMANCE OF A SEMIQUANTITATIVE POINT-OF-CARE ASSAY FOR CRYPTOCOCCOSIS
Tadeo K. Kiiza, Audrey Nimwesiga, Caleb P. Skipper, Richard Kwizera, Lucy Apeduino, Michael Okirwoth, John Bosco Kafufu, Elizabeth Nalintya, Darlisha A. Williams, Joshua Rhein, David B. Meya, David R. Boulware

750  SUPERIOR ACCURACY OF THE Mp1p ANTIGEN ASSAY OVER CULTURES IN DIAGNOSING TALAROMYCOSIS
Ly T. Vo, Thu T. Nguyen, Thanh T. Nguyen, Nguyen Le Nhu Tung, Jasper F. Chan, Patrick C. Woo, Chau V. Nguyen, Nga N. Cao, Kwok-Yung Yuen, Thuy Le
Themed Discussion TD-15 MAKING SENSE OF IT ALL: HIV SUSCEPTIBILITY IN THE FEMALE GENITAL TRACT

Ballroom C 1:30 PM - 2:30 PM

Themed Discussion Leader

Caroline Mitchell, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA

MINI LECTURE: HIV SUSCEPTIBILITY IN THE FEMALE GENITAL TRACT

Caroline Mitchell, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA

1061 GENITAL SECRETIONS FROM WOMEN WITH BACTERIAL VAGINOSIS ENHANCE HIV INFECTION EX VIVO

Maria J. Keller, Richard Hunte, Rebecca Barnett, Joyce Serebrenik, Jessica McWalters, April Dobkin, Jessica Goymer, Laurie Ray, Lilia Espinoza, Jessica M. Atrio, Kerry Murphy, Betsy Herold

1062 DMPA-IM DRIVES CERVICAL TH17 HIV TARGET-CELL ACCUMULATION IN WOMEN IN ECHO TRIAL


1063 INCREASED GENITAL INFLAMMATION IN WOMEN RANDOMIZED TO COPPER IUD IN THE ECHO TRIAL


1059 A COMBINED ESTROGEN/PROGESTIN VAGINAL RING IMPROVES VAGINAL MICROBIAL COMMUNITIES

Nicole H. Tobin, Sarah L. Brooker, Fan Li, Yoninah S. Cramer, Susan L. Rosenkranz, Grace M. Aldrovandi, Robert Coombs, Susan E. Cohn, Carmen D. Zorrilla, Laura E. Moran, Baiba Berzins, Kimberly K. Scarsi, Catherine Godfrey, for the ACTG 5316 Team

Symposium S-08 DOUBLE-EDGED SWORD OF INFLAMMATION

Ballroom A 4:00 AM - 6:00 AM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the role of inflammation in HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with the basic mechanisms of inflammation in HIV infection.

Objectives: At the completion of the session, participants will be able to:

- Describe the role of inflammation in driving vaccine immunity
- Identify the early inflammatory signatures that track with early infection
- Explain the drivers of chronic inflammation
- Describe the potential pathways that can be manipulated to reduce inflammation

Conveners

Giulia Marchetti, University of Milan, Milan, Italy
Douglas Kwon, Harvard Medical School, Cambridge, MA, USA
153  USING SYSTEM BIOLOGY TO UNDERSTAND THE MECHANISMS OF VACCINE EFFICACY
Bali Pulendran, Emory University, Atlanta, GA, USA

154  DECODING THE TRANSCRIPTIONAL INFLAMMATORY CASCADES THAT MAINTAIN HIV RESERVOIR
Susan Pereira Ribeiro, Case Western Reserve University, Cleveland, OH, USA

155  DISSECTING THE DRIVERS OF CHRONIC INFLAMMATION
Krystelle Nganou, National Institutes of Health, Bethesda, MD, USA

156  DEFINING TREATABLE PATHWAYS IN INFLAMMAGING: IS IT NICE TO FOOL WITH MOTHER NATURE?
Michael M. Lederman, Case Western Reserve University, Cleveland, OH, USA

Symposium S-09 ANTIRETROVIRAL THERAPY: THE LONG GAME
Ballroom B 4:00 AM - 6:00 AM

Target Audience: This session is directed to clinicians and scientists who are interested in understanding current challenges and questions regarding antiretroviral treatment for people living with HIV.

Level of Knowledge: It is assumed that the participants have an understanding of the principles of antiretroviral therapy and the antiretroviral agents that are commonly used to treat HIV infection.

Objectives: At the completion of the session, participants will be able to:
• Describe new antiretroviral agents and how they may be used in treatment
• Identify optimal treatments for metabolic complications
• Describe the benefits and limitations of modern ART in children and adolescents
• Discuss the implications of adherence with modern ARVs and the best use of novel adherence measures

Conveners
Nagalingeswaran Kumarasamy, Chennai Antiviral Research and Treatment, Tamil Nadu, India
Angela Colbers, Radboud University Medical Center, Nijmegen, Netherlands

157  NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV
Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

158  PEDIATRIC AND ADOLESCENT ART: A ROAD LESS TRAVELLED
Carolyn Bolton Moore, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

159  METABOLIC COMPLICATIONS OF HIV AND ITS THERAPIES
Jordan E. Lake, University of Texas at Houston, Houston, TX, USA

160  GETTING IT RIGHT: PRACTICAL APPROACHES TO ADHERENCE WITH MODERN ARVs
Jose R. Castillo-Mancilla, University of Colorado Denver, Denver, CO, USA
Symposium S-10 HEPATITIS C: PARALLELS, PITFALLS, AND PROMISE

Ballroom C

4:00 AM - 6:00 AM

Target Audience: This session is directed to clinicians, public health practitioners, and scientists who are interested in understanding the current global epidemiology, clinical interventions, public health implications, prevention, and financing of hepatitis C.

Level of Knowledge: It is assumed that the participants are familiar with basic infectious disease, clinical, and public health terminology and context.

Objectives: At the completion of the session, participants will be able to:

- Describe the global epidemiology of hepatitis C infection
- Explain vertical hepatitis C transmission
- Describe examples of successful programs for the elimination of hepatitis C infection

Conveners

Risha Irvin, Johns Hopkins University, Baltimore, MD, USA
Marina Klein, McGill University Health Centre Research Institute, Montreal, QC, Canada

161 GLOBAL EPIDEMIOLOGY OF HEPATITIS C
4:00 Yvan Hutin, World Health Organization, Geneva, Switzerland

162 MODELING AND EXAMPLES OF HCV ELIMINATION: POSSIBILITIES, ACHIEVEMENTS, AND NEXT STEPS
4:30 Natasha Martin, University of California San Diego, San Diego, CA, USA

163 VERTICAL HEPATITIS C TRANSMISSION: DÉJÀ VU ALL OVER AGAIN?
5:00 Ali Judd, University College London, London, UK

164 HEPATITIS C TREATMENT ON A SHOESTRING
5:30 Isabelle Andrieux-Meyer, Drugs for Neglected Diseases Initiative, Geneva, Switzerland
165 HIV-1 CAPSID-NUCLEAR ENVELOPE INTERACTIONS THAT FACILITATE NUCLEAR IMPORT
Mohamed Husen Munshi, Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak

166 REPORTER VIRUSES WITH PROTEIN BARCODES TO ANALYZE HIV LATENCY ESTABLISHMENT
Eun Hye G. Kim, Maria C. Bermúdez-González, Michael Schotsaert, Ana Fernández-Sesma, Lubbertus C. Mulder, Lara Manganaro, Viviana A. Simon

167 GAG DETERMINANTS OF SPECIFIC GENOME PACKAGING IN HIV-1 AND HIV-2
Jonathan Rawson, Olga A. Nikolaitchik, Xayathed Somoulay, Jennifer A. Yoo, Vinay K. Pathak, Wei-Shau Hu

168 EXPLORING THE REQUIREMENTS FOR HIV-1 GENOME PACKAGING THROUGH A NONVIRAL RNA BINDING
Alice Duchon, Steven Santos, Jianbo Chen, Vinay K. Pathak, Wei-Shau Hu

169LB MULTI-OMICS ANALYSES REVEAL IMMUNOMETABOLIC REPROGRAMMING-DEPENDENT HIV-1 REPLICATION
Haitao Guo, Qi Wang, Li Wang, Khader Gheime, Elena Rampanelli, Carolina Garrido, Rafick-Pierre Sekaly, Merlin L. Robb, Leigh Anne Eller, David M. Margolis, Xian Chen, Lishan Su, Jenny P. Ting

170LB HIGH-RESOLUTION PARTICLE STRUCTURE OF IMMATURE HIV-2
Nathaniel L. Talledge, Huixin M. Yang, Luiza Mendonca, Ke Shi, Hideki M. Aihara, Wei Zhang, Louis M. Mansky

184 HIV ADAPTATION FOLLOWING VERTICAL TRANSMISSION
Jennifer Currenti, Abha Chopra, Minna John, Shay Leary, Elizabeth McKinnon, Eric Alves, Mark Pilkinton, Ramesh Ram, Becker Law, Francine Noel, Simon Mallaf, Joseph Conrad, Spyros Kalyani, Silvana Gaudieri

185 DAILY IMMUNOLOGICAL/VIROLOGICAL VARIATIONS IN AVIREMIC ART-TREATED HIV PARTICIPANTS
Debashree Chatterjee, Tomas Raul Wiche Salinas, Yuwei Zhang, Delphine Planas, Amelie Cattin, Augustine Fert, Etienne Moreira Gabriel, Laurence Raymond Marchand, Josee Girouard, Nicolas Cermakian, Daniel E. Kaufmann, Jean-Pierre Routy, Petronela Ancuta

186 TIME TRENDS OF REPLICATION CAPACITIES OF TRANSMITTED FOUNDER VIRUSES IN ZURICH
Audrey Kelley, Herbert Kuster, Christine Leemann, Kathrin Neumann, Philipp Rindler, Katharina Kuseiko, Dominique L. Braun, Roger Koyos, Karin Metzner, Huldrych F. Günthard, for the Zurich Primary HIV Infection Cohort Study
187  HIGH-THROUGHPUT SINGLE-MOLECULE SEQUENCING TO CHARACTERIZE AB-RESISTANT HIV/SHIV
Sung Hee Ko, Divya Kilam, Mangaiarkarasi Asokan, Dylan Westfall, Amy Ransier, Sam Darko, Daniel Douek, Richard A. Koup, John R. Mascola, James Mullins, Eli A. Boritz

188  ANALYSIS OF COMPARTMENTALIZATION OF HIV-1 IN BONE MARROW
Thuy T. Nguyen, Jenna Honeycutt, Christopher Nixon, Oksana Zakhkarova, Christopher Evans, Joann D. Kuruc, Ben Murrell, Cynthia L. Gay, Douglas D. Richman, J. V. Garcia

189  INTRAHOST EVOLUTION OF HIV-2 P24 CORRELATES WITH PROGRESSION TO AIDS

190  PLATELETS CARRY INFECTIOUS HIV IN cART-SUPPRESSED PATIENTS IN IMMUNOLOGICAL FAILURE
Morgane Bomsel, Fernando Real, Claude Capron, Alexis Sennepin, Aiwei Zhu, Jacques Izopet, Eliseo Eugenin, Elisabeth Rouveix, Elisabeth Cramer-Bordé

191  FOLLICLE MORPHOLOGY AND HIV RNA DISTRIBUTION IN SPLEEN OF HIV+ HUMANIZED DRAGA MICE

192  PERMANENT CONTROL OF HIV-1 PATHOGENESIS IN EXCEPTIONAL ELITE CONTROLLERS
Cristina Gálvez, Concepcion Casado, Maria Pernas, Laura Tarancón-Diez, Carmen Rodriguez, Víctor Sánchez-Merino, Mar Vera, Rebeca S De Pablo-Bernal, Alberto Merino-Mansilla, Jorge Del Romero, Ramon Lorenzo-Redondo, Ezequiel Ruiz-Mateos, Maria Salgado, Javier Martinez-Picado, Cecilio Lopez-Galindez

193  LACK OF DONOR-DERIVED SUPERINFECTION IN HIV+ TO HIV+ KIDNEY & LIVER TRANSPLANTATION
Tania S. Bonny, Charles Kirby, Craig Martens, Christine Durand, Niraj Desai, Sander S. Florman, Diane M. Brown, Dorry Segev, Aaron Tobian, Andrew D. Redd

194  HIV SUPERINFECTION AMONG MSM AND TGW IN SUB-SAHARAN AFRICA: HPTN 075
Philip J. Palumbo, Yinfeng Zhang, Mariya V. Sivay, Xu Guo, Vanessa Cummings, Ericita Hamilton, Wairimu Chege, Arthur Ogendo, Noel Kayange, Ravindra Panchia, Karen Dominguez, Ying Qing Chen, Theodorus Sandfort, Susan H. Eshleman, for the HPTN 075 Study Team

195  GENETIC DETERMINANTS OF hsCRP, D-DIMER, AND IL-6 IN 3 MULTIETHNIC HIV COHORTS
Brad Sherman, Xiaojun Hu, Kanal Singh, Lillian Haine, James Neaton, Jens D. Lundgren, H. Clifford Lane, for the INSIGHT Study Group
196 ABNORMAL IMMUNOMETABOLISM AND GENE ACCESSIBILITY IN ALVEOLAR MACROPHAGES IN HIV
Sara C. Auld, Jolyn Fernandes, Mariam Ahmed, Neel R. Gandhi, Samantha Yeligar, Bashir Staiteh

197 IMPACT OF EARLY ART ON CD8 T CELLS IN MESENTERIC LYMPH NODES DURING SIV INFECTION
Alexis Yero, Omar Farnos, Henintsoa Rabezanahary, Ghita Benmadid-Laktout, Julien Clain, Gina Racine, Jerome Estaquier, Mohammad-Ali Jenabian

198 ENHANCED MUCOSAL IMMUNITY AND SIV SUPPRESSION AFTER MESENCHYMAL STEM-CELL TRANSFER
Mariana Guedes Weber, Lauren Hirao, Abigail Mende, Clarissa Rocha, Joy E. Walters, Juan Arredondo, Bipin Balan, Sonny Elizalde, Smita Iyer, Alice Tarantal, Amir Kol, Satya Dandekar

199 IDENTIFYING CENTRAL COMPONENTS OF THE HIV-1+ PREGNANCY IMMUNE NETWORK
Alexander Cocker, Sarah Dermont, Waheed Khan, Nesrina Imami, Mark Johnson

200 CXCR5+ NK CELLS IN THE LYMPH NODE ARE ASSOCIATED WITH CONTROL OF SHIV INFECTION
Sheikh A. Rahman, James M. Billingsley, Chris C. Ibegbu, Sadia J. Rahman, R. Paul Johnson, Steven E. Bosingner, Rama R. Amara, Vijayakumar Velu

201LB THE ROLE OF CD101 IN HIV/SIV PATHOGENESIS AND MAINTENANCE OF THE VIRAL RESERVOIR
Timothy Hoang, Zachary Strongin, Gregory K. Tharp, Justin L. Harper, Zhan Zhang, Steven E. Bosingner, Deanna Kulp, Mirko Paiardini

202 IMMUNE CONTROL OF LIVE ATTENUATED-HIV INFECTION AND DISEASE IN BLT-HUMANIZED MICE
Shivkumar Biradar, Moses Bility, Robbie B. Mailliard, for the Bility Lab Group

203 FLT3L-MEDIATED EXPANSION OF PLASMACYTOID DCS CONTROLS HIV INFECTION IN HUMANIZED MICE
Tram Pham, Oussama Meziane, Mohammad Alam Miah, Olga Volodina, Chloé Colas, Kathie Bélard, Yuanyi Li, Frédéric Dallaire, Tibor Keler, Jean V. Guimond, Sylvie Lesage, Cheolho Cheong, Élie Haddad, Eric A. Cohen

204 EFFECTS OF CMV ON HIV DNA DIVERSITY IN PERIPHERAL BLOOD CELLS DURING EARLY ART
Antoine Chaillon, Masato Nakazawa, Gemma Caballero, Laura Layman, Brianna Scott, Christy M. Anderson, Sara Gianella

205 GUT MICROBIOTA FACILITATES HIV ACQUISITION IN THE GUT
Angela Wahl, Cara Richardson, Wenbo Yao, Allison Rogala, R. Balfour Sartor, J. V. Garcia

206 KYNURENINE PATHWAY ACTIVITY REMAINS ABNORMAL DESPITE VERY EARLY ART INITIATION
Samuel R. Schnittman, Amelia Deitchman, Gabriele B. Beck-Engeser, HaeLee Ahn, Vanessa A. York, Heather Hartig, Rebecca Hoh, Frederick M. Hecht, Jeffrey N. Martin, Steven G. Deeks, Francesca Aweeka, Peter W. Hunt
207 Trehalose inhibits HIV in CD4+ lymphocytes and macrophages by 2 distinct mechanisms
Pratima Rawat, Simson Hon, Carmen Teodorof-Diedrich, Stephen A. Spector

208 Fecal microvesicles uniquely influence translocating bacteria after SIV infection
Alexander Ortiz, Jacob K. Flynn, Jason Brenchley

Poster P-D01 IMMUNOLOGY OF ACUTE HIV INFECTION
Poster Hall A 2:30 PM - 4:00 PM

258 Integrated analysis of multicellular immune dynamics during hyperacute HIV infection

259 Uncoupled cellular and plasma markers of monocyte activation in early HIV infection
Montse Jiménez, Lucia Pastor Palomo, Victor Urrea, Nuria Izquierdo-Useros, Javier Martinez-Picado, Inacio Mandomando, Chenjerai Jairoce, Bonaventura Clotet, Jorge Carrillo, Denise Naniche, Julià Blanco

260 Immunological and cytokine changes in blood and gut mucosa from PHI by an early ART
Nuria Ciment, Juan Ambrosioni, David Nicolás, M. J Maleno, L. Miralles, Carmen Hurtado, Marta Subirana, Carmen Ligero, Cristina Rodríguez De Miguel, Josep Llach, Michael Meulbroek, Sonsoles Sánchez-Palomino, Jose M. Miro, Montserrat Plana, for the Hospital Clíníc PHI Investigators

Poster P-D02 ANTIBODY RESPONSES TO HIV
Poster Hall A 2:30 PM - 4:00 PM

261 Identification of broadly neutralizing antibodies from SHIV-infected Chinese macaques
Nan Gao, Yanxin Gai, Lina Meng, Chu Wang, Tiejun Gu, Wei Wang, Xiaojun Li, Thomas B. Kepler, Chuan Qin, Xianghui Yu, Feng Gao

262 VH gene polymorphism associated with potent anti-SIV neutralizing antibody induction
Takeo Kuwata, Hiroshi Ishii, Saori Matsuoka, Tsuyoshi Sekizuka, Makoto Kuroda, Shigeyoshi Harada, Shuzo Matsushita, Yohei Seki, Hiromi Sakawaki, Vanessa Hirsch, Tomoyuki Miura, Hirofumi Akari, Tetsuro Matano

263 Poly/autoreactivity and broad neutralization are determined by different mutations
Xiaojun Li, Dongmei Liao, Zhengyang Li, Shobhit Srivastava, Jixi Li, Laurent Verkoczy, Feng Gao

264 Polyfunctional antibody response to short-schedule Ebola vaccine in HIV+/- subjects

265 Pulmonary tuberculosis disease enhances HIV-1 antibody responses
Bukola Adeoye, Alex J. Olson, Lydia Nakiyingi, Yukari C. Manabe, Karen R. Jacobson, Jerrold Ellner, Manish Sagar
<table>
<thead>
<tr>
<th>Poster Session ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-D03 267</td>
<td>CHARACTERIZING “EXCEPTIONAL” CONTROL AMONG HIV ELITE CONTROLLERS</td>
<td>Michael J. Peluso, Peter Burbelo, Shreya Kumar, Sadie Munter, Rebecca Hoh, Sulggi Lee, Peter W. Hunt, Rachel L. Rutishauser, Timothy J. Henrich, Steven G. Deeks</td>
</tr>
<tr>
<td>P-D03 268</td>
<td>HIV-SPECIFIC CD8+ T CELLS EXHIBIT POOR CYTOLYTIC POTENTIAL IN THE HUMAN AIRWAY</td>
<td>Raphael Kamng’Ona, Leonard Mvaya, Joseph Phiri, Elizabeth Chimbayo, Rose Malamba, Anstead Kankwatira, Henry Mwandumba, Kondwani C. Jambo</td>
</tr>
<tr>
<td>P-D03 269LB</td>
<td>HIGH FREQUENCY OF CD8 ESCAPE MUTANTS IN ELITE CONTROLLER AS NEW OBSTACLE TO HIV CURE</td>
<td>María Ángeles Navarrete, Marcial García, Ricardo Ramos, Africa Holguín, Clara Restrepo, Alfonso Cabello, Juan Carlos López-Bernaldo, Francisco Javier De La Hera, Carlos Barros, Manuel Fernández, Vicente Estrada, Miguel Górgolas Hernández-Mora, José M. Benito, Norma Rallón</td>
</tr>
<tr>
<td>P-E01 304</td>
<td>EXPRESSION PROFILING OF HIV LATENTLY INFECTED CELLS VIA NANOSTRING AND MASS CYTOMETRY</td>
<td>Hannah S. Sperber, Tongcui Ma, Nadia R. Roan, Satish K. Pillai</td>
</tr>
<tr>
<td>P-E01 305</td>
<td>EPGENOMIC CHARACTERIZATION OF A PRIMARY CELL MODEL OF HIV LATENCY</td>
<td>Barcly T. Pace, Stuart R. Jefferys, Joel Parker, Raghu Dronamraju, Brian D. Strahl, David M. Margolis, Edward P. Browne</td>
</tr>
<tr>
<td>P-E01 307</td>
<td>PROVIRAL/HUMAN GENOMIC CROSSTALK IN CELLULAR MODELS FOR HIV INFECTION</td>
<td>Ulrike C. Lange, Christoph P. Schwarz, Julia K. Bliek, Thomas Walther, Roxane Verdikt, Carine M. Van Lint, Joachim Hauber</td>
</tr>
</tbody>
</table>
308 DIFFERENTIAL DECAY OF INTACT AND DEFECTIVE PROVIRUS IN INDIVIDUALS ON SUPPRESSIVE ART
Michael J. Peluso, Peter Bacchetti, Kristen D. Ritter, Subul A. Beg, Jun Lai, Jeffrey Martin, Peter W. Hunt, Timothy J. Henrich, Janet Siliciano, Robert Siliciano, Gregory Laird, Steven G. Deeks

309 DISTINCT HIV RESERVOIR MEASURES CORRELATE WITH DEFECTIVE BUT NOT INTACT PROVIRAL DNA
Emmanouil Papasavvas, Livio Azzoni, Brian Ross, Matthew Fair, Amelie Pagliuca, Steven Lada, Guoxin Wu, Paul Zuck, Pablo Tebas, Karam Mounzer, Jay Kostman, Douglas D. Richman, Nicolas Chomont, Bonnie J. Howell, Luis Montaner

310 RISK AND PREVALENCE OF RESIDUAL VIREMIA AFTER cART IN RESOURCE-LIMITED COUNTRIES
Sivaporn Gatechompol, Anchalee Avihingsanon, Lu Zheng, Yajing Bao, Stephen J. Kerr, Nagalingeswaran Kumorasamy, James G. Hakim, Frank Malcorelli, Rob Gerecke, Jeffrey D. Lifson, Mina C. Hosseinipour, Joseph J. Eron, Kiat Ruxrungtham, for the ACTG NWCS 425 Team

311 A NOVEL DDPCR PROTOCOL TO ESTIMATE COPY NUMBERS OF POTENTIALLY INTACT HIV-1 PROVIRUS
Claire Levy, Sean Hughes, Pavitra Roychoudhury, Daniel B. Reeves, Chelsea Amstuz, Haiying Zhu, Meei-Li Huang, Yulun Wei, Marta E. Bull, Noah A. Cassidy, Dara Lehman, Jan McClure, Robert Coombs, Keith Jerome, Florian Hladik

312 QUANTITATIVE HIV-1 SPECIFIC ANTIBODIES AS PREDICTORS OF BLOOD HIV-1 DNA LEVELS
Margaret McManus, Brad Karalius, Kunjal Patel, Deborah Persaud, Katherine Luzuriaga, for the Pediatric HIV/AIDS Cohort Study

313LB LONGITUDINAL QVOA AND IPDA MEASUREMENTS IN CD4 T CELLS FROM ART-SUPPRESSED DONORS
Shane Falcinelli, Jenna Read, Ross Murtagh, Sam Raines, Morgan Dewey, Nancie Archin, David M. Margolis

314 HIV TRANSCRIPTION PROFILE IN BLOOD, GUT, LIVER, AND GENITAL TRACT IN SUPPRESSED WOMEN
Sara Moron-Lopez, Grace Xie, Peggy Kim, Joseph K. Wong, Jennifer C. Price, Najwa Elnachif, Ruth Greenblatt, Phyllis Tien, Nadia R. Roan, Steven A. Yuki

315 INTACT PROVIRUSES FROM NAIVE AND EFFECTOR MEMORY T CELLS MATCH PERSISTENT VIREMIA
Katie Fisher, Bonnie Hiener, Bethany A. Horsburgh, Timothy E. Schluub, Eunok Lee, Vincent Morcilla, John-Sebastian Eden, Susanne Von Stockenstrom, Jeffrey M. Milush, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer

316 HIV Gag p24 PERSISTS IN TISSUE AND CORRELATES WITH IMMUNE RESPONSE
Guoxin Wu, Paul Zuck, Shih Lin Goh, Timothy Schacker, Steven G. Deeks, Daria Hazuda, Peter W. Hunt, Bonnie J. Howell, Schuyler Metzger, Dhrupal Patel, Ashley Haase
317 LACK OF COMPARTMENTALIZATION IN THE LATENT RESERVOIR OF BLOOD AND LYMPH NODES
Charles Kirby, Jada Hackman, Alyssa R. Martin, Alexandra M. Bender, Kyungyoon J. Kwon, Craig Martens, Michael J. Bale, Niraj Desai, Sander S. Florman, Dorry Segev, Aaron Tobian, Christine Durand, Robert Siliciano, Andrew D. Redd

318 CHARACTERIZATION OF CD8+ TRM TOWARD THE CONTROL OF THE HIV RESERVOIR IN CERVIX
Núria Massana, Jon Cantero, Judith Grau-Exposito, Laura Luque-Ballesteros, Josep Castellvi, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Vicenç Falcó, María J. Buzón, Meritxell Genescà

319 FACTORS ASSOCIATED WITH VIRAL CONTROL AFTER STRUCTURED TREATMENT INTERRUPTION
Nikolaus Jilg, Behzad Etemad, Ruth Dele-Oni, Colline Wong, Jesse Fajnzylber, Abbas Mohammad, Evgenia Aga, Ronald Bosch, Daniel R. Kuritzkes, Ian Frank, Jeffrey Jacobson, Jonathan Z. Li

320 VIRAL REBOUND KINETICS FOLLOWING SINGLE AND COMBINATION IMMUNOTHERAPY FOR HIV/SIV
Melanie Prague, Jeffrey Gerold, Irene Balelli, Chloé Pasin, Jonathan Z. Li, Dan Barouch, James Whitney, Alison L. Hill

321 FREQUENCY OF POSTTREATMENT CONTROL VARIES BY ART RESTART AND VIRAL LOAD CRITERIA
Jesse Fajnzylber, Radwa Sharaf, Evgenia Aga, Ronald Bosch, Jeffrey M. Jacobson, Elizabeth Connick, Daniel Skiest, Michael Sneller, Ronald T. Mitsuyasu, Keith Henry, Tae-Wook Chun, Ann Collier, Frederick M. Hecht, Jonathan Z. Li, for the CHAMP Study Team

322 NONSTRUCTURED TREATMENT INTERRUPTIONS CONTRIBUTE TO LATENT HIV-1 RESERVOIR IN PWID
Gregory D. Kirk, Shruti H. Mehta, Jacqui Astemborski, Kristen D. Ritter, Gregory Laird, Robert Siliciano

323 PRESENCE MACROPHAGE-TROPIC HIV-1 VARIANTS FOLLOWING ANALYTIC TREATMENT INTERRUPTION
Viviane M. Andrade, Carla Mavian, Dunja Babic, Thaisa Cordeiro Alvarado, Mark Sharkey, Labelle Barrios, Christian Brander, Judith Dalmau, Michael S. Seaman, Marco Salemi, Javier Martinez-Picado, Mario Stevenson

324 THE ELUSIVE SOURCE OF HIV-1 REBOUND AFTER TREATMENT INTERRUPTION
Laurens Lambrechts, Basiel Cole, Marie-Angélique D. De Scheerder, Zoe Boyer, Ytse Noppe, Katie Fisher, John-Sebastian Eden, Wim Van Criel, Lisa Frenkel, Sarah Palmer, Linos Vandekerckhove

325 HIV POSTTREATMENT CONTROL DESPITE PLASMA VIRAL EVOLUTION AND DUAL INFECTION
Behzad Etemad, Golnaz Namazi, Ying Wen, Nikolaus Jilg, Elmira Esmaeilzadeh, Xin Zhang, Radwa Sharaf, Daniel MacMillan, Ronald Bosch, Evgenia Aga, Jeffrey A. Johnson, Rajesh T. Gandhi, Zabrina Brumme, Mary F. Kearney, Jonathan Z. Li
326 EVALUATING BIOMARKERS FOR HIV REBOUND DURING TREATMENT INTERRUPTION
Marie-Angélique D. De Scheerder, Clarissa Van Hecke, Henrik Zetterberg, Dietmar Fuchs, Nele De Langhe, Sofie L. Rutsaert, Bram Vrancken, Wim Trypsteen, Sarah Palmer, Philippe Lemey, Magnus Gisslén, Linos Vandekerckhove

Poster P-F01 NEUROIMAGING AND ASSOCIATED BIOMARKERS
Poster Hall A
2:30 PM - 4:00 PM

387 REDUCED MEMORY, FUNCTIONAL CONNECTIVITY IN 41- TO 70-YEAR-OLD HIV+ APOE E4 CARRIERS
Fan N. Yang, Margarita Bronshteyn, Sarah A. Flowers, Matthew Dawson, Monica M. Diaz, Harvey R. Fernandez, Princy N. Kumar, G. W. Rebeck, Raymond S. Turner, David J. Moore, Ronald J. Ellis, Xiong Jiang

388 NEUROCOGNITIVE AND VOLUMETRIC CHANGES AFTER 24 WEEKS OF DTG/3TC/ABC DISCONTINUATION
Ignacio Pérez-Valero, Alfonso Cabello, Pablo Ryan, Maria Luisa Montes, Sara De La Fuente Moral, Maria J. Vivancos-Gallego, Guillermo Cuevas, Alberto Diaz De Santiago, Lucio Jesus Garcia-Fraile Fraile, Mario Gil-Correa, Norberto Malpica, Guadalupe Rua, Maria Yllescas, Alicia Gonzalez

389 HIV IS INDEPENDENTLY ASSOCIATED WITH BRAIN MRI WHITE MATTER HYPERINTENSITIES

390 BRAIN AGE BASED ON SLEEP ENCEPHALOGRAPHY IS ELEVATED IN HIV+ ADULTS ON ART
Michael Leone, Haoqi Sun, Christine Boutros, Robert Thomas, Gregory K. Robbins, Shibani S. Mukerji, M. Brandon Westover

391 NEUROINFLAMMATION AND REACTIVE GLIOSIS DURING LONG-TERM CART INITIATED IN ACUTE HIV
Napapon Sailasuta, Phillip Chan, Carlo Sadcalan, Sompong Tipsuk, Duangghathai Suttichom, Nittaya Phanuphak, Shayane Martin, Nisakorn Ratnaratorn, Mantana Pothisri, Netsiri Dumrongpisutikul, Jintanat Ananworanich, Victor Valcour, Sandhya Vasan, Serena S. Spudich, Robert Paul

392 LOWER PHYSICAL ACTIVITY AND FITNESS LEVELS ARE ASSOCIATED WITH SMALLER BRAIN VOLUMES
Brittany Nelson, Sarah A. Cooley, Dominic Reeds, William T. Cade, Anna Boerwinkle, Christopher J. Sorensen, Beau Ances

393 ACTIVE LIFESTYLE IS ASSOCIATED WITH BETTER BRAIN FUNCTION IN PERSONS LIVING WITH HIV
Jeremy Strain, Collin Killgore, Dimitre Tomov, Sarah A. Cooley, Brittany Nelson, Beau Ances

394 EFFECTS OF PERINATAL HIV INFECTION ON THE CORTICAL THICKNESS IN YOUNG ADULTHOOD
Manuela Martin-Bejarano, Beatriz Ruiz-Saez, Ana Martinez De Aragon, Carlos Velo, Mario Gil-Correa, Sara Guillen, Maria Luisa Lorente, Pablo Rojo Conejo, Berta Zamora, Talía Sainz, José Tomás Ramos, Juan Guzman, Maria Luisa Navarro, Maria Isabel González-Tomé, for the NeuroCoRISpe
395 EFFECT OF ANTICHOLINERGIC MEDICATIONS ON BRAIN INTEGRITY IN OLDER HIV-POSITIVE ADULTS  
Sarah A. Cooley, Beau Ances

396 EFFECTS OF VIRAL LOAD ON NEUROIMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE  
Sarah A. Cooley, Jaimie Navid, Julie Wisch, Jane A. O’Halloran, Beau Ances

397 MULTIMODAL BRAIN ABNORMALITIES ASSOCIATED WITH COGNITIVE IMPAIRMENT IN HIV INFECTION  
Christina S. Meade, Xiang Li, Sheri L. Towe, Ryan P. Bell, Syam Gadde, Nan-Kuei Chen, Jing Sui

398 IMPAIRED COGNITION AND REDUCED BRAIN VOLUMES IN YOUTH WITH BEHAVIORALLY ACQUIRED HIV  
Jennifer McGuire, Robert Brown, Ritobrato Datta, Giulia Fadda, Nichole Tuite, Jacqueline Harrison, Steven D. Douglas, Brenda Banwell

399 ALCOHOL USE IS ASSOCIATED WITH DEGRADATION OF BRAIN WHITE MATTER IN HIV INFECTION  

400 MICROSTRUCTURAL MRI CHANGES ASSOCIATED WITH COGNITIVE IMPAIRMENT IN CONTROLLED HIV  
Elizabeth F. Horne, Gina Norato, Lillian Ham, Joseph Snow, Daniel S. Reich, Bryan Smith, Govind Nair, Avindra Nath

443 LONG-TERM ADHERENCE MONITORING OF EMTRICITABINE IN HAIR BY MASS SPECTROMETRY IMAGING  
Elias Rosen, William M. Gilliland, Nicole White, Amanda Poliseno, Heather M. Prince, Angela Kashuba

444 CHARACTERIZING TFV-DP IN DBS FOR U=U IN YOUNG ADULTS WITH PERINATAL HIV INFECTION  

445 COMPARING TFV-DP & FTC-TP IN PBMC, RBC, NEUTROPHILS, & PLATELETS WITH F/TDF VS F/TAF  
Jenna Yager, Jose R. Castillo-Mancilla, Cricket McHugh, Kristina M. Brooks, Mustafa E. Ibrahim, Ryan P. Coyle, Bethany M. Johnson, Laura Roon, Jia-Hua Zheng, Lane R. Bushman, Jennifer J. Kiser, Peter L. Anderson

446 UTILITY OF MINIMALLY INVASIVE SPECIMENS TO INFORM ARV ADHERENCE TEST DEVELOPMENT  
Richard Haaland, Amy Martin, Melkam Mengesha, Chuong Dinh, Jeffrey Fountain, Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F. Kelley

447 REAL-LIFE MANAGEMENT OF DRUG-DRUG INTERACTIONS BETWEEN ANTIRETROvirALS AND STATINS  
Perrine Courlet, Françoise Livio, Susana Alves Saldanha, Alexandra Scherrer, Manuel Battegay, Matthias Cavassini, Marcel Stoeckle, Laurent A. Decosterd, Catia Marzolini, for the Swiss HIV Cohort Study
448 AGING DOES NOT IMPACT DRUG-DRUG INTERACTION MAGNITUDES INVOLVING ANTIRETROVIRAL DRUGS
Felix Stader, Perrine Courlet, Hannah Kinvig, Manuel Battegay, Laurent A. Decosterd, Melissa A. Penny, Marco Siccardi, Catia Marzolini

449 PLASMA & INTRACELLULAR PK AND RENAL SAFETY OF TAF 25MG WITH BOOSTED PI AND LDV/SOF
Kristina M. Brooks, Jose R. Castillo-Mancilla, Mary Morrow, Samantha MaWhinney, Joshua Blum, David L. Wyles, Jia-Hua Zheng, Bethany M. Johnson, Joe Gomez, Ye Ji Choi, Francesca Cendali, Hannah Haas, Lane R. Bushman, Peter L. Anderson, Jennifer J. Kiser

450 HIGH-DOSE RIFAMPICIN FOR THE TREATMENT OF LEPROSY IN HIV PATIENTS TAKING DOLUTEGRAVIR
Hannah Kinvig, Felix Stader, Fazila S. Bunglawala, Rajith Kumar Reddy Rajoli, Nicolas Cotture, Alice E. Howarth, Andrew Owen, Catia Marzolini, Marco Siccardi

451 TOTAL DOLUTEGRAVIR LEVELS DECREASED BUT FREE FRACTION INCREASED BY VALPROIC ACID
Henrieke A. Prins, Pauline Bollen, Kirsten Veltghoven, Bart Rijnders, Theodora de Vries-Sluijs, Els van Nood, Jan Nouwen, Hannelore Bax, Mariana de Mendonca Melo, Annelies Verbon, David M. Burger, Casper Rokx

452 PHARMACOKINETICS OF RUXOLITINIB WITH ART IN HIV-SUPPRESSED INDIVIDUALS (ACTG # A5336)
Selwyn Hurwitz, Sijia Tao, Yong Jiang, Christina Gavegnano, Charles W. Flexner, Randall Tressler, Athé Tisbris, Steven G. Deeks, Carlos del Rio, Edgar T. Overton, Jeffrey J. Lennox, Vincent C. Marconi, Raymond F. Schinazi

Poster P-H01 ANTIRETROVIRAL THERAPY: OUTCOMES IN TREATMENT-NAIVE PATIENTS
Poster Hall A 2:30 PM - 4:00 PM

474 CD4/CD8 RECOVERY AND FIRST-LINE ART: GREATEST IMPROVEMENT WITH INTEGRASE INHIBITORS
Sergio Serrano-Villar, Javier Martínez-Sanz, Raquel Ron, Alba Talavera, Borja Fernández, Francisco Fanjul, Joaquín Portilla, Josefina Muñoz, Concha Amador, Miguel Alberto De Zárraga, Matilde Sanchez-Conde, Sabina Herrera, Pilar Vizcarra, María J. Vivancos-Gallego, Santiago Moreno

475 CLINICAL AND LABORATORY OUTCOMES 24 WEEKS AFTER STARTING DTG VERSUS EFV IN ACUTE HIV
Phillip Chan, Orlanda Goh, Donn J. Colby, Carlo Sacdalan, Camilla Muccini, Nittaya Phanuphak, Suteeraporn Pinyakorn, Praphan Phanuphak, Nittiya Chomchey, Robert Paul, Sandhya Vasan, Serena S. Spudich, Jintanat Ananworanich, Eugène Kroon, for the RV254 Research Group

476 RAPID ART IN BLOOD DONORS WITH ACUTE AND RECENT HIV INFECTION IN SOUTH AFRICA
Karin Van Den Berg, Marion Vermeulen, Sonia Bakkour, Mars Stone, Coreen Barker, Christopher McClure, Darryl Creel, Ute Jentsch, Genevieve Jacobs, Brian Custer, Michael P. Busch, Edward Murphy, for the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)

477 144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT-NAIVE ADULTS $\geq$50 YRS
478  CD4:CD8 NORMALIZATION BY INTEGRASE INHIBITORS AMONG TREATMENT-NAIVE PATIENTS
Alice Zhabokritsky, Leah Szadkowski, Alison McClean, Robert S. Hogg, Curtis Cooper, Marina Klein, Zabrina Brumme, Sharon Walmsley, for the CANOC Collaboration

479  PERSISTENT POOR CLINICAL OUTCOMES FOR AIDS PRESENTATION IN ITALY OVER THE LAST DECADE
Annalisa Mondi, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Antonella Cingolani, Mariana Farenga, Stefano Rusconi, Gabriella De Girolamo, Andrea Gori, Marta Camici, Cristina Mussini, Antonella D’Arminio Monforte, Andrea Antinori, for the Icona Foundation Study Group

480  EMULATION OF AN RCT OF DOLUTEGRAVIR VS BOOSTED-DARUNAVIR IN ADVANCED ART NAIVE

481  FLOW CYTOMETRIC SCREENING OF HLA-B17 IN HIV+ PATIENTS UNDERGOING ABACAVIR THERAPY
Arianna Gatti, Cristina Ceriani, Bruno Brando, Maurizio Mena, Paolo Viganò, Massimo De Paschale, Pierangelo Clerici

482LB  LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS
Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Denis Gusey, Olaf Degen, Juan González-García, Ronald D’Amico, David Dorey, Sandy Griffith, David A. Margolis, Marty St Clair, Peter E. Williams, William Spreen

Poster P-I01 PREVALENCE OF PRETREATMENT RESISTANCE
Poster Hall A  2:30 PM - 4:00 PM

509  PREEXISTING RESISTANCE AND B/F/TAF SWITCH EFFICACY IN AFRICAN AMERICANS
Kristen Andreatta, Michelle L. D’Antoni, Silvia Chang, Ross Martin, Christiana Blair, Sean E. Collins, Kirsten L. White

510  TRANSMITTED DRUG RESISTANCE IN PEOPLE LIVING WITH DIAGNOSED HIV IN CALIFORNIA
Jing Feng, Deanna Sykes, Philip Peters, Joel O. Wertheim

511  TRENDS IN TRANSMITTED DRUG RESISTANCE IN SPAIN THROUGH THE PERIOD 2007-2018
Carlos Guerrero Beltrán, Marta Alvarez, Antonio Aguilera, María Carmen Vidal Ampurdanes, Marina Martinez, Arkaitz Imaiz, Asunción Iborra, Juan L. Gomez-Sirvent, Joaquim Peraire, Joaquín Portilla, Estrella Caballero, Mónica García-Álvarez, José A. Iribarren, Mar Masiá, Federico García

512  US HIV DRUG RESISTANCE: IMPLICATIONS FOR CURRENT AND FUTURE PrEP REGIMENS
513  COUNTRY-LEVEL DRIVERS OF NNRTI RESISTANCE IN SOUTHERN AFRICA  

514  ADVANCE TRIAL: HIGHER RISK OF TREATMENT-EMERGENT RESISTANCE ON FIRST-LINE TDF/FTC/EFV  
  Willem D. Venter, Michelle A. Moorhouse, Simiso Sokhela, Simiso Sokhela, Bryony Simmons, Andrew Hill

515  PRETREATMENT AND ACQUIRED ANTIRETROVIRAL DRUG RESISTANCE IN 4 AFRICAN COUNTRIES  
  Trevor A. Crowell, Brook Danboise, Ajay Parikh, Allahna L. Esber, Alex Kasembeli, Samoel Khamadi, Michael Iroeziindu, Francis Kiweewa, John Owuoth, Joanna Freeman, Jennifer Malia, Linda Jagodzinski, Julie Ake, Christina Polyak, for the AFRICOS Study Group

516  HIV VIROLOGIC FAILURE AND DRUG RESISTANCE AMONG HOSPITAL INPATIENTS IN MALAWI  

517  HIGH LEVELS OF DRUG RESISTANCE IN ART-NAIVE AND PLWH FAILING FIRST-LINE ART IN HAITI  

518  PRETREATMENT HIV DRUG RESISTANCE AND 48-WEEK VIROLOGIC OUTCOMES IN THE ADVANCE TRIAL  
  Mark J. Siedner, Michelle A. Moorhouse, Andrew Hill, Tulio de Oliveira, Richard Lessells, Bryony Simmons, Godspower Akpomiemie, Celicia M. Serenata, Willem D. Venter, Ravindra K. Gupta

519  IMPACT OF PREEXISTING DRUG RESISTANCE ON RISK OF VIROLOGIC FAILURE IN SOUTH AFRICA  

520  TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS PREDICTS VIROLOGIC FAILURE AND RESISTANCE  
  Jose R. Castillo-Mancilla, Yuan Zhao, Jaysingh Brijkumar, Brent Johnson, Alex Edwards, Pillay Selvan, Melendhran Pillay, Pravi Moodley, Mahomed-Yunus Moosa, Daniel R. Kuritzkes, Henry Sunpath, Lane R. Bushman, Lucas Ellison, Peter L. Anderson, Vincent C. Marconi

541  INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID  
  Eve-Marie A. Benson, Shruti H. Mehta, Jacquie Astemborski, David L. Thomas, Gregory D. Kirk
**Poster Sessions**

**Monday, February 24, 2020**

**542** RELATIONSHIPS BETWEEN HEPATIC STEATOSIS AND FRAILTY DIFFER BY HIV SEROSTATUS
Paula Debruyne, Benjamin Barrett, Kristine M. Erlandson, Matthew Budoff, Todd T. Brown, Jennifer C. Price, Wendy Post, Valentina Stosor, Carling Lellock, Gypsyamber D’Souza, Jordan E. Lake

**543** NAFLD AND LIVER FIBROSIS PREDICT HIGH CARDIOVASCULAR RISK IN HIV-MONONEFECTED PATIENT
Giovanni Mazzola, Adriana Cervo, Giovanni Guaraldi, Thomas Krahn, Jovana Milic, Annamaria De Luca, Claudia Gioè, Benedetta Romanin, Marcello Trizzino, Sergio Mazzola, Pietro Colletti, Salvatore Petta, Giada Sebastiani, Antonio Cascio

**544** “FIB-4 FIRST” STRATEGY IN A NAFLD PATHWAY ASSESSMENT FOR HIV MONONEFECTED PATIENTS
Adriana Cervo, Thomas Krahn, Jovana Milic, Sahar Saeed, Bertrand Lebouché, Marina Klein, Philip Wong, Marc Deschenes, Peter Ghali, Antonio Cascio, Giovanni Mazzola, Giovanni Guaraldi, Giada Sebastiani

**545** TRYPTOPHAN CATABOLISM IS ALTERED AMONG PERSONS WITH HIV WHO HAVE STEATOSIS
Andreas D. Knudsen, Marco Gelpi, Søren Bjørnskov, Ditte M. Kirkegaard-Klitbo, Anne-Mette Lebech, Henrik Ullum, Klaus F. Kofod, Øivind Midttun, Per M. Ueland, Jens D. Lundgren, Susanne D. Nielsen

**546** IL-18 IS ASSOCIATED WITH HEPATOSTEATOSIS AND HIGHER LIVER ENZYMES IN PEOPLE WITH HIV
Jae H. Sim, Julia B. Sherman, Kathleen V. Fitch, Sara E. Looby, Jake A. Robinson, Michael Lu, Steven K. Grinspoon, Tricia H. Burdo, Janet Lo

**547** EASL BIOMARKERS DIFFER IN PREDICTING NAFLD, NASH, AND FIBROSIS IN HIV +/- INDIVIDUALS
Ricky Hsu, Laurence Brunet, Jennifer S. Fusco, Gregory Fusco

**548** AN RCT OF Raltegravir- Versus Efavirenz-Based ART in HIV-HCV Coinfection
Thuy Le, Chau V. Nguyen, Thao P. Vu, Ly T. Vo, Thanh T. Nguyen, Thu T. Nguyen, Robert Paul, Lishomwa C. Ndlovu, Dominic Chow, Cecilia M. Shikuma

**549** HEPATIC STEATOSIS ASSOCIATED WITH EXPOSURE TO ELVITEGRAVIR AND Raltegravir
Thomas Benfield, Jens D. Lundgren, Flemming Bendtsen, Susanne D. Nielsen, Ditte M. Kirkegaard-Klitbo

**550** BENEFITS OF RILPIVIRINE FOR LIVER FIBROSIS IN HIV/HCV COINFECTED SUBJECTS
Maria Luisa Montes, Carmen Busca, Antonio Olveira, Luz Martín-Carbonero, Eulalia Valencia, Victoria Moreno, Jose I. Bernardino, Ignacio Pérez-Valero, Rocío Montejano, Rafael Micán, Rosa De Miguel, Jose H. Arribas, Juan González-Garcia

---

**Poster P-J02 HCV: FIBROSIS, MORTALITY, AND OTHER LONG-TERM COMPLICATIONS**

**Poster Hall B**

**2:30 PM - 4:00 PM**
551  ACCURACY OF FIBROSIS-4 FOR CIRRHOSIS IN HIV+ PATIENTS WITH HEPATOCELLULAR CARCINOMA
Jessie Torgersen, Michael J. Kallan, Dena M. Carbonari, Lesley S. Park, Rajni Mehta, Kathryn D’Addeo, Janet Tate, Joseph Lim, Matthew B. Goetz, Maria Rodriguez-Barradas, Norbert Bräu, Sheldon T. Brown, Tamar Taddei, Amy C. Justice, Vincent Lo Re

552  PLASMA MIR-99A AND MIR-100 PREDICT LIVER FIBROSIS PROGRESSION IN HIV/HCV SUBJECTS
Miguel Angel Martinez, Sandra Franco, Daniela Buccione, Beatriz Mothe, Patricia Cobarsi, Lidia Ruiz, Maria Nevot, Ana Jordan-Paiz, Raquel Pluvinet, Lauro Sumoy, Cristina Tural

553  HEPATIC FIBROSIS DETERMINED WITH MRE SIGNIFICANTLY PREDICTS COGNITIVE IMPAIRMENT
Mariana K. Baum, Javier Tamargo, Richard L. Ehman, Chrisina S. Meade, Kenneth E. Sherman, Heidi L. Meeds, Jun Chen, Sabrina S. Martinez, Gustavo G. Zarini, Yongjun Huang, Colby Teeman, Jacqueline Hernandez, Angelique Johnson, Raul Mandler, Adriana Campa, for the MASH Team

554  CHANGES IN LIVER CANCER SURVIVAL IN HIV INFECTION AFTER MANAGEMENT OPTIMIZATION
Miguel Rodriguez-Fernández, Nicolás Merchante, Francisco Rodríguez-Arondo, Borís Revollo, Sofía Ibarra, Esperanza Merino, María J. Galindo, Marta Montero, Francisco Téllez, Antonio Rivero-Juárez, Miguel García-Deltoro, Ignacio D. Santos Gil, Marcial Delgado-Fernández, Juan A. Pineda, for the Grupo para el Estudio de las Hepatitis Víricas (GEHEP-002)

555  LIVER PATHOLOGY IN HIV-POSITIVE SUBJECTS UNDERGOING LIVER TRANSPLANTATION
Roberto Rossotti, Marco Merli, Chiara Mazzarelli, Stefano Di Sandro, Mario L. Camozzi, Giovanna Travi, Raffaella Viganò, Andrea Lauterio, Emanuela Bonoldi, Luca S. Belli, Luciano G. De Carlis, Massimo Puoti

556  EPIDEMIOLOGICAL TREND OF CHRONIC HEPATITIS C IN SPAIN (2000-2015): NATIONWIDE STUDY
Irene Maté-Cano, Alejandro Alvaro-Meca, Paula Martínez-Román, Óscar Brochado Kith, Pablo Ryan, Salvador Resino, Verónica Briz

557  HEPATITIS C COINFECTION AND EXTRAHEPATIC CANcer INCIDENCE AMONG PEOPLE WITH HIV
Sarah J. Willis, H. Nina Kim, Chad J. Achenbach, Edward R. Cachay, Katerina A. Christopoulos, Heidi M. Crane, Ricardo A. Franco, Christopher B. Hurt, Mari M. Kitahata, Richard D. Moore, Michael J. Silverberg, Phyllis Tien, Daniel Westreich, Julia L. Marcus

558  SYNDROME OF VIRAL COINFECTIONS AND INCIDENT END-STAGE RENAL DISEASE
Dahn Jeong, Carmine Rossi, Stanley Wong, Zahid A. Butt, Geoff W. McKee, Jason Wong, Amanda Yu, Mawuena Binka, Maria Alvarez, Prince Adu, Mel Krajden, Naveed Z. Janjua

559  CAUSE OF DEATH AMONG THOSE DIAGNOSED WITH HEPATITIS C IN WASHINGTON, DC, 2009-2017
Jenevieve Opoku, Adam Allston

560  CAUSES OF DEATH IN PERSONS WITH AND WITHOUT HCV INFECTION
Adeel A. Butt, for the ERCHIVES Study Team
Poster P-K01 ANAL AND CERVICAL CANCER
Poster Hall B  2:30 PM - 4:00 PM

619  THE ROLE OF E6/E7 mRNA DETERMINATION FOR ANAL CANCER SCREENING IN HIV-POSITIVE MSM
Ana C. Silva-Klug, Maria Saumoy, Montserrat Torres, Loris Trenti, Sonia Paytubi, Laia Alemany, Isabel Català, Nuria Baixeras, August Vidal, Silvia De Sanjosé, Daniel Podzamczer

620  ANAL CANCER SCREENING: IS IT TIME FOR CYTOLOGY AND HIGH-RISK HPV COTESTING?
Michael Gaisa, Yuxin Liu, John Winters, Ashish A. Deshmukh, Keith M. Sigel

621  LOW ADHERENCE TO TREATMENT AND SURVEILLANCE OF HPV-RELATED ANAL PRECANCER
Richard Silvera, Michael Gaisa, Yuxin Liu, Ashish A. Deshmukh, Keith M. Sigel

622  ANAL PRECANCER SCREENING AMONG MSM: WHAT IS THE BEST STRATEGY?
Jing Sun, Dorothy J. Wiley, Teresa Darragh, Hilary K. Hsu, Nancy Joste, Stephen Young, W. David Hardy, Susheel Reddy, Jeremy J. Martinson, Gypsyamber D’Souza, for the Multicenter AIDS Cohort Study (MACS)

623  NEED FOR OPTIMIZATION OF SCREENING METHODS FOR ANAL INTRAEPITHELIAL NEOPLASIA IN PLWH

624  CERVICAL CANCER KNOWLEDGE AND ATTITUDES AMONG HIV-POSITIVE MEN IN MALAWI
Corrina Moucheraud, Samuel W. Lewis, Misheck Mphande, Ben Allan Banda, Hitler Sigauke, Paul Kawale, Aubrey Dkangoma, Kathryn Dove, Alemayehu Amberbir, Agnes Moses, Sundeep Gupta, Risa M. Hoffman

Poster P-L01 INFLAMMATORY BIOMARKERS AND CARDIOVASCULAR OUTCOMES
Poster Hall B  2:30 PM - 4:00 PM

635  HOST GLYCOMIC DETERMINANTS OF CORONARY ATHEROSCLEROSIS DURING TREATED HIV INFECTION
Leila B. Giron, Susan Langan, David B. Hanna, Juan Lin, Mohammad Damra, Qin Liu, Ian Frank, Mallory Witt, Lawrence Kingsley, Frank J. Palella, Wendy Post, Alan Landay, Todd T. Brown, Mohamed Abdel-Mohsen

636  ADVANCED GLYCATION END PRODUCTS ASSOCIATED WITH CARDIOMETABOLIC RISK ON ART
Vanessa El Kamari, Katherine Rodriguez, Carlee Moser, Judith S. Currier, Theodoros Kelesidis, James H. Stein, Scott K. Howell, Paul J. Beisswenger, Todd T. Brown, Grace A. McComsey

637  SINGLE-CELL TRANSCRIPTOMICS OF HIV HEART TISSUE IDENTIFIES UNIQUE NK CELL POPULATION
Thomas C. Martin, Neil C. Chi, Sara Gianella, Sebastian Preissl, Justin Buchanan, Davey M. Smith, Priscilla Hsie
638 CAROTID PLAQUE BURDEN IN HIV IS ASSOCIATED WITH SOLUBLE MEDIATORS AND MONOCYTES
Dominic Chow, Makoa Mau, Howard Hodis, Yanjie Li, Chathura Siriwardhana, Scott A. Souza, Brooks I. Mitchell, Scott Bowler, Louie Mar A. Ganguancco, Lishomowa C. Ndhlovu, Cecilia M. Shikuma

639 INCREASED LEUKOCYTE/PLATELET INTERPLAY WITH ENDOTHELIUM IN ABC-TREATED HIV PATIENTS
Maria Amparo Blanch-Ruiz, Ainhoa Sanchez-Lopez, Raquel Ortega-Luna, Patricia Garcia-Martinez, Samuel Orden, Maria Angeles Martinez-Cuesta, Ramon Ferrando-Vilata, Maria J. Galindo, Angeles Alvarez, Juan V. Esplugues

640 FIBROBLAST GROWTH FACTOR 21: EFFECT OF HIV THERAPY AND ASSOCIATION WITH CVD RISK
Corrilynn O. Hileman, Sarah E. Scott, Beth A. Zavoda-Smith, Grace A. McComsey

641 MONOCYTE ACTIVATION AND CARDIAC-MRI–DERIVED VASCULAR DYSFUNCTION AMONG WOMEN WITH HIV

642 TESTOSTERONE THERAPY AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION AMONG MEN WITH HIV
Sabina A. Haberlen, Wendy Post, Matthew Budoff, Jordan E. Lake, Adrian Dobs, Frank J. Palella, Michael Plankey, Anne K. Monroe, Lawrence Kingsley, Todd T. Brown

643 POSTDISCHARGE OUTCOMES FOLLOWING ACUTE CORONARY SYNDROME IN HIV
Monica Parks, Eric A. Secemsky, Changyu Shen, Robert W. Yeh, Eunhee Choi, Dhruv Kazi, Priscilla Hsieh

644 INSOMNIA AND RISK OF INCIDENT MYOCARDIAL INFARCTION AMONG PEOPLE LIVING WITH HIV

645 HORMONE USE AND HIV ALTER CARDIOVASCULAR BIOMARKER PROFILES IN TRANSGENDER WOMEN
Jordan E. Lake, Ruibin Wang, Benjamin Barrett, Nicholas Funderburg, Emily Bowman, Paula Debroy, Judy Candelario, Linda Teplin, Jessica McGuinness, Robert Bolan, Heather McKay, Michael Plankey, Todd T. Brown, Judith S. Currier

646 HIV SEVERITY AND INCIDENT HEART FAILURE AMONG PATIENTS IN A LARGE HEALTH CARE SYSTEM
### Poster Sessions • Monday

#### Poster P-M03 METABOLIC COMPLICATIONS

**Poster Hall B**  
2:30 PM - 4:00 PM

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>682</td>
<td><strong>RISK FOR INCIDENT DIABETES IS GREATER IN PREDIABETIC MEN WITH HIV THAN WITHOUT HIV</strong></td>
<td>Laurence Slama, Benjamin Barrett, Alison Abraham, Frank J. Palella, Lawrence Kingsley, Jean-Paul Viard, Jordan E. Lake, Todd T. Brown, for the MACS</td>
</tr>
<tr>
<td>683</td>
<td><strong>GLYCEMIC STATUS AND PHYSICAL FUNCTION AMONG MEN WITH AND WITHOUT HIV</strong></td>
<td>Mary Clare Masters, Jingyan Yang, Jordan E. Lake, Alison Abraham, Lawrence Kingsley, Todd T. Brown, Frank J. Palella, Kristine M. Erlandsson</td>
</tr>
<tr>
<td>684</td>
<td><strong>GREATER INCIDENCE OF DIABETES OVER 10 YEARS AMONG DEPRESSED US VETERANS WITH HIV</strong></td>
<td>Kassem Bourgi, Suman Kundu, Jesse C. Stewart, Matthew Freiberg, Samir K. Gupta</td>
</tr>
<tr>
<td>685</td>
<td><strong>TRICARBOXYLIC ACID METABOLITES PREDICT METABOLIC COMORBIDITIES AND DEATH IN AGING PWH</strong></td>
<td>Corrilynn O. Hileman, Sausan Azzam, Daniela Schlatzer, Kunling Wu, Katherine Tassiopoulos, Roger Bedimo, Ronald J. Ellis, Kristine M. Erlandsson, Susan L. Koletar, Alan Landay, Frank J. Palella, Muralidhar Pallaki, Babafemi Taiwo, Charles L. Hoppel, Robert Kalayjian</td>
</tr>
<tr>
<td>686</td>
<td><strong>ISLATRAVIR METABOLIC OUTCOMES IN PHASE II B TRIAL OF TREATMENT-NAIVE ADULTS WITH HIV-1</strong></td>
<td>Grace A. McComsey, Jean-Michel Molina, Yazdan Yazdanpanah, Edwin DeJesus, Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, Todd A. Correll, Michael N. Robertson, Carey Hwang, George J. Hanna, Peter Sklar</td>
</tr>
</tbody>
</table>

#### Poster P-M04 RENAL DISEASE

**Poster Hall B**  
2:30 PM - 4:00 PM

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>689</td>
<td><strong>eGFR RECOVERY 96 WKS AFTER A TDF TO TAF OR ABC SWITCH FOR TDF-ASSOCIATED eGFR DECLINE</strong></td>
<td>Rosanne Verwijs, Ingeborg Wijting, Marjo Van Kasteren, Jan G. Hollander, Inge Derdelinckx, Guido Van Den Berk, Saskia Vrouwenraets, Mark Claassen, Wouter Bierman, Casper Rokx, Bart Rijnders</td>
</tr>
<tr>
<td>690</td>
<td><strong>CHRONIC KIDNEY DISEASE IN PEOPLE WITH HIV OF AFRICAN ANCESTRY IN THE UK</strong></td>
<td>Lisa Hamzah, Rachel Hung, John Booth, Rachel Hilton, Mark Harber, Catherine Cosgrove, Sarah Pett, Fiona M. Burns, Amanda Clarke, Andrew Ustianowksi, Beatriz Santana-Suarez, Elizabeth Binns-Roemer, Caroline Sabin, Frank Post, for the GEN-AFRICA Study Team</td>
</tr>
</tbody>
</table>
691  **FERRITIN AND TRANSFERRIN INDEPENDENTLY REFLECT RENAL FUNCTION IN PEOPLE WITH HIV**
Harpreet Kaur, Ronald J. Ellis, Donald Franklin, Scott L. Letendre, Asha R. Kallianpur

**Poster P-M05 BONE DISEASE**
**Poster Hall B**
2:30 PM - 4:00 PM

692  **CHANGE IN TRABECULAR BONE SCORE (TBS) AFTER ZOLEDRONIC ACID INFUSION OR TDF SWITCH**
Jennifer Hoy, Stephen J. Kerr, Didier Hans, Nicholas Pocock, Andrew Carr, for the ZeST Study Group

693  **LOW BONE MINERAL DENSITY IN OLDER PEOPLE WITH HIV: THE RENAL-BONE AXIS AND ART**
Elena Alvarez-Barco, Lucy Campbell, Alejandro A. Garcia, Ian Walsh, Willard Tinago, Jennifer J. Brady, Keith Burling, Sebastian Noe, Marie Neuville, Francois Jouret, Mingjin Yan, Hiba Graham, Martin Rhee, Frank Post, Patrick W. Mallon

694  **BONE MINERAL DENSITY IMPROVES IN WOMEN WHO SWITCH FROM TDF/FTC/NNRTI TO ABC/3TC/DTG**
Fowzia Ibrahim, Amanda Samarawickrama, Yvonne Gilleece, Julie Fox, Nargis Hemat, Stephen Kegg, Chloe Orkin, Lisa Hamzah, Jonathan Ainsworth, Birgit Barbini, Lucy Campbell, Frank Post, for the BESTT Trial Team

695  **BONE DENSITY IN ART TREATED HIV+ AND HIV- SUBJECTS IN FOLLOW UP; HIV UPBEAT RESULTS**

**Poster P-M07 MENTAL HEALTH COMPLICATIONS**
**Poster Hall B**
2:30 PM - 4:00 PM

701  **START OR SWITCH OF INTEGRASE INHIBITORS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV**

702  **PTSD SYMPTOMS AND HYPERAROUSAL INFLUENCED BY CHILDHOOD TRAUMA IN WOMEN WITH HIV**
Gretchen Neigh, Vasiliki Michopoulos, Rebecca Hinrichs, Sierra Carter, Igho Ofotokun, Tanja Jovanovic

703  **DYSREGULATED SYNTHESIS OF NEUROTRANSMITTERS IN METHAMPHETAMINE USERS LIVING WITH HIV**
Antonio Chahine, Tulay Koru-Sengul, Daniel J. Feaster, Nichole Klatt, Margaret Roach, Suresh Pallickuth, Mark Sharkey, Jessica Salinas, Mario Stevenson, Savita Pahwa, Dietmar Fuchs, Adam W. Carrico
717 IMPACT OF TREAT-ALL GUIDELINES ON TB INCIDENCE AMONG PLWH IN RIO DE JANEIRO, BRAZIL

718 ESTIMATING TB TRANSMISSION IN PRIMARY CARE CLINICS IN TB/HIV HIGH-BURDEN SETTINGS
Kathrin Zürcher, Carl Morrow, Julien Riou, Simon Bertschinger, Marie Ballif, Keren Middelkoop, Robin Wood, Matthias Egger, Lukas Fenner, for the IeDEA Consortium

719 ALARMING TUBERCULOSIS RATE AMONG PWID IN VIETNAM
Nicolas Nagot, Vu H. Vinh, Khuat T. Oanh, Delphine Rapoud, Hoang T. Giang, Catherine Quillet, Pham M. Khue, Roselyne Vallo, Thanh T. Nham, Jean-Pierre Moles, Don Des Jarlais, Duong T. Huong, Phuong N. Lan, Thuy T. Dong, Didier Laureillard

720 PREVALENCE OF TB SYMPTOMS, DIAGNOSIS, AND TREATMENT AMONG HIV PATIENTS NOT ON ART
Alana T. Brennan, Mharia Maskew, Bruce Larson, Isaac Tsikhurstu, Margaret Bii, Lungisile Vezi, Matthew P. Fox, Willem D. Venter, Peter Ehrenkranz, Sydney Rosen

721 HOUSEHOLD AIR POLLUTION INCREASES RISK FOR PULMONARY TB IN HIV-INFECTED ADULTS
Patrick Katoto, Bihehe Masemo, Amanda S. Brand, Aline Kusinza, Brian Allwood, Richard Van Zyl-Smit, Nadia A. Sam-Agudu, David Dowdy, John Z. Metcalfe, Grant Theron, Kevin Mortimer, Jeroen Vanorbeek, Tim Nawrot, Benoiit Nemery, Jean B. Nachega

722 ALCOHOL USE IS ASSOCIATED WITH INCIDENT TB INFECTION IN HIV+ AND HIV– UGANDAN ADULTS
Sarah B. Puryear, Atukunda Mucunguzi, Laura B. Balzer, Joel Kironde, Judith A. Hahn, Florence Mwangwa, Dalsone Kwariisima, Moses R. Kamy, Maya L. Petersen, Edwin D. Charlebois, Diane V. Havlir, Gabriel Chami, Carina Marquez

723 TUBERCULOSIS EVALUATION AMONG HIV-POSITIVE PATIENTS ON ANTIRETROVIRAL THERAPY
Meaghan L. Peterson, Catherine Nichols, Rena Fukunaga, Joseph S. Cavanaugh, Patricia Hall, Erin Rottinghaus, N. Sarita Shah, Adam MacNeil

724 TUBERCULOSIS PREVENTIVE TREATMENT IN NEW VS EXISTING ANTIRETROVIRAL THERAPY PATIENTS
Meaghan L. Peterson, Rena Fukunaga, Joseph S. Cavanaugh, Allison Moffitt, Adam MacNeil

725 POTENTIAL IMPACT OF LATENT TUBERCULOSIS IN PEOPLE LIVING WITH HIV
Katharina Kusejko, Huldrych F. Günthard, Kyra Zens, Katharine Darling, Nina Khanna, Hansjakob Furrer, Pauline Vetter, Enos Bernasconi, Pietro L. Vernazza, Roger Koyous, Johannes Nemeth, for the Swiss HIV Cohort Study
726  GEOGRAPHIC AND INDIVIDUAL RISK FACTORS FOR TB OR DEATH IN THE BRIEF-TB TRIAL (A5279)
Cynthia Riviere, Marc Antoine Jean Juste, Ritesh Ramchandani, Amita Gupta, Constance A. Benson, Gaerolwe Masheto, Khuanchai Supparatpinyo, Lerato Mohapi, Rodrigo O. Da Silva Escada, Rosie Mngqibisa, Cecilia Kanyama, Deborah Langat, Susan Swindells, Richard E. Chaissen, for the BRIEF TB/A5279 Study Team

727  ADJUSTED ANALYSIS OF EFFECT OF IPT ON ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH HIV
Gerhard B. Theron, Nahida Chakhtoura, Grace Montepiedra, Lisa Aaron, Patrick Jean-Philippe, Adriana Weinberg, Katie McCarthy, Teacler Nemataldzira, Gaerolwe Masheto, Tsungai Chipato, Carolyne Onyango-Makumbi, Amita Gupta

728  HIGH LEVELS OF ALCOHOL USE ASSOCIATED WITH LATENT TB INFECTION IN HIV-POSITIVE ADULTS

729  PRAGMATIC DOSING RECOMMENDATIONS OF RIFAPENTINE-CONTAINING REGIMENS FOR LATENT TB
Kendra K. Radtke, Jennifer E. Hibma, Radojka M. Savic

730  INCREASED HLA-DR EXPRESSION IN MONOCYTES OF PERSONS WITH HIV AND LATENT TB INFECTION
Moises A. Huaman, Steven Juchnowski, David A. Zidar, Cissy Kityo, Sophie Naluwago, Rashidah Nazzinda, Carl J. Fichtenbaum, Chris T. Longenecker

731  INTRAVENOUS BCG VACCINATION IN SIV+ MACAQUES CONFERS HIGH-LEVEL PROTECTION AGAINST TB
Erica C. Larson, Mark A. Rodgers, Amy Ellis, Cassaudenda A. Ameel, Janelle Gleim, Abigail K. Gubernat, Alexis Balgeman, Ryan Moriarty, Pauline Maiello, Patricia A. Darrah, JoAnne L. Flynn, Mario Roederer, Robert A. Seder, Shelby O’Connor, Charles A. Scanga

763  A NOVEL PHARMACOLOGICAL ADHERENCE MEASURE IN PREGNANT AND POSTPARTUM KENYAN WOMEN
Karen Hampanda, Jose R. Castillo-Mancilla, Janet M. Turan, Maricainah Onono, Tobias Odwar, Peter L. Anderson, Lisa L. Abuogi

764  DETECTABLE HIV RNA IN LATE PREGNANCY ASSOCIATED WITH LOW TFV HAIR LEVELS AT BIRTH
Jillian Pintye, Yanling Huo, Deborah Kacanek, Karen Kuncze, Kevin Zhang, Hideaki Okochi, Monica Gandhi

765  EARLY POSTPARTUM VIREMIA PREDICTS LONG-TERM NONSUPPRESSION AND INFANT TRANSMISSION
Megan Landes, Monique Van Lettow, Joep J. Van Oosterhout, Erik Schouten, Thokozani Kalua, Andreas Jahn, Beth A. Tippett Barr

766  VIRAL LOAD MONITORING IN PREGNANCY TO PREDICT PERIPARTUM VIRAEMIA IN SOUTH AFRICA
Jasantha Odayar, Siti Kabanda, Thokozile R. Malaba, Maia Lesosky, Landon Myer
767  **HIGH VIRAL SUPPRESSION AMONG HIV-POSITIVE POSTPARTUM WOMEN: CLUSTER RANDOMIZED TRIAL**  
Appolinaire Tiam, Lauren Greenberg, Vincent Tukei, Thabelo Ramatlapeng, Tsietsi Motsoane, Matseliso Masitha, Matsepeli Nchselhe, Mammatli Chabela, Laura Guay, Heather Hoffman

**Poster Sessions • Monday**

**Poster P-002 CHRONIC DISEASES AND MATERNAL HEALTH: PERSISTENT PROBLEMS FOR PREGNANT AND POSTPARTUM WOMEN**

**Poster Hall B  2:30 PM - 4:00 PM**

768  **CHANGES IN BONE MINERAL DURING AND AFTER LACTATION IN UGANDAN WOMEN ON OPTION B+ ART**  
Florence Nabwire, Ann Prentice, Matthew M. Hamill, Mary Glenn Fowler, Josaphat Byamugisha, Adeodata Kekitiinwa, Gail R. Goldberg

769  **HIGH BLOOD PRESSURE AND ADVERSE BIRTH OUTCOMES IN HIV+ AND HIV− SOUTH AFRICAN WOMEN**  

770  **BLOOD PRESSURE TRAJECTORIES AND ASSOCIATED FACTORS IN PREGNANT HIV− AND HIV+ WOMEN**  
Thokozile R. Malaba, Annibale Cois, Hlengiwe P. Madlala, Mushu Matjila, Landon Myer, Marie-Louise Newell

771  **POSTPARTUM WEIGHT CHANGES IN WOMEN INITIATING DTG VS EFV IN PREGNANCY: DOLPHIN-2**  
Thokozile R. Malaba, Tao Chen, Kenneth Kintu, Christiana Papamichael, Helen Reynolds, Jesca Nakibuka, Catriona Waitt, Eva Maria Hodel, Angela Colbers, Catherine Orrell, Duolao Wang, Mohammed Lamorde, Saye Khoo, Landon Myer, for the Dolphin-2 Trial Team

772  **DOLUTEGRAVIR USE IS ASSOCIATED WITH HIGHER POSTPARTUM WEIGHT COMPARED TO EFAVIRENZ**  

773  **OBESITY, GESTATIONAL WEIGHT GAIN, AND ADVERSE BIRTH OUTCOMES IN SOUTH AFRICAN WOMEN**  
Hlengiwe P. Madlala, Thokozile R. Malaba, Marie-Louise Newell, Landon Myer

774  **FACTORS ASSOCIATED WITH GESTATIONAL DIABETES IN HIV+ AND HIV− WOMEN IN PUNE, INDIA**  
Puja Chebrolu, Mallika Alexander, Ramesh Bhosale, Shilpa Naik, Nikhil Patil, Amita Gupta, Jyoti S. Mathad

**Poster P-P02 EARLY ANTIRETROVIRAL TREATMENT FOR CHILDREN**

**Poster Hall B  2:30 PM - 4:00 PM**

806  **POOR OUTCOME IN EARLY TREATED HIV PERINATALLY INFECTED INFANTS IN AFRICA**  
Alfredo Tagarro, Sara Dominguez Rodriguez, Avy Violari, Mark Cotton, Tacilia Mhampossa, Nigel Klein, Nastassja Ramsagar, Anita Janse Van Rensburg, Osse Behuhuma, Paula Vaz, Andrea Oletto, Paolo Palma, Paolo Rossi, Pablo Rojo Conejo, for the EPICAL Consortium
807 VIRAL RESPONSE IN HIV-INFECTED INFANTS STARTING ART AT 1 MONTH IN SOUTHERN MOZAMBIQUE
Maria G. Lain, Paula Vaz, Nalia Ismael, Anna Cantarutti, Gloria Porcu, Paolo Palma, Nicola Cotugno, Dulce Bila, Stefano Rinaldi, Suresh Pallikkuth, Rajendra Pahwa, Elsa Taibo, Esmeralda Karajeanea, Carlo Giaquinto, Savita Pahwa

808 SEROSTATUS IS A MARKER FOR SUSTAINED VIRAL SUPPRESSION IN EARLY TREATED CHILDREN

809 NK CELLS ARE PRESERVED BY EARLY ART IN HIV-INFECTED CHILDREN WITH LOWER RESERVOIR
Sonia Zicari, Margherita Doria, Sara Dominguez Rodriguez, Nicola Cotugno, Alfredo Tagarro, Pablo Rojo Conejo, Eleni Nastouli, Kathleen Gartner, Nigel Klein, Caroline Foster, Savita Pahwa, Anita De Rossi, Carlo Giaquinto, Paolo Rossi, Paolo Palma, for the EPIICAL Consortium

Poster P-P04 PEDIATRIC 90:90:90
Poster Hall B  2:30 PM - 4:00 PM
815 CHILDREN <15 ARE LESS LIKELY TO BE AN INDEX TESTING CONTACT COMPARED TO ADULTS
Hilary T. Wolf, Melissa Bochnowicz, Kayla Zhang, Teeb Al-Samarrai, Joseph S. Cavanaugh, Shabeen Ally

816 THE CASCADE OF HIV CARE FOR CHILDREN AND ADOLESCENTS IN WEST AFRICAN COHORTS
Désiré L. Dahourou, Karen Malatesté, Sophie Desmonde, Tanoh Eboua, Elom Takassi, Lorna Renner, Marcelline D’Almeida, Madeleine Amorissan-Folquet, Mariam Sylla, Valérian Louroy

817 HIV VIRAL SUPPRESSION IN ADOLESCENTS AND YOUNG ADULTS: A NATIONAL SURVEY IN KENYA
Irene Njuguna, Jillian Neary, Caren Mburu, Danae Black, Kristin Beima-Sofie, Anjuli Wagner, Cyrus Mugo, Yolanda Evans, Brandon Guthrie, Janet Itindi, Alvin Onyango, Laura Oyiengo, Barbra A. Richardson, Dalton Wamalwa, Grace John-Stewart

818 CAN ADHERENCE INTERVENTIONS BE COST-EFFECTIVE AMONG YOUTH WITH HIV?
Anne M. Neilan, Audrey Bangs, Michael Hudgens, Kunjal Patel, Allison Agwu, Aditya Gaur, Catherine Crespi, Keith Horvath, Caitlin Dugdale, Kimberly A. Powers, H. Jonathon Rendina, Kenneth Freedberg, Andrea L. Ciaranello

Poster P-P07 MENTAL HEALTH AND BRAIN DEVELOPMENT IN CHILDREN
Poster Hall B  2:30 PM - 4:00 PM
832 DEPRESSION ASSOCIATED WITH LOWER EXECUTIVE FUNCTIONING IN ASIAN YOUTH LIVING WITH HIV
Wipaporn Natalie Songtaweesin, Christina Chandra, Jiratchaya Sophonphan, Ly Penh Sun, Pradthana Ouncharanum, Pope Kosalaraks, Linda Auspibul, Suparat Kanjanavanit, Chaithawat Ngampiyaskul, Kathleen Malee, Robert Paul, Jintanat Ananworanich, Claude A. Mellins, Thanyawee Puthanakit, for the PREDICT and Resilience Study Group
833  DEPRESSION, SUBSTANCE USE, AND ADHERENCE AMONG LATIN AMERICAN YOUTH LIVING WITH HIV
Daisy Machado, Raquel B. De Boni, Fernanda Maruri, Vanessa A. Rouzier, Brenda Crabtree-Ramirez, Denis Padgett, Fernando A. Mejia, M. Fernanda Rodriguez, Jorge Pinto, Catherine McGowan

834  SUBSTANCE USE IN PERINATALLY INFECTED AND SAME-AGE HIV – ADOLESCENTS IN SOUTH AFRICA
Kirsty Brittain, Landon Myer, Nicole Phillips, Heather Zar, Dan Stein, Jackie Hoare

835  VIRAL SUPPRESSION AND MARIJUANA MODULATE TRANSCRIPTOME BIOPROFILE IN YOUTH WITH HIV
Li Yin, Ashok R. Dinasarapu, Kai-Fen Chang, John W. Sleasman, Maureen Goodenow

836  PROMISING RESULTS FROM A PILOT RCT MENTAL HEALTH INTERVENTION FOR HIV-INFECTED YOUTH

837  LONGITUDINAL STUDY OF NEUROCOGNITIVE DISORDERS AND BRAIN STRUCTURE IN ADOLESCENT HIV
Jackie Hoare, Landon Myer, Sarah Heany, Jean-Paul Fouche, Nicole Phillips, Heather Zar, Dan Stein

838  BRAIN DEVELOPMENT IN TREATED PERINATAL HIV: A LONGITUDINAL NEUROIMAGING STUDY

848  RISK FACTORS FOR NEW HIV INFECTIONS IN THE GENERAL POPULATION IN SUB-SAHARAN AFRICA
Emma Slaymaker, Kathryn A. Risher, Ramadhani Abdul, Milly Marston, Keith Tomlin, Robert Newton, Anthony Ndyanabo, Estelle McLean, Tawanda Dadirai, Daniel Kwaro, Kathy Baisley, Coleman Kishamawe, for the ALPHA Network

849  METRICS OF MOBILITY BY SEX ARE ASSOCIATED WITH HIV INCIDENCE IN RURAL KENYA & UGANDA
Carol S. Camlin, Edwin D. Charlebois, Maya L. Petersen, Laura B. Balzer, Torsten B. Neillands, Dalson Wairisiima, James Ajieko, Gabriel Chamie, Craig R. Cohen, Elizabeth A. Bukusi, Moses R. Kamya, Diane V. Havlir

850  HIV INCIDENCE AND VIRAL BURDEN AT THE COMMUNITY LEVEL IN HPTN 071 (POPART)
Timothy Skalland, Helen Ayles, Ethan A. Wilson, Ayana Moore, Nontha Manda, Justin Bwalya, Nkatya Kasase, Rory Dunbar, Estelle Piwowar-Manning, Susan H. Eshleman, Peter Bock, Sarah Fidler, Richard J. Hayes, Deborah J. Donnell

851  AGE-SPECIFIC HIV INCIDENCE PATTERNS AMONG POPULATION COHORTS IN SUB-SAHARAN AFRICA
Kathryn A. Risher, Georges Reniers, Emma Slaymaker, Alain Vandormael, Mark Urassa, Robert Newton, Tom Lutalo, Louisa Moorhouse, Tawanda Dadirai, Amelia C. Campin, Christophe Fraser, Anne Cori, Milly Marston, Jeffrey Eaton, for the ALPHA Network
852 HIGH HIV INCIDENCE AND VOLUNTEER RETENTION IN A BANGKOK-BASED COHORT OF MSM AND TGW
Tanyaporn Wansom, Sant Muangnoicharoen, Sorachai Nitayaphan, Suchai Kitsiripornchai, Trevor A. Crowell, Leilani Francisco, Qin Li, Peter Dawson, Merlin L. Robb, Kirsten Smith, Elizabeth A. Heger, Punnee Pitsutthithum, Robert J. O'Connell, Sandhya Vasan, for the RV348 Study Group

Poster Sessions • Monday
Poster Sessions

853 HIV AMONG FEMALE SEX WORKERS: RISK FACTORS AND LESSONS FROM A NATIONAL SURVEY
Adedayo O. Adeyemi, Emmanuel Abatta, Olubunmi Fakunle, Ogbonna O. Amanze

854 HIV RISK, BEHAVIOUR, AND SERVICE UPTAKE IN ADOLESCENT GIRLS SELLING SEX IN ZIMBABWE
Mariken M. De Wit, Brian Rice, Elizabeth Fearon, Tendayi Mharadze, Sitholubuhle Maqutshwa, Joanna Busza, Sithembile Musemburi, Amon Mpofu, Owen Mugurungi, Dagmar Hansich, James R. Hargreaves, Frances Cowan

855 TRANSACTIONAL SEX WITH OLDER PARTNERS HEIGHTENS HIV RISKS AMONG AGYW IN TANZANIA
Katherine Rucinski, Gaspar Mbita, Kelly Curran, Albert Komba, Caterina Casalini, Esther Majani, Mary Drake, Anthony Galishi, Yeromino Mlawa, Upendo Kategile, William Kafura, Sheree Schwartz, Stefan Baral

856 FACTORS ASSOCIATED WITH HIV SEROCONVERSION IN YOUNG WOMEN IN SOUTH AFRICA
Lara Lewis, Ayesha B. Kharsany, Cherie Cawood, Hilton Humphries, Brendan Maughan-Brown, David Khanyile

857 SOCIOECONOMIC DISPARITIES ARE ASSOCIATED WITH HIV IN YOUNG MSM WITHIN LATIN AMERICA
Thiago S. Torres, Lara Coelho, Kelika A. Konda, E. Hamid Vega-Ramirez, Oliver A. Elorreaga, Dulce Diaz-Sosa, Brenda Hoagland, Cristina Pimenta, Marcos Benedetti, Beatriz Grinsztejn, Carlos Carceres, Valdiea Veloso, for the ImPrEP Study Team

858 FORCED SEX IN HAITI: IMPLICATIONS FOR THE HIV EPIDEMIC AMONG MSM AND TRANS WOMEN
Nicole Y. Frascino, Lauren Y. Zalla

859 SEXUAL HEALTH OF RURAL AND URBAN YOUNG MALE COUPLES IN THE UNITED STATES
José Benito, Elissa L. Sarno, Kyle Jozsa, Emily Bettin, Michael E. Newcomb

860 BURDEN OF HIV AMONG MEN ATTENDING EMERGENCY DEPARTMENTS IN SOUTH AFRICA
George Mwinnyaa, Elizabeth Hahn, Aditi Rao, Steven J. Reynolds, Andrew D. Redd, Reinaldo Fernandez, Jernelle Miller, Morgan P. Keruly, Roshen Maharaj, Pamela Mda, David Stead, John Black, Thomas C. Quinn, Oliver Laeyendecker, Bhakti Hansoti

861 ROLE OF KEY POPULATIONS AND PAST INTERVENTIONS ON HIV TRANSMISSION IN CAMEROON
Romain Silhol, Sharmistha Mishra, Anna L. Bowring, Christinah Mukandavire, Amrita Rao, Sheree Schwartz, Ubald Tamoufe, Serge Billong, Peter Vickerman, Stefan Baral, Marie-Claude Boily

Poster P-Q02 HIV IN KEY POPULATIONS
Poster Hall D 2:30 PM - 4:00 PM
862  **SEX-SPECIFIC ANALYSES IN ORAL ABSTRACTS FROM CROI 2019**

**William R. Short**, Laura M. Smeaton, Sara H. Bares, Susan E. Cohn, Michelle Dalla Piazza, Sharlaa Badal-Faesen, Sara Gianella, Rosie Mangibisa, Valarie S. Opollo, Anandi N. Sheth, Marjie Van Schalkwyk, Selvamuthu Poongulali, Christina Vernon, Elizabeth Connick, Monica Gandhi

**Poster P-Q03 VIRAL LOAD AND OUTCOMES**  
**Poster Hall D**  
2:30 PM - 4:00 PM

863  **HIGH PROBABILITY OF SURVIVAL IN PATIENTS WHO MAINTAIN VIRAL LOADS <200 COPIES/ML**


**Poster P-Q04 LIFE EXPECTANCY AND MORTALITY**  
**Poster Hall D**  
2:30 PM - 4:00 PM

864  **FIRST HIV VIRAL LOAD REMAINS STRONG PREDICTOR OF TREATMENT SUCCESS IN SOUTH AFRICA**

**Lauren R. Violette**, Jiennchi Dorward, Justice Quame-Amaglo, Katherine Thomas, Connie L. Celum, Nigel Garrett, Paul K. Drain

865  **POPULATION-LEVEL HIV VIRAL LOAD VARIATION BY GENDER, AGE, AND LOCATION IN RAKAI, UGANDA**

Imogen Kyle, Joseph Kagaayi, Godfrey Kigozi, Gertrude Nakigozi, Robert Ssekubugu, Fred Nalugoda, Mary K. Grabowski, Larry W. Chang, Maria Wawer, David Serwadda, Ronald H. Gray, **Thomas Quinn**, Steven J. Reynolds, Oliver Ratmann, for the Rakai Health Sciences Program

866  **DISPARITIES IN VIRAL SUPPRESSION AMONG US ADULTS WITH RECENTLY DIAGNOSED HIV**

Hanna B. Demeke, Stacy M. Crim, Sharoda Dasgupta, John Weiser, R. L. Shouse

867  **HIV+ PERSONS IN RURAL UGANDA WITH FEWER SOCIAL CONNECTIONS HAVE LOWER HIV SUPPRESSION**

Yiqun Chen, Gabriel Chamie, Dalsone Kwarisiima, Laura B. Balzer, Jane Kabami, Atukunda Mucunguzi, Asphas Ovaraganise, Lillian Brown, Edwin D. Charlebois, Tamara D. Clark, Moses R. Kamya, Diane V. Havlir, Maya L. Petersen

868  **LIFE EXPECTANCY GAINS WITH ART IN LATIN AMERICA, 2003-2017**

**Casey Smiley**, Peter Rebeiro, Carina Cesar, Francisco Belanazauran, Brenda Crabtree-Ramirez, Denis Padgett, Eduardo Gotuzzo, Claudia P. Cortes, Jean W. Pape, Valdilea Veloso, Catherine McGowan, Jessica L. Castilho

869  **EXCESS MORTALITY AMONG PLWH WITH MULTIMORBIDITY COMPARED TO HIV-NEGATIVE CONTROLS**

870  EXCESS MORTALITY AFTER CANCER DIAGNOSIS IN PERSONS WITH HIV
Michael J. Silverberg, Varada Sarovar, Derek Satre, Stacey Alexeeff, Wendy Leyden, Jennifer O. Lam, Alexandra N. Anderson, Rulin Hechter, Haihong Hu, Julia L. Marcus, William J. Towner, Qing Yuan, Michael A. Horberg

871  GAINS AND REMAINING CHALLENGES IN MORTALITY AMONG INDIVIDUALS WITH HIV, 1999-2017
Monina Klevens, Maria McKenna

872  A DETAILED LOOK AT HIV MORTALITY IN KING COUNTY, 2016-2018
Andrea L. Martin, Meena Ramchandani, Susan E. Buskin

873  USING MULTISTATE MODELS TO DISENTANGLE MORTALITY & LOSS TO FOLLOW-UP IN HIV+ PATIENTS
Nanina Anderegg, Jonas Hector, Juan Burgos, Laura Jefferys, Michael A. Hobbins, Jochen Ehmer, Matthias Egger

874  INCREASED MORTALITY AMONG PEOPLE AT HIGH RISK FOR HIV IN THE UNITED STATES
Fatma Shebl, Julia H. Foote, Krishna P. Reddy, Yiqi Qian, Kenneth Freedberg, Rochelle P. Walensky, Emily P. Hyle

875  CD4 COUNT PATTERNS OVER TIME IDENTIFY LONG-TERM HIV CARE TRAJECTORIES IN SOUTH AFRICA
Ingrid V. Bassett, Ai Xu, Janet Giddy, Sue Candy, Laura M. Bogart, Andrew Boulle, Lucia Millham, Robert A. Parker, Elena Losina

876  PREDICTIVE VALUE OF THE CD8 COUNTS AND CD4/CD8 RATIO AT 2 YEARS OF SUCCESSFUL ART
Sergio Serrano-Villar, Kunling Wu, Peter W. Hunt, Judith J. Lok, Talia Sainz, Santiago Moreno, Steven G. Deeks, Ronald Bosch

877  EFFECT OF ERECTILE DYSFUNCTION DRUGS ON T CELLS AND IMMUNE MARKERS IN MEN
Jee Won Park, Adrian Dobs, Ken Ho, Frank J. Palella, Eric C. Seaberg, Onyebuchi A. Arah, Otoniel Martinez-Maza, Roger Detels

937  ASSISTED PARTNER NOTIFICATION SERVICES IN KAMPALA, UGANDA
Florence Namimbi, Faridah Akuju, Martin Ssuuna, Esther Nasuuna, Rhoda Mwondha, Stella Alamo, Madina Apolot, Nelson Kalema, Alice Namale, Joanita Kigozi

938  TARGETED PEER MOBILISATION AND ASSISTED PARTNER NOTIFICATION SERVICES INKENYA
Maartje Dijkstra, Khamisi Mohamed, Alex Kigoro, Mahmoud Shally, Abdalla Wesoonga, Teresia Mumba, Nana Mukuria, Margaret Juma, Evans Gichuru, Shaun Palmer, Susan M. Graham, Elisabeth M. van der Elst, Eduard Sanders
939 SCALE-UP OF ASSISTED PARTNER SERVICES (APS) IN BOTSWANA
Matthew R. Golden, Matias Grande, Shreshth Mawandia, Odirile Bakae, Lenna Tau, Goabaone Mogomotsi, Esther Mmatli, Modise Ngombo, Jenny Ledikwe

940 OPTIMIZING TESTING INCREASES YIELD IN HIV CASE FINDING IN 24 COUNTRIES, 2018–2019
Shahul Hameed Ebrahim, Arielle Lasry, Randy Yee, Wayne A Duffus, John Abellera, Shane T Diekman, Jacqueline Rurangirwa, Bakary Drammeh, Tiffany Ahoulou, Michael Grillo, Vincent Wong, Stephanie Behel

941 PARTNER TESTING SERVICES TO ACHIEVE HIV EPIDEMIC CONTROL IN 9 PEPFAR COUNTRIES, 2019
Bakary Drammeh, Shahul Ebrahim, Andrew L. Baughman, Arielle Lasry, Randy Yee, Wayne A Duffus, Jacqueline Rurangirwa, Shane T Diekman, Amy M. Medley, Tiffany Michelle Ahoulou, G. Laissa Ouedraogo, Isabelle Tondoh-Koui, Ismelda Pietersen, Stephanie Behel, for the HIV Testing Services

942 COMPARISON OF INDEX TESTING APPROACHES TO IMPROVE HIV-TESTING EFFICIENCY IN RWANDA
Eric Remera, Elyse Tuyishime, Suthar Amithab, Mugwaneza Placidie

943 EXPANDING HIV IDENTIFICATION BY TESTING CONTACTS OF DECEASED HIV INDEX CLIENTS
Neema Makyaao, Angela Ramadhani, Peris L. Urasa, Leonard Subi, Neusta Kwesigabo, Prosper F. Njau

944 NONENROLLMENT AMONG HIV-POSITIVE KENYAN FEMALE INDEX CLIENTS IN PARTNER NOTIFICATION
Beatrice Wamuti, Monisha Sharma, Emily Kemunto, George Otieno, Christopher Obong’O, Judith Onsomu, Cecilia Audo, Dominic Mutai, Paul Macharia, Rose Bosire, Sarah Masyuko, Kariithi Edward, Mary Mugambi, Carey Farquhar

945 SCALING UP ASSISTED PARTNER NOTIFICATION SERVICES IN WESTERN KENYA
Sarah Masyuko, Monisha Sharma, Emily Kemunto, George Otieno, Christopher Obong’O, Judith Onsomu, Cecilia Audo, Dominic Mutai, Paul Macharia, Beatrice Wamuti, Rose Bosire, Mary Mugambi, Kariithi Edward, Carey Farquhar

946 HIV TESTING AND INTEGRATED HIV/STI/HEPATITIS TESTING, OREGON, 2016
Tim W. Menza, Lindsay Hixson, Jeff Capizzi

947 AN AGE-ADAPTED, EASY-TO-IMPLEMENT SCORE FOR INTEGRATED BUNDLED, RAPID HIV/HCV TESTING
Maria Jesus Perez-Elias, Javier Martinez-Sanz, Alfonso Muriel, María J. Vivancos-Gallego, Ana Moreno, Margarita Herrero-Delgado, Beatriz Romero, Matilde Sanchez-Conde, Almudena Uranga, Pilar Perez Elias, Yolanda De La Fuente-Cortés, Rafael Barea, Juan Carlos Galán, Santos Del Campo, for the DRIVE03 Study Group

948 HIV TESTING CRITERIA TO REDUCE TESTING VOLUME AND INCREASE POSITIVITY IN BOTSWANA
Emily Rowlinson, Jenny Ledikwe, Shreshth Mawandia, Odirile Bakae, Lenna Tau, Matias Grande, Laura Seckel, Goabaone Mogomotsi, Esther Mmatli, Modise Ngombo, Matthew R. Golden
949 FREQUENT HIV TESTING OF MSM AND TGW OF COLOR RESULTS IN EARLIER DIAGNOSIS
Karen W. Hoover, Weiming Zhu, Kenneth L. Dominguez, Kirk D. Henny, Ya-Lin A. Huang, Kashif Iqbal, Mary Tanner, Kevin P. Delaney

977 URINE TENOFOVIR LEVELS BY IMMUNOASSAY PREDICT HIV PROTECTION IN A LARGE PrEP TRIAL
Randy Stalter, Jared Baeten, Deborah J. Donnell, David Glidden, Warren Rodrigues, Guohong Wang, Michael Vincent, Matthew A. Spinnelli, Nelly R. Muго, Kelly Johnson, Andrew Mujuniра, Mark A. Marzinke, Craig W. Hendrix, Monica Gandhi, for the Partners PrEP Study Team

978 PUBLICLY FUNDED HIV PrEP IN BRITISH COLUMBIA: PROGRAM RETENTION AND NEW HIV DIAGNOSES
K. Junine Toy, Cora L. Keeney, Jason Trigg, Wendy W. Zhang, Paul Sereda, Viviane D. Lima, Mark Hull, Katherine Lepik, Martin St-Jean, David M. Moore, Silvia Guillemi, Rolando Barrios, Nancy Yu, Julio S. Montaner

979 POPULATION-LEVEL EFFECTIVENESS OF PrEP AMONG MSM AND TRANSGENDER PERSONS WITH STI
Jade Pagkas-Bather, Christine M. Khosropour, Matthew R. Golden, Julia C. Dombrowski

982 WAXING AND WANING HIV RISK: DYNAMICS OF PrEP ELIGIBILITY IN RAKAI, UGANDA
Victor Ssempijja, Robert Ssekubugu, Godfrey Kigozi, Gertrude Nakigozi, Joseph Kagaayi, Tom Lutalo, Anthony Nydabaho, Anna Mia Ekström, David Serwadda, Thomas C. Quinn, Ronald H. Gray, Maria Wawer, Larry W. Chang, Steven J. Reynolds

983 HIV TESTING PATTERNS AND PrEP INDICATIONS AMONG MSM AND TGW OF COLOR, 2016-2019
Mary Tanner, Weiming Zhu, Kashif Iqbal, Kenneth L. Dominguez, Kirk D. Henny, Karen W. Hoover

984 IMPLEMENTATION OF MOBILE PrEP, STI, AND HIV-PREVENTION SERVICES IN SOUTH FLORIDA
Susanne Doblecki-Lewis, Erin Kobetz, Stefani A. Butts, Katherine Klose, Angela M. McGaugh, Brian B. Leon, Gilliane Narcisse, Jessica Morel, Yue Pan, Gabriel Cardenas, John Byrne, Patrick Whiteside, Marco Torrealba, Daniel J. Feaster, Mario Stevenson
985  **PrEP USE APPROACHING 50% AMONG HIGH-RISK MSM IN WESTERN WASHINGTON**  
Darcy W. Rao, Julia Hood, Rachel Wittenauer, Kelly Naismith, Jonathon Downs, Matthew R. Golden

986  **OPTIMIZING PrEP CASCADE OUTCOMES FOR SEXUAL HEALTH CLINIC NAVIGATION**  
Sarit A. Golub, Zoe D. Unger, Ashanay S. Allen, Chibuzo U. Enemchukwu, Christine M. Borges, Preeti Pathela, Trevor Hedberg, Anisha Gandhi, Zoe R. Edelstein, Julie Myers

987  **NONDAILY USE OF HIV PREEXPOSURE PROPHYLAXIS IN A LARGE ONLINE SAMPLE IN THE US**  
Whitney C. Sewell, Victoria Powell, Douglas Krakower, Kenneth H. Mayer, Aileen Ochoa, Julia L. Marcus

988  **EFFECTIVENESS OF PrEP NAVIGATION MODELS IN THE THRIVE DEMONSTRATION PROJECT**  
Kirk D. Henny, Weiming Zhu, Kenneth L. Dominguez, Kashif Iqbal, Mary Tanner, Karen W. Hoover

989  **TURNING INTENT INTO ACTION: ASSESSING PrEP UPTAKE AT A PUBLIC STI CLINIC**  
Kate Drezner, B.W. Furness, Chantil Thomas, Jason Beverley, Adam Allston, Adam Visconti

990  **DISCOVER: 96-WEEK FOLLOW-UP OF BLACK AND HISPANIC/LATINX STUDY PARTICIPANTS**  

**Poster P-S03 THE PROBLEM OF PERSISTENCE IN PrEP**  
**Poster Hall D**  
2:30 PM - 4:00 PM

991  **FACTORS ASSOCIATED WITH PrEP PERSISTENCE AND ADHERENCE AMONG MSM IN 4 US CITIES**  
Johanna Chapin-Bardales, Amy Martin, Richard Haaland, Catlann Sionean, Ekow Kwa Sey, Kathleen A. Brady, Henry F. Raymond, Jenevieve Opoku, Irene Kuo, Gabriela Paz-Bailey, Cyprian Wejnert, for the NHBS Study Group

992  **HIV-1 INCIDENCE, PrEP UPTAKE, AND ADHERENCE AMONG KENYAN MSM**  
Elizabeth Wahome, Susan M. Graham, Alexander N. Thiong’O, Khamisi Mohamed, Tony H. Oduor, Evans Gichuru, John Mwambi, Maria Prins, Elisabeth M. Van Der Elst, Eduard Sanders

993  **HIGH REPORTED ADHERENCE BUT LOW PrEP LEVELS AMONG KENYAN MEN WHO HAVE SEX WITH MEN**  
Susan M. Graham, Duncan O. Okall, Supriya D. Mehta, Eve Obondi, Robert C. Bailey, Frederick O. Otieno

994  **PREEXPOSURE PROPHYLAXIS CASCADE AMONG MEN WHO HAVE SEX WITH MEN IN ZIMBABWE**  
Lauren Parmley, Tiffany Harris, Innocent Chingombe, Munyaradzi Mapingure, Owen Mugurungi, John H. Rogers, Tsitisi Apollo, Getrude Ncube, Brian K. Moyo, Perpetua Gozhora, Yingfeng Wu, Elizabeth Gonese, Sophia Miller, Avi Hakim, Godfrey Musuka
995  CASCADE TO TRICKLE: REASONS FOR SUBOPTIMAL PrEP USE AMONG AT-RISK US MSM (HPTN 078)
Kenneth H. Mayer, Ethan A. Wilson, James Hughes, Julia Raifman, Jason Farley, D. Scott Batey, Carlos del Río, Lynda Emel, Vanessa Cummings, Susan H. Eshleman, Mark A. Marzinke, Theresa Gamble, Robert H. Remien, Chris Beyrer

Poster P-S04 NEW PREVENTION AGENTS AND ROUTES OF DELIVERY
Poster Hall D  2:30 PM - 4:00 PM

996  SAFETY AND TOLERABILITY OF ONCE-DAILY BIC/FTC/TAF FOR POSTEXPOSURE PROPHYLAXIS
Kenneth H. Mayer, Johnathon B. Holmes, Marcy Gelman, Jessica C. Kraft, Kathy Melbourne, Douglas Krakower, Matthew J. Mimiaga

997  HYPO-OSMOLAR RECTAL DOUCHE DELIVERED TFV DISTRIBUTES TFV DIFFERENTLY THAN ORAL PrEP
Peng Xiao, Sanjeev Gumber, Mark A. Marzinke, Abhijit Date, Thuy Hoang, Justin Hanes, Laura Ensign, Lin Wang, Lisa C. Rohan, Richard Cone, Edward J. Fuchs, Craig W. Hendrix, Francois Villinger

998  THE POTENTIAL FOR A RECTAL MICROBICIDE DOUCHE: FINDINGS FROM AN INTERNATIONAL SURVEY
Rebecca Giguere, Alex Carballo-Diequez, Cody Lentz, Curtis Dolezal, Edward J. Fuchs, Craig W. Hendrix

999  A PHASE I TRIAL OF A RECTALLY ADMINISTERED GEL FORMULATED WITH THE NNRTI IQP-0528
Amer Al-Khouja, Eugenie C. Shieh, Edward J. Fuchs, Mark A. Marzinke, Anthony S. Ham, Karen W. Buckheit, Jennifer Breakey, Ethel D. Weld, Robert W. Buckheit, Craig W. Hendrix

1000  BIODEGRADABLE IMPLANT FOR DELIVERY OF ANTIRETROVIRAL (ARV) AND HORMONAL CONTRACEPTIVE
Linying A. Li, Sai Archana Krovi, Chasity Norton, Ellen Luecke, Zach Demkovich, Pafio Johnson, Christine Areson, Guadalupe Jimenez, Ariane Van Der Straten, Leah M. Johnson

1001  WITHDRAWN

Poster P-T01 SEXUALLY TRANSMITTED INFECTIONS IN SPECIAL POPULATIONS
Poster Hall D  2:30 PM - 4:00 PM

1040  PREVALENCE AND INCIDENCE OF STIs DURING PREGNANCY IN SOUTH AFRICA

1041  STILLBIRTH AND PREVALENT SYPHILIS IN THE US WOMEN'S INTERAGENCY HIV STUDY, 1994-2016
Kristal J. Aaron, Ilene Brill, Zenoria Causey, Rachel Sinkey, Lisa B. Haddad, Anandi N. Sheth, Michael Augenbraun, Audrey French, Stephen J. Gange, Kerry Murphy, Dominika Seidman, Barbara Van Der Pol, Jeanne M. Marrazzo, Mirjam-Colette Kempf, Jodie Dionne-Odom
1042 PREVALENCE OF MYCOPLASMA GENITALIUM AND PERINATAL OUTCOMES IN HIV+ PREGNANT WOMEN
Dvora Joseph Davey, Remco P. Peters, Carolyn Smullin, Dorothy Nyemba, Hunter Green, Andrew Medina-Marino, Jeffrey D. Klausner, Landon Myer

1043 DIAGNOSIS OF SEXUALLY TRANSMITTED INFECTIONS IN PREGNANT WOMEN AND MALE PARTNERS
Nava Yeganeh, Regis Kreitchmann, Jeffrey D. Klausner, Karin Nielsen-Saines, Mei Leng, Pamina M. Gorbach

1044 SEXUALLY TRANSMITTED INFECTIONS AMONG HIV SERODISCORDANT SEXUAL PARTNERS: HPTN 052
Maganizo Chagomerana, Miha C. Hosseinipour, Sharlaa Badal-Faesen, Emily Shava, Sheela Godbole, Victor Akelo, Jose Henrique S. Piloto, Suwat Charanjitalsak, Ravindre Panchia, Myron S. Cohen, for the HPTN 052 Group

1045 HIV TRANSMISSION RISK FACTORS AMONG MEN LIVING WITH HIV WANTING A PREGNANCY IN UGANDA
Pooja Chitneni, Bosco M. Bwana, Moran Owembabazi, Deogratious Tukwasibwe, Alice Najjuma, Johnmary Tumwine, Patricia Smith, Elijah Musinguzi, Cathy Kyampire, Sylvia Natukyunda, Paul Kalyebara, Lynn T. Matthews, Angela Kaida

1046 CHANGES IN SEXUAL RISK BEHAVIORS FOLLOWING AN STI DIAGNOSIS AMONG A COHORT OF MSM
Marjan Javanbakht, Amy Ragsdale, E. India Richter, Steven Shoptaw, Pamina M. Gorbach

1047 VARIATION IN SYPHILIS AMONG BISEXUAL MEN AND ASSOCIATION WITH SYPHILIS IN WOMEN
Chase Cannon, Matthew R. Golden, for the CORES Group

1048 ASSOCIATION OF STI DIAGNOSIS WITH INCIDENT HIV IN A SOUTHERN STATEWIDE COHORT
Heather N. Grome, Peter F. Rebeiro, Meredith Brantley, Dyanne Herrera-Vasquez, Samantha Mathieson, April Pettit

1049 THE BURDEN OF STIs IN AN HIV HYPERENDEMIC COMMUNITY WITH HIGH ART COVERAGE
Mary K. Grabowski, Joseph Kagaayi, Robert Ssekubugu, Jade Jackson, Austin Peer, Godfrey Kigozi, Sarah Kalibbala, Ronald H. Gray, Maria Wawer, Josephine Mpazigi, Stephen Kiboneka, Steven J. Reynolds, Aaron Tobian, Charlotte A. Gaydos, Thomas Quinn

Poster P-U01 RAPID ART INITIATION
Poster Hall D 2:30 PM - 4:00 PM

1069 ASSESSMENT OF IMMEDIATE INITIATION OF ANTIRETROVIAL THERAPY IN NEW YORK CITY
Daniel Bertolino, Erica D’Aquilia, Nadia Nguyen, Denis Nash, Abigail Baim-Lance, Bisrat Abraham

1070 A STRUCTURED ALGORITHM FOR SAME-DAY ART INITIATION: SLATE II TRIAL PRIMARY OUTCOMES
Mhairi Maskew, Alana T. Brennan, Matthew P. Fox, Lungisile Vezi, Willem D. Venter, Peter Ehrenkrantz, Sydney Rosen
1071 ASSOCIATION BETWEEN TIME TO ART AND LOSS TO CARE AMONG NEWLY DIAGNOSED PLWH IN RWANDA
Jonathan Ross, Gad Murenzi, Donald R. Hoover, Qiuhu Shi, Hae-Young Kim, Benjamin Muhoza, Athanase Munyanzwa, Remera Eric, Sabin Nsanzimana, Marcel Yotebieng, Denis Nash, Kathryn Anastos

1072 SAME-DAY ART IN THAILAND: THE IMPACT OF ART INITIATION PERIODS ON TREATMENT OUTCOMES

1073 RAPID START LEADS TO SUSTAINED VIRAL SUPPRESSION IN YOUNG PEOPLE IN THE SOUTH
Lorna Seybolt, Katherine Conner, Isolde Butler, Nicholas Van Sickels, Jason Halperin

Poster P-U02 HIV TEST AND TREAT
Poster Hall D  2:30 PM - 4:00 PM

1074 TREAT-ALL HIV POLICIES AND PATIENT ATTRITION IN SOUTH AFRICA: A PROSPECTIVE STUDY
Dorina Onoya, Cheryl J. Hendrickson, Tembeka Sineke, Mhairi Maskew, Lawrence Long, Matthew P. Fox

1075 IMPACT OF UTT ON VIRAL SUPPRESSION IN SOUTH AFRICA: A NATIONAL COHORT STUDY
Jacob Bor, Matthew P. Fox, Mhairi Maskew, Dorina Onoya, Alana T. Brennan, Noah A. Haber, Till Bärnighausen, Sergio Carmona, Wendy Stevens, Adrian J. Puren, William B. MacLeod

1076 HIV-1 DYNAMICS FOLLOWING UNIVERSAL TESTING-AND-TREATMENT WITHIN HPTN 071 (POPART)
William Probert, Rafael Sauter, Michael Pickles, Anne Cori, Helen Ayles, Peter Bock, Deborah J. Donnell, Sarah Fidler, Richard J. Hayes, Christophe Fraser, for the HPTN 071 (PopART) Study Team

1077 DRAMATIC DECLINE OF NEW HIV DIAGNOSES IN SUBJECTS NATIVE FROM FRANCE
Adrien Le Guillou, André Cabié, Cyrille Delpierre, Pascal Pugliese, Christine Jacomet, Maxime Hentzien, Claudine Duviuc, Olivia Faucher-Zaegel, Laurent Cotte, François Raffi, Firouze Bani-Sadr

Poster P-U03 PROGRESS TOWARDS 90-90-90 AND BEYOND
Poster Hall D  2:30 PM - 4:00 PM

1078 MOBILITY, NEW HIV INFECTIONS, AND PROGRESS TOWARD THE 90-90-90 TARGETS IN NAMIBIA
Andrea Low, Karapremeet K. Sachathep, George Rutherford, Anne-Marie Nitschke, Adam Wolkon, Karen M. Banda, Keisha Jackson, Chelsea Solmo, Hetal Patel, Stephen McCracken, Sally Findley, Nicholas Mutenda

1079 PROGRESS TOWARDS THE 90-90-90 HIV TARGETS IN 11 EU COUNTRIES
1080 IMPROVING HIV CARE IN WEST AFRICA: EFFECTS OF A COMMUNITY TREATMENT OBSERVATORY
Gemma M. Oberth, Solange Baptiste, Wame Mosime, Alain Manouan, Pedro Garcia, Anta M. Traore, Joelle Murara, Raoul M. Boka

1081 ROUTINE LABORATORY DATA FOR ESTIMATING POPULATION VIRAL SUPPRESSION IN SOUTH AFRICA
Elton E. Mukonda, Nei-Yuan M. Hsiao, Landon Myer, Maia Lesosky

1082 POPULATION-BASED HIV IMPACT ASSESSMENTS AND VIRAL LOAD RESULTS: IMPLICATIONS FOR U=U
Gregory C. Chang, Trista Bingham, Katrina Sleeman, Irene Benech, Yen T. Duong, Jessica E. Justman, Suzue Saito, Melissa Metz, Anna Awor, Yohannes Mengistu, Judith Shang, Alice Maida, Nzali Kancheya, Optatus Malewo, Bharat S. Parekh

1083 VIRAL SUPPRESSION TRAJECTORIES AMONG HIGH-NEED PATIENTS IN LOW-BARRIER HIV CARE
Julia C. Dombrowski, Meena Ramchandani, McKenna C. Eastment, Matthew R. Golden

1084 ROUTINE PHARMACY REFILLS PREDICT WOMEN’S PLASMA ARV DETECTION AND VIRAL SUPPRESSION

1085 HIGHER INCOME INEQUALITY IS ASSOCIATED WITH LOWER CUMULATIVE ANTIRETROVIRAL ADHERENCE
Frances Vernon, Mary Morrow, Samantha MaWhinney, Ryan P. Coyle, Stacey Coleman, Lucas Ellison, Jia-Hua Zheng, Lane R. Bushman, Jennifer J. Kiser, Omar Galarraga, Peter L. Anderson, Jose R. Castillo-Mancilla

1086 OPTIMIZATION OF HIV CLINIC INTAKE PROCESS TO REDUCE TIME TO VIRAL SUPPRESSION
Milana Vachuska, Kari Abulhosn, Craig Ballard, Jennifer Blanchard, Lucas Hill

1087 USE CASE FOR NEAR POINT OF CARE HIV VIRAL LOAD: TARGETED TESTING AT LARGE FACILITIES
Prakash Ganesh, Tom Heller, Boniface Chione, Joe Gumulira, Salem Gqusa, Shaukat Khan, Seth McGovern, Angellina Nhlema, Lyse Nkoma, Jillian Sacks, Clement Trapence, Hannock Tweya, Peter Ehrenkranz, Sam J. Phiri

1088LB 3- VS 6-MONTHLY DISPENSING OF ART IN COMMUNITY ART GROUPS: A CLUSTER-RANDOMIZED TRIAL
Geoffrey Fatti, Nicoletta Ngorima-Mabhena, Ashraf Grimwood, Eula Mothibi, Charles Chasela, Risa M. Hoffman, Owen Mugurungi, Tsitsi Apollo, Kudakwashe Takarinda

1089LB F/TAF VS F/TDF FOR PrEP: HOW MUCH IS "BETTER" WORTH?
Rochelle P. Walensky, Tim Horn, Nicole McCann, Kenneth Freedberg, A. David Paltiel
1090 **COST-EFFECTIVENESS OF POINT OF CARE VIRAL LOAD ADOPTION STRATEGIES IN SOUTH AFRICA**  
Sarah Girdwood, Thomas Crompton, Wendy Stevens, **Brooke E. Nichols**

1091 **OUT-OF-POCKET SPENDING ON HEALTH FOR PEOPLE LIVING WITH HIV IN CÔTE D’IVOIRE**  
Rachel Stelmach, Miriam Rabkin, Kouame Abo, Irma Ahoba, Mahena G. Anago, Rodrigo Boccanera, Hermann Brou, Rebecca M. Flueckiger, Kieran Hartsough, Martin Msukwa, Jennifer M. Zech, Rachel Nugent

1092 **ENDING THE HIV EPIDEMIC IN BALTIMORE: A MODELING STUDY**  
Anthony T. Fojo, Parastu Kasaie, David Dowdy, Maunank Shah

1093 **WHAT WILL IT TAKE TO "END THE HIV EPIDEMIC"? AN ECONOMIC MODELING STUDY IN 6 CITIES**  

1094 **ASSESSING THE IMPACT AND COST-EFFECTIVENESS OF HIV AND NCD INTEGRATED CARE IN KENYA**  
Parastu Kasaie, Brian Weir, Melissa Schnure, Chen Dun, Jeff Pennington, Yu Teng, Richard Wamai, Kipkoech Mutai, David Dowdy, Chris Beyrer

1095 **ACHIEVING 95-95-95 MAY NOT BE ENOUGH TO END THE AIDS EPIDEMIC IN SOUTH AFRICA**  
Dobromir Dimitrov, James R. Moore, Deborah J. Donnell, Marie-Claude Boily

1096 **HOW SHOULD WE PRIORITIZE AND MONITOR INTERVENTIONS TO END HIV EPIDEMIC IN AMERICA?**  
Kevin P. Delaney, Samuel Jenness, Jordan A. Johnson, Dawn K. Smith, Karen W. Hoover, Norma Harris, Elizabeth DiNenno
TUESDAY MARCH 10, 2020

Poster Sessions • Tuesday
Poster Hall A  2:30 PM - 4:00 PM

171  B CELLS DIRECT R5-TROPIC HIV INFECTION OF CCR5NEG NAIVE CD4+ T CELLS
Abigail D. Gerberick, Nicolas Sluis-Cremer, Paolo A. Piazza, Charles Rinaldo, Giovanna Rappocciolo, Diana Campbell Deluca

172  TFR REDUCE HIV-1 INFECTED TFH IN VITRO IN AN IL-2 DEPENDENT MANNER
Matthew T. Ollerston, Elizabeth Connick

173  INCREASED BIRC2 AND BIRC3 TRANSCRIPTION ARE ASSOCIATED WITH INCREASED HIV PRODUCTION
Joseph P. Casazza, Quang N. Nguyen, Avery N. Sukienik, David R. Ambrozak, Jianfei Hu, Sam Darko, Amy Ransier, Farida Laboune, Daniel Douek, Richard A. Koup

174  THE ARYL HYDROCARBON RECEPTOR NEGATIVELY REGULATES HIV REPLICATION IN TH17/TH22 CELLS
Debashree Chatterjee, Yuwei Zhang, Huicheng Chen, Tomas Raul Wiche Salinas, Yasmine Smail, Jean-Pierre Routy, Petronela Ancuta

175  ANTI-HIV ACTIVITIES OF THE 12 INTERFERON-ALPHA SUBTYPES
Aexandra Tauzin, Armando Espinosa, Olivia Blake, Fabrizio Mammano

176  LOOP 1 OF HUMAN APOBEC3C REGULATES THE ANTIVIRAL ACTIVITY AGAINST HIV-1
Ananda A. Jaguva Vasudevan, Zeli Zhang, Kannan Balakrishnan, Christoph Gertzen, Ignacio G. Bravo, Gerald G. Schumann, Dieter Häussinger, Holger Gohlke, Carsten Münk

177  LB  IFITM3 REDUCES RETROVIRAL ENV FUNCTION AND IS COUNTERACTED BY GLYCOGAG
Yadvinder S. Ahi, Diborah Yimer, Guoli Shi, SalihA Majdoul, Kazi Rahman, Alan Rein, Alex A. Compton

Poster Sessions • Tuesday
Poster Hall A  2:30 PM - 4:00 PM

209  CHARACTERISATION OF POTENTIAL HIV TARGET MYELOID CELLS IN FORESKIN EPITHELIA
Bokani Nleya, Yamkela Qumbelo, Nobomi Dontsa, Christen Da Costa, Kyle O’hagan, Clive M. Gray, Nyaradzo T. Chigorimbo-Tsikiwa

210  IMPACT OF CCL27 ON HIV-1 TARGET-CELL ABUNDANCE IN THE FORESKIN EPITHELIUM

211  IMPACT OF PENILE CIRCUMCISION ON HIV SUSCEPTIBILITY MARKERS IN THE URETHRA
212  MEDICAL MALE CIRCUMCISION DISCIPLINES THE PENIS: UNDERSTANDING HIV SUSCEPTIBILITY
Cosnet L. Rametse, Micheal Mndini, Sibulelo Mollie, Kyle O’hagan, Nyaradzo T. Chigorimbo-Tsikiwa, Gianguido C. Cianci, Thomas Hope, Clive M. Gray

213  CONDOMLESS RECEPTIVE ANAL INTERCOURSE IS ASSOCIATED WITH MARKERS OF MUCOSAL INJURY
Colleen F. Kelley, Rama R. Amara, Veronika Fedirko, Yijuan Hu, Ilana Pollack, Rami Yacoub, Zhengyi Zhu, Robert Bostick

214  IMMUNE CORRELATES OF ANORECTAL HIV SHEDDING IN MEN ON ANTIRETROVIRAL THERAPY
Yoojin Choi, Irving Salit, Sarah Grech, Marie Sano, Edward Weiss, Rupert Kaul

215  HIV HIGHLY INFECTS GENITAL CD4+ T CELLS WITH REMODELING FOR SURVIVAL AND MIGRATION
Tongcui Ma, Xiaoyu Luo, Ashley George, Trimble Spitzer, Linda Giudice, Warner C. Greene, Nadia R. Roan

216  VAGINAL BACTERIA REGULATE MICRO-RNAs TARGETING THE HIV-HOST INTERACTOME

217  LONG-TERM SEX-DIFFERENCES IN OUTCOMES FOLLOWING ACUTE HIV-1 INFECTION
Sophie Novelli, Pierre Delobel, Olivier Bouchaud, Veronique Avettand-Fenoel, Pascale Fialaire, Sylvie Abel, Faouzi Souala, François Raffi, Pilartxo Catalan, Laurence Weiss, Laurence Meyer, Cécile Goujard, for the ANRS Primo Cohort Study Group

Poster P-B05 HIV SUPPRESSION AND IMMUNE ACTIVATION
Poster Hall A  2:30 PM - 4:00 PM

218  PERSISTENT IMMUNE ACTIVATION IN HIV-1–TREATED SUBJECTS COMPARED WITH NON-HIV CONTROLS
Sophie Novelli, Camille Lecroux, Jacques Reynolds, Agnes Villemant, Laurent Blum, Asma Essat, Veronique Avettand-Fenoel, Odile Launay, Jean-Michel Molina, Cécile Goujard, Christine Bourgeois, Laurence Meyer

219  SOCS PROTEINS AND JAK-STAT PATHWAY DYSREGULATION IN SIV-INFECTED SUPPRESSED MACAQUES
Erandi E. Velarde De La Cruz, Lingyun Wang, Anna Aldovini

220  EFFECT OF HIV SUPPRESSION ON CYTOKINES IN BLOOD AND SEMINAL PLASMA
Stephen A. Rawlings, Felix Torres, Andrea Lisco, Leonid Margolis, Sara Gianella, Christophe Vanpouille

221  MARKERS OF IMMUNE ACTIVATION AND FUNCTION IN OBSE and NONOBSE SUBJECTS WITH HIV
Stefano Savinelli, Emma Haran, Padraig McGhettrick, Alejandro A. Garcia, Willard Tinago, Elena Alvarez-Barco, Eoin Feeney, Alan Landay, Patrick W. Mallon
222 RESIDUAL IMMUNE ACTIVATION IN AFRICANS ON ART PREDICTS CD4 RECOVERY AND VIRAL REBOUND
Stefanie Kroese, Theresa M Rossouw, Helen Steel, Ferdinand Wit, Cissy Kityo, Margaret Siwale, Sulaimon Akamnu, Kishorcharnda Mandalaya, Marleen de Jager, Pascale Ondoa, Peter Reiss, Tobias F. Rinke de Wit, Neeljte A. Kootstra, Raph L. Hamers, for the PanAfrican Studies to Evaluate Resistance (PASER)

223 HIV-RELATED MICROBIOME, PREVIOUS IMMUNODEFICIENCY, AND EXCESS METABOLIC RISK
Marco Gelpi, Beate Vestad, Simen H. Hansen, Kristian Holm, Ninna Drivsholm, Alexandra Goetz, Hedda Hoel, Nikolai Kirkby, Birgitte Lindegaard, Anne-Mette Lebech, Jan Gerstoft, Jens D. Lundgren, Johannes R. Hov, Susanne D. Nielsen, Marius Troseid

224 ALTERED GUT MICROBIOTA AND HOST LIPID METABOLITE PROFILES IN HIV INFECTION
Zheng Wang, Mykhaylo Usyk, Yuming Gou, Simin Hua, Tao Wang, Xiaonan Xue, Irwin J. Kurland, Alan Landay, Kathryn Anastos, Robert C. Kaplan, Robert Burk, Qibin Qi

225 ART REVERSES LOSS OF DIVERSITY & RICHNESS OF INTESTINAL MICROBIOME IN HIV+ NAIVE
Angelica I. Cruz-Lebron, Ramona M. Johnson, Danielle Labbato, Theresa O. Rodgers, Julia C. Kosco, Grace A. McComsey, Alan D. Levine

226 MICROBIOTA MODULATES HIV TARGET-CELL LEVELS AT SITES OF MUCOSAL HIV ACQUISITION
Angela Wahl, Baolin Liao, Cara Richardson, Morgan Chateau, Wenbo Yao, Allison Rogala, R. Balfour Sartor, J. V. García

227 KEY FEATURES OF GUT-MICROBIAL DYSBIOSIS IDENTIFIED IN ALCOHOLIC HIV-1 PATIENTS
Richa Singhal, Kendall Stocke, Smrita Ghare, Manicka Vadhanan, Dmitry Lioznov, Elena Blokhina, Evgeny Krupitsky, Kaku So-Annah, Natalia Gnatienko, Jeffrey H. Samet, Kendall J. Bryant, Robert L. Cook, Matthew Freiiberg, Shirish A. Barve

228 PREVOTELLA IS RELATED TO A DYSREGULATION OF IFN AND T-CELL RESPONSE IN HIV INFECTION
Claudia Pinacchio, Giuseppe P. Innocenti, Letizia Santinelli, Eugenio Nelson Cavallari, Federica Frasca, Carolina Scagnolari, Guido Antonelli, Claudio M. Mastroianni, Gabriella d’Ettorre

229 ANTIINFLAMMATORY EFFECT OF METFORMIN ON MICROBIOTA IN NONDIABETIC PEOPLE WITH HIV
Stéphane Isnard, John Lin, Brandon Fombuena, Thibaut V. Varin, André Marette, Delphine Planas, Meriem Messaoudene, Bertrand Routy, Claude P. Van Der Ley, Ido Kema, Petronela Ancuta, Jonathan Angel, Jean-Pierre Routy

230 FUNCTIONAL RESTORING OF GUT BARRIER AFTER MODULATION OF INTESTINAL MICROBIOTA
Letizia Santinelli, Ranieri Verin, Giuseppe P. Innocenti, Claudia Pinacchio, Eugenio Nelson Cavallari, Gabriella De Girolamo, Anna Maria Pronio, Guido Antonelli, Giancarlo Ceccarelli, Carolina Scagnolari, Vincenzo Vullo, Claudio M. Mastroianni, Giacomo Rossi, Gabriella d’Ettorre
**Poster Sessions**

**Poster P-C01 TUMOR VIRUSES: HPV, EBV, AND KSHV**

**Poster Hall A**

**2:30 PM - 4:00 PM**

254 **DECREASED EXPRESSION OF MUCOSAL TYPE I IFN RESPONSE IN HPV-INFECTED MSM PATIENTS**

Letizia Santinelli, Alessandra Pierangeli, Eugenio Nelson Cavallari, Paolo Gozzo, Giancarlo Ceccarelli, Claudio M. Mastroianni, Raphael Viscidi, Guido Antonelli, Gabriella d’Ettorre, Carolina Scagnolari

255 **HIGH-RISK HUMAN PAPILLOMAVIRUS ONCOPROTEINS DYSREGULATE INTERLEUKIN-1 SIGNALING**

Hee W. Kim, Lk Metthew Lam, Pavithra Rajagopalan, Devraj Basu, Elizabeth A. White

256 **25-HYDROXYCHOLESTEROL INHIBITS HERPESVIRUSES BY ACTIVATING INFLAMMATORY PATHWAYS**

Anna Serquina, Takanobu Tagawa, Joseph Ziegelbauer

257 **ANAL HPV INFECTIONS DO NOT ASSOCIATE WITH RECTAL HIV-RNA SHEDDING IN HIV+ PATIENTS**

Alberto Borghetti, Matteo B. Whalen, Paola Cattani, Veronica De Simone, Simona Marchetti, Marta Goglia, Francesca Lombardi, Davide Moschese, Gianmaria Baldin, Antonella Cingolani, Carlo Ratto, Maurizio Zazzi, Simona Di Giambenedetto

**Poster P-D04 IMMUNOLOGY AND HOST GENETICS**

**Poster Hall A**

**2:30 PM - 4:00 PM**

272 **ASSOCIATION OF HIV AND HOST GENETIC VARIANTS IN ANTIRETROVIRAL THERAPY-NAIVE PERSONS**

Migle Gabrielaite, Adrian G. Zucco, Marc Bennedbaek, Christina Ekenberg, Virginia L. Kan, Giota Touloumi, Linos Vandekerckhove, Dan Turner, James Neaton, H. Clifford Lane, Jens D. Lundgren, Rasmus L. Marvig, for the INSIGHT START Trial Group

273 **CXCR5 EXPRESSION ON HUMAN CD8+ T CELLS IS TIGHTLY REGULATED BY EPIGENETIC MECHANISMS**

Funsho Ogunsibola, Werner Smidt, Veron Romsauran, Thumbi Ndungu, Bruce D. Walker, Julio de Oliveira, Zaza Ndhlovu

274 **ADDITIVE DETRIMENTAL EFFECT OF B*35/39 TYPES IN A LARGE MEXICO/CENTRAL AMERICA COHORT**

Humberto Valenzuela Ponce, Maribel Soto-Nava, Ingrid Y. Escobar-Urías, Rodolfo Pinzón-Meza, Juan Miguel Pascale, Yamitzel Zaldívar, Guillermo Porras-Cortés, Carlos Quant-Durán, Rita Isabel Meza Martínez, Elsa Y. Palou, Marvin Manzanero, Rolando A. Cedillos, Santiago Avila-Ríos, Gustavo Reyes-Terán, for the Mesoamerican HIV Project Group

275 **NATURAL RESISTANCE TO HIV-1 CORRELATES WITH IFNA-CONTROLLED STEROL METABOLISM**

Mara Biasin, Irma Saullle, Salomé Valentina Ibba, Claudio Fenizia, Francesca Vichi, Sergio Lo Caputo, Daria Trabattoni, Mario Clerici

**Poster P-D05 IMMUNOTHERAPY FOR HIV INFECTION**

**Poster Hall A**

**2:30 PM - 4:00 PM**

276 **BASELINE INDUCIBLE HIV P24 INFORMS VIRAL CONTROL DURING INTERFERON-A MONOTHERAPY**

Livio Azzoni, Emmanouil Papasavvas, Pablo Tebas, Karam Mounzer, Jay Kostman, Ian Frank, Bonnie J. Howell, Daria Hazuda, Daniel Holder, Nicolas Chomont, Costin Tomescu, Michael R. Betts, Leticia Kuri Cervantes, Luis J. Montaner
277 LOSARTAN DOES NOT IMPROVE LYMPHATIC TISSUE FIBROSIS OR T-CELL RECOVERY IN HIV
Jason V. Baker, Julian Wolfson, Caryn G. Morse, Frank S. Rhame, Caitlin David, Jodi Anderson, Gary Collins, Greg Knowlton, Jennifer Cachura, Cavan Reilly, Jeffrey Chipman, Gregory Beilman, Russell Tracy, Irini Sereti, Timothy Schacker

278 IL-21 ALTERS TFH DYNAMICS, IMPROVES FLU VACCINE RESPONSE IN OLD SIV+ NHPs UNDER ART
Daniel Kvistad, Suresh Pallikkuth, Tirupataiah Sirupangi, Kyle Russell, Rajendra Pahwa, Constantinos Petrovas, Francois Villinger, Savita Pahwa

279 BUTYROPHILINS: NOVEL IMMUNE CHECKPOINT TARGETS FOR HIV
Sai Vemula, Morgan Monslow, Guoxin Wu, Luca Micci, Laura Garvin-Queen, Min Xu, Lei Ba, Shuo Quan, Yvonne Meng, Steve Carroll, Hussam Shaheen, Daniel Gorman, Daria Hazuda, Bonnie J. Howell

280 BISPECIFIC Au NANOPARTICLES FOR THE ENHANCEMENT OF THE NK IMMUNE RESPONSE AGAINST HIV
Antonio Astorga Gamaza, Mireya L. Borrajo, Carla Serra Peinado, Laura Luque-Ballesteros, Oscar Blanch-Lombarte, Julia G Prado, Juan Lorente, Félix Pumarola, Marc Pellicer, Vicenç Falco, Meritxell Genesca, Victor Puntes, Maria J. Buzón

281 INTERFERON-Α MODULATES THE HOST GLYCOSYLATION MACHINERY DURING TREATED HIV INFECTION
Leila B. Giron, Florent Colomb, Emmanouil Papasavvas, Livio Azzoni, Xiangfan Yin, Alitzel Anzurez, Matthew Fair, Karam Mounzer, Jay Kostman, Pablo Tebas, Una O’Doherty, Qin Liu, Michael R. Betts, Luis J. Montaner, Mohamed Abdel-Mohsen

282 PHASE I/II RANDOMIZED STUDY: THERAPEUTIC DENDRITIC CELL VACCINE PLUS PEGYLATED INF-Α

283 PERSISTENT ANTIVIRAL EFFECT INDUCED BY TYROSINE KINASE INHIBITORS
Lorena Vigón, Sara Rodríguez-Mora, Elena Mateos, Valentín García, Juan Ambrosioni, Virginia Sandonis, Guiomar Bautista, Pillar Pérez-Romero, José Alcami Pertejo, Juan Luis Steegmann, Jose M. Miro, Vicente Planelles, Maria Rosa López-Huertas, Mayte Coiras

284 RATIONAL DONOR FECAL MICROBIOTA TRANSPLANTATION IN HIV (REFRESH STUDY)
Sergio Serrano-Villar, Alba Talavera, Nadia Madrid-Elena, José A. Pérez-Molina, María José Gosalbes, Shrish Budree, Alejandro Vallejo, Ryan J. Elliott, Fernando Dronda, Carolina Gutiérrez, María J. Vivancos-Gallego, Javier Martínez-Sanz, Sabina Herrera, Raquel Ron, Santiago Moreno

285 METHOTREXATE BLOCKS PROLIFERATION NOT INFLAMMATION TO MODULATE IMMUNITY
Michael L. Freeman, Daniela Moisi, Brian Clagett, Leonard Calabrese, Benigno Rodriguez, Michael M. Lederman

286LB ENHANCED COMPLEMENT ACTIVITY DOES NOT IMPROVE PROTECTION IN SHIV-CHALLENGED MACAQUES
David A. Spencer, Benjamin Goldberg, Jérémy Duflo, Timothée Bruel, Olivier Schwartz, Margaret Ackerman, Ann J. Hessell
**Poster Sessions • Tuesday**

**Poster P-E05 ESTABLISHMENT OF THE HIV RESERVOIR**

**Poster Hall A**

**2:30 PM - 4:00 PM**

**327 HIV DIRECTLY INFECTS RESTING MEMORY CD4 T CELLS**

Rodrigo Matus-Nicodemos, David R. Ambrozak, Sam Darko, Amy Ransier, Daniel Douek, Richard A. Koup

**328 ESTABLISHMENT OF THE HIV-1 DNA RESERVOIR MIRRORS THE REPLICATION-COMPETENT RESERVOIR**


**329 CD127+ LYMPHOID MEMORY CD4+ T CELLS PREFERENTIALLY SUBJECT TO LATENT HIV INFECTION**

Feng Hsiao, Julie Frouard, Andrea Gramatica, Guorui Xie, Roland Schwarzer, Xiaoyu Luo, Marielle Cavrois, Warner C. Greene, Nadia R. Roan

**330 UNPRIMED CD8+ LYMPHOCYTES PROMOTE THE ESTABLISHMENT OF HIV LATENCY IN CD4+ T CELLS**

Lavinia Franchitti, Zhan Zhang, Jack Yoon, Mirko Paiardini, Guido Silvestri, Deanna Kulpa

**331 THE HIV ANTI-SENSE TRANSCRIPT AST INDUCES VIRAL LATENCY VIA SEVERAL SILENCING PATHWAYS**

Rui Li, Zahra Gholizadeh, Kaveh Daneshvar, Michelle Pleet, Fatah Kashanchi, Luigi Marchionni, Alan Mullen

**332 LUNG DOUBLE NEGATIVE T CELLS HARBOR HIV IN ACUTE INFECTION AND DURING LONG-TERM ART**

Oussama Meziane, Syim Salahuddin, Tram Pham, Omar Farnos, Amelle Pagliuzzi, Nicolas Chomont, Elaine Thomson, Ron Olivenstein, Marianna Orlova, Erwin Schurr, Eric A. Cohen, Cecilia Costiniuk, Mohammad-Ali Jenabian

**Poster P-E06 CURE STRATEGIES: HUMAN AND ANIMAL STUDIES**

**Poster Hall A**

**2:30 PM - 4:00 PM**

**333 EFFECT OF TAMOXIFEN ON VORINOSTAT-INDUCED HIV RNA EXPRESSION IN WOMEN ON ART (A5366)**

Eileen P. Scully, Atthe Tsibris, Evgenia Aga, Qing Ma, Kate Starr, Kathleen E. Squires, Steven G. Deeks, Elizabeth Connick, Monica Gandhi, Ronald Bosch, Nancie Archin, Jonathan Karn, Daniel R. Kuritzkes, Rajesh T. Gandhi, for the ACTG A5366 Study Team

**334 EFFECTS OF IMMUNE CHECKPOINT THERAPY ON LATENT HIV IN PEOPLE WITH HIV AND MALIGNANCY**


**335 ABX464 DECREASES THE TOTAL HIV RESERVOIR AND HIV TRANSCRIPTION INITIATION IN VIVO**

Sara Moron-Lopez, Silvia Bernal, Jean-Marc Steens, Joseph K. Wong, Javier Martinez-Picado, Steven A. Yukl
336 ATTACKING LATENT HIV WITH CONVERTIBLE CAR-T CELLS, A MODULAR KILLING PLATFORM
Eytan Herzig, Kaman Chan Kim, Thomas A. Packard, Noam Vardi, Roland Schwarzer, Andrea Gramatica, Steven G. Deeks, Steven R. Williams, Kyle Landgraf, Nigel Killeen, David W. Martin, Leor Weinberger, Warner C. Greene

337 CAR-T CELLS AT 15 YEARS: PERSISTENCE OF CD4-ZETA TRANSGENE AND EFFECT ON RESERVOIR

338 PHASE I STUDY OF GENE-MODIFIED CD4+ CELLS AND CD34+ CELLS W/O BUSULFAN IN HIV+ ADULT
Ronald T. Mitsuyasu, Jay Lalezari, Bryan Burke, Mollie Barrett, Jeremy Casey, Alison Knop, Suparna Mishra, Jeffrey Ahlers, Louis Breton, Orit Wolstein, Jeffrey Bartlett, W. David Hardy, Louise Evans, Geoffrey Symonds

339 HIV-SPECIFIC T-CELL RESPONSES IN AN HIV-POSITIVE COHORT POST ALLO-HSCT
Johanna M. Eberhard, Mathieu Angin, Caroline P. Passaes, Maria Salgado, Valérie Monceaux, Gero Hütter, Pascual Balsalobre, Mi Kwon, Jose Luis Diez, Monique Nijhuis, Annemarie Wensing, Javier Martinez-Picado, Julian Schulze Zur Wiesch, Asier Saez-Cirion, for the IciStem Study Group

340 MYCOPHENOLATE MOFETIL FOR DEPLETION OF THE HIV RESERVOIR
Joshua T. Schiffer, Claire Levy, Sean Hughes, Mel Padullo, Katrina Puckett, Eric Helgeson, Robert D. Harrington, Florian Hladik

341 VIRAL RESERVOIR DISRUPTION WITH PANOBINOSTAT AND IFN-Α: FIRST RESULTS

342 IAP ANTAGONISM PROMOTES PD-1 BLOCKADE-MEDIATED ELIMINATION OF HIV IN HUMANIZED MICE
Michael Bobardt, Joseph Kuo, Udayan Chatterji, Norbert Wiedemann, Gregoire Vuagniaux, Philippe Gallay

343 IMPACT OF GS-986, PGT121 AND N6-LS ON CNS IMMUNE ACTIVATION IN SHIV-INFECTED MACAQUES

344 BRENTUXIMAB VEDOTIN REDUCES CD30 EXPRESSION AND GUT HIV DNA LEVELS IN HUMANIZED MICE
Cecilia Prator, Louise Hogan, Shreya Kumar, Cassandra Thanh, Serah Tanno, Tony Pan, Erica Gibson, Norman G. Jones, Jeffrey M. Milush, Vladimir Vrbanac, Timothy J. Henrich

345LB PGT121 AND VESATOLIMOD IN CHRONICALLY TREATED SHIV-INFECTED RHESUS MONKEYS
Dan Barouch, Noe Mercado, Abishek Chandrashekar, Erica Borducchi, Joseph Nkolola, Brian A. Carr, Nathan D. Thomsen, Romas Geleziunas
346LB SUSTAINED HIV REMISSION IN THE LONDON PATIENT: THE CASE FOR HIV CURE
Ravindra K. Gupta, Dimitra Peppa, Matthew Pace, John P. Thornhill, Eleni Nastoulis, Paul Grant, Laura McCoy, Andrew Innes, Simon Edwards, Annemarie Wensing, Monique Nijhuis, Javier Martinez-Picado, John Frater, Eduardo Olavarria, for the CHERUB and iCistem Study Groups

347LB SUSTAINED REMISSION IN A 4-YEAR-OLD HIV-INFECTED CHILD TREATED IN FIRST YEAR OF LIFE
Gloria P. Heresi, Douglas D. Richman, Roukaya Al Hammoud, Gilhen Rodriguez, Norma Perez, James R. Murphy

348LB CCR5Δ32 SCT-INDUCED HIV REMISSION: TRACES OF HIV DNA BUT FADING IMMUNE REACTIVITY
Bjoern-Erik O. Jensen, Dieter Häussinger, Elena Knops, Annemarie Wensing, Javier Martinez-Picado, Monique Nijhuis, Maria Salgado, Jacob D. Estes, Nadine Lübke, Rolf Kaiser, Thomas Harrer, Johannes Fischer, Julian Schulze zur Wiesch, Johanna M. Eberhard, Guido Koble

349LB EDITING OF SIV IN NONHUMAN PRIMATES BY CRISPR-CAS9 IN VIRAL RESERVOIRS
Jennifer Gordon, Tricia H. Burdo, Pietro Mancuso, Chen Chen, Rafal Kaminski, Mark G. Lewis, Kamel Khalili

350LB EFFICIENT DELETION OF CCR5 PROVIDES COMPLETE PROTECTION AGAINST HIV IN XENOGRAFT MICE
Daniel Claiborne, Christian L. Boutwell, Zachary Detwiler, Tao Chen, Radiana Trifonova, David T. Scadden, Tony W. Ho, Todd M. Allen

351 ANTAGONISM OF PPARγ FOR TH17 MUCOSAL IMMUNITY RESTORATION AND HIV-RESERVOIR PURGING
Delphine Planas, Yuwei Zhang, Augustine Fert, Julia M. Ruiz, Jean-Phillipe Goulet, Laurence Raymond Marchand, Huicheng Chen, Tomas Raul Wiche Salinas, Annie Gosselin, Wilfried-Wenceslas Bazie, Caroline Gilbert, Eric A. Cohen, Jean-Pierre Routy, Nicolas Chomont, Petronela Ancuta

352 A JAK1 INHIBITOR SUPPRESSES HIV-1-DRIVEN ABERRANT HOST GENE TRANSCRIPTION
Yang-Hui Yeh, Katharine Jenike, Rachela Calvi, Jennifer Chiarella, Ya-Chi Ho

353 DEVELOPMENT OF A PSEUDOVIRUS DELIVERY SYSTEM FOR HIV-1 ELIMINATION

354 ROMIDEPSIN COMBINED WITH PRO-APOPTOTIC DRUGS REDUCES INTEGRATED HIV DNA
Youry Kim, Ajantha Solomon, Jennifer M. Zerbato, Paul Cameron, James McMahon, Jenny L. Anderson, Sharon R. Lewin, for the Lewin Laboratory

355 NOD2 AND TLR8 AGONISTS ENHANCE IL-15-MEDIATED ACTIVATION OF HIV EXPRESSION
Jasmine Kaur, Jay Lalezari, Rebecca Hoh, Steven G. Deeks, Wade Blair, Tomas Cihlar, Jeffrey Murry
356 HIV-1 GENE EXPRESSION DURING REVERSAL OF LATENCY USING RNA-Seq WITH PROBE ENRICHMENT
Phillip Tomezsko, Silvi Rouskin, Daniel R. Kuritzkes, Athe Tsibris

357 SURFACE ENGINEERING OF EXTRACELLULAR VESICLES TO TARGET HIV PERSISTENCE
Pooja Bhardwaj, Rafal Kaminski, Shivani Desai, Ali Danesh, Amir Afshari, Nicholas Yam, Kamel Khalili, Archana Gupta, Satish K. Pillai

358 IN VITRO MODEL FOR STUDYING T-CELL PROLIFERATION/ SURVIVAL DRIVEN BY HIV INTEGRATION
Machika Kaku, John K. Yoon, John M. Coffin

359LB AMINOBISPHOSPHONATES REVERSE LATENCY IN HIV- SEROPOSITIVE INDIVIDUALS
Sara Selitsky, Matthew Clohosey, Marie Anne Iannone, Susana Garcia-Recio, Jennifer Kirchherr, Carolina Garrido, Yinyan Xu, Shahryar Samir, Ann Marie Weideman, Michael Hudgens, Nilu Goonetilleke, Joel Parker, Natalia Soriano-Sarabia

401 COGNITIVE IMPAIRMENT AMONG HIV-INFECTED MEN WITH LONGITUDINAL FOLLOW-UP
Zheng Wang, Yu Cheng, Eric C. Seaberg, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study

402 PLASMA CITRATE AND SUCCINATE PREDICT NEUROCOGNITIVE IMPAIRMENT IN OLDER PWH
Corrilyn O. Hileman, Sausan Azzam, Kunling Wu, Katherine Tassiopoulos, Roger Bedimo, Ronald J. Ellis, Kristine M. Erlandson, Asha R. Kallianpur, Susan L. Koletar, Alan Landay, Frank J. Palella, Muralidhar Pallaki, Babafemi Taiwo, Robert Kalayjian

403 AGE-ASSOCIATED DEMENTIA AMONG OLDER PEOPLE WITH HIV IN THE US: A MODEL-BASED ANALYSIS

404 A RANDOMISED CONTROLLED TRIAL ON THE EFFECT OF B VITAMINS ON NEURONAL INJURY IN PLHIV
Erika Ahlgren, Lars Hagberg, Lars-Magnus Andersson, Aylin Yilmaz, Åsa Mellgren, Kaj Blennow, Henrik Zetterberg, Magnus Gisslén

405 CONSERVED CSF HIV ANTIBODY RESPONSE IN PATIENTS WITH DIVERSE NEUROLOGIC PHENOTYPES
Isobel A. Hawes, Ryan Schubert, Akshaya Ramesh, Gavin Sowa, Joanna Hellmuth, Magnus Gisslén, Richard W. Price, Michael Wilson

406 A RANDOMIZED TRIAL OF ADJUNCTIVE TELMISARTAN TO REDUCE CNS INFLAMMATION IN ACUTE HIV
Michael J. Peluso, Eugène Kroon, Phillip Chan, Somporn Tipsuk, Carlo Sacdalan, Jennifer Chiarella, Magnus Gisslén, Henrik Zetterberg, Rob Gorelick, Duangthai Suttichom, Napapon Sailasuta, Robert Paul, Jintanat Ananworanich, Serena S. Spudich, for the RV408/SEARCH 018 Study Team
407  **INFLAMMATORY MARKERS SHOW DYNAMIC CHANGES IN ACUTE HIV AND PREDICT COGNITIVE OUTCOMES**  
August A. Longino, Javier R. Lama, Peter Brandes, Eduardo Ruiz, Cecilia Correa, Serena S. Spudich, Christopher D. Pilcher, Kevin Robertson, Rachel A. Bender Ignacio, Ann Duerr

408  **PROTEOMIC CHARACTERIZATION OF CSF EXTRACELLULAR VESICLES IN HIV PATIENTS**  
Debjani Guha, David Lorenz, Vikas Misra, Sukrutha Chettimada, Susan Morgello, Dana H. Gabuzda

409  **EFFECT OF NON-HIV DRUGS ON NEUROCOGNITIVE DOMAINS IN A WELL-TREATED HIV POPULATION**  
Bernadette Jakeman, Alexandra Scherrer, Katharine Darling, Is aure Nadin, Barbara Hasse, Christoph Hauser, Philip E. Tarr, Alexandra Calmy, Ursula Kunze, Marcel Stoeckle, Patrick Schmid, Manuel Battegay, Renaud Du Pasquier, Matthias Cavassini, Catia Marzolini

410  **ANTICHOLINERGIC DRUG USE IN PATIENTS ≥ 65 YEARS OLD IN THE SWISS HIV COHORT STUDY**  
Bernadette Jakeman, Alexandra Scherrer, Huldrych F. Günthard, Matthias Cavassini, Anna Hachfeld, Alexandra Calmy, Patrick Schmid, Enos Bernasconi, Manuel Battegay, Catia Marzolini, for the Swiss HIV Cohort Study

411  **BIOMARKERS OF NUCLEIC ACID OXIDATION AND NEURODEGENERATION IN CSF IN PWH**  
Ronald J. Ellis, David J. Moore, Erin Sundermann, Robert K. Heaton, Todd Hulgan, David C. Samuels, Sanjay R. Mehta, Scott L. Letendre

412  **PREDICTIVE VALIDATION OF AN UGANDAN INFANT EYE-TRACKING TEST OF MEMORY OF HUMAN FACES**  

413  **LOW NEUROSTEROIDS IDENTIFIES A BIOLOGICAL SUBTYPE OF DEPRESSION IN PEOPLE WITH HIV**  
Shibani S. Mukerji, Vikas Misra, David Lorenz, Sukrutha Chettimada, Kiana Keller, Scott L. Letendre, Ronald J. Ellis, Susan Morgello, Robert A. Parker, Dana H. Gabuzda

414  **ANTICHOLINERGIC BURDEN IS ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN PERSONS WITH HIV**  
Asante R. Kamkwalala, Qing Ma, Maile Y. Karris, Erin Sundermann, Ronald J. Ellis, David J. Moore, Leah H. Rubin, Scott L. Letendre

415  **ASSOCIATION BETWEEN LUNG AND COGNITIVE DYSFUNCTION IN MEN WITH HIV INFECTION**  
Yoseob J. Hwang, Seyed M. Nouraie, James T. Becker, Dong Chang, Audrey French, Ken M. Kunisaki, Andrew Levine, Eileen Martin, Meredith C. McCormack, Ned Sacktor, Andrea M. Weinstein, Alison Morris

416  **MITOCHONDRIAL DNA, COGNITIVE FUNCTION, AND FRAILTY IN OLDER ADULTS WITH HIV**  
Carrie Johnston, Michelle Rice, Heather Derry, Chelsie Burchett, Eugenia Siegler, Mary Choi, Marshall Glesby

417  **IMPACT OF WEB-BASED COGNITIVE TRAINING ON WORKING MEMORY IN COCAINE USERS WITH HIV**  
Sheri L. Towe, Yunan Xu, Christina S. Meade
418  RETINAL THINNING CORRELATES WITH BRAIN ATROPHY IN WELL-CONTROLLED HIV INFECTION
Bryan Smith, Katrina Geannopoulos, Ramiro Maldonado, Tianxia Wu, Elizabeth F. Horne, Lillian Ham, Joseph Snow, Govind Nair, Daniel S. Reich, Chuen-Yen Lau, Emily Chew, Avindra Nath

419  GUT MICROBIOTA REGULATE IMMUNE CELL HOMEOSTASIS IN THE CNS
Angela Wahl, Baolin Liao, Cara Richardson, Wenbo Yao, Allison Rogala, R. Balfour Sartor, J. V. Garcia

420  CSF1R INHIBITION TARGETS CNS MACROPHAGES IN AN SIV/MACAQUE MODEL OF HIV CNS DISEASE
Audrey C. Knight, Samuel A. Brill, Megan E. McCarron, Suzanne E. Queen, Lisa Mangus, Kelly A. Metcalf Pate, Sarah E. Beck, Joseph Mankowski

421  METAGENOMIC NEXT-GENERATION SEQUENCING FOR DIAGNOSIS OF CNS INFECTION IN PLWH
Jun Chen, Renfang Zhang, Li Liu, Tangkai Qi, Zhenyan Wang, Wei Song, Yang Tang, Jianjun Sun, Hongzhou Lu

422  EXPRESSION OF HIV-1 INTRON-CONTAINING RNA IN MICROGLIA INDUCES INFLAMMATORY RESPONSES
Hisashi Akiyama, Sallieu Jalloh, Seonmi Park, Gustavo Mostoslavsky, Rahm Gummuluru

423  ACCELERATING CELLULAR SENESCENCE IN THE BRAIN OF SIV-INFECTED YOUNG RHESUS MACAQUES
Fei Wu, Robert Blair, Binhua Ling

424  CNS HIV BEARS ENVELOPE MARKERS CONSISTENT WITH T-CELL ORIGIN IN THE FACE OF ART
Gila J. Lustig, Sandile Cele, Farina Karim, Yashica Ganga, Khadija Khan, Bernadett Gosnell, Mahomed-Yunus Moosa, Rohen Harrichandpursad, Suzaan Marais, Ravindra K. Gupta, Tulio de Oliveira, Katya Govender, John Adamson, Vinod B. Patel, Alex Sigal

425  HIV-1 VIRAL DIVERSITY AND RESISTANCE IN CENTRAL NERVOUS SYSTEM BY DEEP SEQUENCING
Eleni Giatsou, Basma Abd, Isabelle Plu, Nathalie Desiré, Romain Palich, Danielle Seilhean, Vincent Calvez, Anne-Geneviève Marcelin, Aude Jary

426  HIV DIVERSITY IN CSF AND PLASMA OF INDIVIDUALS WITH HIV AND CRYPTOCOCCAL MENINGITIS
Nametso Kelentse, Sikhulile Moyo, Mompati L. Mogwete, Kswana Lechiile, Kaelo Seatla, Natasha O. Moraka, Kesaobaka Molebatsi, Tshoep B. Leeme, David Lawrence, Rosemary Musonda, Ishmael Kasvosve, Thomas S. Harrison, Joseph N. Jarvis, Simani Gaseitsiwe

427  HERPES ZOSTER IN HIV: THE ROLE OF PLEOCYTOSIS IN SECONDARY CSF ESCAPE AND DISCORDANCE
Lars Hagberg, Richard W. Price, Magnus Gisslén

428  BRAIN HIV LATENCY BIOMARKERS
Thomas Gates, John Ng, Tan-Nia Koh, Selviana Dharmadi, Sarah Palmer, Vincent Morcilla, Tory Johnson, Avindra Nath, Lucette A. Cysique, Bruce J. Brew, for the CHIEF Group
429LB HIGH LEVELS OF CELL-ASSOCIATED HIV-1 TRANSCRIPTION IN CSF DESPITE EFFECTIVE cART
Kazuo Suzuki, John Zaunders, Angelique Levert, Chin-Shiou Huang, Takaomi Ishida, Thomas Gates, Caroline Rae, Lauriane Juge, Lucette A. Cysique, John Ng, Bruce J. Brew

430 PLASMA RAMs IN REVERSE TRANSCRIPTASE GENE ASSOCIATE WITH CSF HIV-1 ESCAPE
Mattia Trunfio, Anna Celotti, Francesca Bai, Luigi Celani, Emanuele Focà, Antonella D’Arminio Monforte, Stefano Bonora, Gabriella D’Ettorre, Giovanni Di Perri, Andrea Calcagno

453 INFILTRATION OF bNAb VRC01 INTO THE CEREBROSPINAL FLUID IN HUMANS IN THE RV397 STUDY
Madhu Prabhakaran, Sandeep Narpala, Lucio Gama, Donn J. Colby, Phillip Chan, Carlo Saddalan, Khunthalee Benjapornpong, Jintanot Ananworanich, Nittaya Phanuphak, Suteeraporn Pinyakorn, Trevor A. Crowell, Serena S. Spudich, Adrian B. McDermott, for the RV397 Study Team

454 BICTEGRAVIR/FTC/TAF CSF DIFFUSION IN HIV-INFECTED PATIENTS WITH CNS IMPAIRMENT
Antoine Chéret, Thibault Gelé, Alicia Castro Gordon, Valérie Furlan, Coralie Pallier, Pierre-Hadrien Becker, Pilartxo Catalan, Cécile Goujard, Anne-Marie Taburet, Jacques Gasnault, Hélène Gouget, Aurélie Barrail-Tran

455 A CROSS-SECTIONAL ANALYSIS OF ANTIRETROVIRAL REGIMEN ACTIVITY IN CEREBROSPINAL FLUID

456 PRENATAL EFAVIRENzung EXPOSURE INDEPENDENTLY ASSOCIATED WITH FOETAL CyP2B6 GENOTYPE
Adeniyi Olagunju, Damien Anweh, Ogechi Okafor, Alieu Amara, Oluseye Bolaji, Ebunoluwa Adejuyigbe, Saye Khoo, Andrew Owen

457 ASSOCIATION BETWEEN INTEGRASE INHIBITOR HAIR CONCENTRATIONS AND WEIGHT GAIN IN WOMEN
Cecile D. Lahiri, Cyra Christina Mehta, Christine D. Angert, Craig Sykes, Sheri Weiser, Deborah Gustafson, Audrey French, Adaora Adimora, Deborah Konkle-Parker, Anjali Sharma, Hector Bolivar, Seble Kassaye, Igho Ofotokun, Elizabeth T. Golub, Anandi N. Sheth

458 CLINICAL TRIAL SIMULATION TO IMPROVE HIV PREEXPOSURE PROPHYLAXIS DOSING IN PREGNANCY
Ayyappa Chaturvedula, Rachel K. Scott, Michael J. Fossler, Maria Pyra, Kenneth K. Mugwanyi, Nelly R. Mugo, Jared Baeten, Craig W. Hendrix

459 GENITAL INFLAMMATION DOES NOT DECREASE VAGINAL TFV LEVELS IN WOMEN TAKING ORAL PrEP
460  ARV PENETRATION INTO FEMALE GENITAL TRACT DURING PREGNANCY: EFAVIRENZ AS A CASE STUDY
Oluwasegun I. Eniayewu, Shakir A. Atoyebi, Jacinta Nwogu, Aliu Amara, Oluseye Bolaji, Damien Anwah, Ebunoluwa Adejuyigbe, Marco Siccardi, Saye Khoo, Andrew Owen, Adeniyi Olagunju

461  PK/PD STUDY OF Raltegravir Alone or Combined With Lamivudine as PrEP: An RCT
Julie Fox, Carolina Herrera, Laura Else, Julienne Lwanga, Ming Lee, Aliu Amara, Laura Dickinson, Marta Boffito, Robin J. Shattock, Saye Khoo

462  MODELING-SUPPORTED ISLATRAVIR DOSE SELECTION FOR PHASE III
Deanne J. Rudd, Youfang Cao, Pavan Vaddady, Jay Grobler, Ernest Asante-Appiah, Tracy Diamond, Stephanie O. Kloper, Anjana Grandhi, Peter Sklar, Carey Hwang, Ryan Vargo

463  FosteMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT-EXPERIENCED HIV PATIENTS
Ridhi Parasampuria, Navin Goyal, Katy Moore, Peter Ackerman, Cyril C. Llamoso, Keith Barker, Mindy Magee

464LB  BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM
Arkaitz Imaz, Juan M. Tiraboschi, Jordi Niubo, Javier Martinez-Picado, Mackenzie L. Cottrell, Pere Domingo, Ivan Chivite, EugeniaNegredo, Sandra Morenilla, VictorUrrea, SofiaScevola, Benito Garcia, Angela Kashuba, Daniel Podzamczer

465LB  SAFETY AND PHARMACOKINETICS OF INTRAVENOUS VRC01LS AND 10-1074 IN YOUNG CHILDREN
Edmund V. Capparelli, GbolahanAjibola, KennethMaswabi, Kara Bennett, Michael D. Hughes, Molly PretoriusHolme, Kelly Seaton, Adrian B. McDermott, Marina Caskey, Lucio Gama, Patrick Jean-Philippe, Joseph Makhema, Daniel R. Kuritzkes, Mathias Lichterfeld, Roger L. Shapiro

Poster P-H02 TO THREE OR NOT TO THREE, THAT IS THE QUESTION
Poster Hall A  2:30 PM - 4:00 PM

483  DTG+3TC VS DTG+TDF/FTC (GEMINI 1&2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96
Mark Underwood, Ruolan Wang, Paul Benson, Norma Porteiro, Giuliano Rizzardini, Jose R. Santos, Rickesh Patel, Justin Koteff, Rimigale Urbaitye, Joe Horton, Jörg Sievers, Choy Man, Allan Raymond Tenorio, Jean van Wyk

484  HIV-1 REPLICATION AT <50 C/ml TO 148 WEEKS FOR SWORD-1/ SWORD-2 STUDIES WITH DTG+RPV
Mark Underwood, Kostas Angelis, Ruolan Wang, Joe Horton, Veerle Van Eygen, Jessica Matthews, Lesley Kahl, Jean van Wyk, Brian Wynne

485  LONG-TERM DTG-3TC SWITCH EFFICACY IN PATIENTS WITH ARCHIVED 3TC RESISTANCE
Rosa de Miguel, David Rial, Lourdes Domínguez-Domínguez, Rocio Montejano, Andrés Esteban-Cantos, Otilia Bisbal, Natalia Stella-Ascariz, Paula Aranqure, Mónica García-Álvarez, Belen Alejos, Maria Lagarde, Jose I. Bernardino, Federico Pulido, Jose R. Arribas, for the ART-PRO, PT16/00837-PT16/00678 Study Group
486  EFFECT OF PAST VIROLOGICAL FAILURE ON DOLUTEGRAVIR+LAMIVUDINE AS MAINTENANCE REGIMEN
Roberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Alessandro Tavelli, Vanni Borghi, Laura Galli, Gianmarco Tagliaferri, Franco Maggiolo, Cristina Mussini, Antonella Castagna, Antonella D’Arminio Monforte, Andrea Antoni, for the Icona Foundation Study Group

487  CLINICAL OUTCOMES OF 2-DRUG REGIMENS (2DRS) VS 3-DRUG REGIMENS (3DRS) IN HIV
Lauren Greenberg, for the RESPOND: The International Cohort of Infectious Diseases

488  EFFICACY AND DURABILITY OF 2-DRUG VS 3-DRUG INSTI-BASED REGIMENS: DATA FROM REAL LIFE
Massimiliano Fabbiani, Barbara Rossetti, Arturo Ciccullo, Maria Letizia Oreni, Filippo Lagi, Luigi Celani, Manuela Colafigili, Andrea De Vito, Maria Mazzitelli, Alex Dusina, Stefano Rusconi, Amedeo Capetti, Gaetana Serrantino, Gabriella d’Ettorre, Simona Di Giambenedetto

489  ASSESSING THE VIROLOGIC IMPACT OF ARCHIVED RESISTANCE IN AN HIV-1 SWITCH STUDY, TANGO
Ruolan Wang, Jonathan Wright, Mounir Ait-Khaled, Allan Raymond Tenorio, Maria Claudia Nascimento, Thomas Lutz, Daniel Podzamczer, Richard Moore, Miguel Górgolas Hernández-Mora, Clifford Kinder, Jean van Wyk, Mark Underwood

490  VIROLOGIC FAILURE AND RESISTANCE IN DOLUTEGRAVIR-BASED MAINTENANCE DUAL REGIMENS
Colin Deschanvres, François Raffi, Jacques Reynes, Bruno Hoen, David Rey, Romain Palich, Olivier Robineau, Firouze Bani-Sadr, Claudine Duvivier, Laurent Hoqueloux, Lise Cuzin, Véronique Joly, André Cabié, Clotilde Allavena, for the Dat’AIDS Study Group

491  2-DRUG REGIMEN COMPARABLE TO 3-DRUG REGIMENS UP TO 18 MONTHS IN A REAL WORLD SETTING
Gerald Pierone, Kathy L. Schulman, Jennifer S. Fusco, Vani Vannappagari, Michael Aboud, Leigh Ragone, Gregory Fusco

492  SHALL WE DANCE? EXTENDING TANGO’S RESULTS TO CLINICAL PRACTICE
Gianmaria Baldin, Alberto Borghetti, Arturo Ciccullo, Stefano Rusconi, Amedeo Capetti, Gaetana Serrantino, Manuela Colafigili, Gabriella d’Ettorre, Andrea Giacometti, Maria V. Cossu, William Gennari, Cristina Mussini, Vanni Borghi, Simona Di Giambenedetto

493  VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRETREATMENT IN THE DUALIS STUDY
Eva Wolf, Christoph Boesecke, Annamaria Balogh, Helen Bidner, Christiane Cordes, Hans Heiken, Ivanka Krznaric, Tim Kümmel, Jochen Schneider, Christoph D. Spinner, for the DUALIS Study Group

494  ONCE-DAILY ETRAVIRINE/RALTEGRAVIR (400/800 MG) AS MAINTENANCE REGIMEN
Romain Palich, Yasmine Dudoit, Gilles Peytavin, Minh Le, Cathia Soulie, Roland Tubiana, Clotilde Allavena, Laurence Weiss, Ana Montoya Ferrer, Claudine Duvivier, Olivier Bouchaud, Julie Bottero, Anne-Geneviève Marcelin, Lambert Assoumou, Christine Katlama
**Poster P-H03 ADHERENCE ASSESSMENT AND OTHER ART STRATEGIES**

**Poster Hall A**

2:30 PM - 4:00 PM

495 **PATTERNS OF ADHERENCE IN BICTEGRAVIR- AND Dolutegravir-Based Regimens**

Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, Richard A. Elion

496 **SOCIAL NORMS AND ART ADHERENCE: POPULATION-BASED STUDY OF PERSONS WITH HIV IN UGANDA**

Jessica M. Perkins, Bernard Kakukhikire, Charles Baguma, Justin D. Rasmussen, Carolyn M. Audet, Mark J. Siedner, Jessica E. Haberer, David R. Bangsberg, Alexander C. Tsai

497 **RANDOMIZED STUDY OF AN ART ADHERENCE INTERVENTION USING A SMART-PILL BOTTLE SERVICE**

Grant B. Ellsworth, Leah Burke, Martin T. Wells, Satish Mishra, Matthew Caffrey, David W. Liddle, Malika Madhava, Arsalan K. Muhammad, Curtis O’Neal, Peter L. Anderson, Lane R. Bushman, Lucas Ellison, Josh Stein, Roy M. Guilk

498 **PHARMACIST-DRIVEN RAPID ART REDUCES TIME TO VIROLOGIC SUPPRESSION IN RHODE ISLAND**


499 **DO PRESCRIBING DATA REFLECT ACTUAL TREATMENT IN PEOPLE LIVING WITH HIV (PLWH)?**


500 **INVESTIGATION OF A POTENTIAL COMPOSITE ENDPOINT FOR IMMUNOLOGIC NONRESPONDER TRIALS**

Virginia Sheikh, Therri Usher, Maximilian Rohde, Thamban Valappil, Sarah Connelly, Richard Jefferys, Kimberly Struble, Adam Sherwat, Wendy Carter, Jeffrey S. Murray

501 **TREATMENT INTERRUPTION STRATEGIES FOR NNRTI-BASED ART: DOES THE NRTI MATTER?**

Alice K. Pau, Jacqueline Neuhaus, Edward M. Gardner, Anna Maria Geretti, Kimberly K. Scarsi, John D. Baxter, Nnakelu Eriobu, Virginia L. Kan, Vidar Ormaasen, Sarah Pett, H. Clifford Lane, Andrew N. Phillips, James Neaton, for the INSIGHT SMART Study Group

502 **NO SIGNIFICANT CHANGE ON RESERVOIR IN QUATUOR: A 4/7 DAYS A WEEK MAINTENANCE STRATEGY**

Sidonie Lambert-Niclot, Lambert Assoumou, Pierre De Truchis, Djeneba Bocar Fofana, Karine Amat, Jonathan Bellet, François Raffi, Philippe Morlat, Christine Katlama, Cecile Moins, Dominique Costagliola, Pierre-Marie Girard, Roland Landman, Laurence Morand-Joubert, for the ANRS 170 QUATUOR Study Group

**Poster P-I03 DRUG RESISTANCE IN EXPERIENCED AND POTENTIAL FOR SUCCESSFUL TREATMENT**

**Poster Hall A**

2:30 PM - 4:00 PM

521 **TRENDS AND CHARACTERISTICS OF HIV-1 DRUG RESISTANCE IN THE UNITED STATES (2012-2018)**

Cassidy E. Henegar, Mark Underwood, Leigh Ragone, Harmony Garges, Vani Vannappagari
522 PREVALENCE OF RESISTANCE AND LIMITED THERAPEUTIC OPTIONS IN PATIENTS VIREMIC ON ART
Olivier Robineau, Elisabeth André-Garnier, Lise Cuzin, Solène Sécher, Félicie Dewulf, Fanny Taudière, Laurence Bocket, Raymond Césaire, Virginie Ferré, Ciotilde Allavera, André Cabié, François Raffi

523 FOUR-CLASS RESISTANCE IS RARE IN TREATMENT-EXPERIENCED PATIENTS ACROSS EUROPE
Jurgen Vercauteren, Anne-Mieke Vandamme, Barbara Rossetti, Massimiliano Fabbiani, Francesca Incardona, Kristof Theys, Ana Abecasis, Carole Devaux, Rolf Kaiser, Anders Sönnerborg, Maurizio Zazzi, for the EuResist Network Study Group

524 PRO 140 IN VITRO ACTIVITY IN HTE SUBJECTS WITH A 4-CLASS DRUG-RESISTANT HIV-1 VIRUS
Stefano Rusconi, Francesco Saladini, Silvia Barbaliscia, Andrea Poli, Laura Galli, Roberta Gagliardi, Lidia Gazzola, Daniela Francisci, Francesca Vichi, Emanuele Focà, Maurizio Zazzi, Maria M. Santoro, Arianna Gabrieli, Antonella Castagna, for the PRESTIGIO Registry Study Group

556 RESOLVING HCV SUBTYPES IN A BELGIAN COHORT BY FULL GENOME NEXT-GENERATION SEQUENCING
Kasper T. Christensen, Florian Pierard, Kurt Beuselinck, David Bonsall, Rory Bowden, Katrien Lagrou, Frederik Nevens, Peter Simmonds, Anne-Mieke Vandamme, Eric Van Wijngaerden, Lize Cuypers, Kristel Van Laethem

560 VIROLOGIC PATTERNS OF HCV PATIENTS WITH FAILURE TO SECOND-GENERATION DAA's
Mario Starace, Mariantonietta Pisaturo, Carmine Minichini, Stefania De Pascalis, Margherita Macera, Laura Occhiello, Alessandra Di Fraia, Loredana Alessio, Vincenzo Messina, Ernesto Claro, Tiziana Ascione, Aldo Marrone, Ivan Gentile, Giovanni Battista Gaeta, Nicola Coppola

564 TRANSMISSION OF THE NSSA-RESISTANT VARIANT M28V AMONG ACUTE HIV/HCV COINFECTED MSM
Stephanie Popping, Rosanne Verwijs, Lize Cuypers, Mark Claassen, Guido Van Den Berk, Anja De Weggeheijer, Joop E. Arends, Anne Boerekamps, Richard Molenkamp, Marion Koopmans, Annelies Verbon, Charles Boucher, Bart Rijnders, David Van De Vijver

565 RESISTANCE ANALYSIS IN HCV-3–INFECTED PATIENTS WITHIN THE ITALIAN NETWORK VIRONET-C
Velia Chiara Di Maio, Silvia Barbaliscia, Elisabetta Teti, Caterina Pasquazzi, Stefania Paolucci, Teresa Pollicino, Bianca Bruzzzone, Nicola Coppola, Valeria Micheli, Fausto Baldanti, Giustino Parruti, Mario Angelico, Massimo Andreoni, Carlo Federico Perno, Francesca Ceccherini Silberstein
566  BARRIERS TO DIRECTLY ACTING ANTIVIRALS THERAPY AMONG HIV/HCV-COINFECTED ADULTS
Gina M. Simoncini, Qingjiang Hou, Kate Buchacz, Ellen Tedaldi, Frank J. Palella, Jack Fuhrer, Richard M. Novak, Cynthia Mayer, David E. Koren, Linda A. Battalora, Stockton Mayer, Stacey Purinton, Jun Li, for the HIV Outpatient Study (HOPS) Investigators

567  MEDICAID HCV TREATMENT RESTRICTIONS: SPILLOVER TO THE PRIVATE-PAYER HCV CARE CASCADE?
Rachel Epstein, Jianing Wang, Jake R. Morgan, Shashi Kapadia, Yuhua Bao, Laura F. White, Benjamin P. Linas

568  HEALTH INSURANCE AND DIRECT-ACTING HCV ANTIVIRAL INITIATION IN US WOMEN WITH HIV

569  MOBILE HCV SCREENING IN AN AT-RISK URBAN POPULATION IDENTIFIES SIGNIFICANT FIBROSIS
Jennifer C. Price, Rachel Kanner, Emily Valadao, Yesenia S. Laguardia, Maria Duarte, Norah A. Terrault

570  PROGRESS AND REAL-LIFE CHALLENGES FOR HCV ELIMINATION IN PEOPLE LIVING WITH HIV
Edward R. Cachay, Francesca Torriani, Lucas Hill, Craig Ballard, Abigail Aquino, Huifang Qin, Sonia Jain, Natasha Martin, W. C. Mathews

571  REAL-WORLD EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR HEPATITIS C VIRUS INFECTION
Lourdes Domínguez-Domínguez, Juan Berenguer, Ángela Gil-Martín, Diego Rincón, Antonio Olveira, Inmaculada Fernández, Beatriz Álvarez, Laura Benítez, Ignacio Santos, José Barrio Antoranz, Elvira Poves, Juan E. Losa, Inma Jarrín, María J. Calvo, Juan González-García, for the RUA-VCH Study Group

572  REAL-WORLD EFFECTIVENESS OF SOFOSBUVIR/VELPASVIR FOR HEPATITIS C VIRUS INFECTION
Teresa Aldámiz-Echevarría, Juan Berenguer, Ángela Gil-Martín, Javier García-Samaniego, Laura Márquez, José L. Calleja, Luz Martín-Carbonero, Ana Moreno, Benjamin A. Polo Lorduy, Pablo Ryan, Luisa Consuelo García Buey, María J. Devesa, Inma Jarrín, María J. Calvo, Juan González-García

573  A MULTICENTER REGISTRY IN PATIENTS WITH HIV/HCV COINFECTION ON LEDIPASVIR/SOFOSBUVIR
Stefan Mauss, Cody A. Chastain, Nwora L. Okeke, Kristen M. Marks, Kimberly Workowski, Gregory K. Robbins, Kenneth E. Sherman, Chris Woods, Lawrence Park, Jürgen K. Rockstroh, Susanna Naggie

574  EFFECTIVENESS OF LDV/SOF FOR HIV-POSITIVE PATIENTS WITH HCV GENOTYPE 2 INFECTION
Hsin-Yun Sun, Chia-Jui Yang, Bo-Huang Liou, Wen-Chien Ko, Shu-Hsing Cheng, Yu-Lin Lee, Hung-Jen Tang, Guan-Jhou Chen, Chi-Ying Lin, Chien-Ching Hung, for the Taiwan HIV Study Group
575 EFFECTIVENESS OF DAA IN HIV-POSITIVE PATIENTS WITH HCV GENOTYPE 6 INFECTION
Hsin-Yun Sun, Chien-Yu Cheng, Chi-Ying Lin, Chia-Jui Yang, Ming-Jui Tsai, Bo-Huang Liou, Nan-Yao Lee, Hung-Jen Tang, Yi-Chia Huang, Chien-Ching Hung, for the the Taiwan HIV Study Group

576LB ADHERENCE AND 007-TP DBS LEVELS IN ACTIVE DRUG USERS WITH HCV: THE INCLUD TRIAL
Kristina M. Brooks, Jose R. Castillo-Mancilla, Mary Morrow, Samantha MaWhinney, Sarah E. Rowan, David L. Wyles, Joshua Blum, Ryan T. Huntley, Lana M. Sahal, Arya Tehrani, Laura Roon, Lane R. Bushman, Peter L. Anderson, Jennifer J. Kiser

Poster P-J06 HCV AFTER THE SVR: GONE BUT NOT FORGOTTEN
Poster Hall B 2:30 PM - 4:00 PM

577 OVERALL SURVIVAL IN HIV-POSITIVE LIVER TRANSPLANT RECIPIENTS AND THE ROLE OF DAA S
Roberto Rossoitti, Marco Merli, Chiara Mazzarelli, Stefano Di Sandro, Giovanna Travi, Raffaella Viganò, Andrea Lauterio, Marco Cantone, Maria Cristina Moioli, Luca S. Belli, Luciano G. De Carli, Massimo Puoti

578 HIV COINFECTION AND RISK OF MORBIDITY AND MORTALITY IN HCV PATIENTS TREATED BY DAA
Mathieu Chalouni, Stanislas Pol, Philippe Sogni, Hélène Fontaine, Karine Lacombe, Jean-Marc Lacombe, Laure Esterle, Camille Gilbert, Céline Dorival, Dominique Salmon, Carrat Fabrice, Linda Wittkop, for the ANRS CO22 HEPATHER cohort and ANRS CO13 HEPAVIH cohort Study Groups

579 EFFECT OF DAA REGIMENS ON MORTALITY IN HIV/HCV-COINFECTED PATIENTS WITH CIRRHOSIS
Nicolas Merchante, Francisco Téllez, Angela Camacho-Espejo, Dolores Merino, Maria J. Rios-Villegas, Marina Villalobos, Mohamed Omar Mohamed Balghaiha, Carolina de Freyre-Carrillo, Antonio Rivero, Miguel Raffo, Maria Paniagua-Garcia, Rosario Palacios, Juan Macías, Juan A. Pineda, for the HEPAVIR-Cirrhosis Study Group

580 ALL-CAUSE MORTALITY AND CAUSES OF DEATH IN THE SWISS HEPATITIS C COHORT STUDY
Maroussia Roelens, Barbara Bertisch, Darius Moradpour, Andreas Cerny, Nasser Semmo, Patrick Schmid, Beat Muellhaupt, Christoph Junker, Francesco Negro, Olivia Keiser

581 KINETICS OF EMERGENCE OF LIVER COMPLICATIONS IN HCV-INFECTED PATIENTS AFTER SVR
Anaïs Corma-Gómez, Juan Macías, Francisco Téllez, Luis Morano, Antonio Rivero-Juaréz, Rafael Granados, Marta Santos, Maria Paniagua-García, Francisco Vera, Luis Miguel Real, Jesus Santos, Azucena Bautista, Paloma Geijo, Dolores Merino, Juan A. Pineda, for the RIS-HEP13 and GEHEP 011 Study Groups

582 LIVER STIFFNESS FOR PORTAL HYPERTENSIVE GASTROINTESTINAL BLEEDING AFTER HCV CURE
Anaïs Corma-Gómez, Juan Macías, Francisco Téllez, Luis Morano, Mario Frías, Rafael Granados, Juan C. Alados, Maria Paniagua-García, Francisco Vera, Nicolás Merchante, Rosario Palacios, Ignacio Santos, Paloma Geijo, Dolores Merino, Juan A. Pineda, for the RIS-HEP13 and GEHEP 011 Study Groups
583  TREATMENT WITH DIRECT-ACTING ANTIVIRALS REDUCES HEALTH CARE SERVICE UTILIZATION  
Sahar Saeed, Erica E. Moodie, Sharon Walmsley, Curtis Cooper, Michael John Gill, Alexander Wong, Valerie Martel-Laferriere, Marie-Louise Vachon, Marina Klein, for the Canadian HIV-HCV Co-Infection Cohort Study

584  HCV CURE IN HIV COINFECTION DAMPENS INFLAMMATION AND IMPROVES COGNITION  
Lynn Pulliam, Linda Abadjian, Alex Monte, Bing Sun

585  TELOMERE LENGTH OF CIRRHOTIC HIV/HCV PATIENTS INCREASES AFTER HCV CLEARANCE WITH DAAs  
Silvia S. Molina Carrión, Óscar Brochado Kith, Juan González-García, Juan Berenguer, Cristina Diez, Juan Carlos López-Bernaldo, Elba L. Herrera, Victor Hontanon, Luis Ibañez-Samaniego, Maria Luisa Montes, Salvador Resino, Amanda Fernández-Rodríguez, Maria Á. Jimenez-Sousa

586  T-CELL AND MONOCYTE ACTIVATION CORRELATE AND DECLINE DURING HCV THERAPY FOR HCV/HIV  
Ann W. Auma, Sofi N. Damjanovska, Corinne N. Kowal, Carey Shive, Laura M. Smeaton, Daniel E. Cohen, Debika Bhattacharya, Beverly Alston-Smith, Ashwin Balagopal, Mark Sulikowski, David L. Wyles, Donald D. Anthony

587  IMPACT OF HCV CLEARANCE ON NK CELLS AND HIV TRANSCRIPTION IN COINFECTED SUBJECTS  
Maria L. Polo, Alejandra Urioste, Yanina Ghiglione, Jimena Salido, Ajantha Solomon, Maria J. Rolon, Horacio Salomón, Florencia Quiroga, Gabriela Turk, Sharon R. Lewin, Natalia Lauber

588  CHANGES IN IMMUNE-CELL SUBSETS IN HCV AND HCV/HIV PATIENTS UPON VIRALLY EFFECTIVE DAA  
Elvira S. Cannizzo, Camilla Tincati, Esther Merlini, Anna De Bona, Lorena Van Den Bogart, Roberta Curetti, Spinello Antinori, Antonella D’Arminio Monforte, Giulia Marchetti, Laura Milazzo

589  LIVER FIBROSIS HINDERS NORMALIZATION OF SYSTEMIC INFLAMMATION AFTER HCV ERADICATION  
Clara Restrepo, Beatriz Álvarez, Marcial Garcia, Maria Ángeles Navarrete, Mónica Gutiérrez-Rivas, Laura Prieto, Alfonso Cabello, Sara Nistal, Salvador Resino, Miguel Gorgolas Hernández-Mora, Norma Rallón, José M. Benito

Poster P-K02 CANCERS: KAPOSI SARCOMA, LUNG, BREAST, AND HEMATOLOGIC
Poster Hall B  2:30 PM - 4:00 PM

625  LUNG CANCER INCIDENCE AND RISK FACTORS DIFFER BY HISTOLOGY AMONG HIV+/− VETERANS  
Elizabeth Chiao, Jennifer R. Kramer, Yongquon Dong, Peter A. Richardson, Sarah T. Ahmed, Donna L. White, Christine Hartman, Jose M. Garcia, Suchismita Raychaudhury, Eric A. Engels

626  IMPACT OF UNIVERSAL ART ACCESS ON KAPOSI SARCOMA: RESULTS FROM THE ICONA COHORT  
Alessandra Bandera, Alessandro Cozzi-Lepri, Antonella Cingolani, Francesca Ceccerini Silberstein, Giulia Marchetti, Stefano Rusconi, Valentina Svicher, Roberto Cauda, Francesco Castelli, Andrea Gori, Andrea Antinori, Antonella D’Arminio Monforte, for the Icona Foundation Study Group
Poster Sessions

627LB OUTCOMES AFTER PEGYLATED LIPOSOMAL DOXORUBICIN FOR KAPOSI SARCOMA IN MOZAMBIQUE
Matthew E. Coldiron, Ana Gabriela Gutierrez Zamudio, Rolanda Manuel, Gilda Luciano, Barbara Rutsch, Iza Ciglenecki, Rebecca F. Grais, Laurence Toutous Trellu, Lucas Molfini

628 BREAST CANCER RISK AMONG WOMEN WITH HIV IN NORTH AMERICA (2000-2015)
Sally B. Coburn, Michael J. Silverberg, Richard D. Moore, W. C. Mathews, Julia L. Marcus, Jessica L. Castilho, Mari M. Kitahata, Heidi M. Crane, Marina Klein, Sonia Napravnik, Todd T. Brown, Kala Visvanathan, Bryan Lau, Keri N. Althoff, for the NA-ACCORD of IeDEA

629 BREAST CANCER RISK IN WOMEN LIVING WITH HIV IN SOUTH AFRICA: THE SAM STUDY
Maša Dađovič, Tafadzwa G. Dhokotera, Lina Bartels, Katayoun Taghavi, Frédérique Chammartin, Victor Olago, Elvira Singh, Matthias Egger, Mazvita Sengayi, Julia Bohlius

630 HIV-ASSOCIATED HEMATOLOGIC MALIGNANCIES IN PEOPLE LIVING WITH HIV IN SWEDEN
Oscar Kieri, Piotr Nowak, Anders Sönnerborg, Gaetano Marrone

Poster P-L03 CLUSTERING OF PREDICTORS AND PREDICTION RULES FOR MI RISK
Poster Hall B 2:30 PM - 4:00 PM

647 PLASMA INFLAMMATORY BIOMARKER SIGNATURE ASSOCIATED WITH CVD IN HIV INFECTION
Mohamed El-Far, Madeleine Durand, Carl Chartrand–Lefebvre, Rémi Bunet, Hardik Ramani, Jean–Guy Baril, Benoît Trottier, Samer Mansour, Ali Filali, Petronela Ancuta, Nicolas Chomont, Robert C. Kaplan, Alan Landay, Cécile Tremblay, for the Canadian HIV and Aging Cohort Study (CHACS)

648 ASSOCIATION OF INFLAMMATORY MARKERS WITH CARDIAC INDICES IN THE MACS
Bethel Woldu, Henrique Doria De Vasconcellos, Joseph B. Margolick, Heather McKay, Jared Magnani, Matthew J. Feinstein, Roger Detels, Todd T. Brown, Sean Altekruse, Joao Lima, Katherine Wu, Wendy Post

649 PHENOTYPIC CLUSTERING OF HIV-ASSOCIATED ATHEROSCLEROSIS AND AGE-RELATED OUTCOMES
David B. Hanna, Jee-Young Moon, Bryan Lau, Kathryn Anastos, Russell Tracy, Sabina A. Haberlen, Caitlin A. Moran, Todd T. Brown, Leah H. Rubin, Lawrence Kingsley, Stephen J. Gange, Wendy Post, Robert C. Kaplan, Howard Hodis, for the MACS/WIHS Combined Cohort Study

650 MYOCARDIAL INFARCTION BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) RISK SCORE
Keri N. Althoff, Todd T. Brown, Greer Burkholder, Heidi M. Crane, Joseph Delaney, Richard A. Elion, Karla I. Galaviz, Stephen J. Gange, Michael A. Horberg, Frank J. Palella, Michael J. Silverberg, Janet Tate, Richard D. Moore, for the NA-ACCORD of IeDEA

651 CONTRIBUTION OF TELOMERE LENGTH AND CLINICAL RISK FACTORS TO CORONARY ARTERY DISEASE
Isabella C. Schoepf, Tanja Engel, Marieke Raffenberg, Neeltje A. Kootstra, Peter Reiss, Christian Thorball, Jacques Fellay, Roger Kouyou, Huldrych F. Günthard, Bruno Ledegerber, Philip E. Tarr, for the Swiss HIV Cohort Study
Poster P-L04 STRUCTURAL ISSUES IN HEART DISEASE AND HIV
Poster Hall B 2:30 PM - 4:00 PM

652 PREVALENCE OF SUBCLINICAL MYOCARDIAL ABNORMALITIES IN HIV: SMASH STUDY RESULTS
Katherine Wu, Sabina A. Haberlen, Michael Plankey, Frank J. Palella, Damani A. Piggott, Gregory D. Kirk, Joseph B. Margolick, Wendy Post

653 AORTIC DILATATION IS PRESENT AMONG MEN WITH HIV

654 PREVALENCE OF PULMONARY HYPERTENSION IN HIV-INFECTED PATIENTS AND REDUCED OUTCOME
Nico Reinsch, Hendrik Streeck, Meinhard Mende, Till Neumann, Norbert H. Brockmeyer, Jan Kehrmann, Dirk Schadendorf, Stefan Esser

Poster P-M01 FAT IN FOCUS
Poster Hall B 2:30 PM - 4:00 PM

667 FAT GAINS OCCUR AFTER ART WITHOUT CHANGES IN METABOLIC RATE OR CALORIC INTAKE
Allison Ross Eckard, Abdus Sattar, Jiao Yu, Heather Y. Hughes, Danielle Labbato, Theresa O. Rodgers, Julia C. Kosco, Grace A. McComsey

668 GREATER WEIGHT GAIN AFTER SWITCH TO INSTI-BASED REGIMEN FROM NNRTI VS PI REGIMENS
John Koethe, Aihua Bian, Peter F. Rebeiro, Cathy Jenkins, Kassem Bourgi, Richard D. Moore, Michael Saag, Kathryn Anastos, Julia Fleming, Marina Klein, Viviane D. Lima, Joseph B. Margolick, Timothy R. Sterling, Jordan E. Lake, for the NA-ACCORD of IeDEA

669 BODY COMPOSITION CHANGES OVER THE MENOPAUSAL TRANSITION IN HIV+ AND HIV- WOMEN
Thuy Trang J. Nguyen, Yifei Ma, Rebecca Scherzer, Anjali Sharma, Mark H. Kuniholm, Audrey French, Margaret Fischl, Howard Minkoff, Michael Plankey, Adaora Adimora, Carl Grunfeld, Phyllis Tien

670 RESISTIN GENE POLYMORPHISM RELATED TO WEIGHT GAIN AND PSYCHIATRIC SYMPTOMS ON INSTI
Rumi Minami, Soichiro Takahama, Kazuhiko Koyama, Masahiro Yamamoto

671 ADIPOCYTE DYSFUNCTION DESPITE REDUCED ADIPOSE INFLAMMATION IN DIABETICS WITH HIV
Samuel Bailin, Spyros Kalams, Simon Mallal, Fei Ye, Run Fan, Mona Mashayekhi, Curtis Gabriel, John Koethe, Celestine Wanjalla

672 INCREASED INFLAMMATORY CX3CR1+GPR56+CD57+CD4+ T CELLS IN FAT FROM HIV+ DIABETICS
673  TELMISARTAN DECREASES MONOCYTE CX3CR1 EXPRESSION IN TREATED HIV INFECTION
Jordan E. Lake, Eunice Yeh, Douglas W. Kitch, Anoma Somasunderam, Michael M. Lederman, Judith S. Currier, Netanya S. Utay, for the A5317 Team

674  GUT INTEGRITY MARKERS AND ASSOCIATIONS WITH ADIPOSY IN PEOPLE WITH AND WITHOUT HIV
Allison Ross Eckard, Carlee Moser, Judith S. Currier, Todd T. Brown, Emily Bowman, Peter W. Hunt, Nicholas Funderburg, Grace A. McComsey

675  CONTRIBUTION OF InStI, BMI, PHYSICAL ACTIVITY, CALORIC INTAKE TO WEIGHT GAIN IN PWH
Giovanni Guaraldi, Jovana Milic, Andrea Malagoli, Federica Carli, Marianna Menozzi, Alessandro Raimondi, Giacomo Cusià, Valentina Masi, Michela Belli, Stefano Guaraldi, Cristina Mussini, Todd T. Brown, Jordan E. Lake, Kristine M. Erlandson

676  UNDERSTANDING WHO DOES AND DOES NOT GAIN WEIGHT WITH INTEGRASE INHIBITORS (InStI)

677  DRUG CONCENTRATIONS AND BODY WEIGHT GAIN IN PLWH SWITCHED TO 3TC & DOLUTEGRAVIR (DTG)
Charles Burdet, Giles Peytavin, Minh Le, Roland Landman, Delphine Bachelet, Christine Katlama, Frédéric Raffi, André Cabié, Charlotte Charpentier, Aida Benalycherif, Diane Descamps, Yazdan Yazdanpanah, Véronique Joly, for the Lamidol Study Group

678  RACE IMPACT ON DOLUTEGRAVIR-ASSOCIATED WEIGHT GAIN AMONG PREVIOUSLY ART-NAIVE PLWH

679  DTG PRESCRIBING PATTERNS IN PLWH ≥65 YEARS: THE IMPACT OF 2DR AND WEIGHT GAIN
Giovanni Guaraldi, Stefano Calza, Andrea Calcagno, Jovana Milic, Emanuele Focà, Matteo Rota, Anna Celotti, Benedetto Maurizio Celesia, Stefania Piconi, Annamaria Cattelan, Giuseppe V. De Socio, Giancarlo Orofino, Agostino Riva, Silvia Nozza, Giovanni Di Perri

680  DIABETES, WEIGHT GAIN, AND INTEGRASE INHIBITOR USE IN NORTH AMERICAN HIV+ PERSONS
Peter F. Rebeiro, Cathy Jenkins, Aihua Bian, Jordan E. Lake, Kassem Bourgi, Keri N. Althoff, Michelle Floris-Moore, Michael A. Horberg, Janet Tate, Amanda Willig, Richard D. Moore, Stephen J. Gange, Timothy R. Sterling, John R. Koethe, for the NA-ACCORD of iDeA

681  WEIGHT GAIN AT 18 MONTHS FOR ART-EXPERIENCED PATIENTS WHO SWITCHED TO DTG IN NIGERIA
Jennifer Campbell, Opeyemi Abudioire, Ikechukwu Amamilo, Joseph Harwell, Caroline Middlecote, James Conroy, Williams Egiege, Nere Otubu, Justus Jiboye, Folu Lufadeju, Carolyn Amole, Owens Wiwa, Özge Agbaji, Sulaimon Akanmu, Damien Anweh
### Poster Sessions

<table>
<thead>
<tr>
<th>Poster P-M10</th>
<th>EPIGENETIC AND MITOCHONDRIAL TOXICITIES</th>
<th>Poster Hall B</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>714</strong></td>
<td>IMPACT OF ANTIRETROVIRAL THERAPY INITIATION ON EPIGENETIC AGING AND TELOMERE LENGTH</td>
<td>Andrés Esteban-Cantos, Javier Rodríguez-Centeno, Pilar Barruz, Francisco Gayá, Julián Nevado, Natalia Stella-Ascarriz, Rocio Montejano, Jose I. Bernardino, Eric Florence, Lars Mathiesen, Cédrick Wallet, François Raffi, Berta Rodes, Jose R. Arribas</td>
<td></td>
</tr>
<tr>
<td><strong>715</strong></td>
<td>IN VITRO IMPACT OF TAF ON MITOCHONDRIAL FUNCTION IN IMMUNE CELLS</td>
<td>Eleni Ritou, Rachel Heymans, Theodoros Kelesidis</td>
<td></td>
</tr>
<tr>
<td><strong>716</strong></td>
<td>INFLAMMATION AND MITOCHONDRIAL DYSFUNCTION NOT NRtIs DRIVE EVENTS IN ACTG A5241</td>
<td>Carl J. Fichtenbaum, Timothy M. Stone, Gregory S. Gojanovich, Roman Jandarov, Joseph J. Eron, Rajesh T. Gandhi, Karen T. Tashima, Mariana Gerschenson, for the AIDS Clinical Trials Group</td>
<td></td>
</tr>
</tbody>
</table>

### Poster Sessions - Tuesday

<table>
<thead>
<tr>
<th>Poster P-N03</th>
<th>EARLY BACTERICIDAL ACTIVITY, PK/PD, AND DRUG INTERACTIONS IN TB TREATMENT</th>
<th>Poster Hall B</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>733</strong></td>
<td>EFFECT OF RIFAMYCINS ON PRETOMANID EXPOSURE IN PATIENTS WITH PULMONARY TB</td>
<td>Mahmoud T. Abdelwahab, Elisa Ignatius, Paolo Denti, Kelly E. Dooley, Nikhil Gupte, Rodney Dawson, Grace Barnes, Kim Narunsky, Bronwyn Hendricks, for the APT Study Team</td>
<td></td>
</tr>
<tr>
<td><strong>734</strong></td>
<td>CLINICAL PHARMACOKINETICS AND TOXICODYNAMICS OF LINEZOLID IN THE NIX-TB TRIAL</td>
<td>Marjorie Imperial, Jerry Nedelman, Radojka M. Savic</td>
<td></td>
</tr>
<tr>
<td><strong>735</strong></td>
<td>HIV VIROLOGICAL OUTCOMES DURING TENOFOVIR ALAFENAMIDE AND RIFABUTIN COADMINISTRATION</td>
<td>Shannon Balcombe, Thomas C. Martin, Michael E. Tang, Lucas Hill</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster P-N04</th>
<th>TB: MORTALITY, OUTCOMES, AND END-ORGAN COMPLICATIONS</th>
<th>Poster Hall B</th>
<th>2:30 PM - 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>736</strong></td>
<td>DRUG-RESISTANCE MUTATIONS AND TUBERCULOSIS MORTALITY IN HIGH-BURDEN COUNTRIES</td>
<td>Veronika Skrivankova, Matthias Egger, for the IeDEA TB Genomics Group</td>
<td></td>
</tr>
<tr>
<td><strong>737</strong></td>
<td>CSF TB BACTILLARY LOAD PREDICTS 2-WEEK MORTALITY IN HIV-ASSOCIATED TB MENINGITIS</td>
<td>Emily Martyn, Ananta Bangdiwala, Enock Kagimu, Morris K. Rutakingirwa, John Kasibante, Michael Okirwoth, Gavin Stead, Vincent Wadda, Matt Pullen, Tyler Bold, David B. Meya, David R. Boulware, Nathan C. Bahr, Fiona Cresswell</td>
<td></td>
</tr>
</tbody>
</table>
738  MORTALITY IN ADULT HIV/MDR-TB BY ART USE: INDIVIDUAL PATIENT DATA META-ANALYSIS
Gregory P. Bisson, Mayara Bastos, Jonathon Campbell, Didi Bang, James C. Brust, Petros Isaakidis, Christoph Lange, Giovanni Battista Migliori, Jean William Pape, Domingo Palmero, Stalz C. Vilbrun, Piret Viiklepp, Jonathan W. Walsh, Suzanne Marks

739  CD4 COUNT AND VIRAL LOAD DYNAMICS UNDER DIFFERENT ART REGIMENS IN HIV/TB COINFECTION

740  SUBOPTIMAL TUBERCULOSIS TREATMENT COMPLETION: A MULTICENTER OBSERVATIONAL STUDY
Felipe Ridolfi, Lauren Saag Peetluk, Gustavo Amorin, Megan M. Turner, Marina Cruvinel, Marcelo Cordeiro-Santos, Solange Cavalcante, Afrânio Kritski, Betina Durovni, Bruno Andrade, Timothy R. Sterling, Valéria C. Rolla

741  N-ACETYLCYSTEINE FOR ANTI-TB DRUG-INDUCED LIVER INJURY: A RANDOMISED CONTROLLED TRIAL
Muhammed S. Moosa, Gary Maartens, Hannah Gunter, Shaaizia Allie, Mashiko Setshedi, Mohamed F. Chughlai, Nicole Kramer, Annemie Stewart, Wendy Spearman, Mark Sonderup, Karen Cohen

742  HIV, TUBERCULOSIS, AND CHRONIC LUNG DISEASE AMONG KENYAN ADULTS
Jerry S. Zifodya, Tecla M. Temu, Sarah Masyuko, George Nyale, Jerusha Nyabiage, Dickens Onyango, John Kinuthia, Stephanie Page, Sylvia LaCourse, Carey Farquhar, Kristina Crothers

Poster P-003 NEW PERSPECTIVES IN PMTCT
Poster Hall B  2:30 PM - 4:00 PM

775  CABOTEGRAVIR PHARMACOKINETIC TAIL IN PREGNANCY AND NEONATAL OUTCOMES
Parul Patel, Shanker Thiagarajah, Susan Ford, David A. Margolis, Beth H. Romach, Mark Baker, Kenneth Sutton, Conn M. Harrington, Mark S. Shaefler, William Sreen, Kimberly Smith, Vani Vannappagari

776  RILPIVIRINE IN HIV-1–INFECTED WOMEN INITIATING PREGNANCY: TO SWITCH OR NOT TO SWITCH?
Pierre Frange, Roland Tubiana, Jeanne Sibiude, Ana Canestri, Cedric Arvieux, Cecile Brunet-Cartier, Laurent Cotte, Sophie Matheron, Jacques Reynes, Laurent Mandelbrot, Josiane Warszawski, Jérôme Le Chenadec, for the ANRS EPF C01/C011 Study Group

777  COST-EFFECTIVENESS OF BROADLY NEUTRALIZING ANTIBODIES FOR INFANT HIV PROPHYLAXIS

778  WITHDRAWN
779  HIV SEROCONVERSION DURING PREGNANCY AT ROUTINE ANTENATAL CARE CLINICS IN BOTSWANA
Katrina F. Ortblad, Shreshth Mawandia, Odirile Bakae, Lenna Tau, Matias Grande, Goabaone Mogomotsi, Esther Mmatl, Modise Ngombo, Laura Seckel, Renee Heffron, Jillian Pintye, Jenny Ledikwe

780  TRENDS IN MARIJUANA, ALCOHOL, AND OPIOID USE IN PREGNANT AND POSTPARTUM HIV+ WOMEN
Lynn M. Yee, Deborah Kacanek, Chase Brightwell, Lisa B. Haddad, Jennifer Jao, Kathleen M. Powis, Tzy-Jyun Yao, George R. Seage, Ellen G. Chadwick

781  TRANSMISSION, VARIATION, AND EVOLUTION OF IN UTERO TRANSMITTED HIV-1
Manukumar Honnyayakanahalli Marichannegowda, Michael Mengual, Amit Kumar, Elena E. Giorgi, David R. Martinez, Joshua J. Tu, Xiaojun Li, Sallie Permar, Feng Gao

782  MATERNAL RISK STRATIFICATION TO IDENTIFY HIGH-RISK INFANTS FOR HIV BIRTH TESTING
Haurovi Mafaune, Emma Sacks, Addmore Chadambuka, Emmanuel Tachiwenyika, Francis Simmonds, Reuben Musarandega, Tichaona Nyamundaya, Jennifer Cohn, Agnes Mahomva, Angela Mushavi

783  POINT-OF-CARE TESTING IMPROVES EARLY INFANT DIAGNOSIS IN THE PUBLIC HEALTH SECTOR
Jessica Joseph, Melody Wang, Caroline E. Boeke, Zelalem M. Abate, Charles Atem, Adisus Kebede, Phibeon M. Mangwendeza, Ellen Munemo, Divine Nzuobontane, Shaukat Khan, Trevor Peter, Jilian Sacks

784  EVALUATION OF PERFORMANCE AND USABILITY OF CEPHEID XPERT HIV-1 QUAL ASSAY IN MALAWI
Maggie N. Nyang’Wa, Augustine Choko, Angela Obasi, Chisomo Msefula, Maganizo Chagomerana, Sarah Watters, Kevin Mortimer, Neil Kennedy, Derek Fairley, Nigel Klein, Dagmar Alber

785  EARLY INFANT DIAGNOSIS: STRENGTHEN EXISTING SYSTEMS OR INVEST IN POINT-OF-CARE?
Nicole McCann, Jennifer Cohn, Clare Flanagan, Emma Sacks, Sushant Mukherjee, Addmore Chadambuka, Haurovi Mafaune, Rochelle P. Walensky, Collins O. Odhiambo, Kenneth Freedberg, Oluwarantimi Adetunji, Christopher Panella, Andrea L. Ciaranello

786  MOTIVATIONAL INTERVIEWING RETENTION COUNSELING AND CHILD HIV TESTING IN SOUTH AFRICA
Dorina Onoya, Nelly Jinga, Cornelius Nattey, Constance Mongwenyana, Sithabile Mengadi, Gayle G. Sherman

787  MOTHERS’ ADHERENCE HELPS IN IDENTIFYING MORE INFANTS IN NEED OF EXTENDED PROPHYLAXIS
Sara Dominguez Rodriguez, Pablo Rojo Conejo, Maria G. Lain, Aafaq Liberty, Shaun Barnabas, Elisa López Varela, Kennedy N. Otswombe, Siva Danaviah, Eleni Nastuoli, Miquel Serna Pascual, Viviana Gianuzzi, Carlo Giaquinto, Louise Kuhn, Alfredo Tagarro, for the EPICAL Consortium

788  IMPROVED HEMATOLOGICAL OUTCOMES WITH NEVIRAPINE FOR INFANT HIV POSTNATAL PROPHYLAXIS
Catherine Dollfus, Jérôme Le Chenadec, Laurent Mandelbrot, Roland Tubiana, Albert Faye, Stephane Blanche, Pierre Frange, Josiane Warszawska, for the ANRS C01 et C011
Poster P-005 INTEGRASE STRAND TRANSFER INHIBITORS IN PREGNANCY
Poster Hall B 2:30 PM - 4:00 PM

789 TOXICITY OF INTEGRASE INHIBITORS IN A HUMAN EMBRYONIC STEM-CELL MODEL
Marie-Soleil R. Smith, Hélène C. Côté

790 ESTIMATES OF PERICONCEPTIONAL EXPOSURES TO INTEGRASE INHIBITORS UNITED STATES
Margaret A. Lampe, Jeff Wiener, Jennita Reehuis, Steven R. Nesheim

791 OUTCOMES FOLLOWING PRENATAL EXPOSURE TO DOLUTEGRAVIR: THE DOLOMITE-EPPICC STUDY
Claire Thorne, Virginia Rasi, Karoline Aebi-Popp, Luminita Ene, Marco Floridia, Natalia Mendoza Palomar, Luis M. Prieto, Leigh Ragone, Rebecca Sconza, Carlo Giaquinto, Vani Vannappagari, for the Dolomite-EPPICC Study Group

792 CHANGES IN DTG USE FOLLOWING THE NTD SAFETY SIGNAL IN BOTSWANA
Rebecca Zash, Chelsea Morroni, Gloria K. Mayondo, Modiegi D. Diseko, Judith Mabuta, Mompati O. Mmalane, Joseph Makhema, Mimi Raesima, Tendani Gaolathe, Tumalano Sekoto, Shahnin Lockman, Roger L. Shapiro

Poster P-P03 CHARACTERIZING THE HIV RESERVOIR IN INFANTS AND CHILDREN
Poster Hall B 2:30 PM - 4:00 PM

810 MARKERS OF HIV RESERVOIR SIZE IN INFECTED CHILDREN ON LONG-TERM VIRAL CONTROL
Stefano Rinaldi, Suresh Pallikkuth, Lesley R. De Armas, Rajendra Pahwa, Nicola Cotugno, Pablo Rojo Conejo, Eleni Nastouli, Kathleen Gärtner, Nigel Klein, Caroline Foster, Anita De Rossi, Carlo Giaquinto, Paolo Rossi, Paolo Palma, Savita Pahwa

811 PROVIRAL LANDSCAPE IN CHILDREN PARALLELS ADULTS AND ENABLES RESERVOIR RECONSTRUCTION
Jenna M. Hasson, Mary Grace K. Katusiime, Samuel Smith, Michael J. Bale, Liliana Perez-Rodriguez, Divya Kilam, Wei Shao, Mark Cotton, Eli A. Boritz, John M. Coffin, John W. Mellors, Sean Patro, Gert U. van Zyl, Mary F. Kearney

812 CELL-ASSOCIATED HIV-1 DNA/RNA IN CHILDREN: PERFORMANCE OF REAL-TIME AND DIGITAL PCR
Kathleen Gärtner, Triantafylia Gkouleli, Judith Heaney, Paul Grant, Sara Dominguez Rodriguez, Eloise Busby, Denise O’Sullivan, Moira J. Spyer, Caroline Foster, Pablo Rojo Conejo, Deborah Persaud, Anita De Rossi, Jim Huggett, Eleni Nastouli, for the EPIICAL Consortium

813 ASSESSMENT OF HIV-1 DNA BY SINGLE-GENOME SEQUENCING IN CHILDREN ON SUPPRESSIVE ART
Kathleen Gärtner, Triantafylia Gkouleli, Matthew Byott, Judith Heaney, Moira J. Spyer, Anita De Rossi, Deborah Persaud, Paolo Palma, Carlo Giaquinto, Pablo Rojo Conejo, Caroline Foster, Anne-Genèveve Marcelin, Paolo Rossi, Eleni Nastouli, for the EPIICAL Consortium

814 DIFFERENCES IN THE INDUCED LATENT HIV RESERVOIR IN PERINATAL AND ADULT INFECTIONS
Adit Dhummakupt, Jessica Rubens, Thuy Anderson, Laura Powell, Bareng Nonyane, Lilly V. Siems, Aleisha Collinson-Streng, Tricia Niles, Richard Jones, Vicki Tepper, Allison Agwu, Deborah Persaud
**Poster Sessions - Tuesday**

### Poster P-P06 METABOLIC AND CARDIOVASCULAR COMPLICATIONS IN CHILDREN AND YOUTH

**Poster Hall B  2:30 PM - 4:00 PM**

**826** EFFECT OF INTEGRASE INHIBITORS ON WEIGHT GAIN IN CHILDREN AND ADOLESCENTS WITH HIV  
Sahera Dirajlal-Fargo, Wei Li A. Koay, Matthew E. Levy, Anne K. Monroe, Amanda D. Castel, Natella Rakhmanina, for the DC Cohort Executive Committee

**827** BODY FAT AND LIPID PROFILE CHANGES IN HIV-INFECTED YOUTHS Switched to Dolutegravir  
Vania Giacomet, Samuel Lazzarin, Andrea Manzo, Emma Longoni, Katia Maruca, Paola Erba, Federica Forlanini, GianVincenzo Zuccotti, Stefano Mora

**828** CHER TRIAL COHORT SHOWS GREATER INSULIN RESISTANCE INTO ADOLESCENCE  
Claire Davies, Steve Innes, Mark Cotton, Sara H. Browne, Birhanu Ayele

**829** CARDIOVASCULAR RISK PROFILE: A CLINIC-BASED SAMPLE OF YOUTH LIVING WITH HIV IN THE US  

**830** SOLUBLE CD14 IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION IN SOUTH AFRICAN YOUTH ON ART  
Sahera Dirajlal-Fargo, Jiao Yu, Abdus Sattar, Sana Mahtab, Jennifer Jao, Landon Myer, Heather Zar, Grace A. McComsey

**831** VASCULAR DISEASE, IMMUNE ACTIVATION, AND GUT DYSFUNCTION IN HIV+ UGANDAN CHILDREN  
Sahera Dirajlal-Fargo, Emily Bowman, Danielle Labbato, Zainab Albar, Christine Karungi, Rashidah Nazzinda, Abdus Sattar, Nicholas Funderburg, Cissy Kityo, Victor Musiime, Grace A. McComsey

### Poster P-P08 NOVEL APPROACHES TO PEDIATRIC ANTIRETROVIRAL DOSING AND SAFETY

**Poster Hall B  2:30 PM - 4:00 PM**

**839** IDENTIFICATION OF AGE-APPROPRIATE DOSING STRATEGIES OF BICTEGRAVIR IN NEONATES  
Fazila S. Bunglawala, Rajith Kumar Reddy Rajoli, Hannah Kinvig, Nicolas Cottura, Andrew Owen, Marco Siccardi

**840** SAFETY, PK, AND EFFICACY OF LOW DOSE B/F/TAF IN CHILDREN ≥2 YEARS OLD LIVING WITH HIV  
Carina Rodriguez, Kulkanya Chokephaibulkit, Afaaf Liberty, Renate Strehlau, Riana Van Zyl, Pope Kosalaraksa, Coleen K. Cunningham, Eric J. McGrath, Natella Rakhmanina, Heather Maxwell, Danielle Porter, Sophia R. Majeed, Shaolan S. Xiang, Diana Brainard, Cheryl Pikora

**841** B/F/TAF LOW-DOSE TABLET RELATIVE BIOAVAILABILITY IN HVs AND PK IN CHILDREN WITH HIV  
Sophia R. Majeed, Polina German, Steve K. West, Shaolan S. Xiang, Deqing Xiao, Michael Keeney, Joanna Koziara, PJ Costales, Jenna Scott, Hiba Graham, Cheryl Pikora, Anita Mathias
842 **MARAVIROC SAFETY & PHARMACOKINETICS IN HIV-EXPOSED NEONATES**

Julia C. Rosebush, Brookie Best, Ellen G. Chadwick, Jack Moyo, Elizabeth Smith, Kevin Butler, Sarah Bradford, Kyle Whiston, Sisinyana R. Mathiba, Sherika Hanley, Mariam Aziz, Katy Hayward, Mark Mirochnick, Pearl Samson, for the IMPAACT 2007 Study Team

843 **ABACAVIR SAFETY AND PHARMACOKINETICS IN NORMAL AND LOW BIRTH WEIGHT INFANTS WITH HIV**

Tim R. Cressy, Adrie Bekker, Mae Cababasay, Jiajia Wang, Firdose Nakwa, Elizabeth Smith, Jack Moyo, Ary Violari, Mark Cotton, Bobbie Graham, Lubbe Wiesner, Helena Rabie, Mark Mirochnick, Edmund V. Capparelli, for the IMPAACT P1106 Team

844 **ABACAVIR DOSING, EFFECTIVENESS, AND SAFETY IN YOUNG INFANTS LIVING WITH HIV IN EUROPE**


845 **ABACAVIR SAFETY AND EFFICACY IN YOUNG INFANTS IN SOUTH AFRICAN OBSERVATIONAL COHORTS**

Renee De Waal, Helena Rabie, Karl Technau, Brian Eley, Nosisa Sipambo, Mark Cotton, Andrew Boulle, Robin Wood, Frank Tanser, Geoffrey Fatti, Matthias Egger, Mary-Ann Davies

846 **PHARMACOKINETICS OF Raltegravir in HIV/TB COTREATED INFANTS AND YOUNG CHILDREN**

Paul Krogstad, Pearl Samson, Edward P. Acosta, Jack Moyo, Ellen Townley, Sarah Bradford, Emily Brown, Bobbie Graham, Laura Hovind, Hedy Teppler, Sisinyana R. Mathiba, Mark Cotton, Jana L. Winckler, Tammy Meyers, for the IMPAACT P1101 Study Team

847 **Adequate Dolutegravir Exposure Dosed Bid with Rifampicin in Children 6 To <18 Years**

Hylke Waalewijn, Hilda Mujuru, Pauline Amuge, Mark Cotton, Pauline Bollen, Man Chan, Shabinah Ali, Ebrahim Variava, Shafic Makumbi, Angela Colbers, Diana Gibb, Deborah Ford, David M. Burger, Anna Turkova, for the Odyssey Trial Team

**Poster P-Q06 HIV in Transgender Women and Men**

*Poster Hall D* 2:30 PM - 4:00 PM

878 **Preexposure Prophylaxis Adherence and Persistence in Kenyan Transgender Women and MSM**

Makobu Kimani, Elisabeth M. van der Elst, Oscar Chirro, Fauz Ibrahim, Nana Mukuria, Tobias F. Rinke de Wit, Susan M. Graham, Eduard Sanders

879 **HIV Prevalence and Risk in Male, Transmale, and Transfemale Sex Workers in Zimbabwe**

Marielle Kloek, Laura Van Noord, Sungai T. Chabata, Sithembile Musemburi, Sake De Vlas, Frances Cowan, Jan A. Hontelez

880 **Factors Associated with HIV, HCV, and HSV 2 Serostatus Among US Transgender Women**

Morgan P. Keruly, Andrea L. Wirtz, George Mwinnieya, Sari L. Reisner, ScD, Oliver Laeyendecker, for the American Cohort to Study HIV Acquisition among Transgender Women (LITE) Study Group
881 HIV PREVALENCE AMONG TRANSGENDER MEN AT AN NYC COMMUNITY HEALTH CENTER
Asa Radix, Zil Goldstein, Alexander Harris, Rona Vail

882 PROGRESSION THROUGH THE HIV CARE CONTINUUM FOR TRANSGENDER WOMEN IN THE NA-ACCORD

883 HIV CARE AMONG TRANSGENDER WOMEN IN NORTHERN AND WESTERN PARIS: 2008-2018
Lucas Maisonobe, Florence Michard, Anaenza Freire Maresca, Sylvie Le Gac, Zélie Julia, Juliette Gerbe, Giovanna Rincon Murillo, Elisabeth Rouveix, Yazdan Yazdanpanah

884 IMPROVING DATA ON THE NYC HIV EPIDEMIC BY IDENTIFYING TRANSGENDER PEOPLE ON MEDICAID
Cristina Rodriguez-Hart, Beverly Obeng, Asa Radix, Zil Goldstein, Gagarin Zhao, Lucia V. Torian

885 BUPRENORPHINE TREATMENT IS RELATED TO DECREASED HIV RNA LEVELS AMONG PEOPLE WITH HIV
Jongyeon Kim, Geetanjali Chander, Catherine R. Lesko, Anthony T. Fojo, Richard D. Moore, Bryan Lau

886 AFFORDABLE CARE ACT’S IMPACT ON SUBSTANCE-USE TREATMENT IN PEOPLE WHO INJECT DRUGS
Erik M. Hendrickson, Tarik Benmarhnia, Steffanie A. Strathdee, Jazmine Cuevas-Mota, Richard S. Garfein

887 UNMET NEED FOR MEDICATION-ASSISTED TREATMENT AMONG PERSONS WHO INJECT DRUGS
Senad Handanagic, Dita Broz, Cyprian Wejnert, for the NHBS Study Group

888 UNMET NEEDS AND BARRIERS TO CARE SERVICES AMONG HIV-POSITIVE PERSONS WHO INJECT DRUGS
Sharoda Dasgupta, Yunfeng Tie, Linda Beer, Dita Broz, Quan M. Vu, Hanna B. Demeke

889 ESTIMATING HIV INCIDENCE AMONG PWID: POPULATION- AND FACILITY-BASED APPROACHES
Allison M. McFall, Sunil S. Solomon, Oliver Laeyendecker, Syed Iqbal, Shanmugam Saravanan, Nandagopal Paneerselvam, Pachamuthu Balakrishnan, Aylur K. Srikrishnan, David D. Celentano, Gregory M. Lucas, Shruti H. Mehta

890 OPTIMIZING SOCIAL-NETWORK SAMPLING TO FIND UNDIAGNOSED HIV-INFECTED PWID
Allison M. McFall, Bryan Lau, Carl A. Latkin, Aylur K. Srikrishnan, Santhanam Anand, Canjeevaram K. Vasudevan, Shruti H. Mehta, Sunil S. Solomon

891 LATENT CLASS ANALYSIS OF SUBSTANCE USE AND HIV VL TRAJECTORY PATTERNS AMONG PWH IN DC
Morgan Byrne, Anne K. Monroe, Lindsey J. Powers Happ, Rupali K. Doshi, Michael A. Horberg, Amanda D. Castel, for the DC Cohort Executive Committee
892 MORTALITY AMONG PERSONS WITH HIV WITH A HISTORY OF INJECTION DRUG USE, NEW YORK CITY
   Chitra Ramaswamy, Sarah L. Braunstein
893 HCV, AIDS, LIVING IN US SOUTH ARE RISK FACTORS FOR MORTALITY IN HIV+ SUBSTANCE USERS
894 HIGH MORTALITY RATE AMONGST HIV INFECTED PEOPLE WHO INJECT DRUGS (PWID) IN SCOTLAND
   Rebecca Metcalfe, Andrew McAuley, Saket Priyadarshi, Laura Sills, Sharon Hutchinson
895 ASSOCIATIONS OF ALCOHOL CONSUMPTION WITH VIRAL SUPPRESSION AND ALL-CAUSE MORTALITY
   Adam Trickey, Suzanne Ingle, Lei Zhang, Mario Sarcletti, Matthias Cavassini, Michael Saag, Derek Satre, Michael J. Silverberg, Amy C. Justice, Jonathan Sterne, for the ART-CC and the COMpAAS Consortium

Poster P-Q08 MENTAL HEALTH AND HIV
Poster Hall D  2:30 PM - 4:00 PM
896 DEPRESSION AND VIROLOGIC REBOUND AMONG PATIENTS WITH HIV IN THE UNITED STATES
   Quan M. Vu, R. L. Shouse, John Weiser
897 PREVALENCE AND FACTORS RELATED TO TRAUMA SYMPTOMS AMONG PEOPLE WITH HIV
   Bryan Lau, Karine Yenokyan, Catherine R. Lesko, Mary McCaul, Richard D. Moore, Heidi Hutton, Geetanjali Chander
898 MENTAL HEALTH AND SUBSTANCE ABUSE SERVICES AND RETENTION IN HIV CARE IN NORTH AMERICA
   Cassandra Oliver, Bryan Lau, Keri N. Althoff, Kate Buchacz, Heidi M. Crane, Michael John Gill, Michael A. Horberg, Kenneth H. Mayer, Angel M. Mayor, Richard D. Moore, Asher Schranz, Timothy R. Sterling, April Pettit, Peter Rebeiro, for the NA-ACCORD of IeDEA
899 MORTALITY IN PEOPLE LIVING WITH HIV AND MENTAL HEALTH DISORDERS IN SOUTH AFRICA
   Andreas D. Haas, Yann Ruffieux, Ernest Mokotoane, Johannes P. Mouton, Mpho Tlali, Mary-Ann Davies, Matthias Egger, Gary Maartens, for the IeDEA Southern Africa Collaboration

Poster P-Q09 METHODS IN EPIDEMIOLOGY
Poster Hall D  2:30 PM - 4:00 PM
900 COMPARING METHODS FOR ESTIMATING SEXUAL TRANSMISSION RISK AMONG US ADULTS WITH HIV
   Yunfeng Tie, Sharoda Dasgupta, Linda Beer, Jennifer Fagan, Qian An, R. L. Shouse
901 USING SURVEILLANCE DATA TO MEASURE TRIAL HIV INCIDENCE OUTCOMES: A MODELLING STUDY
   Kate M. Mitchell, Dobromir Dimitrov, James Hughes, Eric Vittinghoff, Albert Y. Liu, Chris Beyrer, Deborah J. Donnell, Marie-Claude Boily
Poster Sessions

902 PAST BEHAVIOR OUTPERFORMS DEMOGRAPHY AND GEOGRAPHY AS PREDICTOR OF MISSED HIV CARE
April Pettit, Aihua Bian, Cassandra Oliver, Peter F. Rebeiro, Bryan E. Shepherd, Jeanne C. Keruly, Kenneth H. Mayer, W. C. Mathews, Richard D. Moore, Heidi M. Crane, Elvin Geng, Sonia Napravnik, Mari M. Kitahata, Michael J. Mugavero, for the CNICS Group

903 THE CD4 DEPLETION MODEL DOES NOT DIFFERENTIATE INCIDENT FROM CHRONIC INFECTION
Michael E. Tang, Sanjuy R. Mehta, Susan J. Little, Christy M. Anderson

904 ESTIMATING INCIDENCE AT A REGIONAL LEVEL WITH THE CD4 DEPLETION MODEL
Sanjay R. Mehta, Michael E. Tang, Christy M. Anderson, Susan J. Little

905 KEY POPULATION SIZE ESTIMATION IN NIGERIA: NOVEL APPROACHES TO SAMPLING AND ANALYSIS
Anne McIntyre, Andrew Mitchell, Samuel Nwafor, Victor Sebastian, Ame M. Schwitters, Julia Lo, Ibrahim Dalhatu, Mahesh Swaminathan, Kristen Stafford, Man Charurat

906 GEOSPATIAL HIV DYNAMICS IN FRANCE: A GRAVITY EFFECT MODEL
Marie-Laure Chaix Baudier, Benoit Visseaux, Lambert Assoumou, Marc Wirden, Lot Florence, Laurence Morand-Joubert, Stephanie Raymond, Laurence Bocket, Constance Delaugerre, Francis Barin, Diane Descamps, Davey M. Smith, Antoine Chaillon, for the ANRS AC43 Study Group

Poster P-R03 POINT-OF-CARE TESTING
Poster Hall D  2:30 PM - 4:00 PM

950 INDETERMINATE HIV RAPID-TEST RESULTS: OUTCOMES AND RISK FACTORS
George Mwinnyaa, Mary K. Grabowski, Ronald H. Gray, Maria Wawer, Larry W. Chang, Joseph Ssekasamvu, Joseph Kagaayi, Godfrey Kigozi, Ronald M. Galiwango, Anthony Nyabando, David Serwadda, Thomas C. Quinn, Steven J. Reynolds, Oliver Laceyendecker, for the The Rakai Community Cohort Study

951 SIGNIFICANT UNDERQUANTIFICATION OF HIV RNA WITHIN ROUTINE SETTINGS IN SOUTH AFRICA
Ahmad Haeri Mazanderani, Tendesayi Kufa-Chakezha, Tanya Murray, Aurelie Mukendi, Faith Moyo, Kate Braithwaite, Karl Technau, Sergio Carmona, Gayle G. Sherman

952 EVALUATION OF A TRUE POC VIRAL LOAD TEST: SAMBA LEUCO-DEPLETED WHOLE BLOOD HIV ASSAY
Gary Brook, Tetiana Stepchenkova, Innocent M. Ali, Sandra Chipuka, Helen Lee

953 MODELING POINT-OF-CARE NUCLEIC ACID TESTS (POC NAT) TO MINIMIZE HIV MISDIAGNOSES
Anne M. Neilan, Jennifer Cohn, Emma Sacks, Aditya Gandhi, Patricia Fassinou, Kenneth Freedberg, Marc N. Kouadio, Rochelle P. Walensky, Andrea L. Ciaranello
954  EVALUATION OF QUALITATIVE AND SEMIQUANTITATIVE HIV POINT-OF-CARE NUCLEIC ACID TESTS  
Lauren R. Violette, Andy M. Cornelius-Hudson, Madison A. Snidarich, Sonny Michael Assennato, Allyson Ritchie, Neha Goel, Pollyanna R. Chavez, Steven Ethridge, Helen Lee, Kevin F. Delaney, Joanne Stekler

955  COMMUNITY-LED HIV SELF-TESTING INCREASES TESTING AND LINKAGE TO CARE OF MEN IN UGANDA  
Joanita Nangendo, Joan Kalyango, Gloria O. Odei, Jane Kabami, Fred Semitata, Anne Katahoire, Charles Karamagi, Rhoda Wanyenze, Moses R. Kamya

956  UPTAKE OF HIV SELF-TESTING AMONGST YOUTH IN TERTIARY EDUCATION COLLEGES IN ZIMBABWE  
Grace McHugh, Andrea L. Koris, Tsitsi Bandason, Katharina Kranzer, Rashida A. Ferrand

957  IS AN UNASSISTED PHARMACY-BASED HIV SELF-TESTING STRATEGY IN MOZAMBIQUE SUFFICIENT?  
Caroline De Schacht, Carlota L. Fonseca, Paula Paulo, Noela Chicuecue, Anibal Fernando, Jalilo E. Chinai, Wilson Da Silva, Sofia Viegas, Sara Van Rompaey, Aliny Couto, C. William Wester

958  HIV SELF-TESTING AMONG KEY POPULATIONS AND SEXUAL PARTNERS OF NEW MOTHERS IN UGANDA  
Esther M. Nasuuna, Florence Namimbi, James Wanyama, Alice Namale, Martin Ssuuna, Alex Mugsami, Joanita Kigozi

959  ACCEPTABILITY OF HIVST DISTRIBUTION BY PREGNANT WOMEN TO MALE PARTNERS: A CLOSER LOOK  
Norma C. Ware, Monique A. Wyatt, Emily E. Pisarski, Andrew Mugurigia, Connie L. Celum

960  "FIRST TO KNOW MY STATUS": ACCEPTABILITY OF HIV SELF-TESTING AMONG SOUTH AFRICAN MEN  
Monique A. Wyatt, Emily E. Pisarski, Adrienne E. Shapiro, Kombi Sausi, Alastair Van Heerden, Oluwafemi A. Adeagbo, Janet Seeley, Connie L. Celum, Ruanne V. Barnabas, Norma C. Ware, for the DO ART Study Team

961  THE IMPACT AND COST OF HIV SELF-TEST DISTRIBUTION IN WORKPLACES IN SOUTH AFRICA  
Cyprian Mostert, Trishanta Kirsten, Linda Sande, Marc D’Elbee, Mohammed Majam, Vincent Zishiri, Willem D. Venter, Karin Hatzold, Cheryl Johnson, Joel M. Francis, Thato Chidankire, Sharon White, Fern Terris-Prestholt, Gesine Meyer-Rath

962  COST-EFFECTIVENESS OF HIV SELF-TESTING AMONG LONG-DISTANCE TRUCK DRIVERS IN KENYA  
Deo Mujwara, Elizabeth Kelvin, Gavin George, Eva Mwai, April D. Kimmel

963  CHARACTERISTICS OF MSM WHO REGISTER FOR HIV SELF-TESTING IN SAO PAULO, BRAZIL  
Ricardo D. Vasconcellos, Vivian I. Avelino-Silva, Ivone P. De Paula, Leda Jamal, Maria Clara Gianna, Flavio Santos, Cristina Santos, Robinson Camargo, Eduardo Barbosa, Gilvane Casemiro, Maria Cristina Abbate, Marly M. Cruz, Aluisio C. Segurado, for the A Hora é Agora - SP
Poster Sessions

1002 HIV-1 DRUG RESISTANCE IN THE DISCOVER PREEXPOSURE PROPHYLAXIS TRIAL

Stephanie W. Cox, Urvi Parikh, Amy Heaps, Breanna J. Goetz, John W. Mellors, Xinan Liu, Ross Martin, Jenny Svarovskaia, Hadas Dvory-Sobol, Scott McCallister, Christian Callebaut

1003 PreP SEROCONVERSION-SEGMENTAL HAIR ANALYSIS FOR UNRAVELING TIMING OF VIRAL RESISTANCE

Brenton T. Lowery, Hideaki Okochi, Karen Kuncze, Nhi Phung, Cheryl McDonald, Matthew A. Spinelli, Anthony Mills, Patricia A. Defechereux, Kathryn Jee, Peter L. Anderson, Robert M. Grant, Monica Gandhi

1004 RENAL IMPAIRMENT IN A PREEXPOSURE PROPHYLAXIS IMPLEMENTATION COHORT IN AUSTRALIA

Hamish McManus, Douglas Drak, Jack E. Heron, Tobias Vickers, Stefanie Vaccher, Iryna Zablotska, Rebecca J. Guy, Benjamin Bavinton, Fengyi Jin, Andrew E. Grulich, Mark Bloch, Catherine C. O’Connor, David Gracey, for the EPIC Study

1005 DEVELOPMENT OF A PrEP EQUITY INDEX TO SET LOCAL TARGETS FOR PrEP COVERAGE

Julie Myers, Sarah L. Braunstein, Zoe R. Edelstein, Alexis Rivera, Njideka Motanya, Oni J. Blackstock

1006 IMPLEMENTATION OF ON-DEMAND PrEP IN A LARGE INTEGRATED HEALTH CARE SYSTEM

J. Carlo Hojilla, Julia L. Marcus, Rachel Herbers, Charles B. Hare, Leo Hurley, Michael J. Silverberg, Derek Satre, Jonathan E. Volk

1007 USE OF HIV PREDICTION MODEL TO EVALUATE PrEP COVERAGE IN A LARGE HEALTH CARE SYSTEM

Julia L. Marcus, Leo Hurley, Michael J. Silverberg, J. Carlo Hojilla, Jacek Skarbinski, Stacey Alexeeff, Douglas Krakower, Jonathan E. Volk

1008 POPULATION-BASED ESTIMATES OF PrEP ACCESS-TO-NEED IN OREGON, 2012-2016

Tim W. Menza, Jeff Capizzi, Lea Bush

1009 STUDY SUGGESTS PrEP ACCESS ISSUE: DISPARITY IN PRIOR AUTHORIZATIONS ACROSS US REGIONS

Kathleen A. McManus, Samuel Powers, Amy Killelea, Sebastian Tello-Trillo, Elizabeth Rogawski Mcquade

1010 FACTORS ASSOCIATED WITH LOSS TO RETENTION AMONG FREE AND FEE-BASED PrEP IN THAILAND

Tanat Chimbunchorn, Oranuch Nampaipsarn, Sita Lujintanon, Surang Janyam, Theeranat Sangprasert, Phonthorn Chanleam, Akarin Hiransuthikul, Matthew Avery, Stephen Mills, Ravipa Vannakit, Reshmie Ramautarsing, Praphan Phanuphak, Nittaya Phanuphak
1011  COSTS OF PROVIDING PREEXPOSURE PROPHYLAXIS FOR HIV PREVENTION IN US HEALTH CENTERS  
Ram K. Shrestha, Nicholas Davis, Megan Coleman, Laura Rusie, Dawn K. Smith

1012  THIRD-PARTY PAYER AND PATIENT OUT-OF-POCKET COSTS FOR PrEP: UNITED STATES, 2017  
Nathan W. Furukawa, Weiming Zhu, Ya-Lin A. Huang, Ram K. Shrestha, Karen W. Hoover

Poster P-507 FACTORS IMPACTING PREVENTION: INTIMATE PARTNER VIOLENCE, WHITE COAT EFFECT, SEX WORK, AND SOCIAL INFLUENCERS  
Poster Hall D  2:30 PM - 4:00 PM

1013  SOCIAL MEDIA INFLUENCERS ENHANCE RECRUITMENT OF YOUNG THAI MSM INTO PrEP INTERVENTION  
Chris Beyrer, Brian Weir, Andrea L. Wirtz, Hsu Hnin Mon, Midnight Poonsaketwattana, Patrick S. Sullivan, Stefan Baral, Chen Dun, for the COPE4YMSM Study Team

1014  PrEP NONADHERENCE, WHITE COAT DOSING, AND HIV RISK AMONG A HIGH-RISK COHORT OF MSM  

1015  IMPACT OF THE “CHARISMA” INTERVENTION PILOT ON PARTNER DISCLOSURE, IPV, AND ADHERENCE  
Elizabeth Montgomery, Sarah T. Roberts, Krishnaveni Reddy, Betsy Tolley, Miriam Hartmann, Ellen Wilson, Florence Mathebula, Danielle Wagner, Seth Zissette, Michele Lanham, Rose Wilcher, Jared Baeten, Thesla Palanee-Phillips

1016  REDUCED RELIANCE ON SEX WORK: RESULTS OF AN INTERVENTION FOR YOUNG WOMEN IN TANZANIA  
Jenny Tiberio, Susie Welty, Joel Ndoyangeje, Christen Said, Ritha Mboneko, Tania Reza, Willi McFarland

Poster P-508 PrEP IN TRANSWOMEN  
Poster Hall D  2:30 PM - 4:00 PM

1017  TRANSPrEP: SOCIAL NETWORK–BASED PrEP ADHERENCE FOR TRANSGENDER WOMEN IN LIMA, PERU  
Jesse L. Clark, Sari L. Reisner, ScD, Amaya G. Perez-Brumer, Leyla Huerta Castillo, Hugo Sanchez, Hideaki Okochi, Maria Mamani Luge, Ximena Salazar, Matthew Mimiaga, Monica Gandhi, Kenneth H. Mayer, Javier R. Lama

1018  PrEP CONTINUUM OF CARE AMONG MSM AND TGW OF COLOR IN THE THRIVE DEMONSTRATION PROJECT  
Kashif Iqbal, Weiming Zhu, Kenneth L. Dominguez, Mary Tanner, Kirk D. Henny, Karen W. Hoover

1019  PrEP INDICATION AND CARE CONTINUUM AMONG TRANSGENDER WOMEN IN THE UNITED STATES  
Jowanna Malone, Sari Reisner, Andrea L. Wirtz, for the American Cohort to Study HIV Acquisition among Transgender Women (LITE) Study Group
1020 DISCOVER: NO EFFECT OF HORMONES ON F/TAF OR F/TDF PK, EFFICACY & SAFETY IN TRANSWOMEN
Michelle S. Cespedes, Sophra R. Majeed, Maria Prins, Ivanka Krznaric, Anita Mathias, Deqing Xiao, Pamela Wong, Jason Hindman, Christoph Carter, Diana Brainard, Moupali Das, Elske Hoornenborg, Peter Ruane, John Phoenix, Jason Halperin

1021 ASSOCIATIONS BETWEEN HORMONE USE, PrEP USE, AND STIGMA IN US TRANSGENDER WOMEN
Jessica L. Maksut, John Mark L. Wiginton, Maria Zlotorzynska, Carrie E. Lyons, Travis Sanchez, Ayden Scheim, Stefan Baral

1022 HIGH PrEP ADHERENCE AND PERSISTENCE IN A NATURALISTIC COHORT OF TRANSGENDER WOMEN
Sarit A. Golub, Augustus Klein, Lila A. Starbuck, Alexander Harris, Amiyah Guerra, Christopher A. Rincon, Pedro Carneiro, Asa Radix

Poster P-S12 MALE CIRCUMCISION AND THE PENILE MICROBIOME
Poster Hall D 2:30 PM - 4:00 PM

1037 LONG-TERM EFFECTIVENESS OF VOLUNTARY MEDICAL MALE CIRCUMCISION FOR HIV PREVENTION
Gideon Loevinsohn, Godfrey Kigozi, Joseph Kagaayi, Fred Nalugoda, Larry W. Chang, David Serwadda, Steven J. Reynolds, Gertrude Nakigozi, Robert Sekubuugu, Maria Wawer, Aaron Tobian, Ronald H. Gray, Mary K. Grabowski, for the Rakai Health Sciences Program

1038 “STYLISH MAN” CLUSTER RCT TO INCREASE MALE CIRCUMCISION FOR ADULT MEN ≥19, UGANDA
Maria Wawer, Godfrey Kigozi, Stephen Mugamba, Amos Zikusooka, Joseph Kagaayi, David Serwadda, Anthony Ndyanabo, Joseph Ssekasanvu, Larry W. Chang, Ronald H. Gray

1039 SEX AND THE PENILE MICROBIOME: POTENTIAL SHARING OF HIV RISK–ASSOCIATED ANAEROBES
Cindy M. Liu, Jessica L. Prodger, Ronald M. Galiwango, Godfrey Kigozi, Aggrey Anok, James Nnamutete, Mathias Agaba, Deo Male, Yahaya Isabire, Malilha Aziz, Daniel Park, Tom De Man, Abigail Onos, Rupert Kaul, Aaron Tobian

Poster P-T02 SEXUALLY TRANSMITTED INFECTIONS: DIAGNOSIS AND PROGNOSIS
Poster Hall D 2:30 PM - 4:00 PM

1050 A POINT-OF-CARE ASSAY FOR DIAGNOSIS OF NEUROSYPHILIS
Hemil Gonzalez, Christina Marra, Igor Koralnik, Lauren Tantalo, Zachary Orban, Gregory D. Huhn

1051 IDENTIFYING AN HIV AND NEURO/OCULAR SYPHILIS CLUSTER IN VERMONT
Devika Singh, Roy Belcher, Daniel Daltry, Abigail Crocker, Jennifer Read

1052 GYRASE A SERINE 91 GENOTYPING PREDICTS GONORREA CIPROFLOXACIN TREATMENT OUTCOME
Jeffrey D. Klausner, Sheldon Morris, Claire C. Bristow, for the NIH/NIAID STAR STI CTG Ciprofloxacin Gyrase A Serine 91 Neisseria Gonorrhoeae Study Group

1053 IMPROVING DIAGNOSIS OF CT/NG AMONG PrEP USERS WITH MULTIPLE SITE SCREENING
Jorge S. Moreira, Ricardo d. Vasconcelos, Vivian I. Avelino-Silva
Poster Sessions

1054 THE PERFORMANCE OF POOLED 3-ANATOMIC-SITE CHLAMYDIA AND GONORRHEA TESTING
Claire C. Bristow, Sanjay R. Mehta, Martin Hoenigl, Susan J. Little

1055 NO EVIDENCE OF CLINICAL IMPACT OF STIs ON SEMINAL HIV BURDEN DURING SUCCESSFUL ART
Christof Stingone, Rossana Scutari, Elisabetta Teti, Lorenzo Piermatteo, Vincenzo Malagnino, Marta Brugneti, Mirko Compagno, Ada Bertoli, Valentina Svircher, Maria M. Santoro, Carlo Federico Perno, Claudia Alteri, Loredana Sarmati, Massimo Andreoni, Francesca Ceccherini Silberstein

Poster P-T03 ISSUES IN CONTRACEPTION
Poster Hall D 2:30 PM - 4:00 PM

1056 RISK OF PELVIC INFLAMMATORY DISEASE WITH CONTRACEPTIVE METHOD USE IN THE ECHO TRIAL

1057 VALIDATING INCIDENT PREGNANCIES AMONG WOMEN USING CONTRACEPTIVES AND ANTIRETROVIRALS
Rena Patel, Beatrice Jakait, Gustavo Amorin, Bryan E. Shepherd, Caitlin Bernard, A. Rain Mocello, Beverly Musick, Marisiana A. Onono, Craig R. Cohen, Elizabeth A. Bukusi, Kara K. Watts-Kaloustian, Constantin T. Yiannoutsos

1058 AN EVALUATION OF AN ENHANCED MODEL OF FP/HIV SERVICE INTEGRATION IN LUSAKA, ZAMBIA
Amy M. Medley, Fatima Tsiouris, Sherri Pals, Brenda Senyana, Susan Hanene, Shadrick Kayeye, Rocio R. Casquete, Arielle Lasry, Mollie Braaten, Meagan Cain, Tiffany Michelle Aholou, Prisca Kasonde, Tina Chisenga, Keith Mweebo, Tiffany Harris

1059 A COMBINED ESTROGEN/PROGESTIN VAGINAL RING IMPROVES VAGINAL MICROBIAL COMMUNITIES
Nicole H. Tobin, Sarah L. Brooker, Fan Li, Yoninah S. Cramer, Susan L. Rosenkranz, Grace M. Aldrovandi, Robert Coombs, Susan E. Cohn, Carmen D. Zorrilla, Laura E. Moran, Baiba Berzins, Kimberly K. Scarsi, Catherine Godfrey, for the ACTG 5316 Team

Poster P-U06 HIV CARE CONTINUUM
Poster Hall D 2:30 PM - 4:00 PM

1097 HIV CARE CASCADE: MEN WHO HAVE SEX WITH MEN & TRANSGENDER WOMEN/GENDERQUEER, ZIMBABWE
Tiffany Harris, Lauren Parmley, Munyaradzi Mapingure, Owen Mugururungi, John H. Rogers, Tsitsi Apollo, Getrude Ncube, Elizabeth Gonese, Brian K. Moyo, Perpetua Gozhora, Godfrey Musuka, Sophia Miller, Yingfeng Wu, Avi Hakim, Innocent Chingombe

1098 IMPACT OF HIV CONTINUUM OF CARE INTERVENTIONS AND PREEXPOSURE PROPHYLAXIS IN KENYA
Liem Binh Luong, Stephen S. Wanjala, Elisabeth Szumilin, Pierre Mendiharath, Yazdan Yazdanpanah, Kenneth Freedberg

1099 DIFFERENCES IN HIV CARE OUTCOMES: US HISPANICS/LATINOS WITH DIAGNOSED HIV INFECTION
Sonia Singh, Yonggang Li, Alexandra Balaji
1100 IMPROVEMENTS ACROSS NAIROBI COUNTY’S HIV CARE CONTINUUM: CASE OF A FAST-TRACK CITY
Sindhu Ravishankar, Eryln Macarayen, Caroline Ngunu, Molly Pezzulo Collier, Harriet Kongin, Jose M. Zuniga, Ingrid Katz

1101 HIV CARE CONTINUUM AMONG NEWLY DIAGNOSED INDIVIDUALS IN MEXICO
Lorena Guerrero-Torres, Yanink Caro-Vega, Erika Barlandas, Brenda Delgado-Avila, Juan Sienna-Madero, José Sifuentes-Osornio, Pablo F. Belaunzaranz-Zamudio, Brenda Crabtree-Ramírez

1102 CHALLENGES TO HIV CARE ENGAGEMENT AMONG MOBILE POPULATIONS IN RURAL KENYA AND UGANDA
James Ayieko, Edwin D. Charlebois, Monica Getahun, Irene Maeri, Patrick Eyul, Pamela M. Murnane, Moses R. Kamya, Elizabeth A. Bukusi, Monica Gandhi, Diane V. Havlir, Carol S. Camlin

1103 PUBLIC HEALTH REFERRALS IMPROVE RE-ENGAGEMENT FOR ART INTERRUPTED PATIENTS
Jon H. Kremer, Lu Wang, Katherine Lepik, Jenny Li, David M. Moore, Kate Salters, Julio S. Montaner, Trevor Corneil, Rolando Barrios

1104 MONITORING PROGRESS OF CARE IN PERSONS NEWLY DIAGNOSED WITH HIV IN SPAIN, 2004-2018
Belen Alejos, Cristina Diez, Maria J. Galindo, Ana Delgado, Santiago Moreno, Federico Pulido, Victor Asensi, Vicente Estrada, Gloria Samperiz, Ines Suárez-Garcia, Angeles Castro, Robert Muga, Inma Jarrin, Juan Berenguer, for the CoRIS

1105 A FIELD-BASED SAMPLING STRATEGY TO REVISE HIV TREATMENT PROGRAM RETENTION ESTIMATES
Theodora Savory, Masuzyo Chitala, Paul Elish, Jake Pry, Cynthia Lupenga, Jacob Mutale, Walusiku Mwansa, Mwansa Lumpa, Kaala Moomba, Carolyn Bolton Moore, Izuukani Sikazwe, Michael Herce

1106 LOSS-TO-FOLLOW-UP RISK FACTORS AFTER ANTIRETROVIRAL THERAPY INITIATION IN UGANDA
Barbara Castelnuovo, Frank Mubiru, Grace Banturaki, Joseph Musaazi, Joseph Kabanda, Michelle Adler, Alice Namale, Rhoda Mwondo, Joanita Kigozi, Agnes Kiragga

1107 HIV STIGMA PREDICTS RETENTION IN CARE AMONG US PATIENTS IN CARE
Catherine Pearson, Mallory Johnson, Torsten B. Neilands, Samantha E. Dilworth, John Saucedo, Michael J. Mbugero, Heidi M. Crane, Rob Fredericksen, W. C. Mathews, Richard D. Moore, Sonia Napravnik, Kenneth H. Mayer, Katerina A. Christopoulos

1108 HOSPITALIZATIONS & MORTALITY DIFFER BY GENDER AMONG LONG-TERM ART PATIENTS IN UGANDA
David Moore, Golshan Massah, Wendy W. Zhang, Josephine Birungi, Mastula Nanfuka, Julia Zhu, Stephen Okoboi, Pontiano Kaleebu, Baker Tibenganas

1109 ALCOHOL USE AND THE HIV CARE CONTINUUM IN ZAMBIA: NATIONALLY REPRESENTATIVE SURVEY
Michael J. Vinikoor, Izuukani Sikazwe, Anjali Sharma, Lloyd Mulenga, John Mayeya, Ravi Paul, Geetanjali Chander, Jenala Chipungu, Laura Murray, Jeremy Kane
1110 RCT OF EARLY REFERRAL OF HIV+ ADULTS STARTING ART TO COMMUNITY-BASED ADHERENCE CLUBS
Jasanthia Odayar, Joanna Allerton, Siti Kabanda, Thoko Malaba, Maia Lesosky, Zodwa Mamanzi, Cathy Kalombo, Landon Myer

1111 DIFFERENTIATED SERVICE DELIVERY FOR HIV CARE: THE FAST-TRACK EXPERIENCE FROM ZAMBIA
Samuel Bosomprah, Isaac Zulu, Michael Herce, Lloyd Mulenga, Minesh P. Shah, Izukanji Sikazwe, Annie Mwila, Helen B. Mulenga, Muhau Mubiana, Mwansa Lumpa, Pamela J. Bachanas, Simon Agolory

1112 DIFFERENTIATED CARE: TIME SPENT IN DIFFERENT ART DELIVERY MODELS IN RURAL ZIMBABWE
Benedikt Christ, Janneke van Dijk, Wesley R. Mukondwa, Cordelia Kunzekwenyika, Ronald Manhibi, David Tasunga, Frédérique Chammartin, Matthias Egger, Marie Ballif, for the International epidemiology Databases to Evaluate AIDS (IeDEA)

1113 PROSPECTIVE STUDY ON IMPACT OF DIFFERENTIATED CARE ON HIV RETENTION IN KEY POPULATION
George Eluwa, Lung Vu, Scott Geibel, Isa Iyortim, Abyie Kalaiwo, Osasuyi Dirisu, Ellen Weiss, sylvia B. Adebaio

1114 COMMUNITY PRIVATE PHARMACY ANTIRETROVIRAL THERAPY REFILL IN KAMPALA, UGANDA
Martin Ssuuna, Shamim Nakade, Joseph Kabanda, Sarah Zalwango, Daniel A. Okello, Christopher Mugara, Donna Kabatesi, Alice Namale, Alex Muganzi, Nelson Kalema, Joanita Kigozi

1115 COMMUNITY-BASED SERVICE DELIVERY OF HIV TREATMENT IN ZAMBIA: COSTS AND OUTCOMES

1116 HIV+ PATIENTS RECEIVING ANTIRETROVIRAL DRUGS THROUGH HOME DELIVERY: A CAUSAL ANALYSIS
Rory F. Leisegang, Keri Calkins, Susan Cleary, Sumanth Karamchand, Felix Hammann, Poobalan Naidoo, Mark Cotton, Jane Ball, David Dowdy, Jean B. Nachega

1117 OUTCOMES OF COMMUNITY-BASED ANTIRETROVIRAL TREATMENT PROGRAM IN NAMIBIA
Naemi Shoopala, Andrew L. Baughman, Assegid T. Mengistu, Kiren Mitruka, Godfrey Woelk, Graham Mutandu, Michael B. De Klerk, Isaac Zulu, Steven Hong, Nicholus Mutenda, Linea Hans, Simon Agolory, Leigh Ann Miller, Eric J. Dziuban, Ndapewa Hamunime

1118 PATIENTS EXPERIENCING VIRAEMIA IN ADHERENCE CLUBS: IS BACK-TO-CLINIC ALWAYS BEST?
Tali Cassidy, Jonathan Euvrard, Claire Keene, Erin Roberts, Rodd Gerstenhaber, Andrew Boulle
1119  **RANDOMIZED TRIAL OF HIV-ASSIST VERSUS GUIDELINES FOR ART SELECTION BY TRAINEES**  
Jesus Ramirez, Manoj Maddali, Saman Nematollahi, Jonathan Z. Li, Maunank Shah

1120  **TRANSITION TO DOLUTEGRAVIR-BASED REGIMEN: NIGERIAN EXPERIENCE AMONG KEY POPULATIONS**  
Moses Katbi, Adefisayo Adedoyin, Kent Klindera, Bartholomew Ochonye, Iyiola Faturiyele, Michele Russell, Oluwatosin Adeoye, Adeoye Adegoye, Tolu A. Alamu

NOTES
WEDNESDAY MARCH 11, 2020

Poster P-A03 VIRUS-CELL INTERACTION AND GENETICS
Poster Hall A  2:30 PM - 4:00 PM

178  SEQUENCE CHANGES CAUSING REV ACTIVITY DIFFERENCES IN HIV-1 PRIMARY ISOLATES
Patrick E. Jackson, Jordan Holsey, Godfrey Dzhivhuho, David Rekosh, Marie-Louise Hammarskjold

179  COMPLEMENTATION MAINTAINS QUASISPECIES OF DRUG-SENSITIVE AND -RESISTANT HIV WITH ART
Laurelle A. Jackson, Sandlele Cele, Tulio de Oliveira, Jennifer Giandhari, Gila J. Lustig, Fabio Zanini, Richard Neher, Alex Sigal

180  DISRUPTION OF A RNA SECONDARY STRUCTURE IN HIV-1 gp41 INDUCES VIRAL LETHALITY
Ana Jordan-Paiz, Maria Nevet, Kevin Lamkiewicz, Marie Lataretu, Sandra Franco, Manja Marz, Miguel Angel Martinez

181  GENETIC IDENTITY AND BIOLOGICAL PHENOTYPE OF EARLY TRANSMITTED FOUNDER HIV-1 VIRUSES

182  NEW HIV-1 CAPSID LABELING SYSTEM DOES NOT SUPPORT UNCOATING DURING NUCLEAR IMPORT
Chenglei Li, Ryan C. Burdick, Mohamed Husen Munshi, Ferri Soheilian, Wei-Shau Hu, Vinay K. Pathak

183  THE HIV ANTISENSE PROTEIN ASP IS A TRANSMEMBRANE PROTEIN OF THE VIRAL ENVELOPE
Zahra Gholizadeh, Yvonne Affram, Juan C. Zapata, Hongshuo Song, Rui Li, Maria Iglesias-Ussel, Krishanu Ray, Olga Latinovic

Poster P-B07 BARRIERS TO TRANSLOCATION
Poster Hall A  2:30 PM - 4:00 PM

231  CELLULAR STRESS BIOMARKERS ARE ASSOCIATED WITH MARKERS OF MICROBIAL TRANSLLOCATION
Carol Vinton, Carly E. Starke, Alexandra Ortiz, Ornella Sortino, Kenneth Knox, Irini Sereti, Jason Brenchley

232  CMV SEROPOSITIVITY AND MICROBIAL TRANSLLOCATION IN HIV ELITE CONTROLLERS
Rayoun Ramendra, Stéphane Isnard, John Lin, Brandon Fombuen, Jing Ouyang, Franck P. Dupuy, Yonglong Zhang, Malcolm Finkelman, Ido Kema, Cécile Tremblay, Nicole Bernard, Jean-Pierre Routy, for the Canadian cohort of HIV+ Slow Progressors and Montreal Primary HIV Infection Study Groups

233  FROM GUT TO BLOOD: REDISTRIBUTION OF ZONULIN IN HIV+ PATIENTS
Max Augustin, Carola Horn, Meryem S. Ercanoglu, Vincent Bondet, Isabelle Suarez, Seung-Hun Chon, Dirk Nierhoff, Elena Knops, Eva Heger, Gerd Fäkenheuer, Jan Rybniker, Darragh Duffy, Michaela Müller-Trutwin, Clara Lehmann

234  GUT BARRIER PROTECTANT INTESTINAL ALKALINE PHOSPHATASE IS REDUCED IN PEOPLE WITH HIV
Charlie F. Saylor, Jae H. Sim, Lediya Churu, Yang Liu, Paul Cavallaro, Fatemeh Adiliaghdam, Kiara Keller, Shibani S. Mukerji, Peter Carolan, Kyle Staller, James Richter, Rich Hodin, Janet Lo
235 IMPACT OF INTRAVENOUS HEROIN AND HIV ON GUT INTEGRITY AND IMMUNE ACTIVATION
Corrilynn O. Hileman, Emily Bowman, Janelle Gabriel, Aaren Kettelhut, Julia C. Kosco, Danielle Labbato, Theresa O. Rodgers, Cheryl A. Smith, Nicholas Funderburg, Grace A. McComsey

236 VALGANCICLOVIR EFFECTS ON GUT AND PULMONARY EPITHELIAL BARRIER MARKERS IN TREATED HIV
Sabrina Sevilla, Gabriele B. Beck-Engeser, Vanessa A. York, Rebecca Hoh, Steven G. Deeks, Jeffrey N. Martin, Barbara L. Shacklett, Laurence Huang, Ma Somsouk, Peter W. Hunt

Poster P-B08 NON-AIDS CONSEQUENCES OF HIV INFECTION
Poster Hall A 2:30 PM - 4:00 PM

237 LIPID ABNORMALITIES MAY CONTRIBUTE TO ALTERED MACROPHAGE PHENOTYPE IN PEOPLE WITH HIV
Emily Bowman, Brian Richardson, Manjusha Kulkarni, Aaren Kettelhut, Janelle Gabriel, Morgan Cichon, Kenneth Riedl, Subha Raman, Susan L. Kolotar, Cheryl A. Cameron, Mark Cameron, Nicholas Funderburg

238 LIPIDOME ALTERATIONS WITH EXERCISE AMONG PEOPLE WITH AND WITHOUT HIV
Emily Bowman, Melissa P. Wilson, Samantha MaWhinney, Catherine M. Jankowski, Nicholas Funderburg, Kristine M. Erlandson

239 FECAL CALPROTECTIN IS ELEVATED IN HIV AND RELATED TO SYSTEMIC INFLAMMATION
Allison Ross Eckard, Nancy L. Haggard, Heather Y. Hughes, Mary Ann O’Riordan, Danielle Labbato, Sarah E. Scott, Grace A. McComsey

240 LONG-TERM ELEVATED IL-6 AND D-DIMER AFTER DELAYED ART INITIATION IN THE START TRIAL
Jason V. Baker, Birgit Grund, Shweta Sharma, Keith Henry, Jennifer Hoy, Stefan Esser, Silvia Nozza, Kiat Ruxrungtham, Adam Rupert, H. Clifford Lane, Jens D. Lundgren, James Neaton, for the INSIGHT START Study Group

241 NON-AIDS—DEFINING EVENTS IN HIV CONTROLLERS VS ART-CONTROLLED PATIENTS
Carmelite Audrey Manto Kuidjo, Alicia Castro Gordon, Cécile Goujard, Laurence Meyer, Olivier Lambotte, Asma Essat, Arnoo Shaiykova, Faroudy Boufassa, Nicolas Noel, for the ANRS CO21 CODEX and CO6 PRIMO Study Groups

242 TOTAL HIV DNA LEVELS DO NOT PREDICT NON-AIDS-DEFINING EVENTS
Colline Wong, Ashley McKhann, Carlee Moser, Alan Landay, Michael M. Lederman, Sara Gianella, Jonathan Z. Li

243 PRINCIPAL COMPONENTS ANALYSIS TO IDENTIFY BIOMARKERS PREDICTIVE OF NON-AIDS EVENTS
Carlee Moser, Peter W. Hunt, Martin Hoenigl, Ashley McKhann, Christophe Vanpouille, Alan Landay, Nicholas Funderburg, Michael M. Lederman, Ronald Bosch, Sara Gianella

244 AGING, TRENDS IN CD4/CD8 RATIO, AND CLINICAL OUTCOMES WITH HIV SUPPRESSION
Richard M. Novak, Carl Armon, Kate Buchacz, Jun Li, Douglas Ward, Frank J. Palella, for the CDC HOPS
245 SYSTEMIC AND VASCULAR INFLAMMATION PREDICT COMORBIDITIES IN TREATED HIV INFECTION

246 GUT MUCOSAL IL22+ T CELLS ARE RELATED WITH INCOMPLETE CD4+ T-CELL EXHAUSTION IN TREATED HIV INFECTION
Isaac Rosado-Sánchez, Ines Herrero-Fernández, Salvador Sobrino, Ana E. Carvajal, Miguel Genebat, Rocío M. De Pablo, Rocío Ruiz, Jorge Sanchez-Villegas, Manuel Leal, Yolanda M. Pacheco

247 INCREASED GUT AND BLOOD CD4+ T-CELL EXHAUSTION IN IMMUNOLOGICAL NONRESPONDERS
Kristina B. Lorvik, Malin H. Meyer-Myklestad, Asle W. Medhus, Marius Lund-Øvresen, Birgitte Stiksrud, Dag Kvale, Anne Ma D. Riise, Dag Henrik Reikvam, Kjetil Tasken

248 NOVEL MECHANISM OF HIV-1 ELITE CONTROL BY ENRICHING GUT DIPEPTIDES AS CCR5-ANTAGONIST
Ujjwal Neogi, Maike Sperk, Flora Mikaeloff, Ashokkumar Manickam, Aanoop T. Ambikan, Kamlendra Singh, Jan Vesterbacka, Anders Sönnerborg

249 NOVEL MECHANISM OF HIV-1 ELITE CONTROL BY ENRICHING GUT DIPEPTIDES AS CCR5-ANTAGONIST
Ujjwal Neogi, Maike Sperk, Flora Mikaeloff, Ashokkumar Manickam, Aanoop T. Ambikan, Kamlendra Singh, Jan Vesterbacka, Anders Sönnerborg

250 DISTINCT INTERFEROMES ASSOCIATE WITH CHRONIC HIV PATHOGENESIS IN THE RECTUM
Stephanie Dillon, Kejun Guo, Guannan Shen, Harry Smith, Miranda E. KroeHL, Katerina Kechris, Cara Wilson, Mario Santiago

251 OPPOSING ASSOCIATIONS OF NK AND MZ B CELLS IN RECTAL EXPLANT MODEL OF HIV INFECTION
S. Abigail Smith, Praveen Kumar Amancha, Phillip M. Murray, Cassie Grimsley-Ackerley, Rama R. Amara, Colleen F. Kelley

252 IgA PRESERVATION IN GUT IN SIVagm INFECTION IS ASSOCIATED WITH INFLAMMATION CONTROL
Philippe Rasche, Cyril Planchais, Beatrice Jacquelin, Marie Lazzereini, Vanessa Contreras, Hugo Mouquet, Nicolas Huot, Michaela Müller-Trutwin

253 ALTERED DNA METHYLATION OF CCR5 IN SIGMOID MUCOSAL TISSUES OF TRANSGENERIC THAI WOMEN
287  THE RV144 VACCINE PRIMED IgG4 AND V1V2-ADCP RESPONSES IN HIV BREAKTHROUGH INFECTIONS
Thembi Mdluli, Dominic Paquin-Proulx, Bonnie Sike, Gina Donofrio, Sorachai Nitayaphan, Punnee Pitisutthithum, Supachai Rerks-Ngarm, Margaret Ackerman, Merlin L. Robb, Nelson L. Michael, Sandhya Vasan, Michael A. Eller, Shelly J. Krebs, Morgane Rolland, for the RV144 Study Group

288  PHASE I/IIA TRIAL OF HIV CLADE C DNA WITH MF59- OR AS01B-ADJUVANTED CLADE C PROTEIN
Nigel Garrett, Cynthia L. Monaco, Philipp Mann, Julia Hutter, Allan C. deCamp, One Dintwe, Georgia Tomaras, Megan Jones, Giuseppe Pantaleo, Song Ding, Olivier Van Der Meeran, Julie McElrath, Larry Corey, James G. Koblin, for the HVTN 108 Study Team

289  MUCOSAL T AND B CELL RESPONSES INDUCED BY ALVAC-HIV/AIDSVAX B/E LATE BOOST STRATEGIES

290  CANDIDATE IMMUNOGENS DIFFERENTIALLY ENGAGE HIV BROADLY NEUTRALIZING PLASMA ANTIBODIES
Irene Abela, Teja Turk, Nikolas Friedrich, Claus Kadelka, Matthias Gloegel, Bruno Ivan, Peter Ruters, Merle Schanz, Roger Kouyos, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study

291  ACUTE INFECTION B-CELL DETERMINANTS PREDICT DEVELOPMENT OF NEUTRALIZATION BREADTH
Samantha Townsley, Gina Donofrio, Ningbo Jian, David Leggat, Vincent Dussupt, Letzibeth Mendez-Rivera, Nicole Doria-Rose, John R. Mascola, Morgane Rolland, Sodsai Tovanabutra, Adrian B. McDermott, Nelson L. Michael, Merlin L. Robb, Shelly J. Krebs, for the RV217 Study Group

292  TARGETING HIV ENV TO CD40 LEADS TO HIV-SPECIFIC POLYCLONAL B CELLS IN HUMANIZED MICE
Veronique Godot, Colas Tcherakian, Laurine Gil, Inaki Cervera-Marzal, Hugo Mouquet, Guangming Li, Liang Cheng, Jean Daniel Lelièvre, Giuseppe Pantaleo, Mireille Centlivre, Sandy Zurawski, Gerard Zurawski, Pierre Milpied, Lishan Su, Yves Levy

293  CD40-TARGETED VACCINE INCREASES MAGNITUDE OF HIV-ENV SPECIFIC RESPONSES
Romain Marlin, Sabine Tricotot, Francis Relouzat, Christiane Moog, Laëtitia Bossevoit, Sandy Zurawski, Gerard Zurawski, Andrés Salazar, Catherine Chapon, Nathalie Dereuddre-Bosquet, Mireille Centlivre, Yves Levy, Roger Le Grand

294  HARNESSING ORIGINAL ANTIGENIC SIN FOR PREVENTING MTCT OF HIV
Ashley N. Nelson, Maria Dennis, Jesse F. Mangold, Katherine N. Li, Riley J. Mangan, George Shaw, Katharine J. Bar, Barton F. Haynes, M. Anthony Moody, Justin Pollara, Koen Van Rompay, Kristina De Paris, Sallie Permar
295  **TBK-1-DC VACCINE INDUCES POLYFUNCTIONAL T CELLS AND CONTROL OF HIV-1 IN THE BLT MOUSE**
Marta Calvet-Mirabent, Maud Deruaz, Serah Tanno, Cristina Delgado-Arévalo, Ildefonso Sánchez-Cerrillo, Carla Serra Peinado, María J. Buzón, Ignacio Santos, Jesús Sanz, Lucio Jesús Garcia-Fraile Fraile, M Ángeles Muñoz-Fernández, Alejandro Balazs, Vladimir Vrbanac, Enrique Martin-Gayo

296  **CMV VACCINE VECTOR-INDUCED PROTECTION AGAINST SIV IN MAURITIAN CYMOMOLGUS MACAQUES**
Justin Greene, Daniel Malouli, Nicholas Maier, Abigail Ventura, Roxanne Gilbride, Whitney Weber, Helen Wu, Junwei Gao, Michael K. Axthelm, Jeremy Smedley, Jeffrey D. Lifson, Klaus F. Picker, Scott Hansen, Jonah Sacha

297LB **SUPERIOR PROTECTION AGAINST SHIV INFECTION BY SAME SITE DNA-PROTEIN COIMMUNIZATION**
Barbara K. Felber, Zhongyan Lu, Xintao Hu, Antonio Valentín, Margherita Rosati, Joshua A. Weiner, Xiaoying Shen, Georgia Tomaras, Celia C. Lebranche, David Venzon, George Shaw, Guido Ferrari, Margaret Ackerman, Barton F. Haynes, George N. Pavlakis

Poster P-D08 IMPACT OF ANTIRETROVIRALS ON THE IMMUNE RESPONSE
Poster Hall A  2:30 PM - 4:00 PM

298  **DOLUTEGRAVIR INCREASES B CELLS AND RESTING MEMORY B CELLS IN RV254**
Supranee Buranapraditkun, Eugène Kroon, Hiroshi Takata, Suthat Chottanapund, Carlo Sacdalan, Duanghathai Suttichom, Ratchapong Kanaprach, Sompong Tipsuk, Khunthalee Benjapornpong, Bessara Nuntapinit, Merlin L. Robb, Jintanat Ananworanich, Sandhya Vasan, Lydie Trautmann, for the on behalf of the SEARCH010/RV254/SEARCH013/RV304 Study Group

299  **CHARACTERIZING ANTIBODY RESPONSES IN ART-TREATED INDIVIDUALS**
Andrew B. Wilson, Yanqin Ren, Eva M. Stevenson, R. Brad Jones, Rebecca Lynch

300  **NEAR NORMALIZATION OF IMMUNE ACTIVATION IN PLWH ON LONG-TERM SUPPRESSIVE ART**
Óscar Brochado Kith, Isidoro Martínez, Juan Berenguer, Luz M. Medrano, Juan González-García, Pilar García-Broncano, María Á. Jimenez-Sousa, Ana Carrero, Víctor Hontanon, M Ángeles Muñoz-Fernández, Juan Carlos López-Bernaldo, Amanda Fernández-Rodríguez, Salvador Resino

301  **REVERSION OF CD4+ T-CELL EXHAUSTION MEDIATED BY PLASMACYTOID DENDRITIC CELLS**

302  **CD8+ SUBSET-DEPENDENT OVEREXPRESSION OF TIGIT AND TIGIT+TIM3 BY HIV DESPITE ART**
Oscar Blanch-Lombarte, Esther Jimenez-Moyano, Dan Ouchi, Adam Pelletier, Aarthi Talla, Ashish Sharma, Ruth Penya, Judith Dalmau, José R. Santos, Rafick-Pierre Sekaly, Bonaventura Clotet, Julia G Prado
303 DYNAMICS OF HIV-SPECIFIC T CELLS ON DURABLE ART DIFFER BY ANTIGEN RECOGNIZED & BY SEX
Eva M. Stevenson, Adam R. Ward, Thomas R. Dilling, John W. Mellors, Rajesh T. Gandhi, Deborah McMahon, Joseph J. Eron, Ronald Bosch, Christina Lalama, Joshua C. Cyktor, R. Brad Jones, for the A5321 Team

Poster Sessions • Wednesday

303 P-E08 ATTACK OF THE CLONES: CLONAL EXPANSION IN THE HIV RESERVOIR
Poster Hall A 2:30 PM - 4:00 PM

360 PARALLEL HIV RNA, INTEGRATION SITE, AND PROVIRAL SEQUENCING IN SINGLE RESERVOIR CELLS
Kevin Einkauf, Matthew Osborn, Ce Gao, Jane Blackmer, Chenyang Jiang, Eric Rosenberg, Xu G. Yu, Mathias Lichterfeld

361 SINGLE-CELL ATLAS AND CLONAL EXPANSION DYNAMICS OF CD4+ T CELLS DURING HIV INFECTION
Jack A. Collora, Delia Pinto-Santini, Siavash Pasalar, Ricardo Alfaro, Carmela Ganoza, Jennifer Chiarella, Rachel Calvi, Javier R. Lama, Serena S. Spudich, Ann Duerr, Ya-Chi Ho

362 TCR SEQUENCING REVEALS CLONAL EXPANSIONS OF INDUCTIBLE RESERVOIRS IN SPECIFIC SUBSETS
Pierre Gantner, Amelie Pagliuzza, Marion Pardons, Moti Ramgopal, Jean-Pierre Routy, Rémi Fromentin, Nicolas Chomont

365 LONGITUDINAL CHARACTERIZATION OF HIV PROVIRUSES IN PEOPLE ON SUPPRESSIVE ART
Annukka Antar, Katharine M. Jenike, Sunyoung Jang, Danielle Rigau, Daniel B. Reeves, Rebecca Hoh, Jeanne C. Keruly, Richard D. Moore, Joshua T. Schiffer, Bareng Nonyane, Frederick M. Hecht, Steven G. Deeks, Janet Siliciano, Ya-Chi Ho, Robert Siliciano

366 IDENTICAL HIV PROVIRUSES ARISE FROM CELL EXPANSION AND INFECTION BY COMMON ANCESTOR
Sean Patro, Aurelie Niyongabo, Shuang Guo, Jason W. Rausch, Michael J. Bale, Andrew Musick, Xiaolin Wu, Liliana Perez-Rodriguez, Wei Shao, Eli A. Boritz, Steven G. Deeks, Frank Maldarelli, Stephen H. Hughes, John M. Coffin, Mary F. Kearney

367 HIGH-THROUGHPUT SEQUENCING OF INTEGRATED HIV-1 REVEALS NOVEL PROVIRAL STRUCTURES
Kevin W. Joseph, Elias K. Halvas, Leah D. Brandt, Sean Patro, Jason W. Rausch, Mary F. Kearney, John M. Coffin, John W. Mellors
368 CELL PROLIFERATION CONTRIBUTES TO THE INCREASE OF GENETICALLY INTACT HIV OVER TIME
Bethany A. Horsburgh, Bonnie Hiener, Katie Fisher, John-Sebastian Eden, Eunok Lee, Susanne von Stockenstrom, Lina Odevall, Jeffrey M. Milush, Teri Liegler, Rebecca Hoh, Rémi Fromentin, Nicolas Chromont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer

369LB TARGETED INSERTION OF HIV AT BACH2 DRIVES CD4 T-CELL GROWTH AND ALTERED PHENOTYPE
Michelle Christian, Michael Dapp, Samuel Scharffenberger, Harold Jones, Chaozhong Song, Anton Krumm, James Mullins, David J. Rawlings

370LB ANTIGEN RESPONSIVE CLONES OF CD4+ T CELLS CONTRIBUTE TO THE INTACT LATENT RESERVOIR
Pilar Mendoza, Julia Jackson, Thiago Oliveira, Christian Gaebler, Victor Ramos, Mila Jankovic, Marina Caskey, Michel Nussenzweig, Lillian B. Cohn

Poster P-E09 CHARACTERIZING LATENT HIV RESERVOIRS
Poster Hall A 2:30 PM - 4:00 PM

371 SINGLE-CELL ANALYSIS OF IN VIVO HIV RESERVOIR UNCOVERS NOVEL MARKERS OF LATENT CELLS
Jason Neidleman, Xiaoyu Luo, Julie Frouard, Feng Hsiao, Grace Xie, Vincent Morcilla, Katherine Sholtis, Rebecca Hoh, Ma Somsouk, Peter W. Hunt, Steven G. Deeks, Nancie Archin, Sarah Palmer, Warner C. Greene, Nadia R. Roan

372 INTACT HIV GENOMES ARE ENRICHED IN MEMORY T CELLS WITH SHORT HALF-LIVES
Vincent Morcilla, Charline Bacchus-Souffan, Katie Fisher, Xiao Qian Wang, Bethany A. Horsburgh, Timothy E. Schluck, Mark Fitch, Rebecca Hoh, Frederick M. Hecht, Jeffrey Martin, Steven G. Deeks, Marc Hellerstein, Joseph M. McCune, Peter W. Hunt, Sarah Palmer

373 “FALSE ART FAILURE” FROM IDENTICAL HYPERMUTATED HIV NUCLEIC ACID IN PLASMA
Johannes C. Botha, Kim Steegen, Lucia Hans, Alan Karstaedt, Sergio Carmona, Denasha Reddy, Mary F. Kearney, John W. Mellors, Gert U. van Zyl

374 ART-TREATED SUBJECTS WITH LOW VIRAL REServoir SHOW UNUSUAL HIV LATENCY DISTRIBUTION
Cristina Gálvez, Victor Urrea, Susana Benet, Lucia Bailon, Andrea Martinez, Beatriz Mothe, Judith Dalmau, Lorna Leaf, Felipe Garcia, Javier Martinez-Picado, Maria Salgado

375 A NEW LONG-READ NGS METHOD TO SEQUENCE HIV1 INSERTION SITES AND ASSOCIATED PROVIRUSES
Maria Artesi, Vincent Hahaut, Basiel Cole, Laurens Lambrechts, Ambroise Marçais, Olivier Hermine, Philip Griebel, Natasa Arsic, Dominique Bron, Carole Charlier, Linos Vandekeurckhove, Michel Georges, Anne Van den Broeke, Keith Durkin

376 COMBINED ASSAYS SHED NEW LIGHT ON HIV-1 PROVIRAL SEQUENCE AND LINKED INTEGRATION SITE
Basiel Cole, Laurens Lambrechts, Maria Artesi, Vincent Hahaut, Wojciech Witkowski, Ytse Noppe, Annemieke Dhondt, Keith Durkin, Anne Van Den Broeke, Linos Vandekeurckhove

377 ULTRADEEP ANALYSIS OF PRETHERAPY HIV PREDICTS GENETICALLY COMPLEX RESERVOIRS
Kristi Huik, Junko Hattori, Valerie F. Boltz, Jason W. Rausch, Wei Shao, Mary F. Kearney, John M. Coffin, Frank Maldarelli
378 HIV CONTROLLERS HAVE LOW FREQUENCIES OF INTACT PROVIRAL DNA
Abena Kwaa, Caroline Garliss, Kristen D. Ritter, Gregory Laird, Joel Blankson

379 EARLY THERAPY OF YOUTH WITH ACUTE/RECENT HIV: EFFECT ON HIV DNA & ANTIBODY (ATN 147)

380 WIDE ANATOMIC DISTRIBUTION OF HIV-INFECTED CELLS IN INDIVIDUALS WITH COMORBID CANCER

381 LOW FREQUENCY OF CTL ESCAPE MUTATIONS IN INTACT PROVIRUSES FROM ELITE CONTROLLERS
Xiaodong Lian, Chenyang Jiang, Ce Gao, Joshua Chevalier, Ben S. Rhee, Jane Blackmer, Kevin Einkauf, Xiaoming Sun, Mary Carrington, Bruce D. Walker, Mathias Lichterfeld, Xu G. Yu

382 TH2 CYTOKINES ARE ASSOCIATED WITH HIGHER LEVELS OF INTACT PROVIRUSES ON ART

383 HIV-1 ENVELOPES FROM PERSISTENT VIREMIA ON ART SHOW REDUCED ANTIBODY SENSITIVITY
Savrina Manhas, Joseph P. Brooker, Elias K. Halvas, John W. Mellors

384 MODELING HIV RESERVOIR DECLINE AFTER ART INITIATION AS A FUNCTION OF NK CELL FEATURES
Elena Vendrame, Geoffrey T. Ivison, Rosemary Vergara, Nancy Q. Zhao, Giovanny J. Martinez-Colón, R. Brad Jones, Joshua C. Cyktor, Hanna Mar, Deborah McMahon, Joseph J. Eron, John W. Mellors, Ronald Bosch, Susan Holmes, Rajesh T. Gandhi, Catherine A. Blish

385 HIV-1 RESERVOIR SIZE CORRELATES TO PD-1 EXPRESSION IN MEN, BUT NOT WOMEN, IN UGANDA
Katherine Yu, Jessica L. Prodger, Eileen P. Scully, Adam Capoferri, Steven J. Reynolds, Jingo Kasule, Taddeo Kityamuweesi, Paul Buule, David Serwadda, Yun-Hee Choi, Andrew D. Redd, Thomas Quinn

386 EFFECT OF TIM-3 BLOCKADE ON T CD8+ AND NK CELLS IN ART-TREATED HIV-INFECTED PATIENTS
Carolina Gutiérrez, Marta Sanz, Nadia Madrid-Elena, Sergio Serrano-Villar, María J Vivancos, Alejandro Vallejo, Francisco J. Hernández-Walias, Santiago Moreno
Poster Sessions

Poster Sessions • Wednesday

Poster Hall A  2:30 PM - 4:00 PM

431  PLASMA AND CSF SCD30 DYNAMICS BEFORE AND AFTER ART INITIATED IN ACUTE HIV
Michael J. Peluso, Bonnie Slike, Phillip Chan, Carlo Sacdalan, Siriwat Akapirat, Linda Jagodzinski, Victor Valcour, Nittaya Phanuphak, Eugène Kroon, Jintanat Ananworanich, Sandhya Vasan, Timothy J. Henrich, Serena S. Spudich, Shelly J. Krebs, for the RV254/SEARCH 010 Study Team

432  QUANTITATION OF CEREBROSPINAL FLUID PLEOCYTOSIS AND HIV-1 RNA DURING ACUTE INFECTION
Phillip Chan, Camilla Muccini, Carlo Sacdalan, Eugène Kroon, Donn J. Colby, Nitiya Chomchey, Peeriya Pruksakaew, Suteeraporn Pinyakorn, Nittaya Phanuphak, Linda Jagodzinski, Victor Valcour, Sandhya Vasan, Jintanat Ananworanich, Serena S. Spudich, for the RV254 Study Team

433  EVOLUTION OF IMMUNE ACTIVATION BIOMARKERS IN CSF IN FIEBIG I-V ACUTE HIV INFECTION
Julian Weiss, Phillip Chan, Carlo Sacdalan, Eugène Kroon, Siriwat Akapirat, Jennifer Chiarella, Victor Valcour, Nittaya Phanuphak, Ningbo Jian, Sandhya Vasan, Jintanat Ananworanich, Bonnie Slike, Shelly J. Krebs, Serena S. Spudich, for the RV254/SEARCH 010 Study

434  ROLE FOR PLATELET ACTIVATION AND ENDOTHELIAL ASSOCIATION IN HIV ENTERO INTO THE BRAIN
Claire E. Lyons, Hannah Schneider, Elizabeth L. Engle, Kevin M. Najarro, Suzanne E. Queen, Craig N. Morrell, Joseph Mankowski, Kelly A. Metcalf Pate

Poster Hall A  2:30 PM - 4:00 PM

435  HIV SUPPRESSION AND CHANGES IN CSF MARKERS IN PATIENTS RANDOMLY SWITCHED TO DTG + 3TC
Juan M. Tiraboschi, Jhon Rojas, Henrik Zetterberg, Jordi Niubo, Johanna Gostner, Antonio Navarro-Alcaraz, Camila Piatti, Dietmar Fuchs, Magnus Gisslén, Esteban Martinez, Daniel Podzamczer

436  BILIRUBIN AS A SURROGATE MARKER OF DOLUTEGRAVIR-ASSOCIATED CNS ADVERSE EVENTS
Elena Alvarez-Barco, Fergal Moran, Ciara Levey, Willard Tinago, Patrick W. Mallon

437  ART INITIATED AT HIGH CD4 NADIR DOES NOT NORMALIZE CSF MARKERS OF IMMUNE ACTIVATION
Frida Rydberg, Aylin Yiilmaz, Lars Hagberg, Dietmar Fuchs, Magnus Gisslén, for the HIV Clinical Research Center, University of Gothenburg

438  INTEGRASE INHIBITOR START OR SWITCH IMPACTS LEARNING IN WOMEN WITH HIV

439  HIV RNA IN CEREBROSPINAL FLUID OFF ART PREDICTS MORE DEPRESSIVE SYMPTOMS ON ART
Oluwakemi Okwuegbuna, Albert Anderson, Jennifer Ludicello, Josue Perez-Santiago, Florin Vaida, Rachel Schrier, Allen McCutchan, Ronald J. Ellis, Scott L. Letendre
**Poster Sessions**

**Poster Sessions • Wednesday**

**Poster P-G04 THE LONG AND THE SHORT OF IT: WHAT IS NEXT FOR LONG ACTINGS**

**Poster Hall A  2:30 PM - 4:00 PM**

440  CSF CXCL-10 IS ASSOCIATED WITH THE PRESENCE OF LOW-LEVEL CNS HIV DURING ART
   Albert Anderson, Bin Tang, Florin Vaida, Oluwakemi Okwuegbuna, Daniel McClernon, Reena Deutsch, Suprateek Kundu, Mariana Cherne, Debralee Cooks, Melanie Crescini, Igor Grant, Ronald J. Ellis, Scott L. Letendre

441  USE OF D/C/F/TAF WITH NEUROLOGIC/PsyCHIATRIC COMORBIDITIES: AMBER SUBGROUP ANALYSIS
   Keith J. Dunn, Richard Simonson, Donghan Luo, Jiyun Cai, David Anderson

442  CLINICAL FEATURES AND OUTCOMES OF PATIENTS STOPPING DTG FOR NEUROPSYCHIATRIC SYMPTOMS
   Andrea Calcagno, Alberto Borghetti, Maurizio Milesi, Jessica Cusato, Mariacristina Tettoni, Antonio D’Avolio, Giovanni Di Perri, Simona Di Giambenedetto, Stefano Bonora

466  CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION
   Susan Ford, Herta Crauwels, Kelong Han, Steefaan Rossen, Feifan Zhang, Jenny O. Huang, David A. Margolis, Kenneth Sutton, Krischan J. Hudson, Peter E. Williams, William Spreen, Parul Patel

467  WITHDRAWN

468  MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV INFECTION

469  DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207
   Eric Daar, Cheryl McDonald, Gordon Crofoot, Peter Ruane, Gary Sinclair, Edwin DeJesus, Mezgebe Berhe, Moti Ramgopal, Heena Patel, Ya-Pei Liu, Rebecca Begley, Diana Brainard, Robert H. Hyland, Martin Rhee

470  PK, FOOD EFFECT, AND SAFETY OF ORAL GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR
   Rebecca Begley, Martin Rhee, Steve K. West, Angela Worth, John Ling, Polina German

471  ANTIRETROVIRAL & RIFAMPICIN COTREATMENT AFFECTS DMPA EXPOSURE: DOSING IMPLICATIONS
   Jose Francis, Paolo Denti, Helen Mcileron, Michelle A. Kendall, Xingye Wu, Kelly E. Dooley, Cindy Firnhaber, Catherine Godfrey, Susan E. Cohn, Rosie Mngqibisa

472  A LONG-ACTING NANOFORMULATED TENOFOVIR PRODRUG
   Denise A. Cobb, Zhiyi Lin, Nathan Smith, Aditya N. Bade, Nagsen Gautam, JoEllyn McMillan, Howard E. Gendelman, Benson Edagwa
473LB SAFTETY AND PK STUDY OF VM-1500A-LAI, A NOVEL LONG-ACTING INJECTABLE THERAPY FOR HIV
Elena Yakubova, Alexey Mazus, Alexey V. Kravchenko, Evgenia Ejova, Elena Smolyarchuk, Vasily Kazey, Saranya Sankar, Igor Niko lin, Sergey Baranovskyi, Alex Khvat, Jenny Remeeva, Suzana Corritori, Nikolay Savchuk, Iain Dukes, Robert Murphy

Poster P-H04 ANTIRETROVIRAL TREATMENT: NEW AGENTS, NEW TARGETS
Poster Hall A 2:30 PM - 4:00 PM

503 CLINICAL SIGNIFICANCE OF GP120 POLYMORPHISMS, TMR IC50, EC, AND HIV-1 SUBTYPE IN BRIGHTE
Margaret Gartland, Peter Ackerman, Frank Mannino, Louise K. Garside, Andrew Clark, Amy Pierce, Mark Krystal, Cyril C. Llamoso, Max Lataille

504 A HIGHLY POTENT AND SAFE ALLOSTERIC HIV-1 INTEGRASE INHIBITOR, STP0404
Seohyun Ahn, UK-II Kim, Won Young Seo, Seongmi Choi, Tatsuya Maehigashi, Jared Lindenberger, Mamuka Kvaratskhelia, Baek Kim, Kyungjin Kim

505 PRECLINICAL DEVELOPMENT OF SECOND GENERATION HIV-1 MATURATION INHIBITORS
Sherimay Ablan, KC Yuvarj, Dibya Ghimire, T.J. Nitz, David E. Martin, Ritu Gaur, Eric O. Freed, Carl Wild

506 PHASE 2 TRIAL OF VPU INHIBITOR BIT225 IN COMBINATION WITH ANTIRETROVIRAL THERAPY
Anchalee Avihingsanon, Carolyn A. Luscombe, Gary D. Ewart, Audrey S. Thomson, Khuanchai Supparatpinyo, Sivaporn Gatechompol, Win Min Han, Michelle Miller, Robert Murphy

507 COMPARABLE EFFICACY OF IBALIZUMAB IN COMBINATION WITH 1 OR 2 FULLY ACTIVE AGENTS
Edwin DeJesus, Colleen S. McGary, Pedro Mesquita, Steven Weinheimer, Zvi Cohen

508 A PHASE 1 DOSE-ESCALATION TRIAL OF HUMAN MONOCLONAL ANTIBODY NL65 IN HEALTHY ADUL T
Alicia T. Widge, Katherine V. Houser, Martin R. Gaudinski, Grace Chen, Cristina Carter, Sophia P. Hickman, Jamie Saunders, Lasonji Holman, Ingelise Gordon, Sarah O’Connell, Edmund V. Capparelli, Mark Connors, Richard A. Koup, John R. Mascola, for the VRC 609 Study Team

Poster P-I04 NOVEL MECHANISMS OF DRUG RESISTANCE AND RESISTANCE TO NEW AGENTS
Poster Hall A 2:30 PM - 4:00 PM

525 SUSCEPTIBILITY TO BNABS OF TRANSMITTED HIV VARIANTS AMONG RECENT INFECTIONS IN FRANCE
Karl Stefic, Mélanie Bouvin-Pley, Asma Essat, Clara Visdeloup, Alain Moreau, Cécile Goujard, Marie-Laure Chaix Baudier, Martine Braibant, Laurence Meyer, Francis Barin, for the ANRS PRIMO Cohort Study Group

526 INVESTIGATION OF INTEGRASE-INHIBITOR RESISTANCE MUTATIONS IN GP41 IN CLINICAL SAMPLES
Hanwei Sudderuddin, Anh Le, Tetyana Kalnyynak, Rob Hollebakken, Kyle Cobarrubias, Jinny Choi, Weiyan Dong, Winnie W. Dong, Walter Scott, Kate Laird, Paul Sereda, Eric O. Freed, Zabrina Brumme, Chanson J. Brumme
527  MAPPING RESISTANCE OF POTENT HIV-1 ENTRY INHIBITORS TARGETING PREFUSION CONFORMATION
Yen-Ting Lai, Megan Demouth, Adam Dingens, Amarendra Pegu, Jesse Bloom, John R. Mascola, Peter D. Kwong

528  META-ANALYSIS OF UNUSUAL AND APOBEC MUTATIONS IN HIV-1 POL NEXT-GENERATION SEQUENCES
Philip L. Tzou, Santiago Avila-Rios, Susan Holmes, Rami Kantor, Sergei L. Kosakovsky Pond, Robert Shafer

529  ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS
Nicolas A. Margot, Renee R. Ram, Martin Rhee, Christian Callebaut

530  SUSCEPTIBILITY OF NRTI-RESISTANT HIV-2 ISOLATES TO A NEW NRTI, GS-9131
Quentin Le Hingrat, Gilles Collin, Samuel Lebourgeois, Benoit Vissieux, Florent Damond, Jade Ghosn, Antoine Bachelard, Valentine Ferré, Sophie Matheron, Charlotte Charpentier, Diane Descamps, for the ANRS CO5 HIV-2 Cohort

531  PHENOTYPIC DORAVIRINE SUSCEPTIBILITY AFTER NNRTI EXPOSURE IN THE PRESTIGIO REGISTRY
Francesco Saladini, Federica Giammarrino, Franco Maggiolo, Micol Ferrara, Giovanni Cenderello, Benedetto Maurizio Celesia, Ferdinando Martellotta, Vincenzo Spagnuolo, Giulio Maria Corbelli, Nicola Gianotti, Maria M. Santoro, Stefano Rusconi, Maurizio Zazzì, Antonella Castagna, for the PRESTIGIO Study Group

532  HIV A1 OR B DO NOT DIFFERENTIALLY IMPACT CABOTEGRAVIR IN VITRO POTENCY OR DURABILITY
Jerry Jeffrey, Marty St Clair, Ping Wang, Chunfu Wang, Zhufang Li, Robert Fridell, Mark Krystal, Jan Van Lunzen, Sandy Griffith, Rónald Da'Amico, David A. Margolis, Kim Smith, William Spreen

533  HLA GENOTYPE IS ASSOCIATED WITH PRETHERAPY ACCESSORY InSTI RESISTANCE MUTATION L74I
Guinevere Q. Lee, Suzanne McCluskey, Nicholas Musinguzi, Zabrina Brumme, Yap Boum, Bosco M. Bwana, Conrad Muzooza, Simone Kigozi, Peter W. Hunt, Jeffrey Martin, David R. Bangsberg, Mark J. Siedner, P. Richard Harrigan, Jessica E. Haberer

534  HIV-1 VIRAL REBOUND AFTER BICTEGRAVIR, DOLUTEGRAVIR, AND CABOTEGRAVIR WASHOUT
Ernesto Cuadra Foy, Nathan Osman, Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Bluma G. Brenner

535LB  MUTATIONS IN THE HIV-1 ENVELOPE GLYCOPROTEIN CONFER BROAD DRUG RESISTANCE
Yuta Hikichi, Rachel Van Duynge, Phuong Pham, Jennifer L. Groebner, Ann Wiegand, John W. Mellors, Mary F. Kearney, Eric O. Freed

536  HIV DRUG RESISTANCE ACROSS ANATOMICAL TISSUES
Sergio Ita, Antoine Chaillon, Maris Kamalu, Jonny Baham, Aimee Chen, Magali Porrachia, Caroline Ignacio, Stephen A. Rawlings, Gabriel A. Wagner, Sara Gianella, Davey M. Smith
537  HIV DRUG RESISTANCE IN FEMALE SEX WORKERS FROM THE DOMINICAN REPUBLIC AND TANZANIA
Wendy Greenawalt, Jessica M. Fogel, William Clarke, Autumn Breaud, Jessie Mbwambo, Samuel Likindikoki, Said Aboud, Yeocy Donastorg, Martha Perez, Clare Barrington, Wendy Davis, Mark A. Marzinke, Noya Galai, Deanna Kerrigan, Susan H. Eshleman

538  RESISTANCE TO INTEGRASE STRAND TRANSFER INHIBITORS AMONG MSM IN THE US: HPTN 078
Jessica M. Fogel, Vanessa Cummings, Ethan A. Wilson, Christophe Fraser, David Bonsall, Theresa Gamble, Carlos Del Rio, D. Scott Batey, Kenneth H. Mayer, Jason Farley, James Hughes, Robert H. Remien, Chris Beyrer, Susan H. Eshleman, for the HPTN 078 Study Team

539  EXPANDED SPECTRUM OF ANTIRETROVIRAL-SELECTED HIV-2 MUTATIONS

540  HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS
Rima K. Acosta, Kristen Andreatta, Michelle L. D’Antoni, Sean E. Collins, Hal Martin, Kirsten L. White

Poster P-J07 HCV EPIDEMIOLOGY: TESTING, TRANSMISSION, AND TRANSMISSION COCONSPIRATORS
Poster Hall B  2:30 PM - 4:00 PM

590  HEPATITIS C TESTING OF INDIVIDUALS WITH HCV/HIV COINFECTION, MASSACHUSETTS 2013-2018
Quynh Vo, Laura Kersanske, Matthew Tumpney, Betsey John, Anthony Osinski, Shauna Onofrey, Daniel Church, Monina Klevens

591  COST-SAVING OF POOLED HCV RNA TESTING TO DIAGNOSE ACUTE HCV IN HIGH-RISK POPULATIONS
Hsin-Yun Sun, Yi-Ting Chen, Wen-Chun Liu, Li-Hsin Su, Yu-Chung Chuang, Yu-Shan Huang, Un-In Wu, Kuan-Yin Lin, Sui-Yuan Chang, Chien-Ching Hung

592  PERSISTENT HIV CONTROLLERS ARE MORE PREDISPOSED TO SPONTANEOUSLY CLEAR HCV

593  HPTN 078: HIGH INCIDENCE OF HEPATITIS C VIRUS INFECTIONS AMONG MSM
Risha Irvin, Jowanna Malone, Theresa Gamble, James Hughes, Jason Farley, Kenneth H. Mayer, Carlos del Rio, D. Scott Batey, Michael Murphy, Oliver Laeyendecker, Batsirai M. Mabvakure, Robert H. Remien, Chris Beyrer, Chloe Thio, for the HPTN 078 Research Team

594  SEX, NOT DRUG USE, IS DRIVING HCV REINFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY
Stephanie H. Factor, Jesse R. Carollo, Gabriela Rodriguez-Caprio, Asa Radix, Stephen M. Dillon, Rona Vail, Kriszcar J. Bungay, Robert Chavez, José Lares-Guia, Daniel S. Fierer, for the New York Acute Hepatitis C Surveillance Network
595  HCV REINFECTION AMONG HIV PATIENTS AFTER DAA THERAPY IN THE COUNTRY OF GEORGIA
Nikoloz Chkhartishvili, Pati Gabunia, Akaki Abutidze, Giorgi Korkotashvili, Otar Chokoshvili, Natia Dvali, Lali Sharvadze, Tengiz Tserrtsvadze

596  HCV REINFECTION AFTER DAA TREATMENT AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO
Lucas Hill, Natasha Martin, Sonia Jain, Francesca Torrini, Xiaoying Sun, Huifang Qin, Craig Ballard, W. C. Mathews, Edward R. Cachay

597  HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT
Mathieu Castry, Anthony Cousien, Jonathan Bellet, Karen Champenois, Gilles Pialoux, Yazdan Yazdanpanah, Dominique Costagliola, Sophie Grabar, Sylvie Deuffic-Burban

598  LARGE HEPATITIS C TRANSMISSION CLUSTER IDENTIFIED AMONG HIV-POSITIVE MSM IN BANGKOK
Win Min Han, Donn J. Colby, Apichaya Khlaiphuengsin, Tanakorn Apornpong, Stephen J. Kerr, Sasiwimol Ubolyam, Eugénie Kroon, Nittaya Phanuphak, Anachai Avihingsanon, Kiat Ruxrungtham, Praphan Phanuphak, Pitis Tangkijvanich

599  ORAL PRESCRIPTION OPIOID USE AS A HIGH-RISK INDICATOR FOR HCV INFECTION
Benjamin A. Hack, Utsav Timalsina, Emily Paku, Brittany Wilkerson, Eshetu Tefera, Stephen Fernandez, Dawn Fishbein

600  SYNDROME OF HCV, PRESCRIPTION OPIOID USE, AND PSYCHIATRIC ILLNESS: A NOVEL FRAMEWORK
Adeel A. Butt, for the ERCHIVES Study Team

601  THE PERFECT ICE STORM: THE MIX OF METH AND HIV SPREADS HEPATITIS C IN THAI MSM
Donn J. Colby, Siriporn Nonenoy, Sataporn Waewklaibong, Jitsupa Peelay, Ratchataporn Meksena, Oranuch Nampaisarn, Jitsipuitt Ariyasiikul, Piranun Hongchookiat, Peeraporn Kaewon, Pradit Chailit, Sirichai Jarupittaya, Nipat Teeratakulprarn, Reshmie Ramaudarising, Praphan Phanuphak, Nittaya Phanuphak

602  HEPATITIS C VIRUS INFECTION AND COINFECTION WITH HIV AMONG PWID IN 10 US CITIES
Johanna Chapin-Bardales, Alice Asher, Dita Broz, Eyasu Teshale, Tonya Hayden, Carlos Blanco, Senad Handanagic, Cyprian Wejnert, for the NHBS HCV Study Group

Poster Sessions • Wednesday

603  HEPATITIS B VIRUS VACCINATION IN A CURRENT-ERA HIV CLINIC
Meagan Deming, Shyam Kottilil

604  IMMUNIZATION RESPONSE IN INFANTS BORN TO HBsAg+ HBeAg+ MOTHERS RECEIVING TDF
Gonzague Jourdain, Patrinelye Traisathith, Nicolas Salvadori, Nantawan Wangsaeng, Woottichai Khamduang, Nicole Ngo-Giang-Huong, for the iTAP Study Group
153 EFFECTIVENESS OF THE NOVEL ADJUVANTED HEPATITIS B VACCINE AMONG HIV AND HCV PATIENTS
Brooke Kimball, Katy Garrett

154 TIMING OF ANTI-HBs ANTIBODIES DECAY IN VACCINATED PLWH/A: A LONG-LASTING RESPONSE
Oliver Epaulard, Alice Tomio, Julien Lupo, Myriam Blanc

155 HIGH INCIDENCE OF HBV INFECTION IN HIV-COINFECTED PATIENTS ACCESSING ART CARE
Nokukhanya Msomi, Kogieuleum Naidoo, Nonhlanhla Yende-Zuma, Kerusha Govender, Nesri Padayatchhi, Jeome Singh, Salim S. Abdool Karim, Quarraisha Abdooll Karim, Koleka Mlisana

156 CHARACTERIZING HBV INFECTION AMONG PERSONS LIVING WITH HIV IN CARE IN URBAN SENEGAL
Adrià Ramírez Mena, Judicaël M. Tine, Ouusseynou Ndiaye, Louise Fortes, Ka Daye, Ndeye Fatou Gnom, Fall Fatou, Moussa Seydi, Gilles Wandeler

157 LIVER FIBROSIS CHANGES OVER 3 YEARS OF TENOFOVIR-BASED ART IN HIV-HBV COINFECTION
Michael J. Vinikoor, Kalongo Hamusonde, Shilpa Iyer, Edford Sinkala, Lloyd Mulenga, Michael Saag, Mary-Ann Davies, Matthias Egger, Gilles Wandeler, for the IeDEA Southern Africa

158 LONG-ACTING TENOFOVIR AND NITAZOXANIDE FORMULATIONS SUPPRESS HBV REPLICATION
Denise A. Cobb, Dhruvkumar Soni, Weimin Wang, Murali Ganesan, Raghubendra S. Dogar, Edward Makarov, Yimin Sun, JoEllyn McMillan, Howard E. Gendelman, Natalia Osna, Carlie Y. Poluektova, Benson Edagwa

159 A RHESUS MACAQUE MODEL OF CHRONIC HBV INFECTION FOR CURE RESEARCH
Sreyas Biswas, Patrick Hashiguchi, Jennifer Stanton, Benjamin N. Bimber, Ulrike Protzer, Jonah Sacha, Benjamin J. Burwitz

160 CYTOKINE PROFILES IN ASYMPTOMATIC ACUTE HEPATITIS B
Kathleen E. Stevens, Eric C. Seaberg, Katherine Cascino, Mallory Witt, Claudia Hawkins, Bernard J. Macatangay, Chloe Thio

161 HBV-RELATED INFLAMMATION IS LINKED TO THE LEVEL OF GENETICALLY INTACT HIV PROVIRUSES
Xiao Qian Wang, Jennifer M. Zerbato, Anchalee Avihingsanon, Katie Fisher, Bethany A. Horsburgh, Timothy E. Schlu, Ajantha Solomon, Jennifer Audsley, Kash P. Singh, Wei Zhao, Megan Crane, Sharon R. Lewin, Sarah Palmer

162 LIVER DISEASE PROGRESSION IN HIV-HBV COINFECTION ON ART IS ASSOCIATED WITH HMGB1
Kasha P. Singh, Jennifer M. Zerbato, Wei Zhao, Sabine Braat, Sreekha Tennakoon, Ajantha Solomon, Gail Matthews, Christopher K. Fairley, Joseph Saseadeusz, Megan Crane, Anchalee Avihingsanon, Jennifer Audsley, Sharon R. Lewin

163 HEPATITIS B VIRUS MUTATIONS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN BOTSWANA
616  **HEPATOCELLULAR CARCINOMA SCREENING AMONG HIV/HBV-COINFECTED INDIVIDUALS IN ZAMBIA**
Carlotta Riebensahm, Helen Chitundu, Belinda Varaidzo Chihota, Edford Sinkala, Lloyd Mulenga, Veronica Sunkutu, Adrià Ramirez Mena, Matthias Egger, Carolyn Bolton Moore, Michael J. Vinikoor, Gilles Wandeler

**Poster P-J09 HAV AND HEV**
**Poster Hall B**
2:30 PM - 4:00 PM

617  **SUBOPTIMAL IMMUNITY TO HEPATITIS A AMONG NYC MSM INITIATING PrEP OR PEP, 2016-2019**
Tarek Mikati, Addie Crawley, Leah Strock, Susan Blank

618  **HEPATITIS E RABBIT GENOTYPE INFECTION IN HIV-INFECTED PATIENTS**
Antonio Rivera-Juárez, Mario Frías, Pedro Lopez-Lopez, Juan Berenguer, Federico García, Juan Macías, Begona Alcaraz, Angeles Castro, Javier Caballero-Gomez, Antonio Rivero, for the Spanish AIDS Research Network

**Poster P-K03 CANCER TREATMENT AND RISK**
**Poster Hall B**
2:30 PM - 4:00 PM

631  **IMMUNO-VIROLOGICAL PARAMETERS IN PEOPLE LIVING WITH HIV UPON ANTI-PD-1/L-1 FOR CANCER**
Jean-Philippe Spano, Joséphine Anna Tine, Amélie Guihot, Cathia Soulie, Anne-Geneviève Marcelin, Marianne Veyri, Marine Baron, Séverine Gibovski, Armelle Lavolé, Alain Makinson, Isabelle Poizot-Martin, Christine Katlama, Dominique Costagliola, Lambert Assoumou, Olivier Lambotte

632  **T-CELL SUBPOPULATION PROFILES AND CANCER RISK FOR HIV+ AND HIV – VETERANS**
Keith M. Sigel, Suman Kundu, Lesley S. Park, Kaku So-Armah, Margaret F. Doyle, Russell Tracy, Janet Tate, Amy C. Justice, Matthew Freiberg

633  **TET2 SNPs AND RISK OF CANCER IN THE START, SMART, AND ESPRIT COHORTS**
Daniel D. Murray, Cameron MacPherson, Birgit Grund, Christina Ekenberg, Adrian G. Zucco, Dahlene Fusco, Julien Gras, Jan Gerstoft, Marie Helleberg, Álvaro H. Borges, Mark Polizzotto, Jens D. Lundgren, for the INSIGHT START, SMART and ESPRIT Study Groups

634  **NEXT-GENERATION SEQUENCING TO PROFILE CANCER-RELATED GENES IN HIV+ PATIENTS**
Margherita Digaetano, Antonio Maiorana, Roberto Sabbatini, Carlotta Rogati, Andrea Cossarizza, Cristina Mussini

**Poster P-L05 CLINICAL AND SUBCLINICAL CARDIOVASCULAR OUTCOMES IN HIV**
**Poster Hall B**
2:30 PM - 4:00 PM

655  **CARDIAC EVENTS IN HIV-INFECTED PATIENTS WHO USE TENOFOVIR ALAFENAMIDE (TAF)**
Brent Appelman, Guido Van Den Berk, Marieke De Regt, Narda Van Der Meche, Daoud Ait Moha, Piter Oosterhof, Joost Vanhommerig, Kees Brinkman

656  **INPATIENT OUTCOMES FOR HIV-INFECTED PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME**
Monica Parks, Eric A. Secemsky, Robert W. Yeh, Changyu Shen, Eunhee Choi, Dhruv Kazi, Priscilla Hsue
657 PREVALENCE AND CORRELATES OF CAROTID PLAQUE IN A MIXED HIV-SEROSTATUS UGANDAN COHORT
Prossy Bibangambah, Linda C. Hemphill, Moses Acan, Alexander C. Tsai, Ruth Sentongo, June-Ho Kim, Mark J. Siedner, Samson Okello

658 MEASURES OF ADIPOSE-TISSUE REDISTRIBUTION AND ATHEROSCLEROTIC CORONARY PLAQUE IN HIV
Milana Bogorodskaya, Kathleen V. Fitch, Markella V. Zanni, Sara E. Looby, Sanjna Iyengar, Steven K. Grinspoon, Suman Srinivasa, Janet Lo

659 MAJOR VASCULAR EVENTS IN ADULTS ON ART IN A SOUTH AFRICAN HIV MANAGEMENT PROGRAMME
Johannes P. Mouton, Renee De Waal, Morna Cornell, Gary Maartens, Karen Cohen

660 ASSOCIATION OF HYPERTENSION AND ART USE IN A POPULATION-BASED COHORT, RAKAI, UGANDA
Grace Mongo-Bua, Victor Ssempijja, Anthony Ndyanabo, Doreen Nabukuku, Jesca Basirma, Edward Kankaka, Fred Nalugoda, Gertrude Nakigozi, Joseph Kagaayi, Larry W. Chang, Ronald H. Gray, Maria Wawer, Godfrey Kigozi, Steven J. Reynolds

Poster P-L06 RHYTHM OF THE BEAT: ARRHYTHMIA AND HIV
Poster Hall B  2:30 PM - 4:00 PM

661 VENTRICULAR ARRHYTHMIA PREVALENCE AND FREQUENCY: THE MULTICENTER AIDS COHORT STUDY

662 ASSOCIATION BETWEEN HIV AND THE PREVALENCE OF ATRIAL FIBRILLATION AND ATRIAL FLUTTER
Ngozi C. Osuji, Sabina A. Haberlen, Hiroshi Ashikaga, Todd T. Brown, Matthew J. Feinstein, Mallory Witt, Lawrence Kingsley, Sean Altekruse, Katherine Wu, Wendy Post

Poster P-L07 INTERVENTIONS TO REDUCE CVD: BENCH TO BEDSIDE
Poster Hall B  2:30 PM - 4:00 PM

663 MitoQ ATTENUATES EX VIVO PROATHEROGENIC EFFECTS OF HIV PLASMA IN CHRONIC TREATED HIV
Eleni Ritou, Rachel Heymans, Theodoros Kelesidis

664 HIV AND AGEING: PRIMARY AND SECONDARY PREVENTION OF CAD AMONG PLHIV
Gaetano Marrone, Olof Elvstam, Anders Sönnerborg

665 COST-EFFECTIVENESS OF STATIN USE IN HIV-POSITIVE PERSONS IN THE USA: THE D:A:D STUDY
David C. Boettiger, Anthony Newall, Andrew N. Phillips, Lene Ryom, Peter Reiss, Eran Bendavid, Fabrice Bonnet, Rainer Weber, Wafaa M. El-Sadr, Matthew Law, James Kahn, Jens D. Lundgren, Caroline Sabin, Dhruv Kazi, for the D:A:D Study Group

666 DEPRESSION COGNITIVE BEHAVIORAL THERAPY TO IMPROVE HIV-CVD RISK: A PILOT RCT
Samir K. Gupta, Ziyue Liu, James E. Slaven, Brittany Polanka, Matthew Freiberg, Jesse C. Stewart
Poster Sessions

Poster P-M06 PULMONARY COMPLICATIONS
Poster Hall B 2:30 PM - 4:00 PM

696  INTERSTITIAL LUNG ABNORMALITIES IN PEOPLE LIVING WITH HIV AND UNINFECTED CONTROLS
Andreas Ronit, Thomas Benfield, Jens D. Lundgren, Jørgen Vestbo, Shoaiib Afzal, Børge Nordestgaard, Klaus F. Kofod, Susanne D. Nielsen, Thomas Kristensen

697  IMPLEMENTATION OF A LUNG CANCER SCREENING INITIATIVE IN HIV-INFECTED SUBJECTS
Patricia Roiz, Jorge Diaz, Javier Martinez-Sanz, Jose L. Casado, Maria Jesus Perez-Elias, Santiago Moreno, Ana Moreno, Sabina Herrera, Maria J. Vivancos-Gallego, Pilar Vizcarra, Ana M. Ayala-Carbonero, Sergio Perez-Pinto, Luis Gorospe, Sergio Serrano-Vilar

698  DIMENSIONS OF SLEEP HEALTH: IMPACT ON QUALITY OF LIFE OF PEOPLE WITH AND WITHOUT HIV
Davide De Francesco, Caroline Sabin, Alan Winston, Patrick W. Mallon, Nicki Doyle, Susan Redline, Ken M. Kunisaki, for the POPPY-Sleep Study Group

699  HIV IS ASSOCIATED WITH WORSE PULMONARY DIFFUSING CAPACITY INDEPENDENT OF EMPHYSEMA
Sarath Raju, Meredith C. McCormack, Jacque Astemborski, M. Brad Drummond, Jing Sun, Robert H. Brown, Gregory D. Kirk

Poster P-M08 FUNCTIONAL STATUS AND FRAILTY
Poster Hall B 2:30 PM - 4:00 PM

704  EXERCISE-INDUCED EPIGENETIC CHANGES IN MUSCLE DIFFER BY HIV SEROSTATUS
Kristine M. Erlandson, Colleen Julian, Iain Konigsberg, Jing Sun, Todd T. Brown, Catherine M. Jankowski

705  EFFECTS OF HIV, AGE, AND SEX ON SKELETAL MUSCLE MASS AND DENSITY
Kristine M. Erlandson, Susan Langan, Jing Sun, Jordan E. Lake, Anjali Sharma, Stefan Adrian, Ann Scherzinger, Frank J. Palella, Lawrence Kingsley, Stephen J. Gange, Phyllis Tien, Michael T. Yin, Todd T. Brown

706  CONSISTENT STATIN USE DOES NOT AFFECT AGE-ASSOCIATED GAIT SPEED AND STRENGTH DECLINES
Kristine M. Erlandson, Susan Langan, Jing Sun, Jordan E. Lake, Frank J. Palella, Lawrence Kingsley, Todd T. Brown

707  PREVALENCE OF PHYSICAL-FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH
Triin Umbleja, Todd T. Brown, Heather Ribaudo, Jennifer A. Schrack, Constance A. Benson, Benigno Rodriguez, Roberto Arduino, Kathleen V. Fitch, Steven K. Grinspoon, Edgar T. Overton, Kristine M. Erlandson, for the ACTG A5361S (PREPARE) Team
**Poster P-M09 MULTIMORBIDITY**

**Poster Hall B**  
2:30 PM - 4:00 PM

708 **CAUSE-SPECIFIC HOSPITALIZATION TRENDS AMONG NORTH AMERICAN PERSONS WITH HIV 2005-2015**  
Thibaut Davy-Mendez, Sonia Napravnik, Kelly Gebo, Keri N. Althoff, M J. Gill, Michael A. Horberg, W. C. Mathews, Joseph J. Eron, Jeffrey Martin, Bryan Lau, Kate Buchacz, Viviane D. Lima, Marina Klein, Stephen A. Berry, for the NA-ACCORD of IeDEA

709 **MODIFIABLE RISK FACTORS AND INCIDENT CKD AND CVD AMONG HIV+ AND HIV− PATIENTS**  
Michael A. Horberg, Wendy Leyden, Rulin Hechter, Jennifer O. Lam, Haihong Hu, Alexandra N. Anderson, Julia L. Marcus, Qing Yuan, Alan S. Go, William J. Towner, Michael J. Silverberg

710 **BASELINE AND ACQUIRED COMORBIDITIES IN PATIENTS INITIATING ART IN THE HOPS, 2008-2018**  
Ellen Tedaldi, Carl Armon, Jun Li, Gina M. Simoncini, Frank J. Palella, Stacey Purinton, Kate Buchacz

711 **WOMEN WITH HIV HAVE HIGH OVERALL BURDEN AND EARLY ACCRUAL OF NON-AIDS COMORBIDITIES**  
Lauren F. Collins, Anandi N. Sheth, Cyra Christina Mehta, Elizabeth T. Golub, Phyllis Tien, Kathryn Anastos, Audrey French, Seble Kassaye, Tonya Taylor, Mirjam-Colette Kempf, Margaret Fischl, Adaora Adimora, Frank J. Palella, Igho Ofotokun

712 **PERSISTENT LOW-LEVEL VIREMIA IS ASSOCIATED WITH NONINFECTIONOUS COMORBIDITIES**  
Allahna L. Esber, Julie Ake, Emmanuel Bahemana, Francis Kiweewa, Jonah Jonah Maswai, John Owuoth, Michael Iroezindu, Christina Polyak, Trevor A. Crowell, for the AFRICOS Study Group

713 **FACTORS ASSOCIATED WITH PSORIASIS: THE INDEPENDENT ROLE OF HLA-B*5701**  
Maxime Hentzien, Lise Cuzin, François Raffi, Christine Jacomet, Jacques Reyes, David Rey, Isabelle Ravaux, Antoine Chéret, Manuelle Viguier, Frounze Bani-Sadr

**Poster P-N05 CRYPTOCOCCAL DISEASE, TALAROMYCOSIS, CMV, AND OTHER OPPORTUNISTIC INFECTIONS**

**Poster Hall B**  
2:30 PM - 4:00 PM

743 **DIAGNOSTIC PERFORMANCE OF A SEMIQUANTITATIVE POINT-OF-CARE ASSAY FOR CRYPTOCOCCOSIS**  
Tadeo K. Kiiza, Audrey Nimwesiga, Caleb P. Skipper, Richard Kizwera, Lucy Apeduno, Michael Okirwoth, John Bosco Kafufu, Elizabeth Nalintya, Darlisha A. Williams, Joshua Rhein, David B. Meya, David R. Boulware

744 **EARLY FUNGICIDAL ACTIVITY AS SURROGATE ENDPOINT FOR CRYPTOCOCCAL MENINGITIS SURVIVAL**  
David R. Boulware, Matt Pullen, Katherine Huppler Hullsiek, Joshua Rhein, Lillian Tugume, Edwin Nuwagira, Kenneth Ssebambulidde, Mahsa Abassi, Radha Rajasingham, Katelyn Pastick, Caleb P. Skipper, Abdu Musubire, Conrad Muzoora, David Meya, for the ASTRO-CM Team
745 EVALUATING THE IMMY SEMI-QUANTITATIVE CrAg LFA IN HIV-POSITIVE PATIENTS IN BOTSWANA

746 HIGH RATES OF MENINGITIS OR MORTALITY AMONG CrAg+ PLHIV WITH CD4 100-200 CELLS/MM³
James H. Wykowski, Paul K. Drain, Sean Galagan, Sabina M. Govere, Connie L. Celum, Mahomed-Yunus Moosa, Carole Wallis

747 CSF CYTOKINES AND CHEMOKINES ASSOCIATED WITH MORTALITY IN CRYPTOCOCCAL MENINGITIS
Elizabeth C. Okafor, Liliane Mukaremera, Nicole Wyman Engen, Katherine Huppler Hullsiek, Lillian Tugume, Kenneth Ssebamuldiidde, Abdu Musubire, Edwin Nuwagira, Edward Mpoza, Darlisha A. Williams, Conrad Muzaora, David Meya, Joshua Rhein, David R. Boulware, for the ASTRO-CM Team

748 TUBERCULOSIS IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS AND ITS IMPACT ON MORTALITY
Morris K. Rutakingirwa, Fiona V. Cresswell, Enoch Kagimu, Edwin Nuwagira, Kenneth Ssebamuldiidde, Lillian Tugume, Edward Mpoza, Joanna Dobbin, Richard Kwizera, Darlisha Williams, Conrad Muzaora, David B. Meya, David R. Boulware, Katherine Huppler Hullsiek, Joshua Rhein

749 THE GLOBAL DISTRIBUTION, DRIVERS, AND BURDEN OF TALAROMYCOSIS, 1964-2017
Chuanyi Ning, Wudi Wei, Bo Xu, Thanh T. Nguyen, Li Ye, Hao Liang, Thuy Le

750 SUPERIOR ACCURACY OF THE Mp1p ANTIGEN ASSAY OVER CULTURES IN DIAGNOSING TALAROMYCOSIS
Ly T. Vo, Thu T. Nguyen, Thanh T. Nguyen, Nguyen Le Nhu Tung, Jasper F. Chan, Patrick C. Woo, Chau V. Nguyen, Nga N. Cao, Kwok-Yung Yuen, Thuy Le

751 IN VITRO ANTIFUNGAL SUSCEPTIBILITY AND ANTIFUNGAL TREATMENT OUTCOME IN TALAROMYCOSIS
Thu T. Nguyen, Hannah Shepard, Ly T. Vo, Thanh T. Nguyen, Thuy Le

752 PREVALENCE OF CMV VIREMIA AND ASSOCIATED RISK IN HIV-INFECTED PERSONS STARTING ART
Shweta Sharma, Mark R. Schleiss, Hansjakob Furrer, Daniel Nixon, Mark Blackstad, Nelmary Hernandez-Alvarado, Dominic Dwyer, Álvaro H. Borges, H. Clifford Lane, Jean-Michel Molina, Jens D. Lundgren, James Neaton, for the INSIGHT and ANRS Groups

753 CMV VIREMIA IN PATIENTS WITH ADVANCED HIV INFECTION: A 48-WEEK FOLLOW-UP STUDY
Paula Suanzes, Adaia Albasanz, Juliana Esperalba, Candela Fernández, Júlia Sellares, Ariadna Torrellà Domingo, Bibiana Planas, Antonio Segura, Mario Martín, Jordi Navarro, Joaquín Burgos, Adrià Curran, Esteban Ribera, Vicenç Falco

754 RISKS OF OPPORTUNISTIC INFECTIONS FOR HIV +/- VETERANS UNDERGOING CANCER CHEMOTHERAPY
Alain Makinson, Lesley S. Park, Kimberly Stone, Maria Rodriguez-Barradas, Sheldon T. Brown, Roxanne Wadia, Kristina Crothers, Cynthia L. Gilbert, Roger Bedimo, Matthew B. Goetz, Fatma Shebl, Jacques Reynes, Vincent Le Moing, Keith M. Sigel
Poster P-N06 NOVEL TB DIAGNOSTICS
Poster Hall B 2:30 PM - 4:00 PM

755  CHARACTERISATION OF SOUTH AFRICA’S XPERT MTB/RIF ULTRA "TRACE" LABORATORY RESULTS
Lesley Scott, Pedro Da Silva, Kyle Fyvie, Gabriel D. Eisenberg, Silence Ndlovu, Puleng S. Marokane, Wendy Stevens

756  URINE-BASED TB SCREENING WITH TB-LAM AND ULTRA IN HIV+ UGANDANS WITH MENINGITIS
Jayne Ellis, Enock Kagimu, Ananta Bangdiwala, Michael Okirwoth, Gerald Mugumya, Vincent Wadda, David R. Boulware, Nathan C. Bahr, Fiona V. Cresswell

757  APPLICABILITY OF URINE LAM TEST IN ADVANCED HIV-INFECTED ADULTS IN UKRAINE
Marta Vasylyev, Svitlana Antonyak, Sergii Antoniak, Natasha Rybak, Vira Buhiichyk, Oleksandra Sluzhynska, Maryana Sluzhynska, Viktor Tretiakov, Tetiana Ismagilova, Iryna Dizha, Yana Sheremeta, Dmytro Skirgiko, Anastasia Mazurenko, Justyna D. Kowalska

758  EVALUATION OF A BLOOD-BASED ANTIGEN TEST FOR TUBERCULOSIS IN INFANTS
Liyan Mao, Sylvia LaCourse, Soyeon Kim, Charles D. Mitchell, Tony Hu

759  PROMISING COMBINED IMMUNOLOGICAL ASSAYS TO DIAGNOSE CHILDHOOD TUBERCULOSIS
Edouard Tuaillon, Mwiya Mwiya, Laurent Kremer, Melany w. Tonga, Duncan Chanda, Marianne Periès, Amandine Pisoni, Karine Bolloré, Roselyne Vallo, Chippeko Kankasa, Philippe Van de Perre, Jean-Pierre Molès, Nicolas Nagot

760  WITHDRAWN

761LB  ACCURACY OF NOVEL BLOOD ASSAY FOR IDENTIFICATION OF TB DISEASE IN PEOPLE WITH HIV
Erik Södersten, Anna Mantsoki, Romain Wyss, David Persing, Sara Banderby, Linda Strömqvist Meuzelaar, Jacqueline Prieto, Devasena Gnanashanmugam, Purvesh Khatri, Stefano Ongarelo, Samuel G. Schumacher, Claudia Denkinger

762LB  PROSPECTIVE VALIDATION OF A BLOOD RNA TB BIOMARKER IN AMBULANT HIV-INFECTED ADULTS
Simon C. Mendelsohn, Andrew Fiore-Gartland, Adam Penn-Nicholson, Humphrey Mulenga, Chris Hikuam, Katie Hadley, Michele Tameris, Craig Innes, William L. Brumskine, Gerhard Walz, Kogielemu Naidoo, Gavin Chuchyard, Thomas J. Scriba, Mark Hatherill, for the CORTIS-HR Study Team
793 **METABOLITES, PRETERM LABOR, AND ANTIRETROVIRAL THERAPY**
Nicole H. Tobin, Aisling Murphy, Fan Li, Sean S. Brummel, Mary Glenn Fowler, James A. McIntyre, Judith S. Currier, Tsungai Chipato, Patricia M. Flynn, Brian Koos, Grace M. Aldrovandi, for the 1077BF/1077FF PROMISE (Promoting Maternal and Infant Survival Everywhere) Team

794 **GENITAL TRACT & PLASMA CYTOKINES & SYSTEMIC T-CELL ACTIVATION IN HIV+ PREGNANT WOMEN**

795 **MATERNAL BIOMARKERS OF ENDOTHELIAL DYSFUNCTION BY HIV/ART STATUS AND BIRTH OUTCOMES**
Gaerolwe Masheto, Sikulile Moyo, Terence Mohammed, Christina Banda, Charlene Raphaka, Mompati O. Mmalane, Joseph Makhma, Roger L. Shapiro, Mosepele Mosepele, Rebecca Zash, Shahnockman

796 **MATERNAL AND CORD PLASMA BIOACTIVE EICOSANOID PROFILES DIFFER IN HIV+ AND HIV- WOMEN**
Kayode Balogun, Lauren Balmert, Jennifer Jao, Shan Sun, Richard Bazinet, Lena Serghides

797 **BREASTMILK MICROBIOME/VIROME OF HIV+ KENYAN WOMEN IS NOT ALTERED BY IMMUNOSUPPRESSION**
Rabia Maqsood, Jennifer Slyker, LaRinda A. Holland, Lily I. Wu, Ruth Nduati, Dorothy Mbori-Ngacha, Grace John-Stewart, Dara Lehman, Efrem Lim

798 **REDUCED BASAL GANGLIA AND TOTAL GREY MATTER VOLUME IN HIV-EXPOSED UNINFECTED NEONATES**
Catherine J. Wedderburn, Nynke A. Groenewold, Annerine Roos, Shunmay Yeung, Jean-Paul Fouche, Andrea M. Rehman, Diana Gibb, Catherine L. Narr, Heather Zar, Dan Stein, Kirsty Donald

799 **POSTNATAL LPV/R EXPOSURE, GROWTH, AND NEUROPSYCHOLOGICAL OUTCOMES AT SCHOOL AGE**
Nicolas Nagot, Mandisa Singata, Amandine Cournil, Joyce Nalugya, Souleymane Tassembedo, James Tumwine, Nicolas Meda, Chipeco Kankasa, Marianne Perriès, Joanne Batting, Ingunn M.S. Engebretsen, Thorkild Tylleskär, Philippe Van De Perre, Grace Ndeezi, Jean-Pierre Mole

800 **MALNUTRITION IN HIV-EXPOSED UNINFECTED CHILDREN IN LONG-TERM OBSERVATIONAL FOLLOW-UP**
Lynda Stranix-Chibanda, Jim Aizire, Nonhlanhla Yende-Zuma, Haseena Cassim, Sherika Hanley, Teacer Nematabadiza, Lucky Makonokaya, Bonus Makanani, Lillian Wambuzi Ogwang, Taha E. Taha, Mary Glenn Fowler, for the PROMOTE Study Team
801 HIGH BODY MASS IN HIV+ & HIV– WOMEN AND THEIR HIV-UNINFECTED INFANTS IN SOUTH AFRICA

802 DISTINCT CORD C-PEPTIDE, ADIPOKINE, AND LIPIDOMIC SIGNATURES BY IN UTERO HIV EXPOSURE
Jennifer Jao, Lauren Balmert, Shan Sun, Thomas Kraus, Brian Kirmse, Mitchell Geffner, Yunping Qiu, Stephen M. Arpadi, Elaine J. Abrams, Derek LeRoith, Rhoda Sperling, Irwin J. Kurland

803 MORE SEVERE DISEASE IN HOSPITALIZED HIV-EXPOSED UNINFECTED VS HIV-UNEXPOSED NEONATES
Kim Anderson, Emma Kalk, Hlengiwe Madlala, Dorothy C. Nyemba, Nisha Jacob, Amy L. Slogrove, Mariette Smith, Max Kroon, Michael Harrison, Brian Eley, Andrew Boulle, Landon Myer, Mary-Ann Davies

804 INFECTIOUS MORBIDITY OF BREASTFED, HIV-EXPOSED UNINFECTED INFANTS IN SOUTH AFRICA

805 HIV EXPOSURE AND HUMAN MILK OLIGOSACCHARIDES MODULATE THE INFANT GUT MICROBIOTA
Sarah L. Brooker, Nicolette Tabin, Fan Li, Louise Kuhn, Grace M. Aldrovandi

819 TUBERCULOSIS INFECTION AND DISEASE IN HIV-INFECTED ADOLESCENTS ON ART: A COHORT STUDY

820 LOWER SIZE-ADJUSTED BONE DENSITY AND MUSCLE FUNCTION IN ZIMBABWEAN CHILDREN WITH HIV
Ruramayi Rukuni, Celia Gregson, Kate Ward, Nicola Crabtree, Andrea M. Rehan, Rashida A. Ferrand

821 BONE MASS REMAINS HIGHER AMONG CHILDREN ON EFAVIRENZ VS LOPINAVIR/RITONAVIR
Yanhan Shen, Renate Strehlau, Stephanie Shiu, Faezah Patel, Megan Burke, Louise Kuhn, Ashraf Coovadia, Michael T. Yin, Stephen M. Arpadi

822 BONE AND RENAL OUTCOMES IN VIROLOGICALLY CONTROLLED ADOLESCENTS SWITCHING TO TDF
Kate Braithwaite, Tristan D. McPherson, Stephen M. Arpadi, Stephanie Shiu, Gillian Sorour, Karl Technau, Michael T. Yin

823 EPIGENETIC AGE IN YOUNG AFRICAN AMERICAN ADULTS WITH PERINATALLY ACQUIRED HIV
Stephanie Shiu, Michael T. Yin, Christian Vivar Ramon, Grace Jang, Anyelina Cantos, Jayesh Shah, Stephen M. Arpadi
824  GLOBAL VARIATIONS IN PUBERTAL GROWTH IN ADOLESCENTS LIVING WITH PERINATAL HIV  
Siobhan Crichton, Julie Jesson, Marie-Hélène Aké-Assi, Erik Belfrage, Mary-Ann Davies, Jorge Pinto, Chloé A. Teasdale, Nguyen Van Lam, Rachel Vreeman, Sebastian Wanless, Paige L. Williams, Marcel Yotebieng, Valériane Leroy, Ruth Goodall, for the CIPHER Global Cohort Collaboration

825  LONG-TERM NONPROGRESSION IN CHILDREN WITH PERINATALLY ACQUIRED HIV  
Charlotte Jackson, Alasdair Bamford, Siobhan Crichton, Ruth Goodall, Philip J. Goulder, Nigel Klein, Laura Marques, Paolo Piononi, Andrew Riordan, Vana Spoulou, Vinicius A. Vieira, Intira J. Collins, for the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group

907  INCREASING CAPACITY FOR DETECTING CLUSTERS OF RAPID HIV TRANSMISSION: UNITED STATES  
Alexandra M. Oster, Nivedha Panneer, Sheryl Lyss, Neeraja Saduvala, Tianchi Zhang, Cheryl B. Ocfemia, Laurie Linley, Meg Watson, Robert P. McClung, William M. Switzer, Joel O. Wertheim, Ellsworth M. Campbell, Angela L. Hernandez, Anne Marie France

908  STATEWIDE HIV-1 TRANSMISSION CLUSTER DETECTION AND PRIORITIZATION FOR RESPONSE  

909  DO PARTNER SERVICES INITIATED FROM MOLECULAR CLUSTERS YIELD NEW OR VIREMIC HIV CASES?  
John A. Schneider, Christina S. Hayford, Irina Tabidze, Joel O. Wertheim, Camden Hallmark, Aditya Khanna, Patrick Janulis, David Kern, Ethan Morgan, Jonathan Ozik, Anna Hotton, Kayo Fujimoto, Richard D’Aquila, Nanette Benbow

910  THE RELATIONSHIP BETWEEN THE HIV TRANSMISSION NETWORK AND CARE CONTINUUM IN LA COUNTY  
Adiba Hassan, Victor De Gruttola, Yunyin W. Hu, Zhijuan Sheng, Kathleen Poortinga, Joel O. Wertheim

911  SOCIODEMOGRAPHIC FACTORS ASSOCIATED WITH HIV CLUSTERING ACROSS BOTSWANA COMMUNITIES  
Sikhulile Moyo, Kara Bennett, Simani Gaseitsiwe, Melissa Zahralban-Steele, Tapiwa Nkhisang, Jean Leidner, Dorcas Maruapula, Molly Preotorius Holme, Etienne Kadima, Tendani Gaolathe, Kathleen Wirth, Joseph Makxema, Max Essex, Shainin Lockman, Vlad Novitsky

912  ASSOCIATIONS BETWEEN PHYLOGENETIC TRANSMISSION CLUSTERS AND HLA PROFILES IN MEXICO  

913  HIV RISK INCREASES WITH POSITIVE TIES IN HIGHLY CONNECTED SOCIOSPATIAL PWID NETWORK  
Steven J. Clipman, Shruti H. Mehta, Aylur K. Srikrishnan, Katie J. Zook, Priya Duggal, Shobha Mohapatra, Shamugam Saravanaan, Nandagopal Paneerselvam, Muniratnam S. Kumar, Elizabeth Ogburn, Allison M. McFall, Gregory M. Lucas, Carl A. Latkin, Sunil S. Solomon
914 USING MOLECULAR EPIDEMIOLOGY TO CHARACTERIZE HIV TRANSMISSION NETWORKS OF TW AND MSM
Jessica E. Long, Joshua T. Herbeck, Hugo Sanchez, Sari Reisner, Kenneth H. Mayer, James Mullins, Javier R. Lama, Ann Duerr

915 PHYLOGENETIC EVIDENCE OF HIV-1 MIXING BETWEEN KEY RISK GROUPS IN COASTAL KENYA
Nduva M. George, Amin S. Hassan, Susan M. Graham, Joakim Esbjörnsson, Eduard Sanders

916 PHYLODYNAMIC EVIDENCE OF HIV TRANSMISSION BETWEEN AGE-DISCREPANT MSM IN KING COUNTY

917 HOMOPHILY IN THE SOCIOSEXUAL NETWORKS OF GAY AND BISEXUAL MEN
Kiffer G. Card, Zishan Cui, Jordan M. Sang, Heather L. Armstrong, Nathan J. Lachowsky, David M. Moore, Robert S. Hogg, for the Momentum Health Study

918 PHYLOGENETIC INSIGHTS ON HIV-1 TRANSMISSION DYNAMICS AMONG MSM AND MIGRANTS IN QUEBEC
Bluma G. Brenner, Nathan Osman, Ernesto Cuadra Foy, Antoine Chaillon, Ruxandra-Ilinca Ibanescu, Isabelle Hardy, Nadine Kronfli, David Stephens, Michel Roger

919 NON-B SUBTYPE HIV INFECTIONS IN GERMANY BEFORE AND AFTER THE EUROPEAN MIGRANT CRISIS
Melanie Stecher, Antoine Chaillon, Christoph Stephan, Jan-Christian Wasmuth, Josef Eberle, Georg M. Behrens, Julia Roider, Christoph D. Spinner, Matthias C. Müller, Elena Knops, Guido Schäfer, Sanjay R. Mehta, Joerg Janne Vehreschild, Martin Hoenigl, for the Translational Platform HIV (TP-HIV) Molecular Epidemiology Team

920 EVALUATION OF HIV TRANSMISSION CLUSTERS AMONG NATIVES AND FOREIGNERS LIVING IN ITALY
Maria M. Santoro, Lavinia Fabeni, Patrizia Lorenzini, Stefano Rusconi, Nicola Gianotti, Andrea Costantini, Loredana Sarmati, Andrea Antinori, Francesca Ceccherini Silberstein, Antonella D’Arminio Monforte, Annalisa Saracino, Enrico Girardi, for the Icona Foundation Study Cohort

921 MOLECULAR ANALYSIS SUGGESTS POST-MIGRATION HIV-1 ACQUISITION AMONG MIGRANTS IN PARIS
Evangelia G. Kostaki, Cathia Soulie, Benoit Visseaux, Alexandre Storto, Charlotte Charpentier, Marc Wirden, Roland Landman, Christine Katlama, Vincent Calvez, Diane Descamps, Federico Garcia, Maria M. Santoro, Dimitrios Paraskevis, Anne-Geneviève Marcelin

922 GEOGRAPHIC PATTERNS IN HIV TRANSMISSION CLUSTERS IN LOS ANGELES COUNTY
Britt Skaathun, Manon Ragonnet-Cronin, Kathleen Poortinga, Zhijuan Sheng, Yunyin W. Hu, Joel O. Wertheim

923 HUMAN MOBILITY PATTERNS GENERATE GEOGRAPHICALLY STRUCTURED SUB-EPIDEMICS IN NAMIBIA
Eugenio Valdano, Justin Okano, Vittoria Colizza, Sally Blower

924 LOCAL AND REGIONAL DYNAMICS OF HIV EPIDEMICS AMONG HIGH-RISK POPULATIONS IN HAITI
Frantz Jean-Louis, Jean Wysler Domercant, Caroline Ignacio, Sara Gianella, Guethina Galbaud, Davey M. Smith, Antoine Chaillon
925  **MAPPING AND CHARACTERISING HIV TRANSMISSION HOTSPOTS IN SUB-SAHARAN AFRICA**  
*Caroline Bulstra, Jan A. Hontelez, Federica Giardina, Richard Steen, Nico Nagelkerke, Till Bärnighausen, Sake de Vlas*

926  **GEOGRAPHIC CHARACTERISTICS OF HIV GENETIC CLUSTERS AMONG NEWLY DIAGNOSED CASES IN NC**  

**Poster Halls**  
**Poster Sessions** • Wednesday 
**Poster Sessions** • Wednesday 
**Poster Hall D**  2:30 PM - 4:00 PM

927  **HIV TRACE VS PHYLOGENETIC ANALYSIS: UNRAVELING TRANSMISSION CLUSTERS IN SPAIN**  
*Carlos Guerrero Beltrán, Evangelia G. Kostaki, Luca Carioti, Marta Alvarez, Julian Olalla, María Carmen Vidal Ampurdanes, Marta Montero, Silvia García-Bujalance, José-Ramón Blanco, María Rivero, Lucio Jesus García-Fraile Fraile, Maria M. Santoro, Dimitrios Paraskevis, Federico García*

928  **RECONSTRUCTION AND ESTIMATION OF DIRECTED HIV-1 TRANSMISSION USING DEEP SEQUENCES**  
*Nicholas Bbosa, Depriotgtius Ssemwangq, Alfred Ssekagiri, Yunia Mayanja, Ubaldo M. Bahemuka, Janet Seeley, Deenan Pillay, Christophe Fraser, Pontiano Kaleebu, Oliver Ratmann, for the PANGEA Consortium*

929  **CONCORDANCE OF METHODS IN IDENTIFYING MOLECULAR HIV CLUSTERS**  
*Vladimir Novitsky, Jon Steingrimsson, Mark Howison, Fizza S. Gillani, Yuanning Li, Akarsh Manne, Matthew C. Spence, Theodore Marak, Philip A. Chan, Thomas Bertrand, Utpala Bandy, Nicole Alexander-Scott, Casey Dunn, Joseph Hogan, Rami Kantor*

930  **USE OF PHYLOGENETIC ANALYSIS TO INFER THE DIRECTION OF HIV TRANSMISSION**  
*Yinfeng Zhang, Chris Wymant, Oliver Laeyendecker, Kate Grabowski, Matthew D. Hall, Sarah E. Hudelson, Estelle Piwowar-Manning, Marybeth McCauley, Johnstone Kumwenda, Mina C. Hosseinipour, Ying Qing Chen, Myron S. Cohen, Christophe Fraser, Susan H. Eshleman, for the HPTN 052 Study Team*

931  **NEAR REAL-TIME IDENTIFICATION OF RECENT HIV INFECTION BY PID-NGS IN NORTH CAROLINA**  

932  **IMPLICATIONS OF NEXT-GENERATION SEQUENCING FOR DRUG RESISTANCE AND CLUSTER DETECTION**  
*Randall V. Collura, Wendy Patterson, Carol-Ann Swain, Eva Pradhan, William M. Switzer, Alexandra M. Oster, Bridget J. Anderson*
Poster P-Q12 HIV GENETIC DIVERSITY
Poster Hall D  2:30 PM - 4:00 PM

933  PERSISTENT AND NONRANDOM RECOMBINATION IN NEAR FULL-LENGTH HIV GENOMES FROM UGANDA
Heather E. Grant, Emma B. Hodcroft, Deogratius Ssemwanga, John Kitayimbwa, Paul Kellam, Tulio De Oliveira, Rebecca N. Nsubuga, Samantha Lykett, David L. Robertson, Oliver Ratmann, Christophe Fraser, Deenan Pillay, Pontiano Kaleebu, Andrew Leigh Brown, for the PANGEA-HIV Consortium

934  JACKHAMMER RT-PCR RECOVERS DIVERSE ARCHIVAL VIRAL GENOMES FROM KINSHASA, 1983
Sophie Gryseels, Thomas D. Watts, Thomas Quinn, Philippe Lemey, Henry Francis, Oliver Laeyendecker, Michael Worobey

935  A THIRD COMPLETE GENOME ESTABLISHES HIV-1 SUBTYPE L
Julie Yamaguchi, Ana Vallari, Carole McArthur, Larry Shiresley, Gavin Cloherty, Michael Berg, Mary A. Rodgers

936  WHOLE-GENOME SEQUENCING SHOWS INCREASING HIV-1 SUBTYPE COMPLEXITY AMONG MSM IN THE UK
Jean L. Mbisa, Juan Ledesma, David F. Bibby, Carmen M. Fernandez Manso, Peter Kirwan, Alison E. Brown, Hodan Mohamed, Yuen T. Chan, Gary Murphy, David Dunn, Caroline Sabin, Valerie Delpech, Kate El Bouzidi, Anna Maria Geretti, for the UK HIV Drug Resistance Database

Poster P-R05 HIV TEST PERFORMANCE
Poster Hall D  2:30 PM - 4:00 PM

965  THE RATIONALE FOR A 3-TEST HIV DIAGNOSTIC ALGORITHM: BALANCING ACCURACY AND COST
Jeffrey Eaton, Anita Sands, Magdalena Barr-Dichiara, Muhammad S. Jamil, Thokozani Kalua, Andreas Jahn, Rachel Baggaley, Cheryl Johnson

966  FALSE-POSITIVE 4TH GENERATION HIV TEST RESULTS IN THE EMERGENCY DEPARTMENT
Gabriel A. Wagner, Ryan Anson, Nicole Gamache-Kocok, Kushagra Mathur, Megan Lo, Jeffrey H. Burack, Annette Shaieb, Jill Blumenthal, Susan J. Little, Martin Hoenigl

967  EVALUATION OF VIRAL SUPPRESSION ON RAPID HIV TEST REACTIVITY AMONG MSM, NHBS, 2017
Shamaya Whitby, Amanda Smith, Johanna Chapin-Bardales, Rebecca Rossetti, Cyprian Wejnert, Silvina Masciotra, for the for the NHBS Study Group

968  PERFORMANCE OF ORAQUICK RAPID TEST ON HIV DIAGNOSIS AMONG CADAVERS IN KISUMU, KENYA
Frankline O. Mboya, Anthony Waruru, Alex Sila, Dickens Onyango, Solomon Sava, Lily Nyaga, Mary Mwangome, Nyakeriga Nyakeriga, Muthoni Junghae, Paul K. Musingila, Frank L. Basiyie, Kimberly McCarthy, Boaz Oyar, Peter W. Young

969  DRIED BLOOD SPOTS PROVIDE SIMPLIFIED ACCURATE MEASUREMENT OF HIV VIRAL LOAD
Torin Schaafisma, Katherine Thomas, Heidi Van Rooyen, Maryam Shahmanesh, Jared Baeten, Connie L. Celum, Ruanne V. Barnabas, for the DO ART Study Team
Poster Sessions

970 AUTOMATED HIGH-THROUGHPUT QUANTIFICATION OF LOW-LEVEL HIV-1 PLASMA VIREMIA
Jana L. Jacobs, Melissa A. Tosiano, Dianna L. Koontz, Andrew Worlock, Karen Harrington, Sonia Bakkour, Michael P. Busch, John W. Mellors

971 HEAT-INACTIVATED/LYOPHILIZED HIV VIRUS FOR USE IN PROFICIENCY TESTING PROGRAMS
Raul Louzao, Thomas M. Denny, Heidi M. Register, Wes Rountree, Ambrosia Garcia, Cassandra Porth, Andrea Pappas, Clare Morris, Sarah Gilbert, Bhavna M. Hora, Feng Gao

972 IDENTIFYING RECENT HIV INFECTIONS IN REAL-WORLD SETTINGS IN KENYA AND ZIMBABWE
Brian Rice, Mariken M. De Wit, Kathryn A. Risher, Susie Welty, Sungai T. Chabata, Frances Cowan, Georges Reniers, Gary Murphy, Jeffrey Eaton, George Rutherford, James R. Hargreaves

973 STAGING OF HIV-1C INFECTION AMONG PATIENTS IN ART IN BOTSWANA USING PROVIRAL DNA
Manon Ragonnet-Cronin, Tanya Golubchik, Sibhulile Moyo, Christophe Fraser, Max Essex, Vlad Novitsky, Erik Volz, for the PANGEA Consortium

974 NOVEL CRITERIA FOR DIAGNOSING ACUTE HIV IN A MULTINATIONAL ART-INITIATION STUDY
Trevor A. Crowell, Justin Ritz, Robert Coombs, Lu Zheng, Joseph J. Eron, John W. Mellors, Gert U. van Zyl, Javier R. Lama, Kiat Ruxrungtham, Beatriz Grinsztejn, Roberto Arduino, Lawrence Fox, Jintanat Ananworanich, Eric Daar, for the AIDS Clinical Trials Group (ACTG) A5354 Study Team

975 IMPROVING CLASSIFICATION FOR RECENT HIV INFECTION USING TOP SCORING PAIRS
Athena Chen, Oliver Laeyendecker, Charles S. Morrison, Susan H. Eshleman, Ingo Ruczinski

976 EVALUATION OF CROSS-SECTIONAL HIV INCIDENCE TESTING IN THE HPTN 071 (POPART) TRIAL
Ethan B. Klock, Oliver Laeyendecker, Reinaldo Fernandez, Ethan A. Wilson, Estelle Prowar-Manning, Sam Griffith, B Kosloff, Anneen Van Deventer, Sarah Fidler, Helen Ayles, Peter Bock, Deborah J. Donnell, Richard J. Hayes, Susan H. Eshleman, for the HPTN 071 (PopART) Study Team

977 HIV PREVENTION AND DRUG-USER HEALTH CARE ON SITE AT A SYRINGE-EXCHANGE PROGRAM
Andrea L. Jakubowski, Irene L. Soloway, Mercedes L. Guzman, Christine Fitzsimmons, Leonardo Domínguez-Gomez, Franklin Ramirez, Brackets Kaplan, Brent Gibson, Joseph DeLuca, Julia H. Arnsten, Brianna L. Norton

978 HIGH PREVALENCE OF PrEP INDICATION IN PEOPLE WHO INJECT DRUGS IN BOSTON, MA, 2018
Joel J. Earlywine, Katie Biello, Angela R. Bazzi
1025 PROPHYLACTIC EFFECT OF PrEP AGAINST HBV INFECTION AMONG MSM
Daisuke Mizushima, Misao Takano, Haruka Uemura, Yasuyuki Yanagawa, Takahiro Aoki, Koji Watanabe, Hiroyuki Gatanaga, Shinichi Oka

1026 HAV AND HBV VACCINATION COVERAGE AND ACCEPTABILITY AMONG MSM ON PrEP
Paul Le Turnier, Isabelle Charreau, Audrey Gabassi, Diane Carette, Laurent Cotte, Gilles Pialoux, Cécile Tremblay, Bruno Spire, Marie-Laure Chaix Baudier, Laurence Meyer, Catherine Capitant, Constance Delaugerre, Jean-Michel Molina, François Raffi, for the ANRS IPERGAY Study Group

Poster P-S10 BIOLOGICAL MEASURES OF PrEP
Poster Hall D  2:30 PM - 4:00 PM

1027 HIGH PrEP ADHERENCE BASED ON TFV-DP LEVELS IN THAI 15-19-YEAR-OLD MSM AND TRANSWOMEN
Wipaporn Natalie Songtaweesin, Thanyawee Puthanakit, Surinda Kawichai, Tim R. Cressev, Prissana Wongharn, Tuangtip Theerawit, Somsong Teeratakulpisarn, Danai Linjongrut, Surang Janyam, Nittaya Phanuphak

1028 DRUG LEVELS, ADHERENCE, AND RISKS FOR LOW ADHERENCE IN THE DISCOVER PrEP STUDY
Susanne Doblecki-Lewis, Olamide Dosekun, Moti Ramgopal, Jay Gladstein, Mezgebe Berhe, Kevin Nguyen, Jason Hindman, Yongwu Shao, Ramin Ebrahimi, Diana Brainard, Moupalxi Das, Scott McCallister, Adriano Lazzarin, Gerold F. Lang, Peter L. Anderson

1029 COMPARISON OF TFV-DP AND WISEPILL ADHERENCE AMONG YOUNG KENYAN WOMEN USING PrEP
Maria Pyra, Elizabeth A. Bukusi, Nelly R. Mugo, Kenneth Ngure, Kevin Oware, Catherine Kiptinness, Katherine Thomas, Lindsey Garrison, Peter L. Anderson, Jared Baeten, Jessica E. Haberer

1030 HIV RISK AND OBJECTIVELY MEASURED PrEP ADHERENCE IN YOUNG KENYAN WOMEN
Jessica E. Haberer, Nelly R. Mugo, Elizabeth A. Bukusi, Kenneth Ngure, Kevin Oware, Catherine Kiptinness, Maria Pyra, Katherine Thomas, Lindsey Garrison, Jared Baeten

1031 USING A MOBILE APP AND DRIED BLOT SPOTS TO ASSESS ADHERENCE TO EVENT-DRIVEN PrEP
Vita Jongen, Elske Hoornenborg, Mark A. Van Den Elshout, Liza N. Coyer, Udi Davidovich, Henry J. De Vries, Maria Prins, Maarten F. Schim Van Der Loeff, for the Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative

1032 USE OF A TENOFOVIR URINE TEST TO IMPROVE PrEP ADHERENCE

Poster P-S11 PrEP IN CISGENDER WOMEN
Poster Hall D  2:30 PM - 4:00 PM

1033 DETERMINANTS OF HIV PREEXPOSURE PROPHYLAXIS INITIATION IN WOMEN AT HIGH RISK FOR HIV
Rachel K. Scott, Shawnika Hull, Jim C. Huang, Adam Visconti, Megan Coleman, Peggy Ye, Pam Lotke, Dhirsha Balaji, Jason Beverley, Alison Ward, Jennifer Holiday, Richard A. Elion
1034 PRENATAL PrEP EXPOSURE AND LONGITUDINAL BIRTH OUTCOMES IN KENYA
Julia C. Dettinger, John Kinuthia, Laurén Gómez, Jillian Pintye, Joshua Stern, Nancy M. Ngumbau, Ben O. Odhiambo, Mary M. Marwa, Salphine A. Wattoyi, Felix Abuna, Jared Baeten, Grace John-Stewart

1035 WOMEN ARE LESS LIKELY TO BE TESTED FOR HIV OR OFFERED PrEP AT TIME OF STI DIAGNOSIS
Caitlin S. Yumori, Jason Zucker, Deborah Theodore, Michelle Chang, Caroline Carnevale, Jacek Słowiński, Elijah LaSota, Susan Olender, Peter Gordon, Alwyn Cohall, Magdalena Sobieszczuk

1036 RESULTS FROM A PrEP DEMONSTRATION PROJECT FOR AT-RISK CISGENDER WOMEN IN THE US
Jill Blumenthal, Sonia Jain, Feng He, Ryan M. Kofron, Eric Ellorin, Jamila Stockman, Gifty Ntim, Peter L. Anderson, Katya Calvo, Richard Haubrich, K. Rivet Amico, David J. Moore, Sheldon Morris, Raphael J. Landovitz

1060 CONTRACEPTIVE USE INDUCES DURABLE SHIFTS IN THE FEMALE GENITAL-TRACT MICROBIOTA
Bryan P. Brown, Maricianah Onono, Gonasangrie Nair, Thesla Palanee-Phillips, Caitlin W. Scoville, Rubina Bunjun, Tanko F. Ramla, Kate Heller, Jared Baeten, Steven E. Bosingier, Adam Burgener, Jo-Ann Passmore, Renee Heffron, Heather Jaspan

1061 GENITAL SECRETIONS FROM WOMEN WITH BACTERIAL VAGINOSIS ENHANCE HIV INFECTION EX VIVO
Marla J. Keller, Richard Hunte, Rebecca Barnett, Joyce Serebrenik, Jessica McWalters, April Dobkin, Jessica Goymer, Laurie Ray, Lilia Espinoza, Jessica M. Atrio, Kerry Murphy, Betsy Heroïd

1062 DMPA-IM DRIVES CERVICAL TH17 HIV TARGET-CELL ACCUMULATION IN WOMEN IN ECHO TRIAL

1063 INCREASED GENITAL INFLAMMATION IN WOMEN RANDOMIZED TO COPPER IUD IN THE ECHO TRIAL

1064 ELEVATED GENITAL CYTOKINES IN HIV-INFECTED WOMEN USING COPPER AND LEVONORGESTREL IUDs
Jo-Ann Passmore, Musalula Sinkala, Nai-Chung Hu, Shameem Jaumdally, Hoyam Gamieldien, Smritee Dabee, Heidi Jones, Donald R. Hoover, Nontokozo Langwenya, Landon Myer, Catherine S. Todd

1065 MOLECULAR PERTURBATIONS INDUCED BY DMPA, COPPER IUD, AND LNG IMPLANT IN ECHO TRIAL
1066 COOPER IUD AND LEVONORGESTREL IMPLANT INCREASE GENITAL INFLAMMATION IN THE ECHO TRIAL

1067 DOUCHING IS ASSOCIATED WITH RECTAL INFLAMMATION IN HIV-NEGATIVE SEXUAL MINORITY MEN
Angela M. McLaugh, Charlene Miller, Justice King, Kathryn McManus, Maria L. Alcaide, Jose Bauermeister, Christian Grov, Jennifer A. Manuzak, Courtney Broedlow, Robert Parisi, Darling Martinez, Nichole Klett, Adam W. Carrico

1068 SEXUAL VIOLENCE EXPOSURE DYSREGULATES HIV-ASSOCIATED IMMUNE BIOMARKERS IN WOMEN
Annette Aldous, Jason Daniels, Christopher Joy, Mariel Jais, Kaleigh Connors, Hani Mohamed, Brendan Capozzi, Sam Simmons, Manya Magnus, Afsoon Roberts, Gary Simon, Mimi Ghosh

Poster P-U09 LINKAGE TO CARE
Poster Hall D  2:30 PM - 4:00 PM

1121 POOR LINKAGE TO CARE AMONG HIV+ PERSONS IN EMERGENCY DEPARTMENTS IN SOUTH AFRICA
Bhakti Hansoti, Aditi Rao, Elizabeth Hahn, Sofia Ryan, Nomzamo Mvandaba, Yandisa Nyanisa, Victoria Chen, Pamela Mda, Roshen Maharaj, David Stead, John Black, Steven J. Reynolds, Jean B. Nachega, Thomas Quinn, for the WISE Study Group

1122 LINKAGE TO CARE AND VIRAL SUPPRESSION FASTER OVER TIME AMONG NEW HIV DIAGNOSES IN DC
Rupali K. Doshi, Jenevieve Opoku, Adam Allston

1123 TRENDS IN LINKAGE INTO CARE AFTER "TEST AND START" AMONG ADOLESCENTS AND YOUNG ADULTS

1124 ENGAGEMENT IN CARE AND VIRAL SUPPRESSION AMONG NEWLY DIAGNOSED HIV-INFECTED PERSONS
Amsalu B. Ayana

1125 FREQUENT DETECTION OF UNDIAGNOSED HIV WITHIN EMERGENCY DEPARTMENTS IN BOTSWANA
Jillian Pintye, Katrina F. Ortblad, Sheshith Mwandianga, Odirile Bakae, Lenna Tau, Matias Grande, Gobaone Mogomotsi, Esther Mmatli, Modise Ngombo, Laura Seckel, Renee Heffron, Jenny Ledikwe

Poster P-U10 PREVENTION STRATEGIES
Poster Hall D  2:30 PM - 4:00 PM

1126 COMBINATION HIV PREVENTION STRATEGIES TO MEET THE 2030 ENDING THE HIV EPIDEMIC GOALS
Samuel Jenness, Jordan Johnson, Karen W. Hoover, Dawn K. Smith, Kevin P. Delaney
1127 COMMUNITY HIV-PREVENTION SERVICES IMPROVE THE HIV TREATMENT CASCADE IN 5 COUNTRIES
Mansoor S. Farahani, Andrea Low, Karampreet K. Sachathep, Neena M. Philip, Wolfgang Hladik, Andrew Voetsch, Godfrey Musuka, Andrew F. Auld, Shrirish Balachandra, Jackson Okuku, Amee M. Schwitters, Bharat S. Parekh, Hetal Patel, David Hoos, Jessica E. Justman

1128 OPTIMIZING HIV PREVENTION EFFORTS WITHOUT NEW INVESTMENT CAN REDUCE INCIDENCE
Evin Jacobson, Katherine A. Hicks, Justin Carrico, Stephanie L. Sansom

1129 IMPACT OF COMBINATION HIV PREVENTION IN ZIMBABWE: A MULTIDISTRICT TRANSMISSION MODEL
Jan A. Hontelez, Isaac Taramusi, Gerald Shambira, Roel Bakker, Caroline Bulstra, Frances Cowan, Godfrey Matisne, Suzette M. Matthijsses, Cai M. Rui, Richard Steen, Mutsa Mhangara, Amon Mpofu, Sake de Vlas

1130 IMPLEMENTATION OF U=U IN REAL LIFE IN ITALY: RESULTS FROM THE ICONA COHORT
Giordano Madeddu, Andrea De Vito, Alessandro Cozzi-Lepri, Antonella Cingolani, Franco Maggiolo, Carlo Federico Perno, Roberta Gagliardini, Giulia Marchetti, Annalisa Saracino, Antonella D’Arminio Monforte, Andrea Antinori, Enrico Girardi, for the ICONA Foundation Study Group

1131 IMPACT OF PrEP AND TasP ON INCIDENCE OF HIV DIAGNOSES IN 48 HIGHEST-BURDEN US AREAS
Robertino Mera Giler, Staci Bush, Trevor Hawkins, Moupali Das, Julius Asubonteng, Scott McCallister

1132 IMPACT OF FOOD INSECURITY ON THE HIV EPIDEMIC IN SUB-SAHARAN AFRICA (2015–2017)
Andrea Low, Elizabeth Gummerson, Amee M. Schwitters, Rogerio Bonifacio, Nicholus Mutenda, Karampreet K. Sachathep, Choice Ginindza, Avi Hakim, Danielle T. Barradas, James Juma, Samuel Biraro, Keisha Jackson, Neena M. Philip, Steven Hong, Sally Findley

1133 GEOGRAPHIC ESTIMATE OF SEXUAL HIV TRANSMISSION BURDEN IN ERA OF U=U: DC COHORT DATA
Hana Akselrod, Morgan Byrne, Anne K. Monroe, Matthew E. Levy, Rachel Denyer, Adam Klein, Michael A. Horberg, Amanda D. Castel, Rupali K. Doshi, Alessandra Secco, Jose Lucar, Leah Squires, Stefanie Schroeter, Debra A. Benator, for the DC Cohort Executive Committee

1134 LATE PRESENTATION PERSISTS UNDER UTT IN SOUTH AFRICA: A NATIONAL COHORT STUDY
Jacob Bor, Matthew P. Fox, Cornelius Nattey, Brendan Maughan-Brown, Mhairi Maskew, Dorina Onoya, Alana T. Brennan, Till Bärnighausen, Hanisha Yapa, Sergio Carmona, Wendy Stevens, Adrian J. Puren, William B. MacLeod

1135 CD4 COUNT AT ART INITIATION IN THE UTT ERA: AN INTERRUPTED TIME SERIES ANALYSIS
H. Manisha Yapa, Hae-Young Kim, Kathy Petoumenos, Frank Post, Avachana Jiamsakul, Jan-Walter De Neve, Frank Tanser, Collins C. Iwuji, Kathy Baisley, Maryam Shahmanesh, Deenan Pillay, Mark J. Siedner, Till Bärnighausen, Jacob Bor
1136  USING SOCIAL NETWORKS TO REACH INDIVIDUALS WITH LOW CD4 AT HIGH RISK OF DEATH
Lillian Brown, Yiqun Chen, Laura B. Balzer, Gabriel Chamie, James Ayieko, Dalsone Kwarisimia, Jane Kabami, Norton Sang, Edwin D. Charlebois, James Peng, Yusuf Mwinike, Elizabeth A. Bukusi, Moses R. Kamya, Diane V. Havlir, Maya L. Petersen

Poster P-U12 HIV CASE FINDING
Poster Hall D  2:30 PM - 4:00 PM

1137  IMPROVING HIV CASE-FINDING WITH MACHINE LEARNING
Pavlo Smyrnov, Yulia Sereda, Artem Lytvyn, Olga Denisuk

1138  HIV SCREENING IN EMERGENCY DEPARTMENTS: LINKAGE WORKS, BUT WHAT ABOUT RETENTION?
Kushagra Mathur, Jill Blumenthal, Gabriel A. Wagner, Lucy Horton, Miriam Zuazo, George Lara-Paez, Megan Lo, Gary M. Vilke, Christopher J. Coyne, Susan J. Little, Martin Hoenigl

1139  EXPERIENCE FROM THE LARGEST WESTERN US EMERGENCY DEPARTMENT ON ENDING THE EPIDEMIC
Kathleen Jacobson, Sanjay Arorooa, Chun Nok Lam, Mikheala Go, Mike Menchine

Poster P-U13 SUBSTANCE USE AND HIV PREVENTION AND TREATMENT
Poster Hall D  2:30 PM - 4:00 PM

1140  WITHDRAWN

1141  HRSA’S RYAN WHITE HIV/AIDS PROGRAM RESPONSE TO THE OPIOID EPIDEMIC
Nicole S. Chavis, Pamela W. Klein, Stacy Cohen, Letha Healey, Antigone Dempsey, Heather Hauck, Laura W. Cheever

1142  SEARCH TEST & TREAT INTERVENTION IMPROVES VIRAL SUPPRESSION AMONG HAZARDOUS DRINKERS
Sarah B. Puryear, Dalsone Kwarisimia, James Ayieko, Judith A. Hahn, Atukunda Mucunguzi, Sabina Ogachi, Laura B. Balzer, Vivek Jain, Edwin D. Charlebois, Craig R. Cohen, Elizabeth A. Bukusi, Maya L. Petersen, Diane V. Havlir, Moses R. Kamya, Gabriel Chamie

1143  END OF HIV EPIDEMIC AMONG PWID IN A LOW-MIDDLE INCOME COUNTRY: THE HAI PHONG CASE
Nicolas Nagot, Khuat T. Oanh, Duong T. Huong, Delphine Rapoud, Hoang T. Giang, Catherine Quillet, Pham M. Khue, Laurent Michel, Roselyne Vallo, Jonathan Feeleymer, Vu H. Vinh, Didier Laureillard, Philippe Van De Perre, Jean-Pierre Molès, Don Des Jarlais

1144  ENDING THE HIV EPIDEMIC AMONG PEOPLE WHO INJECT DRUGS: A COST-EFFECTIVENESS ANALYSIS
Emanuel Krebs, Xiao Zang, Benjamin Enns, Jeong E. Min, Bohdan Nosyk, for the Localized Economic Modeling Study Group
1145 INTEGRATING ANTIRETROVIRAL TREATMENT AND HARM REDUCTION SERVICES ON HIV AND OVERDOSE
Javier Cepeda, Annick Borquez, Christopher Magana, Anh T. Vo, Claudia Rafful, Maria Gudeia Rangel-Gomez, Maria Elena Medina-Mora, Steffanie A. Strathdee, Natasha Martin

1146 SMARTPHONE INTERVENTION TO REDUCE HEAVY DRINKING IN HIV CARE: EFFECT ON ART ADHERENCE
Deborah S. Hasin, Efrat Aharonovich, Barry S. Zingman, Malka Schlesinger, Claire Walsh

NOTES
POSTER SESSIONS BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day and poster hall (listed in parenthesis below). Posters should be displayed for the duration of the conference. Poster categories are designated by color in the poster hall as follows: Purple for Basic Science, Red for Clinical, and Blue for Epidemiology/Public Health.

A. VIROLOGY
P-A01 SHARPENING THE CUTTING EDGE (Monday in Poster Hall A)
P-A02 HOST FACTORS AFFECTING HIV REPLICATION (Tuesday in Poster Hall A)
P-A03 VIRUS-CELL INTERACTION AND GENETICS (Wednesday in Poster Hall A)

B. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS
P-B01 WHERE IS HIV GOING AND WHAT IS IT DOING (Monday in Poster Hall A)
P-B02 HIV, SIV, AND IMMUNE REGULATION (Monday in Poster Hall A)
P-B03 MICROBIOMIC AND METABOLIC MANIFESTATIONS OF HIV INFECTION (Monday in Poster Hall A)
P-B04 FACTORS AFFECTING HIV TRANSMISSION (Tuesday in Poster Hall A)
P-B05 HIV SUPPRESSION AND IMMUNE ACTIVATION (Tuesday in Poster Hall A)
P-B06 HIV AND THE MICROBIOME (Tuesday in Poster Hall A)
P-B07 BARRIERS TO TRANSLLOCATION (Wednesday in Poster Hall A)
P-B08 NON-AIDS CONSEQUENCES OF HIV INFECTION (Wednesday in Poster Hall A)
P-B09 GUT PATHOGENESIS (Wednesday in Poster Hall A)

C. HIV-ASSOCIATED TUMOR VIRUSES
P-C01 TUMOR VIRUSES: HPV, EBV, AND KSHV (Tuesday in Poster Hall A)

D. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY
P-D01 IMMUNOLOGY OF ACUTE HIV INFECTION (Monday in Poster Hall A)
P-D02 ANTIBODY RESPONSES TO HIV (Monday in Poster Hall A)
P-D03 CD8 T CELL RESPONSES (Monday in Poster Hall A)
P-D04 IMMUNOLOGY AND HOST GENETICS (Tuesday in Poster Hall A)
P-D05 IMMUNOTHERAPY FOR HIV INFECTION (Tuesday in Poster Hall A)
P-D06 THE ROAD TO A BETTER VACCINE: CLINICAL TRIALS AND COHORT STUDIES (Wednesday in Poster Hall A)
P-D07 PRECLINICAL VACCINE STUDIES (Wednesday in Poster Hall A)
P-D08 IMPACT OF ANTIRETROVIRALS ON THE IMMUNE RESPONSE (Wednesday in Poster Hall A)

E. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE
P-E01 MECHANISMS OF HIV LATENCY (Monday in Poster Hall A)
P-E02 MEASURING THE HIV RESERVOIR (Monday in Poster Hall A)
P-E03 HIV PERSISTENCE IN TISSUES AND CELLS (Monday in Poster Hall A)
P-E04 INSIGHTS FROM ANALYTICAL TREATMENT INTERRUPTION (Monday in Poster Hall A)
P-E05 ESTABLISHMENT OF THE HIV RESERVOIR (Tuesday in Poster Hall A)
P-E06 CURE STRATEGIES: HUMANS AND ANIMAL STUDIES (Tuesday in Poster Hall A)
P-E07 HIV CURATIVE STRATEGIES: IN VITRO STUDIES (Tuesday in Poster Hall A)
P-E08 ATTACK OF THE CLONES: CLONAL EXPANSION IN THE HIV RESERVOIR (Wednesday in Poster Hall A)
P-E09 CHARACTERIZING LATENT HIV RESERVOIRS (Wednesday in Poster Hall A)
P-E10 IMMUNE PRESSURE ON THE HIV RESERVOIR (Wednesday in Poster Hall A)
### F. NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS
- **P-F01** NEUROIMAGING AND ASSOCIATED BIOMARKERS (Monday in Poster Hall A)
- **P-F02** NEUROCOGNITION: BIOMARKERS, THERAPIES, AND OUTCOMES (Tuesday in Poster Hall A)
- **P-F03** CNS RESERVOIRS, ESCAPE, AND IMMUNOLOGY (Tuesday in Poster Hall A)
- **P-F04** ACUTE HIV INFECTION AND CNS RESPONSES (Wednesday in Poster Hall A)
- **P-F05** ART RESPONSES, SWITCHES, AND TOXICITY RELEVANT TO THE CNS (Wednesday in Poster Hall A)

### G. CLINICAL PHARMACOLOGY
- **P-G01** NOVEL MEASURES OF DRUG ADHERENCE (Monday in Poster Hall A)
- **P-G02** WHAT’S NEW IN DRUG INTERACTIONS (Monday in Poster Hall A)
- **P-G03** PHARMACOKINETICS AND PHARMACODYNAMICS IN SPECIAL POPULATIONS AND BODY SITES (Tuesday in Poster Hall A)
- **P-G04** THE LONG AND THE SHORT OF IT: WHAT IS NEXT FOR LONG ACTINGS (Wednesday in Poster Hall A)

### H. ANTIRETROVIRAL THERAPY: PRE-CLINICAL DATA, RANDOMIZED TRIALS, EFFICACY AND EFFECTIVENESS STUDIES
- **P-H01** ANTIRETROVIRAL THERAPY: OUTCOMES IN TREATMENT NAIVE-PATIENTS (Monday in Poster Hall A)
- **P-H02** TO THREE OR NOT TO THREE, THAT IS THE QUESTION (Tuesday in Poster Hall A)
- **P-H03** ADHERENCE ASSESSMENT AND OTHER ART STRATEGIES (Tuesday in Poster Hall A)
- **P-H04** ANTIRETROVIRAL TREATMENT: NEW AGENTS, NEW TARGETS (Wednesday in Poster Hall A)

### I. HIV DRUG RESISTANCE
- **P-I01** PREVALENCE OF PRETREATMENT RESISTANCE (Monday in Poster Hall A)
- **P-I02** DRIVERS OF VIROLOGIC FAILURE AND RESISTANCE EMERGENCE ON EARLY LINES OF THERAPY (Monday in Poster Hall A)
- **P-I03** DRUG RESISTANCE IN EXPERIENCED AND POTENTIAL FOR SUCCESSFUL TREATMENT (Tuesday in Poster Hall A)
- **P-I04** NOVEL MECHANISMS OF DRUG RESISTANCE AND RESISTANCE TO NEW AGENTS (Wednesday in Poster Hall A)
- **P-I05** DRUG RESISTANCE IN SPECIAL POPULATIONS (Wednesday in Poster Hall A)

### J. HEPATITIS VIRUSES AND LIVER COMPLICATIONS
- **P-J01** HCV: HEPATIC STEATOSIS AND ITS COMPLICATIONS (Monday in Poster Hall B)
- **P-J02** HCV: FIBROSIS, MORTALITY, AND OTHER LONG-TERM COMPLICATIONS (Monday in Poster Hall B)
- **P-J03** RESISTANCE TO HCV DRUGS (Tuesday in Poster Hall B)
- **P-J04** RESISTANCE TO PAYING FOR HCV DRUGS (Tuesday in Poster Hall B)
- **P-J05** HCV THERAPEUTICS: GETTING REAL (Tuesday in Poster Hall B)
- **P-J06** HCV AFTER THE SVR: GONE BUT NOT FORGOTTEN (Tuesday in Poster Hall B)
- **P-J07** HCV EPIDEMIOLOGY: TESTING, TRANSMISSION, AND TRANSMISSION COCONSPIRATORS (Wednesday in Poster Hall B)
- **P-J08** HBV: PATHOGENESIS, EPIDEMIOLOGY, PREVENTION, AND THERAPY (Wednesday in Poster Hall B)
- **P-J09** HAV AND HEV (Wednesday in Poster Hall B)

### K. AIDS-RELATED MALIGNANCIES
- **P-K01** ANAL AND CERVICAL CANCER (Monday in Poster Hall B)
- **P-K02** CANCERS: KAPOSI SARCOMA, LUNG, BREAST, AND HEMATOLOGIC (Tuesday in Poster Hall B)
- **P-K03** CANCER TREATMENT AND RISK (Wednesday in Poster Hall B)
L. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-L01 INFLAMMATORY BIOMARKERS AND CARDIOVASCULAR OUTCOMES (Monday in Poster Hall B)
P-L02 HORMONES AND HEART DISEASE (Monday in Poster Hall B)
P-L03 CLUSTERING OF PREDICTORS AND PREDICTION RULES FOR MI RISK (Tuesday in Poster Hall B)
P-L04 STRUCTURAL ISSUES IN HEART DISEASE AND HIV (Tuesday in Poster Hall B)
P-L05 CLINICAL AND SUBCLINICAL CARDIOVASCULAR OUTCOMES IN HIV (Wednesday in Poster Hall B)
P-L06 RHYTHM OF THE BEAT: ARRHYTHMIA AND HIV (Wednesday in Poster Hall B)
P-L07 INTERVENTIONS TO REDUCE CVD: BENCH TO BEDSIDE (Wednesday in Poster Hall B)

M. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-M01 FAT IN FOCUS (Tuesday in Poster Hall B)
P-M02 ADIPOSE TISSUE AND OBESITY (Tuesday in Poster Hall B)
P-M03 METABOLIC COMPLICATIONS (Monday in Poster Hall B)
P-M04 RENAL DISEASE (Monday in Poster Hall B)
P-M05 BONE DISEASE (Monday in Poster Hall B)
P-M06 PULMONARY COMPLICATIONS (Wednesday in Poster Hall B)
P-M07 MENTAL HEALTH COMPLICATIONS (Monday in Poster Hall B)
P-M08 FUNCTIONAL STATUS AND FRAILTY (Wednesday in Poster Hall B)
P-M09 MULTIMORBIDITY (Wednesday in Poster Hall B)
P-M10 EPIGENETIC AND MITOCHONDRIAL TOXICITIES (Tuesday in Poster Hall B)

N. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS
P-N01 INCIDENCE, PREVALENCE, AND RISK FACTORS FOR TB IN PEOPLE LIVING WITH HIV (Monday in Poster Hall B)
P-N02 LATENT TB INFECTION: RISK FACTORS, TREATMENT, AND PREVENTION (Monday in Poster Hall B)
P-N03 EARLY BACTERICIDAL ACTIVITY, PK/PD, AND DRUG INTERACTIONS IN TB TREATMENT (Tuesday in Poster Hall B)
P-N04 TB: MORTALITY, OUTCOMES, AND END-ORGAN COMPLICATIONS (Tuesday in Poster Hall B)
P-N05 CRYPTOCOCCAL DISEASE, TALAROMYCOSIS, CMV, AND OTHER OPPORTUNISTIC INFECTIONS (Wednesday in Poster Hall B)
P-N06 NOVEL TB DIAGNOSTICS (Wednesday in Poster Hall B)

O. MATERNAL AND FETAL HIV
P-O01 VIREMIA AND ADHERENCE IN PREGNANCY AND POSTPARTUM (Monday in Poster Hall B)
P-O02 CHRONIC DISEASES AND MATERNAL HEALTH: PERSISTENT PROBLEMS FOR PREGNANT AND POSTPARTUM WOMEN (Monday in Poster Hall B)
P-O03 NEW PERSPECTIVES IN PMTCT (Tuesday in Poster Hall B)
P-O04 ENHANCING INFANT DIAGNOSIS AND PROPHYLAXIS (Tuesday in Poster Hall B)
P-O05 INTEGRASE STRAND TRANSFER INHIBITORS IN PREGNANCY (Tuesday in Poster Hall B)
P-O06 IMPLICATIONS OF IMMUNE ACTIVATION AND INFLAMMATION IN PREGNANCY AND BREASTFEEDING (Wednesday in Poster Hall B)
P. PEDIATRICS AND ADOLESCENTS

P-P01 HEALTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN (Wednesday in Poster Hall B)
P-P02 EARLY ANTIRETROVIRAL TREATMENT FOR CHILDREN (Monday in Poster Hall B)
P-P03 CHARACTERIZING THE HIV RESERVOIR IN INFANTS AND CHILDREN (Tuesday in Poster Hall B)
P-P04 PEDIATRIC 90:90:90 (Monday in Poster Hall B)
P-P05 COINFECTIONS, COMPLICATIONS, AND PATTERNS OF DISEASE IN CHILDREN AND YOUTH (Wednesday in Poster Hall B)
P-P06 METABOLIC AND CARDIOVASCULAR COMPLICATIONS IN CHILDREN AND YOUTH (Tuesday in Poster Hall B)
P-P07 MENTAL HEALTH AND BRAIN DEVELOPMENT IN CHILDREN (Monday in Poster Hall B)
P-P08 NOVEL APPROACHES TO PEDIATRIC ANTIRETROVIRAL DOSING AND SAFETY (Tuesday in Poster Hall B)

Q. EPIDEMIOLOGY

P-Q01 HIV INCIDENCE (Monday in Poster Hall D)
P-Q02 HIV IN KEY POPULATIONS (Monday in Poster Hall D)
P-Q03 VIRAL LOAD AND OUTCOMES (Monday in Poster Hall D)
P-Q04 LIFE EXPECTANCY AND MORTALITY (Monday in Poster Hall D)
P-Q05 T CELL PATTERNS (Monday in Poster Hall D)
P-Q06 HIV IN TRANSGENDER WOMEN AND MEN (Tuesday in Poster Hall D)
P-Q07 SUBSTANCE USE AND HIV (Tuesday in Poster Hall D)
P-Q08 MENTAL HEALTH AND HIV (Tuesday in Poster Hall D)
P-Q09 METHODS IN EPIDEMIOLOGY (Tuesday in Poster Hall D)
P-Q10 PHYLOGENETICS AND HIV TRANSMISSION (Wednesday in Poster Hall D)
P-Q11 MOLECULAR METHODS TO EVALUATE TRANSMISSION (Wednesday in Poster Hall D)
P-Q12 HIV GENETIC DIVERSITY (Wednesday in Poster Hall D)

R. TESTING

P-R01 ASSISTED PARTNER NOTIFICATION (Monday in Poster Hall D)
P-R02 HIV TESTING STRATEGIES (Monday in Poster Hall D)
P-R03 POINT-OF-CARE TESTING (Tuesday in Poster Hall D)
P-R04 HIV SELF-TESTING (Tuesday in Poster Hall D)
P-R05 HIV TEST PERFORMANCE (Wednesday in Poster Hall D)
P-R06 DIAGNOSING EARLY HIV INFECTION (Wednesday in Poster Hall D)

S. PREVENTION INTERVENTIONS

P-S01 PrEP EFFECTIVENESS (Monday in Poster Hall D)
P-S02 PrEP ELIGIBILITY UPDATE AND MODES OF DELIVERY (Monday in Poster Hall D)
P-S03 THE PROBLEM OF PERSISTENCE IN PrEP (Monday in Poster Hall D)
P-S04 NEW PREVENTION AGENTS AND ROUTES OF DELIVERY (Monday in Poster Hall D)
P-S05 PrEP DRUG RESISTANCE AND RENAL IMPAIRMENT (Tuesday in Poster Hall D)
P-S06 PrEP SCALE-UP: COST AND SYSTEM-BASED FACTORS (Tuesday in Poster Hall D)
P-S07 FACTORS IMPACTING PREVENTION: INTIMATE PARTNER VIOLENCE, WHITE COAT EFFECT, SEX WORK, AND SOCIAL INFLUENCERS (Tuesday in Poster Hall D)
P-S08 PrEP IN TRANSWOMEN (Tuesday in Poster Hall D)
P-S09 PREVENTION IN IDU AND LINKAGE WITH HEPATITIS VACCINATION (Wednesday in Poster Hall D)
P-S10 BIOLOGICAL MEASURES OF PrEP (Wednesday in Poster Hall D)
P-S11 PrEP IN CISGENDER WOMEN (Wednesday in Poster Hall D)
P-S12 MALE CIRCUMCISION AND THE PENILE MICROBIOME (Tuesday in Poster Hall D)
T. CONTRACEPTION, SEXUALLY TRANSMITTED INFECTIONS, AND REPRODUCTIVE HEALTH

P-T01 SEXUALLY TRANSMITTED INFECTIONS IN SPECIAL POPULATIONS (Monday in Poster Hall D)
P-T02 SEXUALLY TRANSMITTED INFECTIONS DIAGNOSIS AND PROGNOSIS (Tuesday in Poster Hall D)
P-T03 ISSUES IN CONTRACEPTION (Tuesday in Poster Hall D)
P-T04 MAKING SENSE OF IT ALL: HIV SUSCEPTIBILITY IN THE FEMALE GENITAL TRACT (Wednesday in Poster Hall D)

U. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE

P-U01 RAPID ART INITIATION (Monday in Poster Hall D)
P-U02 HIV TEST AND TREAT (Monday in Poster Hall D)
P-U03 PROGRESS TOWARDS 90-90-90 AND BEYOND (Monday in Poster Hall D)
P-U04 VIRAL SUPPRESSION, ADHERENCE, AND MORE (Monday in Poster Hall D)
P-U05 MODELLING, COSTING, AND COST-EFFECTIVENESS (Monday in Poster Hall D)
P-U06 HIV CARE CONTINUUM (Tuesday in Poster Hall D)
P-U07 DIFFERENTIAL SERVICE DELIVERY (Tuesday in Poster Hall D)
P-U08 COMMUNITY ART (Tuesday in Poster Hall D)
P-U09 ANTIRETROVIRAL THERAPY DELIVERY (Tuesday in Poster Hall D)
P-U09 LINKAGE TO CARE (Wednesday in Poster Hall D)
P-U10 PREVENTION STRATEGIES (Wednesday in Poster Hall D)
P-U11 LATE PRESENTATION TO HIV CARE (Wednesday in Poster Hall D)
P-U12 HIV CASE FINDING (Wednesday in Poster Hall D)
P-U13 SUBSTANCE USE AND HIV PREVENTION AND TREATMENT (Wednesday in Poster Hall D)
The following index list presenting authors as of February 7, 2020. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook on the CROI website.

<table>
<thead>
<tr>
<th>Author Name</th>
<th>Index</th>
<th>Presenting Author(s)</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron, Kristal J</td>
<td>1041</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdelwahab, Mahmoud</td>
<td>733</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abela, Irene</td>
<td>290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abella, Irene</td>
<td>290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abe, Soehyun</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abougi, Lisa Lynn</td>
<td>763</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acosta, Rima Kulkarni</td>
<td>540</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeoye, Bukola</td>
<td>265</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeyemi, Adebayo Olubumi</td>
<td>853</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alghilen, Erika</td>
<td>404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahn, Seohyun</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuogi, Lisa Lynn</td>
<td>763</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adam, Kristal J</td>
<td>1041</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdelwahab, Mahmoud</td>
<td>733</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abela, Irene</td>
<td>290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abella, Irene</td>
<td>290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abe, Soehyun</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abougi, Lisa Lynn</td>
<td>763</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acosta, Rima Kulkarni</td>
<td>540</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeoye, Bukola</td>
<td>265</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeyemi, Adebayo Olubumi</td>
<td>853</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alghilen, Erika</td>
<td>404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahn, Seohyun</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuogi, Lisa Lynn</td>
<td>763</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acosta, Rima Kulkarni</td>
<td>540</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeoye, Bukola</td>
<td>265</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeyemi, Adebayo Olubumi</td>
<td>853</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alghilen, Erika</td>
<td>404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahn, Seohyun</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuogi, Lisa Lynn</td>
<td>763</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acosta, Rima Kulkarni</td>
<td>540</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeoye, Bukola</td>
<td>265</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeyemi, Adebayo Olubumi</td>
<td>853</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alghilen, Erika</td>
<td>404</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ahn, Seohyun</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuogi, Lisa Lynn</td>
<td>763</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acosta, Rima Kulkarni</td>
<td>540</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeoye, Bukola</td>
<td>265</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeyemi, Adebayo Olubumi</td>
<td>853</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Index of Presenting Authors

Gupta, Samir Kumar 666
Gurung, Sitaji 829
Guthrie, Brandon 42

Haaland, Richard 446
Haas, Andreas D 899
Haber, Jessica E 1030
Haberlen, Sabina A 642
Hack, Benjamin A 599
Haeri Mazanderani, Ahmad 953
Hagins, Debbie P 36
Halperin, Jason 1073
Halvas, Elias K 383
Hamers, Raph L 222
Han, Win Min 598
Handanagic, Senad 887
Hanna, David B 649
Hansoti, Bhakti 1121
Harrington, Mark 10
Harijanto, Caroline 341
Hasin, Deborah S 1146
Hassan, Adiba 910
Hasson, Jenna Mohammad 811
Hawes, Isobel Anne 405
Healey, Letha 1141
Heffron, Renee 109
Hendrickson, Erik Michael 886
Henrich, Timothy J 72
Herce, Michael 1111
Heresi, Gloria P 347
Hertzman, Michael A 709
Heron, Elizabeth Francesca 879
Horne, Elizabeth Francesca 879
Horsburgh, Bethany A 368
Hoy, Jennifer 692
Hsu, Denise C 77, 343
Hu, Tony 758
Huang, Rachel 690
Hu, Yuan-J 161
Huang, Yoseph Joseph 415
Hyle, Emily P 403

- I -
Imaz, Arkaiz 464
Innes, Steve 828
Iqbal, Kashif 1018, 1124
Irvin, Risha 593
Isnard, Stéphane 229
Ita, Sergio 336

-J-
Jackson, Charlotte 825
Jackson, Laurelle Anne 179
Jackson, Patrick Evan Hager 178
Jacobs, Jana L 970
Jacobsen, Evin 1128
Jacobsen, Kathleen 1139
Jain, Mamta K 893
Jaksic, Bernadette 409, 410
Jambo, Kondwani C 268
Jambo, Patrick Evan Hager 178
Jambon, Kudu Indrajaya 341
Hasin, Deborah S 1146
Hassan, Adiba K 953
Hasson, Jenna Mohammad 953
Hashim, Deborah S 1146
Hassan, Adiba K 953
Hasson, Jenna Mohammad 811
Hawes, Isobel Anne 405
Healey, Letha 1141
Heffron, Renee 109
Hendrickson, Erik Michael 886
Henrich, Timothy J 72
Herce, Michael 1111
Heresi, Gloria P 347
Hertzman, Michael A 709
Heron, Elizabeth Francesca 879
Horn, Elizabeth Francesca 879
Horsburgh, Bethany A 368
Hoy, Jennifer 692
Hsu, Denise C 77, 343
Hu, Tony 758
Huang, Rachel 690
Hu, Yuan-J 161
Huang, Yoseph Joseph 415
Hyle, Emily P 403

- K -
Kaku, Machika 358
Kamikawala, Asante R 414
Kasai, Parastu 1094
Katobi, Moses 1120
Katoto, Patrick 721
Kaur, Harpreet 691
Kaur, Jasmine 355
Kazer, Samuel Weisgurt 258
Keating, Mary F 5
Keiser, Olivia 580
Kelentze, Nametso 426
Kelesi, Theodos 663, 715
Keller, Marla J 1061
Kelley, Audrey 186
Kelley, Colleen F 213
Kefford, Kerri 630
Kepner, Darix Ssebaggala 1123
Kizat, Tadeo Kizat 743
Kim, Eun Hye Grace 166
Kim, Jongyeon 885
Kim, Soyeon 139
Kim, Youry 354
Kimani, Makobu 878
Kimball, Brooke 605
Kimmel, April D 962
Kirby, Charles 317
Kirk, Gregory D 322
Kirkegaard-Kdlo, Ditte 593
Klausner, Jeffrey David 1052
Klevens, Monica 871
Klock, Ethan Brian 976
Knight, Audrey C 420
Knox, Justin Ryan 146
Knuelsen, Andreas Dehlbæk 545
Ko, Sung Hee 187
Koay, Wei Li Adeline 826
Koetle, John 668
Koopen, Jelle 124
Kostaki, Evangelia Georgia 921
Krebs, Emanuel 1144
Krebs, Shelly J 291
Kreitmann, Regis 1043
Kremer, Jorn Hayden 1103
Krogstad, Paul 846
Kuhn, Louise 135
Kulpa, Deanna 330
Kuo, Alex J 6
Kuri Cervantes, Leticia 119
Kuwata, Takeo 262
Kvistad, Daniel 278
Kwa, Abena 378

- L -
LaCourse, Sylvia 138
Laing, Celeste Deille 457
Lai, Yen-Ting 527
Lain, Maria Grazia 807
Lake, Jordan E 645, 673
Lam, Jennifer O 646
Lambert-Nicolot, Sidonie 502
Lambrecht, Laurens 324
Lampe, Margaret A 790
Landes, Megan 765
Lange, Ulrike C 307
Lau, Bryan 897
Lau, Jillian SY 334
Le, Thuy 548
Le Grand, Roger 293
Le Hingrat, Quentin 530
Le Roux, Stanzi Maria 804
Le Turner, Paul 1026
Lechilie, Kwana 745
Lederman, Michael M 156
Lee, Guinevere O 533
Lee, Jennifer S 863
Lehman, Dana 577
Leigh Brown, Andrew 933
Leiseegang, Rory Forsyth 1116
Leone, Michael 390
Leska, Catherine R 882
Levy, Claire 311
Lewis, Lara 856
Li, Chenglei 182
Li, Jonathan Z 519
Li, Ninying Alice 1000
Li, Xiaojun 263
Lian, Xiaodong 381
Longino, August Andrew 407
Louzaol, Raul 971
Low, Andrea 1078, 1132
<table>
<thead>
<tr>
<th>Author Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rodriguez, Carina</td>
</tr>
<tr>
<td>Rodriguez-Hart, Cristina</td>
</tr>
<tr>
<td>Romero, Fabio</td>
</tr>
<tr>
<td>Ronit, Andreas</td>
</tr>
<tr>
<td>Rosebud, Julia</td>
</tr>
<tr>
<td>Rosen, Elias</td>
</tr>
<tr>
<td>Ross, Jonathan</td>
</tr>
<tr>
<td>Rossetti, Barbara</td>
</tr>
<tr>
<td>Rossoitt, Roberto</td>
</tr>
<tr>
<td>Rowlinson, Emily</td>
</tr>
<tr>
<td>Ruane, Peter</td>
</tr>
<tr>
<td>Rucinski, Katherine</td>
</tr>
<tr>
<td>Rudd, Deanne</td>
</tr>
<tr>
<td>Ruederman, Stephanie</td>
</tr>
<tr>
<td>Ruel, Theodore</td>
</tr>
<tr>
<td>Ruiz-Mateos, Ezequiel</td>
</tr>
<tr>
<td>Rukuni, Surumaya</td>
</tr>
<tr>
<td>Rust, Blake</td>
</tr>
<tr>
<td>Ruttingerirva, Morris</td>
</tr>
<tr>
<td>Rydberg, Frida</td>
</tr>
<tr>
<td>Sacks, Emma</td>
</tr>
<tr>
<td>Saed, Sahar</td>
</tr>
<tr>
<td>Saez-Cirion, Aser</td>
</tr>
<tr>
<td>Sailsuta, Napapon</td>
</tr>
<tr>
<td>Saladini, Francesco</td>
</tr>
<tr>
<td>Santinelli, Letizia</td>
</tr>
<tr>
<td>Sanz, Marta</td>
</tr>
<tr>
<td>Samo, Elissha</td>
</tr>
<tr>
<td>Savic, Radojka</td>
</tr>
<tr>
<td>Savinelli, Stefano</td>
</tr>
<tr>
<td>Savory, Theodora</td>
</tr>
<tr>
<td>Sax, Paul</td>
</tr>
<tr>
<td>Saylor, Charles</td>
</tr>
<tr>
<td>Scanga, Charles</td>
</tr>
<tr>
<td>Schafsma, Torin</td>
</tr>
<tr>
<td>Scharfenberger, Samuel</td>
</tr>
<tr>
<td>Schiffer, Joshua</td>
</tr>
<tr>
<td>Schinazi, Raymond</td>
</tr>
<tr>
<td>Schneider, John</td>
</tr>
<tr>
<td>Schnittman, Samuel</td>
</tr>
<tr>
<td>Schoepf, Isabella</td>
</tr>
<tr>
<td>Schuetz, Alexandra</td>
</tr>
<tr>
<td>Schulz, Thomas</td>
</tr>
<tr>
<td>Scott, Lesley</td>
</tr>
<tr>
<td>Scott, Rachel</td>
</tr>
<tr>
<td>Scully, Eileen</td>
</tr>
<tr>
<td>Scutari, Rossana</td>
</tr>
<tr>
<td>Seang, Kemaire</td>
</tr>
<tr>
<td>Sebba, Shokor</td>
</tr>
<tr>
<td>Seekaew, Pich</td>
</tr>
<tr>
<td>Sengupta, Devi</td>
</tr>
<tr>
<td>Serghides, Lenia</td>
</tr>
<tr>
<td>Serquina, Anna</td>
</tr>
<tr>
<td>Serrano-Villar, Sergei</td>
</tr>
<tr>
<td>Sette, Paola</td>
</tr>
<tr>
<td>Sevilla, Sabrina</td>
</tr>
<tr>
<td>Shafer, Robert</td>
</tr>
<tr>
<td>Shaha, Maunank</td>
</tr>
<tr>
<td>Sharma, Shweta</td>
</tr>
<tr>
<td>Shebi, Fatma</td>
</tr>
<tr>
<td>Sheik, Virginia</td>
</tr>
<tr>
<td>Sherman, Brad</td>
</tr>
<tr>
<td>Shiau, Stephanie</td>
</tr>
<tr>
<td>Short, Charlotte</td>
</tr>
<tr>
<td>Short, William</td>
</tr>
<tr>
<td>Shouse, Ruke</td>
</tr>
<tr>
<td>Shrestha, Ram</td>
</tr>
<tr>
<td>Siedner, Mark</td>
</tr>
<tr>
<td>Sigal, Alex</td>
</tr>
<tr>
<td>Sigel, Keith</td>
</tr>
<tr>
<td>Silicano, Janet</td>
</tr>
<tr>
<td>Silva-Klug, Ana</td>
</tr>
<tr>
<td>Silvers, Richard</td>
</tr>
<tr>
<td>Silverberg, Michael</td>
</tr>
<tr>
<td>Sim, Jae H</td>
</tr>
<tr>
<td>Simoncini, Gina</td>
</tr>
<tr>
<td>Simonetti, Francesco</td>
</tr>
<tr>
<td>Singh, Devika</td>
</tr>
<tr>
<td>Singh, Kasha</td>
</tr>
<tr>
<td>Singh, Sonia</td>
</tr>
<tr>
<td>Skaathun, Britt</td>
</tr>
<tr>
<td>Skalland, Timothy</td>
</tr>
<tr>
<td>Slama, Laurence</td>
</tr>
<tr>
<td>Slaymaker, Emma</td>
</tr>
<tr>
<td>Smiley, Casey</td>
</tr>
<tr>
<td>Smith, Brian</td>
</tr>
<tr>
<td>Smith, Janet</td>
</tr>
<tr>
<td>Smith, Marie-Soleil</td>
</tr>
<tr>
<td>Smith, S Abigail</td>
</tr>
<tr>
<td>Smith, Marie</td>
</tr>
<tr>
<td>Stader, Felix</td>
</tr>
<tr>
<td>Staitieb, Bashar</td>
</tr>
<tr>
<td>Stalter, Randy</td>
</tr>
<tr>
<td>Starace, Mario</td>
</tr>
<tr>
<td>Stecher, Melanie</td>
</tr>
<tr>
<td>Stefek, Karl</td>
</tr>
<tr>
<td>Stemmach, Rachel</td>
</tr>
<tr>
<td>Strain, Jeremy</td>
</tr>
<tr>
<td>Stranix-Chibanda, Lynda</td>
</tr>
<tr>
<td>Styer, Linda</td>
</tr>
<tr>
<td>Suanzes, Paula</td>
</tr>
<tr>
<td>Sun, Hsin-Yun</td>
</tr>
<tr>
<td>Sun, Jing</td>
</tr>
<tr>
<td>Suzuki, Kazuo</td>
</tr>
<tr>
<td>Sagaard, Ole</td>
</tr>
<tr>
<td>Tagarro, Alfredo</td>
</tr>
<tr>
<td>Tang, Michael</td>
</tr>
<tr>
<td>Tanner, Mary</td>
</tr>
<tr>
<td>Tedaldi, Ellen</td>
</tr>
<tr>
<td>Telwatte, Sushama</td>
</tr>
<tr>
<td>Temfack, Elivs</td>
</tr>
<tr>
<td>Thakur, Kiran</td>
</tr>
<tr>
<td>Thorne, Claire</td>
</tr>
<tr>
<td>Tiam, Appolinaire</td>
</tr>
<tr>
<td>Tien, Phyllis</td>
</tr>
<tr>
<td>Tiraboschi, Juan</td>
</tr>
<tr>
<td>Tobin, Nicole H</td>
</tr>
<tr>
<td>Tomesko, Phillip</td>
</tr>
<tr>
<td>Tomoy, Dimitre</td>
</tr>
<tr>
<td>Tordoff, Diana</td>
</tr>
</tbody>
</table>

---

Index of Presenting Authors

1. Rodríguez-Fernández, Miguel
2. Rodriguez-Hart, Cristina
3. Romero, Fabio
4. Ronit, Andreas
5. Rosebud, Julia
6. Rosen, Elias
7. Ross, Jonathan
8. Rossetti, Barbara
9. Rossoitt, Roberto
10. Rowlinson, Emily
11. Ruane, Peter
12. Rucinski, Katherine
13. Rudd, Deanne
14. Ruederman, Stephanie
15. Ruel, Theodore
16. Ruiz-Mateos, Ezequiel
17. Rukuni, Surumaya
18. Rust, Blake
19. Ruttingerirva, Morris
20. Rydberg, Frida

---

Poster Sessions

CROI 2020

Index of Presenting Authors
Torgersen, Jessie 551
Tonbio, Mabel 641
Torres, Thiago Silva 857
Towe, Sheri L 417
Toy, K Junine 978
Trickey, Adam 895
Trunfio, Mattia 430
Truong, Hong-Ha M 142
Tukei, Betty Bawuba 43

-U-
Umbleja, Triin 707
Underwood, Mark 483, 484
Usery, Faith 149

-V-
Vachuska, Milana 1086
Valdano, Eugenio 923
Valenzuela Fonce, Humberto 274
Van De Perre, Philippe 799
Van De Vijver, David 564
Van Den Hof, Malon 838
Vannappagarai, Vani 521
Vasconcelos, Ricardo De Paula 963
Vasylyev, Marta 757
Velarde De La Cruz, Erandi E 219
Velu, Vijayakumar 200
Vendrame, Elena 384
Venter, Willem Daniel Francois 514
Vernon, Frances 1085
Verwij, Rosanne 689
Vestad, Beate 223
Vignon, Lorena 283
Villinger, Francois 997
Vinikoor, Michael J 609, 1109
Vinton, Carol 231
Violette, Lauren R 864, 954
Vo, Ly Trieu 750
Vo, Quynh 590
Volkow, Patricia 67
Vourli, Georgia 1079
Vu, Quan M 896

-W-
Waalewijn, Hylke 847
Wagner, Gabriel A 966
Wahl, Angela 205, 226, 419
Wahome, Elizabeth 992
Wald, Anna 57
Walensky, Rochelle P 1089
Wamuti, Beatrice 944
Wang, Ruolan 489
Wang, Xiao Qian 613
Wang, Zheng 224
Wang, Zheng 401
Wanjalla, Celestine 672
Wansom, Tanyaporn 852
Ward, Adam R 303
Ward, Amanda E 21
Ware, Norma C 959
Wawer, Maria 1038
Wedderburn, Catherine J 798
Weiss, Julian 29, 433
Welty, Susie 1016
Wensel, David 20
Whitby, Shamaya 967
White, Elizabeth A 255
Whitney, Bridget M 644
Whitney, James 79
Widge, Alicia T 508
Willis, Sarah J 557
Wilson, Andrew B 299
Woldu, Bethel 648
Wolf, Eva 493
Wolf, Hilary T 815
Wong, Colline 242
Wu, Fei 423
Wu, Kunling 876
Wu, Yuntao 19
Wyatt, Monique A 960
Wykowski, James H 746

-Y-
Yager, Jenna 445
Yamaguchi, Julie 935
Yang, Fan Nils 387
Yapa, H Manisha 1135
Yazdanpanah, Yazdan 883
Yee, Lynn M 780
Yeh, Yang-Hui 352
Yero, Alexis 197
Yin, Li 835
Yu, Katherine 385
Yumori, Caitlin Sachiko 1035

-Z-
Zash, Rebecca 792
Zazzi, Maurizio 523
Zhabokritsky, Alice 478
Zhang, Weiyang 270
Zhang, Yinfeng 930
Zhou, Shuntau 931
Zicari, Sonia 809
Ziegelbauer, Joseph 66
Zifodya, Jerry Simbarashe 742
Zuck, Paul 316
Zürcher, Kathrin 718
PLAZA LEVEL
Poster Sessions ........................................ Poster Hall A, B
Registration and Cafeteria ................................ Main Lobby
Bag and Coat Check ........................................ Room 107

2ND FLOOR
Opening Session, Plenaries ......................... Auditorium/Hall C
Poster Sessions ........................................ Poster Hall D
Speaker Ready Room ........................................ 200
IAS–USA Office ............................................. 203

3RD FLOOR
Opening Session, Plenaries ......................... Auditorium Balcony
Oral Sessions, Themed Discussions, Workshops,
and Symposia Breakout Rooms .................... Ballroom A, B, C, 304/306
New Mother’s Room ......................................... 307
Personal Considerations Room ...................... 308
Simultaneous Overflow Room ....................... 302
Additional Overflow Room .............................. 312

Networking Areas: 303, 305, Cafeteria, Poster Halls A, B, D
Gender Neutral Bathroom: by 300

KEY
❤ First Aid
Exit Fire Exit
Food/Beverage
Restrooms
## Conference Schedule

<table>
<thead>
<tr>
<th>TIME</th>
<th>SUNDAY, MARCH 8, 2020</th>
<th>MONDAY, MARCH 9, 2020</th>
<th>TUESDAY, MARCH 10, 2020</th>
<th>WEDNESDAY, MARCH 11, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 AM</td>
<td></td>
<td>CONTINENTAL BREAKFAST 7:00 AM–8:30 AM</td>
<td>CONTINENTAL BREAKFAST 7:00 AM–8:30 AM</td>
<td>CONTINENTAL BREAKFAST 7:00 AM–8:30 AM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2ND FLOOR: PREFUNCTION AREA OUTSIDE OF AUDITORIUM</td>
<td>2ND FLOOR: PREFUNCTION AREA OUTSIDE OF AUDITORIUM</td>
<td>2ND FLOOR: PREFUNCTION AREA OUTSIDE OF AUDITORIUM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*BREAKFAST NETWORKING SESSION FOR NEW INVESTIGATORS 7:15 AM–8:15 AM ROOM 110</td>
<td>*BREAKFAST NETWORKING SESSION FOR NEW INVESTIGATORS 7:15 AM–8:15 AM ROOM 110</td>
<td>*BREAKFAST NETWORKING SESSION FOR NEW INVESTIGATORS 7:15 AM–8:15 AM ROOM 110</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>SPECIAL SESSION 8:00 AM–8:50 AM</td>
<td>THE HITCHHIKER’S GUIDE TO NIH REVIEW FOR HIV/AIDS RESEARCH BALLROOM BC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>WORKSHOP 9:00 AM–12:25 PM</td>
<td>PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES BALLROOM BC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>OPENING SESSION 5:00 PM–7:00 PM</td>
<td>BERNARD FIELDS LECTURE N’GALY-MANN LECTURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td>PERFORMANCE BY THE BOSTON CHILDREN’S CHORUS AUDITORIUM / HALL C / AUDITORIUM BALCONY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>WELCOME RECEPTION 7:00 PM–9:00 PM 3RD FLOOR: BOYLSTON HALLWAY</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Please note: Breakfast Networking Session For New Investigators is limited to New Investigator Scholarship awardees who signed up in advance

** SPECIAL LUNCH-TIME SESSION 12:10PM-1:20PM (APPROXIMATE) AUDITORIUM / HALL C / AUDITORIUM BALCONY